6. パーキンソン病 Disease details / Clinical trials / Drug dev / DR info


臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

薬物ごとの開発者(Primary Sponsor)、臨床試験情報(抜粋)です。
(11C)PE2I   
   Weill Medical College of Cornell University
      2018   Phase 1/Phase 2   NCT03675282   United States;
(2-chloro-5-[11C]methoxy-N-(((3s,5s,7s)-3,5,7-trifluoroadamantan-1-yl)methyl) benzamide)   
   Juha Rinne / PET Centre
      2018   Phase 2   EUCTR2018-000405-23-FI   Finland;
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid   
   AbbVie Inc
      2011   Phase 3   EUCTR2008-001329-33-GB   Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
      2010   Phase 3   EUCTR2008-001329-33-CZ   Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
      2009   -   EUCTR2008-001329-33-PT   Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
   Abbott Healthcare Products B.V.
      2009   -   EUCTR2006-005186-18-CZ   Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2008   Phase 3   EUCTR2006-005186-18-GB   Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2008   -   EUCTR2006-005186-18-PT   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2006-005186-18-DE   Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
   Abbott Laboratories
      2009   -   EUCTR2006-000578-53-DE   Germany;New Zealand;United States;
   Solvay Pharmaceuticals B.V.
      2009   -   EUCTR2006-005186-18-NL   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   Phase 3   EUCTR2006-005186-18-ES   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2007   -   EUCTR2006-005186-18-FI   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
(2S)-3-(3,4-dihydroxyphenyl)-2hydrazino-2methylprop acid   
   AbbVie Inc
      2011   Phase 3   EUCTR2008-001329-33-GB   Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
      2010   Phase 3   EUCTR2008-001329-33-CZ   Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
      2009   -   EUCTR2008-001329-33-PT   Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
(2S)-3-(3,4-dihydroxyphenyl)-2hydrazino-2methylpropanoic acid   
   Abbott Healthcare Products B.V.
      2009   -   EUCTR2006-005186-18-CZ   Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2008   Phase 3   EUCTR2006-005186-18-GB   Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2008   -   EUCTR2006-005186-18-PT   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2006-005186-18-DE   Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
   Abbott Laboratories
      2009   -   EUCTR2006-000578-53-DE   Germany;New Zealand;United States;
   Solvay Pharmaceuticals B.V.
      2009   -   EUCTR2006-005186-18-NL   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   Phase 3   EUCTR2006-005186-18-ES   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2007   -   EUCTR2006-005186-18-FI   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
(3beta, 5beta, 25R)-spirostan-3-ol   
   Phytopharm plc
      2011   -   EUCTR2010-018534-44-HU   Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
      2011   -   EUCTR2010-018534-44-DE   Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
      2011   -   EUCTR2010-018534-44-CZ   Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
      2010   Phase 2   EUCTR2010-018534-44-GB   Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
(3ß, 5ß, 25R)-spirostan-3-ol   
   Phytopharm plc
      2011   -   EUCTR2010-018534-44-HU   Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
      2011   -   EUCTR2010-018534-44-DE   Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
      2011   -   EUCTR2010-018534-44-CZ   Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
      2010   Phase 2   EUCTR2010-018534-44-GB   Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
(6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol   
   Schwarz BioSciences Inc.
      2008   -   EUCTR2004-000148-26-HU   Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
      2008   -   EUCTR2004-000148-26-AT   Austria;Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
      2004   Phase 3   EUCTR2004-000148-26-ES   Austria;Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
      2004   -   EUCTR2004-000148-26-SE   Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
      2004   -   EUCTR2004-000148-26-FI   Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
      2004   -   EUCTR2004-000148-26-CZ   Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
(R)-troloxamide quinone   
   BioElectron Technology Corporation (formerly Edison Pharmaceuticals Inc.)
      2016   Phase 2   EUCTR2015-001786-10-GB   Germany;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-001786-10-DE   Germany;United Kingdom;United States;
(S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol   
   Axxonis Pharma GmbH
      2006   -   EUCTR2005-001006-12-DE   Austria;Czech Republic;Germany;Italy;
      2006   -   EUCTR2005-001006-12-CZ   Austria;Czech Republic;Germany;Italy;
      2006   -   EUCTR2005-001006-12-AT   Austria;Czech Republic;Germany;Italy;
(S)-(+)-2-(4-(3-fluorobenzyl)oxybenzyl)aminopropanamide methanesulfonate   
   Merck Serono S.A. - Geneva
      2011   -   EUCTR2009-017174-20-AT   Austria;Canada;France;Germany;South Africa;
      2010   -   EUCTR2009-017174-20-DE   Austria;Canada;France;Germany;South Africa;
(minus)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate   
   Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
      2007   -   EUCTR2006-000577-29-DE   Germany;United States;
00000   
   Genzyme Corporation
      2017   Phase 2   EUCTR2016-000657-12-IT   Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
000000   
   Genzyme Corporation
      2017   Phase 2   EUCTR2016-000657-12-IT   Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
009-0   
   Alexza Pharmaceuticals, Inc.
      2018   Phase 1   NCT03822364   Netherlands;
009-1   
   Alexza Pharmaceuticals, Inc.
      2018   Phase 1   NCT03822364   Netherlands;
009-2   
   Alexza Pharmaceuticals, Inc.
      2018   Phase 1   NCT03822364   Netherlands;
009-3   
   Alexza Pharmaceuticals, Inc.
      2018   Phase 1   NCT03822364   Netherlands;
009-4   
   Alexza Pharmaceuticals, Inc.
      2018   Phase 1   NCT03822364   Netherlands;
009-5   
   Alexza Pharmaceuticals, Inc.
      2018   Phase 1   NCT03822364   Netherlands;
009-A0   
   Alexza Pharmaceuticals, Inc.
      2019   Phase 1   NCT04157933   Netherlands;
009-A1   
   Alexza Pharmaceuticals, Inc.
      2019   Phase 1   NCT04157933   Netherlands;
009-A2   
   Alexza Pharmaceuticals, Inc.
      2019   Phase 1   NCT04157933   Netherlands;
009-A3   
   Alexza Pharmaceuticals, Inc.
      2019   Phase 1   NCT04157933   Netherlands;
023145028   
   BIAL-Portela & Ca, S.A.
      2021   Phase 4   EUCTR2020-002754-24-IT   Germany;Italy;Portugal;Spain;United Kingdom;
043906039   
   OSPEDALE SANTA MARIA DELLA MISERICORDIA
      2021   Phase 3   EUCTR2018-004892-11-IT   Italy;
1. Tesofensine (NS 2330)   
   Boehringer Ingelheim
      2003   Phase 2   NCT00148512   Austria;El Salvador;France;Germany;Netherlands;Spain;United Kingdom;
100   
   Orion Corporation
      2011   -   EUCTR2010-022200-46-LV   Finland;Germany;Latvia;Lithuania;
      2011   -   EUCTR2010-022200-46-LT   Finland;Germany;Latvia;Lithuania;
      2011   -   EUCTR2010-022200-46-FI   Finland;Germany;Latvia;Lithuania;
      -   -   EUCTR2010-022200-46-DE   Finland;Germany;Latvia;Lithuania;
11C-PBR28   
   William Charles Kreisl
      2015   Phase 2   NCT02702102   United States;
11C-PiB   
   Oriental Neurosurgery Evidence-Based-Study Team
      2017   Phase 2   NCT03555292   China;
11C-Raclopride   
   Orion Corporation Orion Pharma
      2007   -   EUCTR2007-002496-14-FI   Finland;
11C]PBR28   
   AstraZeneca AB
      2012   -   EUCTR2011-004803-19-SE   Finland;Sweden;
      2012   -   EUCTR2011-004803-19-FI   Finland;Sweden;
11C]SMW139   
   Juha Rinne / PET Centre
      2018   Phase 2   EUCTR2018-000405-23-FI   Finland;
125   
   Orion Corporation
      2011   -   EUCTR2010-022200-46-LV   Finland;Germany;Latvia;Lithuania;
      2011   -   EUCTR2010-022200-46-LT   Finland;Germany;Latvia;Lithuania;
      2011   -   EUCTR2010-022200-46-FI   Finland;Germany;Latvia;Lithuania;
      -   -   EUCTR2010-022200-46-DE   Finland;Germany;Latvia;Lithuania;
15O H2O   
   Umeå University Hospital
      2015   Phase 2   EUCTR2015-003045-26-SE   Sweden;
15O]H2O   
   Umeå University Hospital
      2015   Phase 2   EUCTR2015-003045-26-SE   Sweden;
18-FDTBZ   
   Chang Gung Memorial Hospital
      2015   Phase 2   NCT02599753   Taiwan;
18F florbetaben   
   Institute for Neurodegenerative Disorders
      2016   Phase 2   EUCTR2015-004129-15-ES   Spain;
18F- DTBZ   
   Chang Gung Memorial Hospital
      2012   Phase 2   NCT02039024   Taiwan;
18F-AV-133   
   Avid Radiopharmaceuticals
      2012   Phase 2/Phase 3   NCT01550484   Australia;United States;
      2010   Phase 1/Phase 2   NCT01503944   United States;
   Renji Hospital (South Court), School of Medicine, Shanghai Jiao Tong University
      2020   Phase 0   ChiCTR2000036137   China;
18F-AV-45   
   Avid Radiopharmaceuticals
      2010   Phase 1/Phase 2   NCT01503944   United States;
18F-DOPA   
   University of Alberta
      2021   Phase 3   NCT04706910   Canada;
      2017   Phase 3   NCT03042416   Canada;
18F-DOPA PET   
   National Taiwan University Hospital
      2017   -   NCT03973502   Taiwan;
18F-DTBZ   
   Chang Gung Memorial Hospital
      2013   Phase 2   NCT02059733   Taiwan;
      2011   Phase 2   NCT01759888   Taiwan;
      2010   Phase 2   NCT01283347   Taiwan;
18F-DTBZ AV-133   
   Chang Gung Memorial Hospital
      2011   Phase 2   NCT01556100   -
18F-FDG   
   Chang Gung Memorial Hospital
      2010   Phase 2   NCT01824056   Taiwan;
   Huashan Hospital Affiliated to Fudan University
      2020   Phase 0   ChiCTR2000037856   China;
   Nagoya City Rehabilitation Agency
      2019   -   JPRN-UMIN000036908   Japan;
   Renji Hospital (South Court), School of Medicine, Shanghai Jiao Tong University
      2020   Phase 0   ChiCTR2000036137   China;
18F] LBT-999   
   ZIONEXA
      2021   Phase 3   EUCTR2019-000247-27-FR   France;
18F]-(E)-N-(3-iodoprop-2-enyl)-2b-carbofluoroethoxy-3b-(4'-methylphenyl)nortropane   
   Umeå University Hospital
      2015   Phase 2   EUCTR2015-003045-26-SE   Sweden;
18F]FE-PE2I   
   AstraZeneca AB
      2012   -   EUCTR2011-004803-19-SE   Finland;Sweden;
      2012   -   EUCTR2011-004803-19-FI   Finland;Sweden;
   Umeå University Hospital
      2015   Phase 2   EUCTR2015-003045-26-SE   Sweden;
18F]MC225   
   University Medical Center Groningen
      2022   Phase 2   EUCTR2021-005024-37-NL   Netherlands;
1[(6- Allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]-   
   Axxonis Pharma GmbH
      2006   -   EUCTR2005-001006-12-AT   Austria;Czech Republic;Germany;Italy;
1[(6- Allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea   
   Axxonis Pharma GmbH
      2006   -   EUCTR2005-001006-12-DE   Austria;Czech Republic;Germany;Italy;
      2006   -   EUCTR2005-001006-12-CZ   Austria;Czech Republic;Germany;Italy;
      2006   -   EUCTR2005-001006-12-AT   Austria;Czech Republic;Germany;Italy;
1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]-   
   Axxonis Pharma GmbH
      2006   -   EUCTR2005-001006-12-AT   Austria;Czech Republic;Germany;Italy;
1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea   
   Axxonis Pharma GmbH
      2006   -   EUCTR2005-001006-12-DE   Austria;Czech Republic;Germany;Italy;
      2006   -   EUCTR2005-001006-12-CZ   Austria;Czech Republic;Germany;Italy;
      2006   -   EUCTR2005-001006-12-AT   Austria;Czech Republic;Germany;Italy;
2,5-Dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide   
   BIAL Portela & Cª, S.A.
      2011   Phase 3   EUCTR2010-022366-27-GB   Argentina;Australia;Belgium;Chile;Czech Republic;Estonia;India;Israel;Korea, Republic of;Russian Federation;South Africa;United Kingdom;
      2011   Phase 3   EUCTR2010-022366-27-BE   Belgium;Czech Republic;Estonia;United Kingdom;
      2011   -   EUCTR2010-022366-27-CZ   Argentina;Australia;Belgium;Chile;Czech Republic;Estonia;India;Israel;Korea, Republic of;Russian Federation;South Africa;United Kingdom;
      2010   -   EUCTR2010-022366-27-EE   Belgium;Czech Republic;Estonia;United Kingdom;
2-[[[(2R)-1-[1-[(4-CHLORO-3-METHYLPHENYL)METHYL]-4- PIPERIDINYL]-5-OXO-2-PYRROLIDINYL]CARBONYL]AMINO]- N,N,6-TRIMETHYL-4-PYRIDINECARBOXAMIDE,DIHYDROCHLORIDE   
   Alkahest, Inc.
      2020   Phase 2   EUCTR2019-001657-42-SK   Estonia;Germany;Hungary;Poland;Slovakia;United States;
      2019   Phase 2   EUCTR2019-001657-42-DE   Estonia;Germany;Hungary;Poland;Slovakia;United States;
207-3120   
   Aston University
      2018   Phase 2   EUCTR2017-004297-34-GB   United Kingdom;
25330   
   Regional Dementia Research Centre, Dept of Neurology
      2018   Phase 4   EUCTR2017-002707-10-DK   Denmark;
3- (9,10- Didehydro- 6- methyl- 8?- ergolinyl)-1,1- diethylurea hydrogenmaleate   
   Axxonis Pharma GmbH
      2006   -   EUCTR2005-001006-12-DE   Austria;Czech Republic;Germany;Italy;
      2006   -   EUCTR2005-001006-12-CZ   Austria;Czech Republic;Germany;Italy;
      2006   -   EUCTR2005-001006-12-AT   Austria;Czech Republic;Germany;Italy;
3-(3,4-Dihydroxyphenyl)-L-alanine   
   Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
      2007   -   EUCTR2006-000577-29-DE   Germany;United States;
6036937.00.01   
   BIAL-Portela & Ca, S.A.
      2021   Phase 4   EUCTR2020-002754-24-IT   Germany;Italy;Portugal;Spain;United Kingdom;
6abeta - apomorphine-10,11-diol hydrochloride hemihydrate   
   Britannia Pharmaceuticals Limited
      2006   Phase 3   EUCTR2006-000391-32-GB   Germany;Netherlands;United Kingdom;
      2006   -   EUCTR2006-000391-32-NL   Germany;Netherlands;United Kingdom;
      2006   -   EUCTR2006-000391-32-DE   Germany;Netherlands;United Kingdom;
6aß - apomorphine-10,11-diol hydrochloride hemihydrate   
   Britannia Pharmaceuticals Limited
      2006   Phase 3   EUCTR2006-000391-32-GB   Germany;Netherlands;United Kingdom;
      2006   -   EUCTR2006-000391-32-NL   Germany;Netherlands;United Kingdom;
      2006   -   EUCTR2006-000391-32-DE   Germany;Netherlands;United Kingdom;
75   
   Orion Corporation
      2011   -   EUCTR2010-022200-46-LV   Finland;Germany;Latvia;Lithuania;
      2011   -   EUCTR2010-022200-46-LT   Finland;Germany;Latvia;Lithuania;
      2011   -   EUCTR2010-022200-46-FI   Finland;Germany;Latvia;Lithuania;
      -   -   EUCTR2010-022200-46-DE   Finland;Germany;Latvia;Lithuania;
8-OHdG   
   Nagoya University Graduate School of Medicine
      2015   -   JPRN-UMIN000019082   Japan;
A-dopamine   
   InBrain Pharma SAS
      2020   Phase 1;Phase 2   EUCTR2020-000155-12-FR   France;
   University Hospital, Lille
      2020   Phase 1/Phase 2   NCT04332276   France;
AAV2-GDNF   
   Brain Neurotherapy Bio, Inc.
      2020   Phase 1   NCT04167540   United States;
AB1010   
   AB Science
      2015   Phase 2   EUCTR2010-024424-26-SK   Bulgaria;Czech Republic;France;Germany;Hungary;Romania;Slovakia;South Africa;Spain;United States;
ABBV-0805   
   AbbVie
      2020   Phase 1   NCT04127695   Puerto Rico;United States;
ABBV-951   
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2020   Phase 3   EUCTR2019-004235-23-IT   Australia;Canada;Italy;Japan;Netherlands;Russian Federation;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002144-85-IT   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
   AbbVie
      2022   Phase 1   NCT05094050   United States;
      2021   Phase 3   NCT04750226   Australia;United States;
      2020   Phase 3   NCT04380142   Australia;United States;
      2020   Phase 3   NCT04379050   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   NCT03781167   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2018   Phase 1   NCT03374917   United States;
      2017   Phase 1   NCT03033498   United States;
   AbbVie Deutschland
      2020   Phase 3   EUCTR2018-002144-85-DE   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002144-85-NL   Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002144-85-GB   Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002144-85-ES   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002144-85-DK   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002144-85-BE   Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
   Abbvie Deutschland GmbH & Co. KG
      2021   Phase 3   EUCTR2019-004235-23-SE   Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-004235-23-DE   Australia;Canada;Germany;Italy;Japan;Netherlands;Russian Federation;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004235-23-NL   Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004235-23-GB   Australia;Canada;Japan;Russian Federation;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004235-23-DK   Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
ABT-SLV187   
   AbbVie
      2015   Phase 3   NCT02549092   Australia;Canada;Germany;Greece;Italy;Korea, Republic of;Spain;Sweden;United States;
      2014   Phase 3   NCT02082249   Japan;Korea, Republic of;Taiwan;
   AbbVie (prior sponsor, Abbott)
      2011   Phase 2   NCT01479127   Japan;
   Abbott Japan Co., Ltd.
      -   Phase 2   JPRN-JapicCTI-111699   -
ACP-103   
   ACADIA PHARMACEUTICALS INC.
      2009   -   EUCTR2007-003035-22-IT   Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom;
   ACADIA Pharmaceuticals Inc.
      2004   Phase 2   NCT00087542   United States;
   Acadia Pharmaceuticals Inc
      2009   Phase 2;Phase 3   EUCTR2007-003035-22-AT   Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom;
      2008   Phase 2;Phase 3   EUCTR2007-003035-22-FR   Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom;
      2008   -   EUCTR2007-003051-36-SE   Austria;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-003051-36-PT   Austria;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-003051-36-ES   Austria;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-003051-36-BE   Austria;Belgium;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-003051-36-AT   Austria;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002906-23-BG   Bulgaria;France;United Kingdom;
      2007   -   EUCTR2007-002906-23-GB   Bulgaria;France;United Kingdom;
      2007   -   EUCTR2007-002906-23-FR   Bulgaria;France;United Kingdom;
   National Institute of Neurological Disorders and Stroke (NINDS)
      2004   Phase 2   NCT00086294   United States;
ACR325   
   NeuroSearch A/S
      2009   Phase 1   NCT01023282   Germany;
AD-810N (zonisamide)   
   Dainippon Sumitomo Pharma Co., Ltd.
      -   Phase 3   JPRN-JapicCTI-070377   -
      -   -   JPRN-JapicCTI-050099   -
ADS-5102   
   Adamas Pharmaceuticals, Inc.
      2015   Phase 3   EUCTR2014-003739-20-FR   Austria;France;Germany;Spain;United States;
      2015   Phase 3   EUCTR2014-003739-20-ES   Austria;Germany;Spain;United States;
      2015   Phase 3   EUCTR2014-003739-20-DE   Austria;France;Germany;Spain;United States;
      2015   Phase 3   EUCTR2014-003739-20-AT   Austria;Germany;Spain;United States;
      2015   Phase 3   EUCTR2014-003738-24-ES   Austria;Germany;Spain;United States;
      2015   Phase 3   EUCTR2014-003738-24-DE   Austria;Germany;Spain;United States;
      2015   Phase 3   EUCTR2014-003738-24-AT   Austria;Germany;Spain;United States;
      2014   Phase 3   NCT02274766   Austria;France;Germany;Spain;United States;
      2014   Phase 3   NCT02202551   Austria;Canada;France;Germany;Spain;United States;
      2014   Phase 3   NCT02136914   Canada;United States;
ADS-5102 (extended release amantadine HCl)   
   Adamas Pharmaceuticals, Inc.
      2011   Phase 2/Phase 3   NCT01397422   United States;
ADX48621   
   Addex Pharma S.A.
      2011   Phase 2   NCT01336088   Austria;France;Germany;United States;
   Addex Pharma SA
      2011   Phase 2   EUCTR2010-022517-25-DE   Austria;France;Germany;United States;
      2011   -   EUCTR2010-022517-25-AT   Austria;France;Germany;United States;
AFFITOPE® PD01A   
   Affiris AG
      2016   Phase 1   NCT02618941   Austria;
      2014   Phase 1   NCT02216188   Austria;
      2012   Phase 1   NCT01568099   Austria;
AFFITOPE® PD01A + Adjuvant   
   Affiris AG
      2015   Phase 1   NCT02758730   Germany;
AFQ056   
   NOVARTIS FARMA
      2012   -   EUCTR2011-004378-27-IT   Austria;Canada;Germany;Hungary;Italy;Spain;United States;
      2012   -   EUCTR2011-002074-23-IT   Austria;Canada;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
      2011   -   EUCTR2011-002073-30-IT   Canada;European Union;Germany;Italy;Spain;Switzerland;United States;
      2009   -   EUCTR2008-008712-98-IT   Finland;France;Germany;Italy;Spain;
   Novartis
      2009   Phase 2   NCT00986414   Australia;Canada;Finland;France;Germany;Italy;Japan;Spain;
      2009   Phase 2   NCT00888004   Germany;
      2007   Phase 2   NCT00582673   Germany;
   Novartis Farmacéutica, S.A.
      2012   -   EUCTR2011-002074-23-ES   Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
   Novartis Pharma AG
      2010   -   EUCTR2010-019418-25-FR   Finland;France;Germany;Italy;
      2010   -   EUCTR2010-019418-25-FI   Finland;France;Germany;Italy;
      2009   -   EUCTR2008-008712-98-FR   Finland;France;Germany;Italy;Spain;
      2009   -   EUCTR2008-008712-98-FI   Finland;France;Germany;Italy;Spain;
      2009   -   EUCTR2008-008712-98-DE   Finland;France;Germany;Italy;Spain;
   Novartis Pharma Services AG
      2012   -   EUCTR2011-004378-27-SK   Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
      2012   -   EUCTR2011-004378-27-HU   Austria;Canada;France;Germany;Hungary;Italy;Spain;United States;
      2012   -   EUCTR2011-004378-27-DE   Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
      2012   -   EUCTR2011-004378-27-AT   Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
      2012   -   EUCTR2011-002074-23-SK   Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
      2012   -   EUCTR2011-002074-23-HU   Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
      2012   -   EUCTR2011-002074-23-DE   Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
      2012   -   EUCTR2011-002074-23-AT   Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
      2007   -   EUCTR2007-002900-16-DE   Germany;
      -   -   EUCTR2011-002073-30-DE   Canada;France;Germany;Hungary;Italy;Spain;United States;
   Novartis Pharma Sevices AG
      2010   -   EUCTR2010-019418-25-DE   Australia;Canada;Finland;France;Germany;Italy;Japan;
   Novartis Pharmaceuticals
      2012   Phase 2   NCT01491932   Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
      2012   Phase 2   NCT01491529   Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
      2011   Phase 2   NCT01385592   Canada;France;Germany;Hungary;Italy;Spain;United States;
      2010   Phase 2   NCT01173731   Australia;Canada;Finland;France;Germany;Italy;Spain;United States;
AFQ056 with L-dopa   
   Novartis
      2010   Phase 2   NCT01092065   United States;
AFQ065   
   Novartis Pharma AG
      2010   -   EUCTR2010-019418-25-FI   Finland;France;Germany;Italy;
   Novartis Pharma Sevices AG
      2010   -   EUCTR2010-019418-25-DE   Australia;Canada;Finland;France;Germany;Italy;Japan;
AHA Exergame System   
   Campus Neurológico Sénior
      2018   -   NCT03891069   Portugal;
AKST4290   
   Alkahest, Inc.
      2020   Phase 2   NCT04369430   Estonia;Germany;Hungary;Poland;Slovakia;United States;
      2020   Phase 2   EUCTR2019-001657-42-SK   Estonia;Germany;Hungary;Poland;Slovakia;United States;
      2019   Phase 2   EUCTR2019-001657-42-DE   Estonia;Germany;Hungary;Poland;Slovakia;United States;
ALTROPANE®   
   Molecular NeuroImaging
      2006   Phase 2   NCT00397228   United States;
AMANTADINE HYDROCHLORIDE   
   CHU de Toulouse
      2010   -   EUCTR2009-016143-19-AT   Austria;France;
AMBROSAN 60mg Tablets   
   Joint Research Office
      2016   Phase 2   EUCTR2015-002571-24-GB   United Kingdom;
ANAVEX2-73   
   Anavex Life Sciences Corp.
      2019   Phase 2   NCT04575259   Australia;Spain;
      2018   Phase 2   EUCTR2017-004335-36-ES   Spain;
ANHYDROUS CARBIDOPA   
   BIAL-Portela & Ca, SA
      2009   -   EUCTR2009-012897-12-RO   Romania;
   Impax Laboratories, LLC
      2020   Phase 3   EUCTR2018-002234-21-GB   Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-002233-37-PL   Canada;Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002234-21-ES   Czech Republic;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002234-21-DE   Czech Republic;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002234-21-CZ   Czech Republic;Czechia;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002233-37-IT   Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002233-37-GB   Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002233-37-DE   Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002233-37-CZ   Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
AP-CD/LD   
   Intec Pharma Ltd.
      2012   Phase 2   NCT00947037   Israel;
AP09004   
   Intec Pharma Ltd.
      2009   Phase 2   NCT00918177   Israel;
APL-130277   
   SUNOVION PHARMACEUTICALS
      2016   Phase 2   EUCTR2016-001762-29-IT   Italy;
   SUNOVION PHARMACEUTICALS INC
      2018   Phase 3   EUCTR2016-003456-70-IT   Austria;France;Germany;Italy;Spain;United Kingdom;
      2018   Phase 3   EUCTR2016-000637-43-IT   Austria;Canada;France;Germany;Italy;Spain;United Kingdom;United States;
   Sunovion
      2018   Phase 3   NCT03391882   Austria;France;Germany;Italy;Spain;United Kingdom;
      2017   Phase 2   NCT03292016   United States;
      2017   Phase 2   NCT03187301   Italy;United States;
      2015   Phase 3   NCT02542696   Austria;Canada;France;Germany;Italy;Spain;United Kingdom;United States;
      2015   Phase 3   NCT02469090   Canada;United Kingdom;United States;
      2014   Phase 2   NCT02228590   United States;
   Sunovion Pharmaceuticals Inc.
      2018   Phase 3   EUCTR2016-003456-70-ES   Austria;Spain;United Kingdom;
      2018   Phase 3   EUCTR2016-003456-70-DE   Austria;France;Germany;Italy;Spain;United Kingdom;
      2018   Phase 3   EUCTR2016-003456-70-AT   Austria;France;Germany;Italy;Spain;United Kingdom;
      2018   Phase 3   EUCTR2016-000637-43-ES   Austria;Canada;France;Germany;Italy;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-000637-43-AT   Austria;Canada;France;Germany;Italy;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003456-70-GB   Austria;France;Germany;Italy;Spain;United Kingdom;
      2016   Phase 3   EUCTR2016-000637-43-GB   Austria;Canada;France;Germany;Italy;Spain;United Kingdom;United States;
   Sunuvion Pharmaceuticals Inc
      2016   Phase 3   EUCTR2016-000636-18-GB   Canada;United Kingdom;United States;
APO-go   
   SUNOVION PHARMACEUTICALS INC
      2018   Phase 3   EUCTR2016-003456-70-IT   Austria;France;Germany;Italy;Spain;United Kingdom;
   Sunovion
      2017   Phase 2   NCT03292016   United States;
   Sunovion Pharmaceuticals Inc.
      2018   Phase 3   EUCTR2016-003456-70-ES   Austria;Spain;United Kingdom;
      2018   Phase 3   EUCTR2016-003456-70-DE   Austria;France;Germany;Italy;Spain;United Kingdom;
      2018   Phase 3   EUCTR2016-003456-70-AT   Austria;France;Germany;Italy;Spain;United Kingdom;
      2017   Phase 3   EUCTR2016-003456-70-GB   Austria;France;Germany;Italy;Spain;United Kingdom;
   University Medical Center Groningen
      2016   Phase 2;Phase 3   EUCTR2016-000102-11-NL   Netherlands;
      2015   Phase 2   EUCTR2014-000657-36-NL   Netherlands;
APO-go®   
   Criceto IKM B.V.
      2020   Phase 1;Phase 2   EUCTR2019-003315-60-NL   Netherlands;
APOKINON   
   CHU Rennes
      2021   Phase 4   EUCTR2021-000826-89-FR   France;
   CHU Toulouse
      2007   -   EUCTR2006-005318-11-FR   France;
   CHU de Rennes
      2016   Phase 3   EUCTR2016-002454-20-FR   France;
   CHU de Toulouse
      2010   Phase 3   EUCTR2010-018650-12-FR   France;
APOMORFINA CLORIDRATO   
   SUNOVION PHARMACEUTICALS INC
      2018   Phase 3   EUCTR2016-003456-70-IT   Austria;France;Germany;Italy;Spain;United Kingdom;
APOMORPHINE HYDROCHLORIDE HEMIHYDRATE   
   Criceto IKM B.V.
      2020   Phase 1;Phase 2   EUCTR2019-003315-60-NL   Netherlands;
APORON   
   Criceto IKM B.V.
      2020   Phase 1;Phase 2   EUCTR2019-003315-60-NL   Netherlands;
AQW051   
   NOVARTIS FARMA
      2012   -   EUCTR2011-001092-39-IT   Germany;Italy;United States;
   Novartis Pharma Services AG
      2011   -   EUCTR2011-001092-39-DE   France;Germany;Italy;United States;
   Novartis Pharmaceuticals
      2011   Phase 2   NCT01474421   France;Germany;Italy;United States;
ARICEPT   
   Eisai Limited
      2002   Phase 3   NCT00165815   Germany;Ireland;
AS2   
   University College London
      2015   Phase 2   EUCTR2014-002697-37-GB   United Kingdom;
ASyn Mab   
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 2   EUCTR2020-004997-23-IT   Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd
      2021   Phase 2   EUCTR2020-004997-23-FR   Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-004997-23-AT   Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-000087-15-FR   Austria;France;Germany;Spain;United States;
      2017   Phase 2   EUCTR2017-000087-15-ES   Austria;France;Germany;Spain;United States;
      2017   Phase 2   EUCTR2017-000087-15-DE   Austria;France;Germany;Spain;United States;
      2017   Phase 2   EUCTR2017-000087-15-AT   Austria;France;Germany;Spain;United States;
   Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
      2021   Phase 2   EUCTR2020-004997-23-ES   Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
ATH-1017   
   Athira Pharma
      2022   Phase 2   NCT04831281   United States;
ATM FOG in PD   
   Medical University of South Carolina
      2013   Phase 3   NCT03651856   United States;
AV-101   
   VistaGen Therapeutics, Inc.
      2022   Phase 2   NCT04147949   -
AVALOX - 400   
   SUNOVION PHARMACEUTICALS
      2016   Phase 2   EUCTR2016-001762-29-IT   Italy;
AVE8112   
   Michael J. Fox Foundation for Parkinson's Research
      2013   Phase 1   NCT01803945   United States;
AVP-923   
   Avanir Pharmaceuticals
      2003   Phase 3   NCT00056524   United States;
AVP-923-45   
   Avanir Pharmaceuticals
      2013   Phase 2   NCT01767129   Canada;United States;
AZD0328   
   King's College London
      2021   Phase 2   NCT04810104   Norway;
AZD3241 300 mg BID   
   AstraZeneca
      2012   Phase 2   NCT01603069   United States;
AZD3241 600 mg BID   
   AstraZeneca
      2012   Phase 2   NCT01603069   United States;
AZD3241 Alternative titration scheme with formulation 1 or 2   
   AstraZeneca
      2011   Phase 1   NCT01457807   United Kingdom;
AZD3241 ER formulation 1   
   AstraZeneca
      2011   Phase 1   NCT01457807   United Kingdom;
AZD3241 Extended release tablets   
   AstraZeneca AB
      2012   -   EUCTR2011-004803-19-SE   Finland;Sweden;
      2012   -   EUCTR2011-004803-19-FI   Finland;Sweden;
AZILECT 1 mg comprimidos   
   Teva Pharmaceutical Industries Ltd
      2009   Phase 4   EUCTR2009-011541-24-ES   France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
AZILECT®   
   University Hospital, Clermont-Ferrand
      2013   Phase 4   NCT01765257   France;
Aadipose-Derived Mesenchymal Stem Cells   
   Taiwan Mitochondrion Applied Technology Co., Ltd.
      2022   Phase 1   NCT05094011   -
Abdominal compression   
   Vanderbilt University Medical Center
      2020   Early Phase 1   NCT04620382   United States;
Acamprosate   
   Baylor College of Medicine
      2006   -   NCT00640952   United States;
Accordion Pill Carbidopa/Levodopa   
   Intec Pharma Ltd.
      2018   Phase 2   NCT03576638   -
Accordion Pill ¿ Carbidopa/Levodopa 50/   
   INTEC PHARMA LTD
      2016   Phase 3   EUCTR2015-003513-24-IT   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003512-20-IT   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
Accordion Pill? Carbidopa/Levodopa 50/   
   Intec Pharma, Ltd.
      2016   Phase 3   EUCTR2015-003513-24-ES   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003512-20-ES   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
Accordion Pill¿ Carbidopa/levodopa   
   INTEC PHARMA LTD
      2018   Phase 2   EUCTR2018-001209-95-IT   Italy;Spain;
Accordion Pill™ Carbidopa/Levodopa   
   Intec Pharma Ltd.
      2016   Phase 3   NCT02615873   Bulgaria;Germany;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2016   Phase 3   NCT02605434   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
Accordion Pill™ Carbidopa/Levodopa 50/   
   Intec Pharma, Ltd.
      2017   Phase 3   EUCTR2015-003513-24-SK   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003513-24-HU   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003513-24-GB   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003513-24-DE   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003513-24-BG   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003512-20-SK   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003512-20-PL   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003512-20-HU   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003512-20-GB   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
ActiMyo recording   
   Institut de Myologie, France
      2016   -   NCT02785978   France;
Active Investigational Treatment ENT-01   
   Enterin Inc.
      2020   Phase 2   NCT04483479   United States;
      2019   Phase 1   NCT03938922   United States;
      2018   Phase 2   NCT03781791   United States;
Active comparator   
   Alexza Pharmaceuticals, Inc.
      2018   Phase 1   NCT03822364   Netherlands;
Active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.   
   Biogen Idec
      2003   Phase 2   NCT00451815   -
Active drug: pimavanserin 17mg (2 strength tablets)   
   University Hospital, Strasbourg, France
      2020   Phase 2   NCT03947216   France;
Active tDCS   
   National Cheng-Kung University Hospital
      2015   Phase 1/Phase 2   NCT02917122   -
Active tPCS   
   Western University, Canada
      2019   -   NCT04054960   Canada;
Adaptor: Hakko Adaptor   
   AbbVie (prior sponsor, Abbott)
      2011   Phase 2   NCT01479127   Japan;
Adjuvant without active component   
   Affiris AG
      2015   Phase 1   NCT02758730   Germany;
      2014   Phase 1   NCT02267434   Austria;
Administration of stable isotope-labelled leucine-   
   University Hospital, Montpellier
      2013   -   NCT02263235   France;
Agomelatine or PIacebo   
   Second Affiliated Hospital of Soochow University
      2019   Phase 4   NCT03977441   -
AlloRx   
   The Foundation for Orthopaedics and Regenerative Medicine
      2022   Phase 1   NCT05152394   Antigua and Barbuda;
Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg)   
   The University of Texas Health Science Center, Houston
      2017   Phase 1   NCT02611167   United States;
Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg)   
   The University of Texas Health Science Center, Houston
      2017   Phase 1   NCT02611167   United States;
Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg)   
   The University of Texas Health Science Center, Houston
      2017   Phase 1   NCT02611167   United States;
Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg)   
   The University of Texas Health Science Center, Houston
      2017   Phase 1   NCT02611167   United States;
Allopurinol   
   Kamatani Naoyuki
      2019   Phase 1   JPRN-jRCTs031190115   Japan;
Alternating, 10 sec High-Frequency, 10 sec Low-Frequency Stimulation   
   The Cleveland Clinic
      2021   Phase 1   NCT05022147   United States;
Alternating, 10 sec High-Frequency, 50 sec Low-Frequency Stimulation   
   The Cleveland Clinic
      2021   Phase 1   NCT05022147   United States;
Alternating, 50 sec High-Frequency, 10 sec Low-Frequency Stimulation   
   The Cleveland Clinic
      2021   Phase 1   NCT05022147   United States;
Alternating, 50 sec High-Frequency, 50 sec Low-Frequency Stimulation   
   The Cleveland Clinic
      2021   Phase 1   NCT05022147   United States;
Amantadin-ratiopharm   
   CHU de Toulouse
      2010   -   EUCTR2009-016143-19-AT   Austria;France;
Amantadine   
   CHU de Toulouse
      2012   Phase 2   EUCTR2011-005201-75-FR   France;
   Comprehensive clinical study group concerning diagnosis, treatment, and prevention of the neurological disorders
      2007   -   JPRN-UMIN000000780   Japan;
   Department of Neurology, Juntendo University School of Medicine
      2013   -   JPRN-UMIN000010596   Japan;
   Northwestern University
      2011   Phase 3   NCT01652534   United States;
   Oregon Health and Science University
      2009   -   NCT00794313   United States;
   Rabin Medical Center
      2010   -   NCT01190553   -
      2008   Phase 2   NCT00600093   Israel;
   Rush University Medical Center
      2013   Phase 2   NCT01789047   United States;
      2010   Phase 4   NCT01071395   Austria;Canada;France;United States;
   University Hospital, Toulouse
      2012   Phase 2   NCT01538329   France;
Amantadine HCl ER   
   Adamas Pharmaceuticals, Inc.
      2014   Phase 3   NCT02153632   Canada;France;Germany;Spain;United States;
Amantadine HCl ER tablets   
   Adamas Pharmaceuticals, Inc.
      2014   Phase 3   NCT02153645   Canada;France;Germany;Spain;United States;
Amantadine HCl Extended Release   
   Osmotica Pharmaceutical Corp.
      2014   Phase 3   EUCTR2014-001132-10-ES   Canada;France;Germany;Spain;United States;
      2014   Phase 3   EUCTR2014-001131-36-ES   Canada;France;Germany;Spain;United States;
      2014   -   EUCTR2014-001132-10-FR   Canada;France;Germany;Spain;United States;
Amantadine HCl Extended Release Capsule   
   Adamas Pharmaceuticals, Inc.
      2015   Phase 3   EUCTR2014-003739-20-FR   Austria;France;Germany;Spain;United States;
      2015   Phase 3   EUCTR2014-003739-20-ES   Austria;Germany;Spain;United States;
      2015   Phase 3   EUCTR2014-003739-20-DE   Austria;France;Germany;Spain;United States;
      2015   Phase 3   EUCTR2014-003739-20-AT   Austria;Germany;Spain;United States;
      2015   Phase 3   EUCTR2014-003738-24-ES   Austria;Germany;Spain;United States;
      2015   Phase 3   EUCTR2014-003738-24-DE   Austria;Germany;Spain;United States;
      2015   Phase 3   EUCTR2014-003738-24-AT   Austria;Germany;Spain;United States;
Amantadine hydrochloride (HCl)   
   Adamas Pharmaceuticals, Inc.
      2015   Phase 3   EUCTR2014-003739-20-FR   Austria;France;Germany;Spain;United States;
      2015   Phase 3   EUCTR2014-003739-20-ES   Austria;Germany;Spain;United States;
      2015   Phase 3   EUCTR2014-003739-20-DE   Austria;France;Germany;Spain;United States;
      2015   Phase 3   EUCTR2014-003739-20-AT   Austria;Germany;Spain;United States;
      2015   Phase 3   EUCTR2014-003738-24-ES   Austria;Germany;Spain;United States;
      2015   Phase 3   EUCTR2014-003738-24-DE   Austria;Germany;Spain;United States;
      2015   Phase 3   EUCTR2014-003738-24-AT   Austria;Germany;Spain;United States;
Amantadine sulfate   
   Jee-Young Lee
      2011   Phase 4   NCT01313845   Korea, Republic of;
Ambroxol   
   Lawson Health Research Institute
      2015   Phase 2   NCT02914366   Canada;
   University College, London
      2016   Phase 2   NCT02941822   United Kingdom;
Ambroxol Hydrochloride   
   Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
      2022   Phase 2   NCT05287503   Italy;
Ambroxol hydrochloride   
   Joint Research Office
      2016   Phase 2   EUCTR2015-002571-24-GB   United Kingdom;
Ampreloxetine   
   THERAVANCE BIOPHARMA ANTIBIOTICS, INC.
      2019   Phase 3   EUCTR2018-003289-15-IT   Austria;Bulgaria;Canada;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
   Theravance Biopharma
      2019   Phase 3   NCT03829657   Argentina;Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
   Theravance Biopharma Ireland Limited
      2020   Phase 3   EUCTR2018-003289-15-DE   Austria;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003289-15-HU   Austria;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003289-15-ES   Austria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Ampreloxetine chydrochloride   
   Theravance Biopharma Ireland Limited
      2019   Phase 3   EUCTR2018-003289-15-PL   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Ampreloxetine hydrochloride   
   Theravance Biopharma Ireland Limited
      2020   Phase 3   EUCTR2018-003941-41-PT   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-003941-41-AT   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-003289-15-PT   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003941-41-PL   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003941-41-IT   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003941-41-HU   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003941-41-GB   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003941-41-ES   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003941-41-EE   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003941-41-BG   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003289-15-GB   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003289-15-EE   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003289-15-DK   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003289-15-BG   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003289-15-AT   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Ampyra first,   
   University of Miami
      2012   Phase 1/Phase 2   NCT01491022   United States;
Anle138b   
   MODAG GmbH
      2020   Phase 1   NCT04685265   United Kingdom;
Anti-Parkinson medication   
   Beth Israel Deaconess Medical Center
      2016   -   NCT02994719   United States;
Anti-Parkinsonian Drugs   
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2014   -   NCT04928079   -
Antiparkinsonian Agent(s)   
   Sage Therapeutics
      2016   Phase 2   NCT03000569   United States;
Aplindore   
   Ligand Pharmaceuticals
      2008   Phase 2   NCT00623324   United States;
Aplindore MR tablets   
   Neurogen Corporation
      2008   Phase 2   NCT00809302   United States;
Apo-go®   
   Britannia Pharmaceuticals Limited
      2014   Phase 3   EUCTR2013-000980-10-NL   Austria;Denmark;France;Germany;Netherlands;Spain;
      2014   Phase 3   EUCTR2013-000980-10-DK   Austria;Denmark;France;Germany;Netherlands;Spain;
      2013   Phase 3   EUCTR2013-000980-10-AT   Austria;Denmark;France;Germany;Netherlands;Spain;
   STADA Arzneimittel AG
      2014   Phase 3   EUCTR2013-000980-10-FR   Austria;Denmark;France;Germany;Netherlands;Spain;
      2014   Phase 3   EUCTR2013-000980-10-ES   Austria;Denmark;France;Germany;Netherlands;Spain;
Apokinon   
   CHU de Rennes
      2009   Phase 3   EUCTR2008-006045-10-FR   France;
Apokyn   
   Sunovion
      2017   Phase 2   NCT03292016   United States;
Apomor   
   Sunovion Pharmaceuticals Inc.
      2018   Phase 3   EUCTR2016-003456-70-DE   Austria;France;Germany;Italy;Spain;United Kingdom;
      2018   Phase 3   EUCTR2016-003456-70-AT   Austria;France;Germany;Italy;Spain;United Kingdom;
Apomorp   
   Sunovion Pharmaceuticals Inc.
      2017   Phase 3   EUCTR2016-003456-70-GB   Austria;France;Germany;Italy;Spain;United Kingdom;
Apomorphine   
   CHU de Toulouse
      2010   Phase 3   EUCTR2010-018650-12-FR   France;
   Clinique Beau Soleil
      2018   Phase 4   NCT02940912   France;
   Fondation Ophtalmologique Adolphe de Rothschild
      2016   Phase 4   NCT02688465   France;
   Oregon Health and Science University
      2009   Phase 2   NCT00758368   United States;
      2005   Phase 2   NCT00472355   United States;
   Rennes University Hospital
      2021   Phase 4   NCT04887467   France;
      2017   Phase 3   NCT02864004   France;
   University Hospital, Toulouse
      2007   -   NCT00524914   France;
   University Medical Center Groningen
      2017   Phase 2   NCT02702076   Netherlands;
      2016   Phase 2;Phase 3   EUCTR2016-000102-11-NL   Netherlands;
      2015   Phase 2   EUCTR2014-000657-36-NL   Netherlands;
Apomorphine (2.5mg/ml)   
   University Medical Center Groningen
      2015   Phase 2   NCT02230930   Netherlands;
Apomorphine HCl injection   
   Mylan Bertek Pharmaceuticals
      2001   Phase 3   NCT00200525   -
      2001   Phase 3   NCT00145171   -
      1999   Phase 3   NCT00142545   United States;
      1999   Phase 2/Phase 3   NCT00200512   United Kingdom;
Apomorphine Hydrocloride Hemihydrate   
   SUNOVION PHARMACEUTICALS
      2016   Phase 2   EUCTR2016-001762-29-IT   Italy;
Apomorphine Injectable Solution   
   University of Calgary
      2021   Phase 2/Phase 3   NCT04879134   Canada;
Apomorphine Nasal Powder   
   Britannia Pharmaceuticals Limited
      2006   Phase 3   EUCTR2006-000391-32-GB   Germany;Netherlands;United Kingdom;
      2006   -   EUCTR2006-000391-32-NL   Germany;Netherlands;United Kingdom;
      2006   -   EUCTR2006-000391-32-DE   Germany;Netherlands;United Kingdom;
   Britannia Pharmaceuticals Ltd.
      2006   Phase 2/Phase 3   NCT00346827   -
Apomorphine hydrochloride   
   Britannia Pharmaceuticals Limited
      2014   Phase 3   EUCTR2013-000980-10-NL   Austria;Denmark;France;Germany;Netherlands;Spain;
      2014   Phase 3   EUCTR2013-000980-10-DK   Austria;Denmark;France;Germany;Netherlands;Spain;
      2013   Phase 3   EUCTR2013-000980-10-AT   Austria;Denmark;France;Germany;Netherlands;Spain;
   Britannia Pharmaceuticals Ltd.
      2014   Phase 3   NCT02006121   Austria;Denmark;France;Germany;Netherlands;Spain;United Kingdom;
   Kyowa Kirin Co., Ltd.
      2007   Phase 2   NCT00610103   Japan;
   STADA Arzneimittel AG
      2014   Phase 3   EUCTR2013-000980-10-FR   Austria;Denmark;France;Germany;Netherlands;Spain;
      2014   Phase 3   EUCTR2013-000980-10-ES   Austria;Denmark;France;Germany;Netherlands;Spain;
   SUNOVION PHARMACEUTICALS INC
      2018   Phase 3   EUCTR2016-000637-43-IT   Austria;Canada;France;Germany;Italy;Spain;United Kingdom;United States;
   Vectura Group plc
      2006   Phase 2   EUCTR2006-005509-79-GB   United Kingdom;
      2006   Phase 2   EUCTR2006-004582-33-GB   United Kingdom;
      2005   Phase 2   EUCTR2005-005120-13-GB   United Kingdom;
Apomorphine hydrochloride 1.8mg inhalation powder, pre-dispensed   
   Vectura Limited
      2009   -   EUCTR2008-004447-11-GB   Germany;Italy;United Kingdom;
      -   -   EUCTR2008-004447-11-DE   Germany;Italy;United Kingdom;
Apomorphine hydrochloride 2.8mg inhalation powder, pre-dispensed   
   Vectura Limited
      2009   -   EUCTR2008-004447-11-GB   Germany;Italy;United Kingdom;
      -   -   EUCTR2008-004447-11-DE   Germany;Italy;United Kingdom;
Apomorphine hydrochloride 4.0 mg inhalation powder, pre-dispensed   
   Vectura Limited
      2009   -   EUCTR2008-004447-11-GB   Germany;Italy;United Kingdom;
      -   -   EUCTR2008-004447-11-DE   Germany;Italy;United Kingdom;
Apomorphine hydrochloride 5.8 mg inhalation powder, pre-dispensed   
   Vectura Limited
      2009   -   EUCTR2008-004447-11-GB   Germany;Italy;United Kingdom;
      -   -   EUCTR2008-004447-11-DE   Germany;Italy;United Kingdom;
Apomorphine infusion   
   US WorldMeds LLC
      2015   Phase 3   NCT02339064   United States;
Aricept 5 mg-Filmtabletten   
   Eisai Limited
      2004   -   EUCTR2004-003355-39-AT   Austria;
Aricept 5mg-Filmtabletten   
   Eisai Limited
      2004   -   EUCTR2004-003355-39-AT   Austria;
Aripiprazole   
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2003   Phase 4   NCT00095810   United States;
Armodafinil   
   NYU Langone Health
      2011   -   NCT01256905   United States;
Artane   
   First Affiliated Hospital of Xinjiang Medical University
      2007   -   ChiCTR-TRC-07000027   China;
Atomoxetine   
   Hubert Fernandez
      2016   Early Phase 1   NCT02879136   United States;
   Johns Hopkins University
      2005   -   NCT00286949   United States;
   Medical University of South Carolina
      2012   Phase 2   NCT01738191   United States;
   University of Pennsylvania
      2004   Phase 4   NCT00304161   United States;
Atypical Antipsychotics   
   Pontifical Catholic University of Argentina
      2015   -   NCT02409823   -
Autologous mesenchymal stem cells   
   Belarusian Medical Academy of Post-Graduate Education
      2017   Phase 2/Phase 3   NCT04146519   Belarus;
Azathioprine   
   Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
      2019   Phase 2   EUCTR2018-003089-14-GB   United Kingdom;
Azilect   
   Dresden University of Technology
      2011   -   EUCTR2010-023756-82-DE   Germany;
   Institut de Recerca de l'Hospital de la santa Creu i Sant Pau
      2007   -   EUCTR2007-004400-12-ES   Spain;
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.
      2011   -   EUCTR2009-015161-31-DE   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
      2011   Phase 3   EUCTR2009-013552-72-GB   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2011   -   EUCTR2009-015162-57-PT   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2009-015161-31-PT   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2011   Phase 3   EUCTR2009-015162-57-GB   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-015162-57-BG   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-015161-31-GB   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2011   -   EUCTR2009-015161-31-BG   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2011   -   EUCTR2009-013552-72-BG   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      -   -   EUCTR2009-013552-72-DE   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
   Merck Sharp & Dohme corp.
      2011   Phase 3   EUCTR2009-015162-57-NL   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
   Schering Corporation, división Schering-Plough Research
      2010   Phase 3   EUCTR2009-013552-72-ES   Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
   Schering-Plough Research Institute, a division of Schering Corporation
      2011   Phase 3   EUCTR2009-015162-57-LV   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-015162-57-LT   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-015162-57-FI   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-015162-57-ES   Austria;Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
      2011   Phase 3   EUCTR2009-015162-57-CZ   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-013552-72-CZ   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2011   -   EUCTR2009-015162-57-SE   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2009-015162-57-PL   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2009-015162-57-AT   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2009-015161-31-PL   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2011   -   EUCTR2009-015161-31-CZ   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2011   -   EUCTR2009-013552-72-PL   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2010   Phase 3   EUCTR2009-015161-31-IT   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2009-015161-31-FR   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2009-013552-72-HU   Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2009-013552-72-FI   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-015161-31-SE   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-015161-31-NL   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-015161-31-FI   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-015161-31-AT   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-013552-72-SE   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-013552-72-IT   Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
   Schering-Plough Research Institute, division of Schering Corporation
      2011   -   EUCTR2009-015162-57-IT   Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
   Technische Universität Dresden
      2009   Phase 4   NCT00902941   Germany;
      2009   -   EUCTR2008-005085-30-DE   Germany;
   Teva Pharmaceuticals Industries LtD
      2005   Phase 3   EUCTR2005-001416-42-GB   Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
   University of British Columbia
      2013   -   NCT02207387   Canada;
Azilect®   
   H. Lundbeck A/S
      2011   Phase 3   NCT01479530   China;
      2011   Phase 3   NCT01268891   Korea, Republic of;
   Teva Pharma GmbH
      2014   -   NCT02384512   Germany;
B-CIT and SPECT imaging   
   Institute for Neurodegenerative Disorders
      2006   Phase 2   NCT00404170   United States;
B-STN DBS   
   Vanderbilt University Medical Center
      2006   -   NCT00282152   United States;
B6, B12, L-methylfolate   
   North Shore Long Island Jewish Health System
      2006   -   NCT00853879   United States;
BAVISANT HYDROCHLORIDE MONOHYDRATE   
   BenevolentAI Bio
      2017   Phase 2   EUCTR2017-000877-35-GB   Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-000877-35-ES   Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-000877-35-DE   Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-000877-35-CZ   Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
BEFIRADOL   
   Neurolixis SAS
      2021   Phase 2   EUCTR2020-006053-22-SE   Sweden;
BEN-2001   
   BenevolentAI Bio
      2017   Phase 2   NCT03194217   United States;
BENSERAZIDE HYDROCHLORIDE   
   BIAL-Portela & Ca, SA
      2009   -   EUCTR2009-012897-12-RO   Romania;
   Bial - Portela & Ca, S.A.
      2022   Phase 4   EUCTR2020-002754-24-DE   Germany;Italy;Portugal;Spain;United Kingdom;
      2021   Phase 4   EUCTR2020-002754-24-ES   Germany;Italy;Portugal;Spain;United Kingdom;
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2011   -   EUCTR2010-022363-35-DE   Germany;
BF 2.649   
   Bioprojet
      2007   Phase 2   NCT00642928   France;
      2007   -   EUCTR2007-003512-57-FR   France;
BF2.649   
   BIOPROJET
      2010   -   EUCTR2009-013886-24-SE   Czech Republic;Germany;Sweden;
      2010   -   EUCTR2009-013886-24-DE   Czech Republic;Germany;Sweden;
      2009   -   EUCTR2009-013886-24-CZ   Czech Republic;Germany;Sweden;
      2009   -   EUCTR2009-013885-14-FR   France;Spain;
      2009   -   EUCTR2009-013885-14-ES   France;Spain;
BF2.649 (Pitolisant)   
   Bioprojet
      2010   Phase 3   NCT01066442   Germany;
BF2.649 (pitolisant)   
   Bioprojet
      2009   Phase 3   NCT01036139   France;
BI-Sifrol®   
   Boehringer Ingelheim
      2004   Phase 4   NCT02231905   -
BIA 3-202   
   BIAL - Portela & Cª, SA
      2006   -   EUCTR2006-001793-24-PT   Austria;Portugal;
      2006   -   EUCTR2006-001793-24-AT   Austria;Portugal;
   Bial - Portela C S.A.
      2005   Phase 2   NCT02834507   -
      2005   Phase 1   NCT02778594   Portugal;
      2005   Phase 1   NCT02774564   Portugal;
      2001   Phase 1   NCT02763852   Portugal;
      2001   Phase 1   NCT02763839   Portugal;
      2000   Phase 1   NCT02763800   United Kingdom;
      2000   Phase 1   NCT02763787   United Kingdom;
BIA 3-202 (200 mg)   
   Bial - Portela C S.A.
      2006   Phase 1   NCT02772614   Switzerland;
BIA 6-512   
   Bial - Portela C S.A.
      2006   Phase 1   NCT03097211   Portugal;
      2006   Phase 1   NCT03095105   Germany;
      2006   Phase 1   NCT03094156   Portugal;
      2005   Phase 1   NCT03095092   Portugal;
      2005   Phase 1   NCT03093389   Portugal;
      2004   Phase 1   NCT03091868   Portugal;
BIA 6-512 100 mg dose   
   Bial - Portela C S.A.
      2004   Phase 1   NCT03091543   Portugal;
BIA 6-512 200 mg dose   
   Bial - Portela C S.A.
      2004   Phase 1   NCT03091543   Portugal;
BIA 6-512 25 mg dose   
   Bial - Portela C S.A.
      2004   Phase 1   NCT03091543   Portugal;
BIA 6-512 50 mg dose   
   Bial - Portela C S.A.
      2004   Phase 1   NCT03091543   Portugal;
BIA 9 1067   
   Bial - Portela C S.A.
      2018   Phase 1   NCT04265027   United Kingdom;
BIA 9-1067   
   BIAL - PORTELA & Cª, S.A.
      2011   -   EUCTR2010-021860-13-IT   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Russian Federation;Slovakia;Spain;
   BIAL - Portela & Ca, S.A.
      2011   Phase 3   EUCTR2010-021860-13-RO   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
      2011   -   EUCTR2010-021860-13-SK   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
      2011   -   EUCTR2010-021860-13-ES   Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain;
      2011   -   EUCTR2010-021860-13-DE   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
      2011   -   EUCTR2010-021860-13-CZ   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
      2011   -   EUCTR2010-021860-13-BG   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
      2011   -   EUCTR2010-021860-13-AT   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
      2010   -   EUCTR2010-021860-13-PT   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
      2010   -   EUCTR2010-021860-13-LV   Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain;
      2010   -   EUCTR2010-021860-13-LT   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
      2010   -   EUCTR2010-021860-13-HU   Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain;
   BIAL Portela & Cª, S.A.
      2011   Phase 3   EUCTR2010-022366-27-GB   Argentina;Australia;Belgium;Chile;Czech Republic;Estonia;India;Israel;Korea, Republic of;Russian Federation;South Africa;United Kingdom;
      2011   Phase 3   EUCTR2010-022366-27-BE   Belgium;Czech Republic;Estonia;United Kingdom;
      2011   -   EUCTR2010-022366-27-CZ   Argentina;Australia;Belgium;Chile;Czech Republic;Estonia;India;Israel;Korea, Republic of;Russian Federation;South Africa;United Kingdom;
      2010   -   EUCTR2010-022366-27-EE   Belgium;Czech Republic;Estonia;United Kingdom;
   BIAL – Portela & Cª, S.A.
      2021   Phase 3   EUCTR2020-005011-52-PT   Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom;
      2021   Phase 3   EUCTR2020-005011-52-FR   Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom;
      2021   Phase 3   EUCTR2020-005011-52-CZ   Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom;
      2021   Phase 3   EUCTR2020-005011-52-BG   Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom;
      2021   Phase 3   EUCTR2020-005011-52-BE   Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom;
   BIAL-Portela & Ca, S.A.
      2021   Phase 4   EUCTR2020-002754-24-IT   Germany;Italy;Portugal;Spain;United Kingdom;
      2021   Phase 3   EUCTR2020-005011-52-IT   Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom;
      2020   Phase 4   EUCTR2020-001175-32-IT   Germany;Italy;Portugal;Spain;United Kingdom;
   BIAL-Portela & Ca, SA
      2009   -   EUCTR2009-012897-12-RO   Romania;
   Bial - Portela & Cª, S.A.
      2008   -   EUCTR2008-003869-72-PT   Portugal;
   Bial - Portela C S.A.
      2016   Phase 4   NCT02847442   Germany;
      2014   Phase 1   NCT02305030   -
      2014   Phase 1   NCT02305017   -
      2011   Phase 3   NCT01568073   Austria;Portugal;
      2011   Phase 3   NCT01227655   Portugal;
      2011   Phase 1   NCT02170376   France;
      2011   Phase 1   NCT01520987   United States;
      2010   Phase 2   NCT01568047   Romania;Ukraine;
      2010   Phase 1   NCT02169414   France;
      2010   Phase 1   NCT02101190   France;Russian Federation;
      2010   Phase 1   NCT01532115   France;
      2009   Phase 2   NCT01568034   Portugal;Romania;Ukraine;
      2009   Phase 1   NCT02169466   Portugal;
      2009   Phase 1   NCT02169440   Portugal;
      2009   Phase 1   NCT01536366   Portugal;
      2009   Phase 1   NCT01533116   Canada;
      2009   Phase 1   NCT01533077   Canada;
      2009   Phase 1   NCT01532141   France;
      2009   Phase 1   NCT01532128   France;
      2009   Phase 1   NCT01519284   Portugal;
      2009   Phase 1   NCT01515891   Switzerland;
      2008   Phase 1   NCT02169895   Canada;
      2008   Phase 1   NCT02169479   Canada;
      2008   Phase 1   NCT02169453   Canada;
      2008   Phase 1   NCT02092168   France;
      2008   Phase 1   NCT02071810   France;
      2007   Phase 1   NCT01520727   France;
BIA 9-1067 (test)   
   Bial - Portela C S.A.
      2019   Phase 1   NCT03820037   United Kingdom;
BIA 9-1067 micronized   
   Bial - Portela C S.A.
      2014   Phase 1   NCT02305316   -
BIA 9-1067 non-micronized   
   Bial - Portela C S.A.
      2014   Phase 1   NCT02305316   -
BIA9 1067   
   Bial - Portela C S.A.
      2018   Phase 1   NCT04265027   United Kingdom;
BIIB014   
   BIOGEN IDEC LTD
      2006   Phase 2   EUCTR2006-003490-27-GB   United Kingdom;
   Biogen Idec
      2007   Phase 2   NCT00442780   Former Serbia and Montenegro;Israel;Poland;Serbia;
      2007   Phase 2   NCT00438607   India;Israel;United Kingdom;
BIIB054   
   BIOGEN IDEC RESEARCH LIMITED
      2018   Phase 2   EUCTR2016-004610-95-IT   Australia;Austria;Canada;France;Germany;Israel;Italy;Spain;Sweden;United Kingdom;United States;
   Biogen
      2019   Phase 1   NCT03716570   Japan;
      2018   Phase 2   NCT03318523   Austria;Canada;France;Germany;Israel;Italy;Spain;United Kingdom;United States;
      2015   Phase 1   NCT02459886   United States;
   Biogen Idec Research Limited
      2018   Phase 2   EUCTR2016-004610-95-GB   Austria;Canada;France;Germany;Israel;Italy;Spain;United Kingdom;United States;
      2018   Phase 2   EUCTR2016-004610-95-FR   Austria;Canada;France;Germany;Israel;Italy;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2016-004610-95-ES   Austria;Canada;France;Germany;Israel;Italy;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2016-004610-95-DE   Austria;Canada;France;Germany;Israel;Italy;Spain;United Kingdom;United States;
      2018   Phase 2   EUCTR2016-004610-95-AT   Austria;Canada;France;Germany;Israel;Italy;Spain;United Kingdom;United States;
BIIB094   
   Biogen
      2019   Phase 1   NCT03976349   Canada;Israel;Norway;Spain;United Kingdom;United States;
BT   
   University of Valencia
      2020   -   NCT04353947   Spain;
BTRX-246040   
   BlackThorn Therapeutics, Inc.
      2018   Phase 2   NCT03608371   United States;
BTX-A   
   Shanghai Tongji Hospital, Tongji University
      2017   -   ChiCTR-INR-17012013   China;
Balance   
   Affiliated Lianyungang Hospital of Xuzhou Medical University
      2017   -   ChiCTR-IPR-17011875   China;
   Ankara Yildirim Beyazit University
      2019   -   NCT04420910   Turkey;
   Boston University Charles River Campus
      2011   -   NCT02302144   United States;
   Domen Kazuhisa
      2018   -   JPRN-jRCTs052180158   Japan;
   Gansu Provincial Hospital
      2020   Phase 0   ChiCTR2000035872   China;
   Gazi University
      2018   -   NCT03587168   Turkey;
   Hyogo College of Medicine
      2018   -   JPRN-UMIN000033454   Japan;
   Istanbul Kültür University
      2018   -   NCT03827746   Turkey;
   Juntendo University
      2015   -   JPRN-UMIN000016591   Japan;
   Karolinska Institutet
      2010   -   NCT01417598   Sweden;
   National Taiwan University Hospital
      2007   Phase 1   NCT01301651   Taiwan;
   Rehabilitation Institute of Chicago
      2010   -   NCT01228851   United States;
   Sage Bionetworks
      2015   -   NCT02696603   United States;
   Shanghai Tongji Hospital
      2014   -   ChiCTR-TRC-14004707   China;
   Shanghai University of Sport
      2020   -   ChiCTR2000038852   china;
   The Hong Kong Polytechnic University
      2021   -   NCT04665869   Hong Kong;
      2018   -   NCT04048291   Hong Kong;
   Tianjin Huanhu Hospital
      2019   -   ChiCTR1900022715   China;
   Tsinghua University Yuquan Hospital
      2019   Phase 0   ChiCTR1900027210   China;
   University Hospital, Basel, Switzerland
      2016   -   NCT02935842   Switzerland;
   University of California, San Francisco
      2010   Phase 2   NCT01162226   United States;
   University of Houston
      2019   -   NCT04146454   United States;
   University of Kiel
      2011   -   NCT02253563   -
   University of Manitoba
      2017   -   NCT03232996   Canada;
   University of Nevada, Las Vegas
      2014   Phase 2   NCT02230267   United States;
   University of Pavia
      2014   -   NCT03314597   -
   University of Sao Paulo General Hospital
      2015   -   NCT02488265   Brazil;
   University of Valencia
      2021   -   NCT04963894   Spain;
   University of Vigo
      2018   -   NCT03882398   Spain;
   Xianhui Feng
      2020   Phase 0   ChiCTR2000034323   China;
   Yeditepe University
      2021   -   NCT04694872   Turkey;
Balance Training   
   Bezmialem Vakif University
      2018   -   NCT04228887   Turkey;
Balance Training with Nintendo Wii Fit   
   Sao Camilo University Center
      2009   -   NCT01580787   -
Bavisant dihydrochloride monohydrate   
   BENEVOLENTAI BIO
      2017   Phase 2   EUCTR2017-000877-35-IT   Czech Republic;Czechia;Germany;Italy;Poland;Spain;United Kingdom;United States;
   BenevolentAI Bio
      2017   Phase 2   EUCTR2017-000877-35-GB   Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-000877-35-ES   Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-000877-35-DE   Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-000877-35-CZ   Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
Beam   
   University Medical Center Groningen
      2018   -   NCT03532984   Brazil;Germany;Hungary;Japan;Netherlands;
Bee venom   
   Assistance Publique - Hôpitaux de Paris
      2011   Phase 2   NCT01341431   France;
Benserazide   
   Bial - Portela C S.A.
      2011   Phase 3   NCT01568073   Austria;Portugal;
      2011   Phase 3   NCT01227655   Portugal;
   First Affiliated Hospital of Xinjiang Medical University
      2007   -   ChiCTR-TRC-07000027   China;
   The Affiliated Brain Hospital of Nanjing Medical University (Nanjing Brain Hospital)
      2020   Phase 4   ChiCTR2000039201   China;
Berachin   
   CuraSen Therapeutics, Inc.
      2020   Phase 2   EUCTR2020-003796-17-GB   United Kingdom;
Best Medical Treatment   
   German Parkinson Study Group (GPS)
      2006   Phase 4   NCT00354133   France;Germany;
Best médical treatment   
   Poitiers University Hospital
      2011   Phase 2   NCT01291537   France;
Betaquik MCT supplement   
   Université de Sherbrooke
      2021   -   NCT04322461   -
Better   
   University of California, San Francisco
      2020   -   NCT04428112   United States;
Biofluid samplings   
   Michael J. Fox Foundation for Parkinson's Research
      2015   -   NCT02572713   Canada;United States;
Biological/Vaccine: Allogeneic HB-adMSCs   
   Hope Biosciences Stem Cell Research Foundation
      2021   Phase 2   NCT04995081   United States;
Bisphosphonates   
   FONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE
      2010   -   EUCTR2010-018904-94-IT   Italy;
Blood analysis   
   University Hospital, Strasbourg, France
      2020   Phase 2   NCT03947216   France;
Blood draw   
   Howard Gendelman, MD
      2013   Phase 1   NCT01882010   United States;
BoNT-A   
   Western University, Canada
      2011   Phase 2   NCT02427646   -
Bone marrow derived mesenchymal stem cells   
   Guangzhou General Hospital of Guangzhou Military Command
      2011   Phase 1/Phase 2   NCT01446614   China;
Botulinum Toxin   
   University Health Network, Toronto
      2014   Phase 4   NCT02472210   -
Botulinum Toxin Type B (Myobloc)   
   Solstice Neurosciences
      2007   Phase 2   NCT00515437   United States;
Botulinum Toxin: Xeomin   
   University Hospital, Clermont-Ferrand
      2009   Phase 3   NCT00909883   France;
Botulinum toxin   
   AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
      2011   -   EUCTR2009-017412-32-IT   Italy;
   Rabin Medical Center
      2009   Phase 1   NCT00767546   -
Botulinum toxin type A   
   University of Calgary
      2020   Phase 2/Phase 3   NCT04277247   Canada;
Bromocriptine   
   Boehringer Ingelheim
      2003   Phase 3   NCT00240409   China;
      1999   Phase 3   NCT02172573   -
   Sandoz
      2012   Phase 4   NCT01673724   Korea, Republic of;
Bromocriptine and other dopamine agonists   
   Boehringer Ingelheim
      1998   Phase 4   NCT02233023   -
Bumetanide white, oblong, scored tablet   
   B&A Therapeutics
      2019   Phase 2   NCT03899324   France;
Bupleurum+Ginkgo   
   Xuanwu Hospital, Beijing
      2008   Phase 2   NCT01416818   China;
Buspirone   
   Oregon Health and Science University
      2016   Phase 1   NCT02589340   United States;
   University of Rochester
      2016   Phase 2   NCT02803749   United States;
Buspirone Hydrochloride   
   Imperial College London-Imperial College Healthcare NHS Trust
      2015   Phase 4   EUCTR2014-005422-35-GB   United Kingdom;
Buspirone hydrochloride   
   Contera Pharma
      2020   Phase 2   EUCTR2017-003415-19-IT   France;Germany;Italy;Spain;
      2018   Phase 2   EUCTR2017-003415-19-ES   France;Germany;Spain;
Butylphthalide   
   The Second Affiliated Hospital of Soochow University
      2016   -   ChiCTR-IPR-16009395   China;
   Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
      2018   Phase 4   ChiCTR1800017084   China;
   Zhujiang Hospital of Southern Medical University
      2019   Phase 0   ChiCTR1900023725   China;
Bydureon   
   University College London
      2014   Phase 2   EUCTR2013-003363-64-GB   United Kingdom;
   University College London Comprehensive Clinical Trial Unit
      2019   Phase 3   EUCTR2018-003028-35-GB   United Kingdom;
Bydureon 2 mg powder and solvent for prolonged-release suspension   
   Stockholm Health Care Services
      2019   Phase 2   EUCTR2019-000732-26-SE   Sweden;
Byetta 5 micrograms   
   University College London
      2010   Phase 2   EUCTR2009-018137-37-GB   United Kingdom;
CADD-Legacy ambulatory infusion pump   
   AbbVie
      2017   Phase 3   NCT02799381   Finland;Greece;Hungary;Italy;Slovakia;Spain;United States;
CADD-Legacy® 1400 ambulatory infusion pump   
   AbbVie
      2013   Phase 3   NCT01960842   Japan;Korea, Republic of;Taiwan;
      2009   Phase 3   NCT00660673   Australia;Canada;Czech Republic;Czechia;Israel;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;United States;
   AbbVie (prior sponsor, Abbott)
      2009   Phase 3   NCT00660387   New Zealand;United States;
      2009   Phase 3   NCT00360568   Germany;New Zealand;United States;
      2009   Phase 3   NCT00357994   Germany;United States;
      2008   Phase 3   NCT00335153   Australia;Canada;Czech Republic;Finland;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2006   Phase 4   NCT00141518   Norway;Sweden;
CAPTURE   
   Westfälische Wilhelms-Universität Münster
      2019   -   NCT03638479   Germany;
CARBIDOPA (CD)   
   NEURODERM LTD.
      2016   Phase 2   EUCTR2015-005814-31-IT   Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States;
CARBIDOPA (FU)   
   NOVARTIS FARMA
      2004   -   EUCTR2004-000185-12-IT   Finland;Italy;Sweden;United Kingdom;
CARBIDOPA ANIDRA   
   NOVARTIS FARMA
      2005   -   EUCTR2005-001032-72-IT   Czech Republic;Italy;Portugal;
CARBIDOPA FU   
   VERNALIS DEVELOPMENT LIMITED
      2006   -   EUCTR2006-004112-51-IT   Italy;
CARBIDOPA INN   
   NOVARTIS FARMA
      2005   -   EUCTR2005-001032-72-IT   Czech Republic;Italy;Portugal;
CARBIDOPA LEVODOPA   
   IMPAX LABORATORIES, INC.
      2010   -   EUCTR2009-017238-39-IT   France;Germany;Italy;
CARBIDOPA MONOHYDRATE   
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2016   Phase 3   EUCTR2016-001403-23-IT   European Union;Finland;Greece;Hungary;Italy;Slovakia;Spain;United States;
   AbbVie Deutschland GmbH & Co. KG
      2018   Phase 3   EUCTR2016-001403-23-HU   European Union;Finland;Greece;Hungary;Slovakia;Spain;United States;
      2017   Phase 3   EUCTR2016-001403-23-GR   European Union;Finland;Greece;Hungary;Slovakia;Spain;United States;
      2017   Phase 3   EUCTR2016-001403-23-FI   European Union;Finland;Greece;Hungary;Slovakia;Spain;United States;
      2017   Phase 3   EUCTR2014-004865-26-GR   Australia;Canada;European Union;Germany;Greece;Italy;Spain;Sweden;United States;
      2016   Phase 3   EUCTR2016-001403-23-SK   European Union;Finland;Greece;Hungary;Slovakia;Spain;United States;
      2016   Phase 3   EUCTR2016-001403-23-ES   European Union;Finland;Greece;Hungary;Slovakia;Spain;United States;
      2015   Phase 3   EUCTR2014-004865-26-SE   Australia;Canada;European Union;Germany;Greece;Italy;Spain;Sweden;United States;
      2015   Phase 3   EUCTR2014-004865-26-ES   Australia;Canada;European Union;Germany;Greece;Italy;Spain;Sweden;
      2015   Phase 3   EUCTR2014-004865-26-DE   Australia;Canada;European Union;Germany;Italy;Spain;Sweden;
      2015   -   EUCTR2014-004865-26-IT   Australia;Canada;European Union;Germany;Italy;Spain;Sweden;
   Centre for Human Drug Research
      2020   Phase 2   EUCTR2020-000686-16-NL   Netherlands;
   Civitas Therapeutics, Inc.
      2012   -   EUCTR2012-000181-37-GB   Israel;Serbia;United Kingdom;
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2010   -   EUCTR2009-017416-33-DE   Germany;
   Novartis Pharma Services AG
      2008   -   EUCTR2007-003134-42-DE   Germany;
CARBODOPA LEVADOPA   
   Institute for Neurodegenerative Disorders
      2005   -   EUCTR2004-001485-41-ES   Spain;United Kingdom;
CD   
   Yagi Michio
      2021   Phase 1   JPRN-jRCT2051200104   Japan;
CD-LD CR   
   Impax Laboratories, LLC
      2006   Phase 2   NCT00279825   United States;
CD-LD IR   
   Impax Laboratories, LLC
      2015   Phase 2   NCT02271503   United States;
      2006   Phase 2   NCT00279825   United States;
      2005   Phase 2   NCT00253084   United States;
CDNF   
   Herantis Pharma Plc
      2018   Phase 1;Phase 2   EUCTR2018-000346-19-SE   Finland;Sweden;
      2018   Phase 1;Phase 2   EUCTR2018-000346-19-FI   Finland;Sweden;
      2017   Phase 1;Phase 2   EUCTR2015-004175-73-FI   Finland;
   Renishaw Neuro Solutions Ltd.
      2019   Phase 1;Phase 2   EUCTR2017-005170-19-FI   Finland;Sweden;
      2018   Phase 1;Phase 2   EUCTR2017-005170-19-SE   Finland;Sweden;
CEP-1347   
   Cephalon
      2002   Phase 2/Phase 3   NCT00040404   Canada;Puerto Rico;United States;
CEP1347   
   Cephalon
      2002   Phase 2/Phase 3   NCT00040404   Canada;Puerto Rico;United States;
CERE-120   
   Ceregene Inc.
      2008   -   EUCTR2007-006721-27-GB   United Kingdom;
      2008   -   EUCTR2007-006721-27-AT   Austria;United Kingdom;
CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])   
   Ceregene
      2006   Phase 2   NCT00400634   United States;
CERE-120: Adeno-Associated Virus Delivery of Neurturin   
   Sangamo Therapeutics
      2009   Phase 1/Phase 2   NCT00985517   United States;
CERETEC (TM) Estabilizado   
   IDIBAPS
      2016   Phase 2   EUCTR2015-004238-85-ES   Spain;
CITICOLIN*1G/4ML IM IV 5 F   
   PIAM FARMACEUTICI S.P.A.
      2016   Phase 4   EUCTR2014-005562-30-IT   Italy;
CITICOLINA SODICA   
   PIAM FARMACEUTICI S.P.A.
      2016   Phase 4   EUCTR2014-005562-30-IT   Italy;
CJH1 (CLR4001)   
   Alexandra Marine and General Hospital
      2012   Phase 1/Phase 2   NCT01684475   Canada;
CLE   
   Impax Laboratories, LLC
      2010   Phase 3   NCT01130493   France;Germany;Italy;United States;
CLENBUTEROL HYDROCHLORIDE   
   CuraSen Therapeutics, Inc.
      2020   Phase 2   EUCTR2020-003796-17-GB   United Kingdom;
CO   
   University of Manitoba
      2014   -   NCT02007785   Canada;
COMTAN   
   AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELE
      2010   -   EUCTR2010-019396-29-IT   Italy;
   IMPAX LABORATORIES, INC.
      2010   -   EUCTR2009-017238-39-IT   France;Germany;Italy;
COMTAN 200* 60 CPR   
   KYOWA HAKKO UK LTD
      2005   -   EUCTR2004-000817-20-IT   Italy;Latvia;Lithuania;Spain;
COMTAN®   
   BIAL - Portela & Cª, SA
      2006   -   EUCTR2006-001793-24-PT   Austria;Portugal;
CP   
   Nagai Masahiro
      2016   Phase 2   JPRN-jRCTs061180060   Japan;
CPL500036   
   Celon Pharma S.A.
      2021   Phase 2   EUCTR2020-006004-16-PL   Poland;
CST-103   
   CuraSen Therapeutics, Inc.
      2020   Phase 2   EUCTR2020-003796-17-GB   United Kingdom;
      -   Phase 2   EUCTR2020-006067-28-BE   Australia;Belgium;New Zealand;United Kingdom;
CST-107   
   CuraSen Therapeutics, Inc.
      -   Phase 2   EUCTR2020-006067-28-BE   Australia;Belgium;New Zealand;United Kingdom;
CST-139   
   CuraSen Therapeutics, Inc.
      2020   Phase 2   EUCTR2020-003796-17-GB   United Kingdom;
CVD00118-E   
   PREXTON THERAPEUTICS B.V.
      2017   Phase 2   EUCTR2017-000135-14-IT   Austria;France;Germany;Italy;Spain;United Kingdom;
   Prexton Therapeutics B.V.
      2017   Phase 2   EUCTR2017-000135-14-GB   Austria;Germany;Spain;United Kingdom;
      2017   Phase 2   EUCTR2017-000135-14-ES   Austria;Germany;Italy;Spain;United Kingdom;
      2017   Phase 2   EUCTR2017-000135-14-DE   Austria;Germany;Italy;Spain;United Kingdom;
      2017   Phase 2   EUCTR2017-000135-14-AT   Austria;Germany;Spain;United Kingdom;
CVL-751   
   Cerevel Therapeutics LLC
      2021   Phase 3   EUCTR2019-002952-17-IT   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
      2020   Phase 3   EUCTR2019-002951-40-IT   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
      2020   Phase 3   EUCTR2019-002950-22-IT   Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
      2020   Phase 3   EUCTR2019-002949-38-IT   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
   Cerevel Therapeutics, LLC
      2021   Phase 3   EUCTR2019-002952-17-DE   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
      2021   Phase 3   EUCTR2019-002952-17-BG   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
      2021   Phase 3   EUCTR2019-002951-40-BG   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
      2021   Phase 3   EUCTR2019-002949-38-BG   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United States;
      2020   Phase 3   EUCTR2019-002952-17-HU   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
      2020   Phase 3   EUCTR2019-002952-17-CZ   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
      2020   Phase 3   EUCTR2019-002951-40-HU   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
      2020   Phase 3   EUCTR2019-002951-40-ES   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
      2020   Phase 3   EUCTR2019-002951-40-DE   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
      2020   Phase 3   EUCTR2019-002951-40-CZ   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
      2020   Phase 3   EUCTR2019-002950-22-HU   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
      2020   Phase 3   EUCTR2019-002949-38-PL   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
      2020   Phase 3   EUCTR2019-002949-38-HU   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
      2020   Phase 3   EUCTR2019-002949-38-ES   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
      2020   Phase 3   EUCTR2019-002949-38-DE   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
      2020   Phase 3   EUCTR2019-002949-38-CZ   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United States;
      2020   Phase 1   NCT04295642   United States;
CVN424 High Dose   
   Cerevance Beta, Inc.
      2019   Phase 2   NCT04191577   United States;
CVN424 Low Dose   
   Cerevance Beta, Inc.
      2019   Phase 2   NCT04191577   United States;
CVT-301   
   Acorda Therapeutics
      2019   Phase 1   NCT03887884   United States;
      2015   Phase 3   NCT02352363   Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
      2015   Phase 3   NCT02242487   Canada;Czech Republic;Czechia;Poland;Spain;United States;
      2013   Phase 2   NCT01777555   Italy;Serbia;United Kingdom;United States;
      2012   Phase 2   NCT01617135   Israel;Serbia;United Kingdom;
   Civitas Therapeutics, Inc.
      2016   Phase 3   EUCTR2015-005626-19-CZ   Canada;Czech Republic;Poland;Spain;United States;
      2016   Phase 3   EUCTR2015-005067-17-CZ   Canada;Czech Republic;Poland;Spain;United States;
      2015   Phase 3   EUCTR2014-003799-22-HU   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom;
      2015   Phase 3   EUCTR2014-003799-22-GB   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003799-22-ES   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom;
      2015   Phase 3   EUCTR2014-003799-22-DE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003799-22-CZ   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003799-22-BE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-003799-22-AT   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom;United States;
      2013   -   EUCTR2012-005822-31-IT   Italy;Serbia;United Kingdom;United States;
      2013   -   EUCTR2012-005822-31-GB   Italy;Serbia;United Kingdom;United States;
      2012   -   EUCTR2012-000181-37-GB   Israel;Serbia;United Kingdom;
   Civitas Therapeutics, a wholly owned subsidiary of Acorda
      2016   Phase 3   EUCTR2015-005626-19-ES   Canada;Czech Republic;Poland;Spain;United States;
   Civitas Therapeutics, a wholly owned subsidiary of Acorda Therapeutics, Inc.
      2016   Phase 3   EUCTR2015-005067-17-ES   Canada;Czech Republic;Poland;Spain;United States;
CVT-301 (Dose Level 1)   
   Acorda Therapeutics
      2016   Phase 1   NCT02812394   United States;
CVT-301 (Dose Level 2)   
   Acorda Therapeutics
      2016   Phase 1   NCT02812394   United States;
CVT-301 High Dose   
   Acorda Therapeutics
      2014   Phase 3   NCT02240030   Canada;Czech Republic;Czechia;Poland;Spain;United States;
CVT-301 Low Dose   
   Acorda Therapeutics
      2014   Phase 3   NCT02240030   Canada;Czech Republic;Czechia;Poland;Spain;United States;
CVT-301, LIP   
   Acorda Therapeutics
      2016   Phase 1   NCT02807675   United States;
CVXL-0107   
   CleveXel Pharma
      2016   Phase 2   NCT02641054   France;
CX-8998   
   Jazz Pharmaceuticals
      2019   Phase 2   NCT03436953   United States;
CYMBALTA   
   CHU de Toulouse
      2010   Phase 3   EUCTR2010-018650-12-FR   France;
Cabaser   
   Institute for Neurodegenerative Disorders
      2005   -   EUCTR2004-001485-41-GB   Spain;United Kingdom;
Cabaseril   
   Institute for Neurodegenerative Disorders
      2005   -   EUCTR2004-001485-41-GB   Spain;United Kingdom;
      2005   -   EUCTR2004-001485-41-AT   Austria;Spain;United Kingdom;
Cabaseril, 1,0 mg Tablette   
   Axxonis Pharma GmbH
      2006   -   EUCTR2005-001006-12-AT   Austria;Czech Republic;Germany;Italy;
Cabaseril, 2,0 mg Tablette   
   Axxonis Pharma GmbH
      2006   -   EUCTR2005-001006-12-AT   Austria;Czech Republic;Germany;Italy;
Cabergoline   
   Axxonis Pharma GmbH
      2006   -   EUCTR2005-001006-12-DE   Austria;Czech Republic;Germany;Italy;
      2006   -   EUCTR2005-001006-12-CZ   Austria;Czech Republic;Germany;Italy;
      2006   -   EUCTR2005-001006-12-AT   Austria;Czech Republic;Germany;Italy;
   Institute for Neurodegenerative Disorders
      2005   -   NCT00129181   Austria;Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-001485-41-GB   Spain;United Kingdom;
      2005   -   EUCTR2004-001485-41-ES   Spain;United Kingdom;
      2005   -   EUCTR2004-001485-41-AT   Austria;Spain;United Kingdom;
   Pfizer
      2004   Phase 4   NCT00174239   Australia;Italy;Spain;United Kingdom;
   Technische Universität Dresden
      2005   Phase 4   NCT00153972   Germany;
Caffeine   
   Department of Neurology, Juntendo University
      2016   -   JPRN-UMIN000022187   Japan;
   Kyowa Kirin Co., Ltd.
      2019   Phase 1   NCT03970798   Japan;
   McGill University Health Center
      2014   Phase 3   NCT01738178   Brazil;Canada;
Caffeine 100-200 mg BID   
   Ron Postuma
      2007   Phase 2/Phase 3   NCT00459420   Canada;
Caffeine alkaloid   
   Ron Postuma
      2010   Phase 2   NCT01190735   Canada;
Calcium   
   VA Office of Research and Development
      2011   Phase 2   NCT01119131   United States;
Cannabidiol   
   University of Colorado, Denver
      2018   Phase 2   NCT03582137   United States;
      2016   Phase 2   NCT02818777   United States;
Cannabidiol (CBD)   
   King's College London
      2020   Phase 2   EUCTR2019-003623-37-GB   United Kingdom;
Cannabis Oil   
   University Health Network, Toronto
      2018   Phase 2   NCT03639064   -
Cannabis, Medical   
   OMNI Medical Services, LLC
      2018   Phase 2   NCT03944447   United States;
Capsaicin   
   University of Florida
      2017   -   NCT03321019   United States;
      2014   Phase 1/Phase 2   NCT02183519   United States;
Capsaicin vapor   
   University of Florida
      2015   Phase 1   NCT02390089   United States;
Capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)   
   Novartis
      2005   Phase 3   NCT00134966   Canada;Czech Republic;Czechia;Israel;Italy;Poland;Portugal;Turkey;United States;
Carbidopa   
   BIAL-Portela & Ca, S.A.
      2021   Phase 4   EUCTR2020-002754-24-IT   Germany;Italy;Portugal;Spain;United Kingdom;
   Bial - Portela C S.A.
      2011   Phase 3   NCT01568073   Austria;Portugal;
      2011   Phase 3   NCT01227655   Portugal;
   Department of Neuroscience, neurology
      2007   -   EUCTR2007-004985-41-SE   Sweden;
   Dept of Neuroscience, Uppsala University
      2008   -   EUCTR2008-003581-26-SE   Sweden;
   Fujita Health University School of MedicineDepartment of Gastroenterology
      2020   Phase 4   JPRN-UMIN000040889   Japan;
   Juntendo University School of Medicine
      2017   -   JPRN-UMIN000025645   Japan;
   Kansai Medical University
      2012   -   JPRN-UMIN000007896   Japan;
   Kyoto University
      2017   Phase 1,2   JPRN-UMIN000030084   Japan;
   Merck Sharp & Dohme Corp.
      2009   Phase 1   NCT00845000   United States;
   National Institute of Neurological Disorders and Stroke (NINDS)
      2007   Phase 1/Phase 2   NCT00547911   United States;
   NeuroDerm Ltd.
      2011   Phase 1/Phase 2   NCT01229332   Israel;
   Oregon Health and Science University
      2009   Phase 2   NCT01399905   United States;
   Orion Corporation Orion Pharma
      2007   -   EUCTR2007-002496-14-FI   Finland;
      2006   Phase 4   EUCTR2006-001755-36-GB   Germany;Sweden;United Kingdom;
      -   -   EUCTR2006-001755-36-DE   Germany;Sweden;United Kingdom;
   Orion Corporation Orion Pharma, FI-02200 Espoo, Finland
      2006   -   EUCTR2006-001755-36-SE   Germany;Sweden;United Kingdom;
   Orion Corporation, ORION PHARMA
      2005   -   EUCTR2004-005234-39-FI   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2004   -   EUCTR2004-000185-12-FI   Finland;Italy;Sweden;United Kingdom;
   Orion Corporation, ORION PHARMA, Finland
      2005   Phase 4   EUCTR2004-005234-39-GB   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
   Orion Corporation, ORION PHARMA, 02200 Espoo, Finland
      2008   -   EUCTR2004-005234-39-DE   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2004-000185-12-GB   Austria;Finland;Italy;Sweden;United Kingdom;
      2006   -   EUCTR2004-005234-39-LV   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2006   -   EUCTR2004-005234-39-LT   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2005   Phase 4   EUCTR2004-005234-39-IE   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2005   -   EUCTR2004-005234-39-SE   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2005   -   EUCTR2004-005234-39-DK   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2004   -   EUCTR2004-000185-12-SE   Finland;Italy;Sweden;United Kingdom;
      2004   -   EUCTR2004-000185-12-AT   Austria;Finland;Italy;Sweden;United Kingdom;
   Orion Corporation, Orion Pharma
      2011   Phase 2   NCT01296464   Finland;Sweden;
   Solvay Pharmaceuticals BV.
      2008   -   EUCTR2006-005186-18-IT   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
   Solvay Pharmaceuticals GmbH
      2006   -   EUCTR2005-002654-21-NO   Norway;Sweden;
      2005   -   EUCTR2005-002654-21-SE   Sweden;
   The Affiliated Brain Hospital of Nanjing Medical University (Nanjing Brain Hospital)
      2020   Phase 4   ChiCTR2000039201   China;
   Vanderbilt University Medical Center
      2017   Phase 4   NCT03115827   United States;
   Yagi Michio
      2021   Phase 1   JPRN-jRCT2051200104   Japan;
Carbidopa 200mg oral dose   
   Daniel Claassen
      2020   Phase 1   NCT04246437   United States;
Carbidopa 65 mg capsule   
   Orion Corporation
      2017   Phase 2   EUCTR2015-004507-23-HU   Finland;Germany;Hungary;Latvia;
      2017   Phase 2   EUCTR2015-004507-23-FI   Finland;Germany;Hungary;Latvia;
      2016   Phase 2   EUCTR2015-004507-23-LV   Finland;Germany;Hungary;Latvia;
      2016   Phase 2   EUCTR2015-004507-23-DE   Finland;Germany;Hungary;Latvia;
Carbidopa Levodopa   
   Neurocrine Biosciences
      2018   Phase 1   NCT03496870   United States;
Carbidopa Monohydrate   
   Abbott Healthcare Products B.V.
      2009   -   EUCTR2006-005186-18-CZ   Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2008   Phase 3   EUCTR2006-005186-18-GB   Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2008   -   EUCTR2006-005186-18-PT   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2006-005186-18-DE   Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
   Abbott Laboratories
      2009   -   EUCTR2006-000578-53-DE   Germany;New Zealand;United States;
   Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
      2007   -   EUCTR2006-000577-29-DE   Germany;United States;
   Solvay Pharmaceuticals B.V.
      2009   -   EUCTR2006-005186-18-NL   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   Phase 3   EUCTR2006-005186-18-ES   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2007   -   EUCTR2006-005186-18-FI   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
Carbidopa Pill   
   XenoPort, Inc.
      2009   Phase 1/Phase 2   NCT00914602   United States;
Carbidopa and Levodopa 25mg/   
   NeuroDerm Ltd.
      2019   Phase 3   NCT04006210   Austria;Belgium;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
Carbidopa and Levodopa Controlled Release Tablets   
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2022   Phase 4   NCT04952194   -
Carbidopa and Levodopa Tablets, USP   
   Impax Laboratories, LLC
      2020   Phase 3   EUCTR2018-002233-37-PL   Canada;Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002233-37-IT   Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002233-37-GB   Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002233-37-DE   Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002233-37-CZ   Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
Carbidopa and Levodopa tablets, USP   
   NEURODERM LTD.
      2020   Phase 3   EUCTR2018-004156-37-IT   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
   NeuroDerm Ltd.
      2020   Phase 3   EUCTR2018-004156-37-SK   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004156-37-SE   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004156-37-PT   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004156-37-NL   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004156-37-GB   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004156-37-ES   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004156-37-BE   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004156-37-AT   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004156-37-HU   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004156-37-CZ   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
Carbidopa monohydrate   
   AbbVie Inc
      2011   Phase 3   EUCTR2008-001329-33-GB   Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
      2010   Phase 3   EUCTR2008-001329-33-CZ   Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
      2009   -   EUCTR2008-001329-33-PT   Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
Carbidopa, levodopa, entacapone   
   Novartis
      2005   Phase 4   NCT00143026   Australia;Philippines;Taiwan;Thailand;
Carbidopa- Levodopa   
   Oregon Health and Science University
      2008   Phase 2   NCT00745277   United States;
Carbidopa-4'-Monophosphate   
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2019   Phase 3   EUCTR2018-002144-85-IT   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
   AbbVie Deutschland
      2020   Phase 3   EUCTR2018-002144-85-DE   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002144-85-NL   Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002144-85-GB   Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002144-85-ES   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002144-85-DK   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002144-85-BE   Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
   Abbvie Deutschland GmbH & Co. KG
      2021   Phase 3   EUCTR2019-004235-23-SE   Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-004235-23-DE   Australia;Canada;Germany;Italy;Japan;Netherlands;Russian Federation;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004235-23-NL   Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004235-23-GB   Australia;Canada;Japan;Russian Federation;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004235-23-DK   Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
Carbidopa-Levodopa   
   Northwestern University
      2011   -   NCT01528592   United States;
   Oregon Health and Science University
      2008   Phase 2   NCT00745277   United States;
Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet   
   Western University, Canada
      2021   -   NCT04590612   -
Carbidopa-levodopa   
   Baylor College of Medicine
      2006   Phase 4   NCT00590122   United States;
Carbidopa/Levodopa, immediate release   
   Intec Pharma Ltd.
      2009   Phase 2   NCT00918177   Israel;
Carbidopa/Levodopa/Entacapone   
   Novartis Pharmaceuticals
      2008   Phase 4   NCT00601978   United States;
Carbidopa/l-dopa/entacapone   
   Molecular NeuroImaging
      2004   Phase 2   NCT00200447   -
Carbidopa/levodopa   
   Institute for Neurodegenerative Disorders
      2005   -   NCT00129181   Austria;Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-001485-41-GB   Spain;United Kingdom;
      2005   -   EUCTR2004-001485-41-AT   Austria;Spain;United Kingdom;
Carbidopa/levodopa, as prescribed by treating physician   
   University of Michigan
      2020   -   NCT04821830   United States;
Carbidopa/levodopa/entacapone   
   Novartis
      2008   Phase 4   NCT00642356   United States;
   Novartis Pharmaceuticals
      2005   Phase 4   NCT00219284   Puerto Rico;United States;
      2004   Phase 3   NCT00099268   Austria;Belgium;Canada;Finland;France;Germany;Greece;Italy;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
Carbidopamonohydraat   
   Centre for Human Drug Research
      2020   Phase 2   EUCTR2020-000686-16-NL   Netherlands;
Carbodopa/levadopa   
   Institute for Neurodegenerative Disorders
      2005   -   EUCTR2004-001485-41-ES   Spain;United Kingdom;
Carbon Fiber Ankle Foot Orthosis (AFO)   
   University of Texas Southwestern Medical Center
      2016   -   NCT03192046   United States;
Carbon-14 BIA 28-6156   
   Bial R&D Investments, S.A.
      2021   Phase 1   NCT05220072   United Kingdom;
Cardiac monitoring   
   University Hospital, Strasbourg, France
      2020   Phase 2   NCT03947216   France;
Carnosine supplementation   
   Slovak Academy of Sciences
      2017   -   NCT03330470   Slovakia;Taiwan;
Carvedilol   
   Cedars-Sinai Medical Center
      2019   Phase 2   NCT04218968   United States;
   Michele Tagliati, MD
      2019   Phase 2   NCT03775096   United States;
Catapres ampoules   
   Summit (Cambridge) Ltd.
      2007   -   EUCTR2007-004654-81-GB   United Kingdom;
Ceftriaxone   
   BrainX Corporation
      2019   Phase 2   NCT03413384   Taiwan;
Cerebral Dopamine Neurotrophic Factor   
   Herantis Pharma Plc.
      2018   Phase 1/Phase 2   NCT03775538   Finland;Sweden;
      2017   Phase 1/Phase 2   NCT03295786   Finland;Sweden;
Champix   
   VU University Medical Center
      2012   Phase 3   EUCTR2012-001530-34-NL   Netherlands;
Chinese herbal medicine treatment   
   Hong Kong Baptist University
      2021   Phase 2/Phase 3   NCT05001217   -
Chocolate   
   Technische Universität Dresden
      2009   -   NCT00906763   Germany;
Circadin®   
   University College London
      2015   Phase 2   EUCTR2014-002697-37-GB   United Kingdom;
Citalopram   
   University of Michigan
      2021   Phase 2   NCT04497168   United States;
   Western University, Canada
      2021   -   NCT04590612   -
Citicolina 1000 mg/die   
   PIAM FARMACEUTICI S.P.A.
      2016   Phase 4   EUCTR2014-005562-30-IT   Italy;
Clarithromycin   
   Kyowa Kirin Co., Ltd.
      2019   Phase 1   NCT04070495   Japan;
Clarithromycin (Not used as of 4/2020)   
   Nicolaas Bohnen, MD, PhD
      2018   Phase 1/Phase 2   NCT03440112   United States;
Clarium 50 mg Retardtabletten   
   Desitin Arzneimittel GmbH
      2009   -   EUCTR2009-012419-16-DE   Germany;
Clartihromycin, amoxicillin, and omeprazole   
   University of California, Los Angeles
      2008   Phase 3   NCT00664209   United States;
Clenbuterol HCl   
   CuraSen Therapeutics, Inc.
      2020   Phase 2   EUCTR2020-003796-17-GB   United Kingdom;
Clenbuterol Hydrochloride   
   CuraSen Therapeutics, Inc.
      -   Phase 2   EUCTR2020-006067-28-BE   Australia;Belgium;New Zealand;United Kingdom;
Clonazepam   
   Seoul National University Hospital
      2016   Phase 2   NCT02789592   Korea, Republic of;
Clonidine   
   Hospices Civils de Lyon
      2019   Phase 2   NCT03552068   France;
Clonidine (Catapressan)   
   Hospices Civils de Lyon
      2012   -   NCT01796483   France;
Clonidine hydrochloride   
   Summit (Cambridge) Ltd.
      2007   -   EUCTR2007-004654-81-GB   United Kingdom;
Clozapine   
   Memorial Hospital of Rhode Island
      1993   -   NCT00004826   -
CoQ10   
   University of Rochester
      2004   Phase 2   NCT00076492   United States;
Coarse wheat bran   
   University of Florida
      2021   -   NCT04829760   United States;
Cocoa   
   Oxford Brookes University
      2017   -   NCT03288155   Italy;
Coenzyme Q10   
   National Institute of Neurological Disorders and Stroke (NINDS)
      1998   Phase 2   NCT00004731   United States;
Coenzyme Q10 Nanodispersion (Nanoquinone)   
   Technische Universität Dresden
      2003   Phase 3   NCT00180037   Germany;
Coenzyme Q10 with vitamin E   
   Weill Medical College of Cornell University
      2008   Phase 3   NCT00740714   Canada;United States;
Cogane™ (PYM50028)   
   Phytopharm
      2009   Phase 1   NCT00875316   United Kingdom;
Cohort 1:Nilotinib Oral Capsules (150mg or 300mg)   
   Northwestern University
      2017   Phase 2   NCT03205488   United States;
Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1)   
   Northwestern University
      2017   Phase 2   NCT03205488   United States;
Combination Product: L-dopa 70mg/carbidopa   
   Impel NeuroPharma Inc.
      2018   Phase 2   NCT03541356   Australia;
Combination Product: ND0612 Solution for SC infusion   
   NeuroDerm Ltd.
      2019   Phase 3   NCT04006210   Austria;Belgium;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
Combination Product: Sanacoach Parkinson (SCP)   
   Zuyderland Medisch Centrum
      2021   -   NCT05164783   Netherlands;
Combination Product: continuous oral delivery of levodopa/carbidopa   
   SynAgile Corporation
      2021   Phase 2   NCT04778176   Italy;Luxembourg;
Combination injection of EPO and G-CSF   
   Yonsei University
      2013   Phase 1/Phase 2   NCT02018406   Korea, Republic of;
Comparator: carbidopa   
   Merck Sharp & Dohme Corp.
      2007   Phase 1   NCT00505843   United States;
Comparator: levodopa   
   Merck Sharp & Dohme Corp.
      2007   Phase 1   NCT00505843   United States;
Comtan   
   Kyowa Hakko U.K. Limited
      2004   -   EUCTR2004-000817-20-ES   Italy;Latvia;Lithuania;Spain;
Comtan®   
   BIAL - Portela & Ca, S.A.
      2011   Phase 3   EUCTR2010-021860-13-RO   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
      2011   -   EUCTR2010-021860-13-SK   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
      2011   -   EUCTR2010-021860-13-ES   Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain;
      2011   -   EUCTR2010-021860-13-DE   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
      2011   -   EUCTR2010-021860-13-CZ   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
      2011   -   EUCTR2010-021860-13-BG   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
      2011   -   EUCTR2010-021860-13-AT   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
      2010   -   EUCTR2010-021860-13-PT   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
      2010   -   EUCTR2010-021860-13-LV   Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain;
      2010   -   EUCTR2010-021860-13-LT   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
      2010   -   EUCTR2010-021860-13-HU   Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain;
   Bial - Portela C S.A.
      2006   Phase 2   NCT03103399   -
      2006   Phase 1   NCT03094156   Portugal;
      2005   Phase 2   NCT02834507   -
      2004   Phase 1   NCT03091868   Portugal;
Comtan®   
   BIAL - PORTELA & Cª, S.A.
      2011   -   EUCTR2010-021860-13-IT   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Russian Federation;Slovakia;Spain;
Comtess   
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2010   -   EUCTR2009-017416-33-DE   Germany;
   Dept of Neuroscience, Uppsala University
      2008   -   EUCTR2008-003581-26-SE   Sweden;
   Eisai Limited
      2007   Phase 3   EUCTR2006-002937-20-FR   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
      2007   -   EUCTR2006-002937-20-HU   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
      2007   -   EUCTR2006-002937-20-ES   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
      2006   -   EUCTR2006-002937-20-LV   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
      2006   -   EUCTR2006-002937-20-LT   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
      2006   -   EUCTR2006-002937-20-EE   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
      2006   -   EUCTR2006-002937-20-CZ   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
   Kyowa Hakko U.K. Limited
      2005   -   EUCTR2004-000817-20-AT   Austria;Italy;Latvia;Lithuania;Spain;
      2004   Phase 3   EUCTR2004-000817-20-GB   Austria;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2004   -   EUCTR2004-000817-20-LV   Italy;Latvia;Lithuania;Spain;
      2004   -   EUCTR2004-000817-20-LT   Italy;Latvia;Lithuania;Spain;
      2004   -   EUCTR2004-000817-20-ES   Italy;Latvia;Lithuania;Spain;
Comtess®   
   Orion Corporation, Orion Pharma
      2002   Phase 4   NCT00247247   Germany;
Continuous Apomorphine infusion   
   Rennes University Hospital
      2009   Phase 3   NCT01039090   France;
Continuous Release Dopamine Agonists   
   University of Toledo Health Science Campus
      2007   Phase 3   NCT00465452   United States;
Continuous Subcutaneous Lisuride Infusion   
   Axxonis Pharma AG
      2006   Phase 3   NCT00408915   Germany;
Continuous intrajejunal infusion of levodopa-carbidopa   
   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
      2014   Phase 4   NCT02480803   Netherlands;
Control   
   Johns Hopkins University
      2018   Phase 1   NCT03069911   United States;
Controlled-release levodopa / carbidopa   
   Pfizer
      2004   Phase 4   NCT00174239   Australia;Italy;Spain;United Kingdom;
Conventional medication   
   Hong Kong Baptist University
      2021   Phase 2/Phase 3   NCT05001217   -
Creatine   
   University of Rochester
      2007   Phase 3   NCT00449865   Canada;United States;
      2003   Phase 2   NCT00063193   United States;
Cu(II)ATSM   
   Collaborative Medicinal Development Pty Limited
      2017   Phase 1   NCT03204929   Australia;
CyberKnife   
   Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology
      2015   Phase 2   NCT02406105   Poland;
Cystoscopic injection of Botox into the urinary bladder   
   Stanford University
      2009   Phase 4   NCT01421719   United States;
D-serine (~2g/day)   
   Herzog Hospital
      2003   Phase 4   NCT00215904   Israel;
DA-9701   
   Seoul National University Hospital
      2016   Phase 4   NCT02775591   Korea, Republic of;
      2013   Phase 4   NCT03022201   Korea, Republic of;
DA-9805   
   Dong-A ST Co., Ltd.
      2018   Phase 2   NCT03189563   United States;
DAAOI-P   
   China Medical University Hospital
      2016   Phase 2   NCT04470037   Taiwan;
DATscan and SPECT imaging   
   Institute for Neurodegenerative Disorders
      2005   -   NCT00129181   Austria;Germany;Italy;Spain;United Kingdom;
DC158AM   
   PIERRE FABRE MEDICAMENT
      2008   Phase 3   EUCTR2007-002195-34-FR   France;
DCI   
   Hamamatsu University School of Medicine
      2015   -   JPRN-UMIN000019524   Japan;
   Ito Hidefumi
      2016   Phase 2   JPRN-jRCTs051180098   Japan;
   Osaka Redcross HospitalWakayama Prefectural Medical College
      2016   Phase 2   JPRN-UMIN000022533   Japan;
   Ouchi Yasuomi
      2015   -   JPRN-jRCTs041180070   Japan;
DCS   
   IRCCS National Neurological Institute C. Mondino Foundation
      2019   -   NCT04620863   Italy;
DEBRUMYL   
   PIERRE FABRE MEDICAMENT
      2008   Phase 3   EUCTR2007-002195-34-FR   France;
DM   
   Guangdong Provincial People's Hospital
      2020   Phase 0   ChiCTR2000039475   China;
DM-1992   
   Depomed
      2012   Phase 2   NCT01515410   United States;
DNL151   
   Denali Therapeutics Inc.
      2019   Phase 1   NCT04056689   Belgium;Netherlands;United Kingdom;United States;
DNL201   
   Denali Therapeutics Inc.
      2018   Phase 1   NCT03710707   United States;
DNS-7801 (high dose)   
   Dart NeuroScience, LLC
      2017   Phase 2   NCT03306329   United States;
DNS-7801 (low-dose)   
   Dart NeuroScience, LLC
      2017   Phase 2   NCT03306329   United States;
DPA   
   Assistance Publique - Hôpitaux de Paris
      2012   -   NCT02319382   France;
DPA-714-PET/MRI   
   University of Alabama at Birmingham
      2018   Phase 1/Phase 2   NCT03457493   United States;
DUODOPA   
   CHU de Poitiers
      2010   -   EUCTR2010-020769-25-FR   France;
DUODOPA®Intestinal Gel   
   Abbott Healthcare Products B.V.
      2009   -   EUCTR2006-005186-18-CZ   Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2008   Phase 3   EUCTR2006-005186-18-GB   Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2008   -   EUCTR2006-005186-18-PT   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2006-005186-18-DE   Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
   Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
      2007   -   EUCTR2006-000577-29-DE   Germany;United States;
   Solvay Pharmaceuticals B.V.
      2009   -   EUCTR2006-005186-18-NL   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   Phase 3   EUCTR2006-005186-18-ES   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2007   -   EUCTR2006-005186-18-FI   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
DaTSCAN 74 MBq/ml solution for injection   
   ZIONEXA
      2021   Phase 3   EUCTR2019-000247-27-FR   France;
DaTSCAN™   
   Michael J. Fox Foundation for Parkinson's Research
      2015   -   NCT02572713   Canada;United States;
DaTSCAN™ Ioflupane (123I) Injection   
   GE Healthcare
      2020   Phase 3   NCT04193527   China;
Dacepton 5 mg/ml infuusioneste, liuos   
   Eero Pekkonen
      2016   Phase 4   EUCTR2016-001690-33-FI   Finland;
Daily ingestion of Lactobacillus plantarum PS128   
   Professor Lu Neurological Clinic
      2019   -   NCT04389762   Taiwan;
Dark chocolate ( cocoa)   
   Technische Universität Dresden
      2013   -   NCT02275884   Germany;
Deanol pyroglutamate   
   PIERRE FABRE MEDICAMENT
      2008   Phase 3   EUCTR2007-002195-34-FR   France;
Deep Brain Stimulation   
   Beth Israel Deaconess Medical Center
      2016   -   NCT02994719   United States;
Deep brain stimulation   
   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
      2014   Phase 4   NCT02480803   Netherlands;
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2014   -   NCT04928079   -
Deferiprone   
   ApoPharma
      2016   Phase 2   NCT02728843   Canada;France;Germany;United Kingdom;
   Imperial College London
      2012   Phase 2   NCT01539837   United Kingdom;
   University Hospital, Lille
      2016   Phase 2   NCT02655315   Austria;Czech Republic;Czechia;France;Germany;Netherlands;Portugal;Spain;United Kingdom;
      2011   -   NCT02880033   France;
      2009   Phase 2/Phase 3   NCT00943748   France;
Deferiprone (Ferriprox)   
   Imperial College London
      2011   Phase 2   EUCTR2011-001148-31-GB   United Kingdom;
Deferiprone 600 mg delayed release tablet   
   ApoPharma
      2017   Phase 2   EUCTR2015-004344-19-DE   Canada;France;Germany;United Kingdom;
      2016   Phase 2   EUCTR2015-004344-19-GB   Canada;France;Germany;United Kingdom;
   ApoPharma Inc.
      2016   Phase 2   EUCTR2015-004344-19-FR   Canada;France;Germany;Italy;United Kingdom;United States;
Deferiprone DR   
   Centre Hospitalier Régional et Universitaire de Lille
      2016   Phase 3   EUCTR2015-003679-31-ES   Spain;
      2016   Phase 2   EUCTR2015-003679-31-PT   Austria;Czech Republic;Netherlands;Portugal;Spain;
      2016   Phase 2   EUCTR2015-003679-31-NL   Austria;Czech Republic;Netherlands;Portugal;Spain;
      2016   Phase 2   EUCTR2015-003679-31-FR   Austria;Czech Republic;France;Netherlands;Portugal;Spain;
      2016   Phase 2   EUCTR2015-003679-31-CZ   Austria;Czech Republic;Netherlands;Portugal;Spain;
      2016   Phase 2   EUCTR2015-003679-31-AT   Austria;Czech Republic;France;Germany;Netherlands;Portugal;Spain;United Kingdom;
Desmopressin Acetat   
   Universität Mainz, Klinik und Poliklinik für Neurologie
      2008   -   EUCTR2008-003966-25-DE   Germany;
Desmotabs   
   Johannes Gutenberg University Mainz
      2009   Phase 4   NCT00806468   Germany;
Desmotabs® 0,2 mg Tabletten   
   Universität Mainz, Klinik und Poliklinik für Neurologie
      2008   -   EUCTR2008-003966-25-DE   Germany;
Desmotabs® 0,2mg Tabletten   
   Universität Mainz, Klinik und Poliklinik für Neurologie
      2008   -   EUCTR2008-003966-25-DE   Germany;
Determination of drug effects through amantadine cessation   
   Seoul National University Hospital
      2020   -   NCT04260581   Korea, Republic of;
Dexdor   
   Clínica Universidad de Navarra/Universidad de Navarra
      2016   Phase 4   EUCTR2016-002680-34-ES   Spain;
      2014   -   EUCTR2014-000868-17-ES   Spain;
Dexmedetomidine   
   Beijing Tiantan Hospital
      2022   -   NCT05197439   China;
   Clinica Universidad de Navarra, Universidad de Navarra
      2017   Phase 4   NCT02982512   Spain;
      2014   Phase 4   NCT02256319   Spain;
   Diskapi Teaching and Research Hospital
      2013   Phase 4   NCT01789385   Turkey;
   Shanghai Jing'an District Central Hospital
      2016   Phase 0   ChiCTR2000037957   China;
   The First Affiliated Hospital of University of Science and Technology of China (Southern District Phase 2)
      2021   Phase 0   ChiCTR2100048680   China;
   University of Wisconsin, Madison
      2012   Phase 4   NCT01721460   United States;
   West China Hospital, Sichuan University
      2016   -   ChiCTR-IOR-16010168   China;
Dexmedetomidine Hydrochloride Infusion   
   Vanderbilt University
      2008   Phase 2/Phase 3   NCT00608231   United States;
Dextromethorphan   
   National Institute of Neurological Disorders and Stroke (NINDS)
      1993   Phase 2   NCT00001365   United States;
Different diets   
   Sheba Medical Center
      2014   -   NCT02274324   -
Dihydroergotoxine Mesylate   
   Nanjing First Hospital Affiliated to Nanjing Medical University
      2017   -   ChiCTR-IPR-17011155   China;
Dipivefrin   
   katsuno Masahisa
      2017   Phase 2   JPRN-jRCTs041180018   Japan;
Dipivefrine   
   Nagoya University
      2017   -   JPRN-UMIN000026128   Japan;
Dipraglurant   
   Addex Pharma S.A.
      2021   Phase 2/Phase 3   NCT05116813   United States;
      2021   Phase 2/Phase 3   NCT04857359   United States;
   Addex Pharma SA
      2011   Phase 2   EUCTR2010-022517-25-DE   Austria;France;Germany;United States;
      2011   -   EUCTR2010-022517-25-AT   Austria;France;Germany;United States;
Ditropan elixir   
   Summit (Cambridge) Ltd.
      2007   -   EUCTR2007-004654-81-GB   United Kingdom;
Docosahexaenoic Acid (DHA)   
   VA Office of Research and Development
      2012   Phase 1   NCT01563913   United States;
Domperidone   
   Canadian Network for Observational Drug Effect Studies, CNODES
      2013   -   NCT02500108   Canada;
   Kansai Medical University
      2012   -   JPRN-UMIN000007896   Japan;
   Royal Brisbane and Women's Hospital
      2005   Phase 1   NCT00103597   Australia;
   Seoul National University Hospital
      2013   Phase 4   NCT03022201   Korea, Republic of;
Domperidone (drug)   
   University Health Network, Toronto
      2006   Phase 2   NCT00305331   Canada;
Dompéridone   
   CHU de Toulouse
      2010   Phase 3   EUCTR2010-018650-12-FR   France;
Donepezil   
   Clinical Research Center, Utano National Hospital, National Hospital Organization
      2010   -   JPRN-UMIN000003080   Japan;
   Designated Research, National Hospital Organization
      2011   Phase 3   JPRN-UMIN000005403   Japan;
   Inje University
      2015   Phase 2   NCT02415062   Korea, Republic of;
   Kansai Medical University
      2013   -   JPRN-UMIN000010752   Japan;
   Kyung Hee University Hospital
      2017   Phase 4   NCT03011476   Korea, Republic of;
   National Hospital Organization, Sendai-Nishitaga Hospital
      2013   -   JPRN-UMIN000009958   Japan;
   National Hospital of Utano
      2013   -   JPRN-UMIN000010778   Japan;
   National Institute of Neurological Disorders and Stroke (NINDS)
      2002   Phase 4   NCT00030979   United States;
   Newcastle-upon-Tyne Hospitals NHS Trust
      2013   Phase 3   NCT01014858   United Kingdom;
   Oregon Health and Science University
      2018   Early Phase 1   NCT03599726   United States;
      2014   Phase 2   NCT02206620   United States;
      2011   Phase 4   NCT01521117   United States;
      2005   -   NCT00912808   -
   Per Borghammer
      2013   -   NCT02012595   Denmark;
      2013   -   NCT01877538   Denmark;
   University of Chicago
      2016   Phase 2   NCT02857244   United States;
   Yonsei University
      2015   Phase 2   NCT02450786   Korea, Republic of;
   Zealand University Hospital
      2020   Phase 4   NCT04117178   Denmark;
Donepezil Sandoz   
   Regional Dementia Research Centre, Dept of Neurology
      2018   Phase 4   EUCTR2017-002707-10-DK   Denmark;
DopaFuse Delivery System   
   SynAgile Corporation
      2021   Phase 2   EUCTR2020-003372-41-IT   Italy;Luxembourg;Spain;
      2021   Phase 1;Phase 2   EUCTR2020-003372-41-ES   Italy;Luxembourg;Spain;
Dopamine   
   Medical Corporation Abe Neurology Clinic
      2016   -   JPRN-UMIN000024859   Japan;
   University Hospital, Clermont-Ferrand
      2013   Phase 4   NCT01780467   France;
Dopamine Agent   
   I.R.C.C.S. Fondazione Santa Lucia
      2014   Phase 4   NCT03151460   Italy;
Dopamine Agonists (pramipexole, ropirinole)   
   University of Toronto
      2015   Phase 2   NCT02347059   Canada;
Dopaminergic Agonist + Apomorphine   
   Rennes University Hospital
      2019   -   NCT03693872   France;
Dopaminergic Agonists   
   Sandoz
      2012   Phase 4   NCT01683253   Korea, Republic of;
Doxepin and Zopiclone   
   McGill University Health Center
      2011   Phase 0   NCT01489982   Canada;
Droxidopa   
   Chelsea Therapeutics
      2013   Phase 3   NCT01927055   United States;
      2012   Phase 1/Phase 2   NCT01331122   Canada;United States;
      2010   Phase 3   NCT01176240   United States;
   Colorado Springs Neurological Associates
      2016   -   NCT03173781   United States;
   Henry Ford Health System
      2015   Phase 2   NCT02066571   United States;
   Loma Linda University
      2021   Phase 2   NCT03446807   United States;
   National Institute of Neurological Disorders and Stroke (NINDS)
      2007   Phase 1/Phase 2   NCT00547911   United States;
   St. Joseph's Hospital and Medical Center, Phoenix
      2018   Phase 2   NCT03567447   United States;
   Vanderbilt University Medical Center
      2017   Phase 4   NCT03115827   United States;
      2016   Phase 1   NCT02897063   United States;
   William Ondo, MD
      2018   Phase 4   NCT03229174   United States;
Droxidopa 100 MG [Northera]   
   Alberto Espay, MD, MSc
      2019   Phase 4   NCT04510922   United States;
Duloxetine   
   Ando Rina
      2015   Phase 2   JPRN-jRCTs061180028   Japan;
   CHU de Toulouse
      2010   Phase 3   EUCTR2010-018650-12-FR   France;
   Department of Neurology, Juntendo University School of Medicine
      2015   -   JPRN-UMIN000016734   Japan;
   Ehime University HospitalDept. of Clinical pharmacology and Neurology
      2014   Phase 2   JPRN-UMIN000016893   Japan;
   University Hospital, Toulouse
      2011   Phase 3   NCT01504178   France;
   University of Chicago
      2016   Phase 2   NCT02857244   United States;
Duloxetine hydrochloride   
   Eli Lilly and Company
      2007   Phase 4   NCT00437125   Italy;
Duodopa   
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2016   Phase 3   EUCTR2016-001403-23-IT   European Union;Finland;Greece;Hungary;Italy;Slovakia;Spain;United States;
   AbbVie Deutschland GmbH & Co. KG
      2018   Phase 3   EUCTR2016-001403-23-HU   European Union;Finland;Greece;Hungary;Slovakia;Spain;United States;
      2017   Phase 3   EUCTR2016-001403-23-GR   European Union;Finland;Greece;Hungary;Slovakia;Spain;United States;
      2017   Phase 3   EUCTR2016-001403-23-FI   European Union;Finland;Greece;Hungary;Slovakia;Spain;United States;
      2017   Phase 3   EUCTR2014-004865-26-GR   Australia;Canada;European Union;Germany;Greece;Italy;Spain;Sweden;United States;
      2016   Phase 3   EUCTR2016-001403-23-SK   European Union;Finland;Greece;Hungary;Slovakia;Spain;United States;
      2016   Phase 3   EUCTR2016-001403-23-ES   European Union;Finland;Greece;Hungary;Slovakia;Spain;United States;
      2015   Phase 3   EUCTR2014-004865-26-SE   Australia;Canada;European Union;Germany;Greece;Italy;Spain;Sweden;United States;
      2015   Phase 3   EUCTR2014-004865-26-ES   Australia;Canada;European Union;Germany;Greece;Italy;Spain;Sweden;
      2015   Phase 3   EUCTR2014-004865-26-DE   Australia;Canada;European Union;Germany;Italy;Spain;Sweden;
      2015   -   EUCTR2014-004865-26-IT   Australia;Canada;European Union;Germany;Italy;Spain;Sweden;
   Department of Neuroscience, neurology
      2007   -   EUCTR2007-004985-41-SE   Sweden;
   Dept of Neuroscience, Uppsala University
      2008   -   EUCTR2008-003581-26-SE   Sweden;
   Institut de Recerca del Hospital de la Santa Creu i Sant Pau
      2015   Phase 4   EUCTR2015-002631-17-ES   Spain;
   LobSor Pharmaceuticals AB
      2015   Phase 1   NCT02448914   Sweden;
   Organisation name was not entered
      2008   -   EUCTR2008-003225-16-FI   Finland;
   Poitiers University Hospital
      2011   Phase 2   NCT01291537   France;
Duodopa LD/CD 20/5 mg/mL   
   NEURODERM LTD.
      2018   Phase 3   EUCTR2017-002780-17-IT   Austria;France;Italy;Netherlands;Spain;United States;
   NeuroDerm Ltd.
      2018   Phase 3   EUCTR2017-002780-17-FR   Austria;France;Italy;Netherlands;Spain;United States;
      2018   Phase 3   EUCTR2017-002780-17-ES   Austria;France;Italy;Netherlands;Spain;United States;
Duodopa gel intestinale   
   Solvay Pharmaceuticals BV.
      2008   -   EUCTR2006-005186-18-IT   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
Duodopa intestinal gel   
   Solvay Pharmaceuticals GmbH
      2005   -   EUCTR2005-002654-21-SE   Sweden;
Duodopa intestinalgel   
   Solvay Pharmaceuticals GmbH
      2006   -   EUCTR2005-002654-21-NO   Norway;Sweden;
Duodopa, 20 mg/ml + 5 mg/ml, intestinal gel   
   AbbVie Inc
      2011   Phase 3   EUCTR2008-001329-33-GB   Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
      2010   Phase 3   EUCTR2008-001329-33-CZ   Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
      2009   -   EUCTR2008-001329-33-PT   Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
   Abbott Laboratories
      2009   -   EUCTR2006-000578-53-DE   Germany;New Zealand;United States;
Duodopa, levodopa 20 mg/ml + carbidopa 5 mg/ml, intestinal gel   
   Academic Medical Center
      2014   -   EUCTR2014-004501-32-NL   Netherlands;
Dynacirc CR (Isradipine)   
   Northwestern University
      2008   Phase 2   NCT00753636   United States;
E2007   
   EISAI LTD UK
      2007   Phase 3   EUCTR2007-000801-30-IT   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
      2007   -   EUCTR2006-005714-12-IT   Italy;
      2006   Phase 3   EUCTR2006-002339-26-IT   Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004314-33-IT   Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2004   -   EUCTR2004-000361-35-IT   Czech Republic;Italy;
   Eisai Inc.
      2007   Phase 2   NCT00451633   Germany;Italy;
      2007   Phase 2   NCT00427011   United States;
      2006   Phase 3   NCT00360412   Germany;
      2005   Phase 2   NCT00165789   United States;
   Eisai Limited
      2007   Phase 3   EUCTR2007-000801-30-PL   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
      2007   Phase 3   EUCTR2007-000801-30-FR   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
      2007   Phase 3   EUCTR2007-000801-30-ES   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
      2007   Phase 3   EUCTR2006-002937-20-FR   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
      2007   -   EUCTR2007-000801-30-LV   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
      2007   -   EUCTR2007-000801-30-LT   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
      2007   -   EUCTR2007-000801-30-HU   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
      2007   -   EUCTR2007-000801-30-EE   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
      2007   -   EUCTR2007-000801-30-CZ   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
      2007   -   EUCTR2006-002937-20-HU   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
      2007   -   EUCTR2006-002937-20-ES   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
      2007   -   EUCTR2006-002339-26-PT   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-002339-26-HU   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-002339-26-ES   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-002339-26-DE   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   Phase 3   NCT00360308   France;
      2006   Phase 3   NCT00286897   Austria;Belgium;Czech Republic;Estonia;Former Serbia and Montenegro;France;Germany;Hungary;Israel;Italy;Lithuania;Poland;Portugal;Serbia;South Africa;Spain;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2005-004314-33-GB   Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2005-004314-33-ES   Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2006-002937-20-LV   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
      2006   -   EUCTR2006-002937-20-LT   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
      2006   -   EUCTR2006-002937-20-EE   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
      2006   -   EUCTR2006-002937-20-CZ   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
      2006   -   EUCTR2006-002339-26-SE   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2006-002339-26-LT   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2006-002339-26-GB   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2006-002339-26-EE   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2006-002339-26-CZ   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2006-002339-26-BE   Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2006-002339-26-AT   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004314-33-SE   Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004314-33-PT   Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004314-33-LT   Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004314-33-HU   Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004314-33-EE   Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004314-33-DE   Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004314-33-CZ   Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004314-33-BE   Austria;Belgium;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2005-004314-33-AT   Austria;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2004   Phase 2   NCT01172379   Czech Republic;France;Germany;Italy;Serbia;Spain;
      2004   -   EUCTR2004-000361-35-CZ   Czech Republic;Italy;
E2027   
   Eisai Inc.
      2021   Phase 2   NCT04764669   Canada;United States;
EBIXA®   
   Chru de Lille
      2009   -   EUCTR2008-008210-38-FR   France;
ELC200   
   Novartis Pharma AG
      2006   -   EUCTR2005-001032-72-PT   Czech Republic;Italy;Portugal;
      2006   -   EUCTR2005-001032-72-CZ   Czech Republic;Italy;Portugal;
EMD 128130   
   MERCK KGaA
      2004   Phase 3   EUCTR2004-001594-25-ES   Austria;Finland;Spain;
   MERCK S.P.A.
      2004   -   EUCTR2004-001593-10-IT   Italy;United Kingdom;
   National Institute of Neurological Disorders and Stroke (NINDS)
      2001   Phase 2   NCT00009048   United States;
EMD128130   
   Merck KGaA
      2005   Phase 3   EUCTR2005-000444-84-GB   Austria;Finland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-000444-84-ES   Austria;Finland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2004-001593-10-GB   Italy;United Kingdom;
      2005   -   EUCTR2005-000444-84-FI   Finland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2005-000444-84-AT   Austria;Finland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-001594-25-AT   Austria;Finland;Spain;
      2004   -   EUCTR2004-001594-25-FI   Finland;Spain;
EN   
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2010   -   EUCTR2009-017416-33-DE   Germany;
ENA713   
   Research and Enterprise Department
      2012   Phase 2   EUCTR2011-003053-25-GB   United Kingdom;
ENA713B   
   NOVARTIS FARMA
      2008   -   EUCTR2007-000350-31-IT   France;Italy;Spain;
ENT-01   
   Enterin Inc.
      2017   Phase 1/Phase 2   NCT03047629   United States;
ENTACAPONE INN   
   NOVARTIS FARMA
      2005   -   EUCTR2005-001032-72-IT   Czech Republic;Italy;Portugal;
EPI-589   
   BioElectron Technology Corporation (formerly Edison Pharmaceuticals Inc.)
      2016   Phase 2   EUCTR2015-001786-10-GB   Germany;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-001786-10-DE   Germany;United Kingdom;United States;
   PTC Therapeutics
      2016   Phase 2   NCT02462603   Germany;United Kingdom;United States;
EPI-743   
   University of South Florida
      2013   Phase 2   NCT01923584   United States;
ER CD-LD   
   Impax Laboratories, LLC
      2016   Phase 2   NCT03007888   United States;
ER tablet 100 mg AZD3241   
   AstraZeneca
      2012   Phase 2   NCT01527695   Sweden;
ER tablet 25 mg AZD3241   
   AstraZeneca
      2012   Phase 2   NCT01527695   Sweden;
ETHNODYNE VISIO   
   University Hospital, Strasbourg, France
      2016   -   NCT02815800   France;
EXN-32 (CARBIDOPA E LEVODOPA)   
   DR. REDDY’S LABORATORIES LIMITED
      2017   Phase 2   EUCTR2017-000262-30-IT   Italy;
EXN-44(LEVODOPA)   
   DR. REDDY’S LABORATORIES LIMITED
      2017   Phase 2   EUCTR2017-000262-30-IT   Italy;
Ebixa   
   H. Lundbeck A/S
      2007   Phase 3   EUCTR2005-002038-36-GR   Austria;France;Germany;Greece;Italy;Spain;United Kingdom;
      2006   Phase 4   EUCTR2005-002038-36-GB   Austria;France;Germany;Greece;Italy;Spain;United Kingdom;
      2006   Phase 3   EUCTR2005-002038-36-FR   Austria;France;Germany;Greece;Italy;Spain;United Kingdom;
      2006   -   EUCTR2005-002038-36-DE   Austria;France;Germany;Greece;Italy;Spain;United Kingdom;
      2006   -   EUCTR2005-002038-36-AT   Austria;France;Germany;Greece;Italy;Spain;United Kingdom;
   Neurologisk afdeling F
      2005   Phase 2   EUCTR2004-004139-74-DK   Denmark;
   Neuropsychiatric clinic
      2006   -   EUCTR2005-004109-27-SE   Sweden;
Electroacupuncture   
   Nantes University Hospital
      2014   -   NCT02236260   France;
Eliprodil   
   National Institute of Neurological Disorders and Stroke (NINDS)
      1999   Phase 2   NCT00001929   United States;
Elobixibat   
   Hatano Taku
      2020   -   JPRN-jRCTs031200172   Japan;
Eltoprazine HCl   
   Amarantus BioScience Holdings, Inc.
      2015   Phase 2   NCT02439125   United States;
   PsychoGenics Inc
      2010   -   EUCTR2009-015928-28-SE   Sweden;
Eltoprazine Hydrochloride   
   Amarantus BioScience Holdings, Inc.
      2015   -   EUCTR2015-000373-13-DE   France;Germany;Sweden;United States;
Embryonic dopamine cell implant surgery   
   University of Colorado, Denver
      1995   Phase 3   NCT00038116   United States;
Entacapon   
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2010   -   EUCTR2009-017416-33-DE   Germany;
Entacapone   
   AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELE
      2010   -   EUCTR2010-019396-29-IT   Italy;
   Assistance Publique - Hôpitaux de Paris
      2006   Phase 4   NCT00373087   France;
   BIAL - Portela & Cª, SA
      2006   -   EUCTR2006-001793-24-PT   Austria;Portugal;
      2006   -   EUCTR2006-001793-24-AT   Austria;Portugal;
   Bial - Portela C S.A.
      2011   Phase 3   NCT01568073   Austria;Portugal;
      2011   Phase 1   NCT02170376   France;
      2009   Phase 1   NCT01519284   Portugal;
   Dept of Neuroscience, Uppsala University
      2008   -   EUCTR2008-003581-26-SE   Sweden;
   Eisai Limited
      2007   Phase 3   EUCTR2006-002937-20-FR   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
      2007   -   EUCTR2006-002937-20-HU   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
      2007   -   EUCTR2006-002937-20-ES   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
      2006   -   EUCTR2006-002937-20-LV   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
      2006   -   EUCTR2006-002937-20-LT   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
      2006   -   EUCTR2006-002937-20-EE   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
      2006   -   EUCTR2006-002937-20-CZ   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
   Geriatric Hospital of Hainan
      2019   -   ChiCTR1900022534   China;
   IMPAX LABORATORIES, INC.
      2010   -   EUCTR2009-017238-39-IT   France;Germany;Italy;
   KYOWA HAKKO UK LTD
      2005   -   EUCTR2004-000817-20-IT   Italy;Latvia;Lithuania;Spain;
   Kansai Medical University
      2010   -   JPRN-UMIN000003601   Japan;
   Kyowa Hakko U.K. Limited
      2005   -   EUCTR2004-000817-20-AT   Austria;Italy;Latvia;Lithuania;Spain;
      2004   Phase 3   EUCTR2004-000817-20-GB   Austria;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2004   -   EUCTR2004-000817-20-LV   Italy;Latvia;Lithuania;Spain;
      2004   -   EUCTR2004-000817-20-LT   Italy;Latvia;Lithuania;Spain;
      2004   -   EUCTR2004-000817-20-ES   Italy;Latvia;Lithuania;Spain;
   National Institute of Neurological Disorders and Stroke (NINDS)
      2007   Phase 1/Phase 2   NCT00547911   United States;
   Novartis
      2003   Phase 2   NCT00237263   United States;
   Orion Corporation Orion Pharma
      2007   -   EUCTR2007-002496-14-FI   Finland;
      2006   Phase 4   EUCTR2006-001755-36-GB   Germany;Sweden;United Kingdom;
      -   -   EUCTR2006-001755-36-DE   Germany;Sweden;United Kingdom;
   Orion Corporation Orion Pharma, FI-02200 Espoo, Finland
      2006   -   EUCTR2006-001755-36-SE   Germany;Sweden;United Kingdom;
   Orion Corporation, ORION PHARMA
      2005   -   EUCTR2004-005234-39-FI   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2004   -   EUCTR2004-000185-12-FI   Finland;Italy;Sweden;United Kingdom;
   Orion Corporation, ORION PHARMA, Finland
      2005   Phase 4   EUCTR2004-005234-39-GB   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
   Orion Corporation, ORION PHARMA, 02200 Espoo, Finland
      2008   -   EUCTR2004-005234-39-DE   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2004-000185-12-GB   Austria;Finland;Italy;Sweden;United Kingdom;
      2006   -   EUCTR2004-005234-39-LV   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2006   -   EUCTR2004-005234-39-LT   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2005   Phase 4   EUCTR2004-005234-39-IE   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2005   -   EUCTR2004-005234-39-SE   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2005   -   EUCTR2004-005234-39-DK   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2004   -   EUCTR2004-000185-12-SE   Finland;Italy;Sweden;United Kingdom;
      2004   -   EUCTR2004-000185-12-AT   Austria;Finland;Italy;Sweden;United Kingdom;
   Uppsala University
      2008   Phase 4   NCT00906828   Sweden;
   Yagi Michio
      2021   Phase 1   JPRN-jRCT2051200104   Japan;
Entacapone 400mg oral dose   
   Daniel Claassen
      2020   Phase 1   NCT04246437   United States;
Entacapone and carbidopa   
   Orion Corporation, Orion Pharma
      2008   Phase 2   NCT00562198   Finland;
Entecapone   
   NOVARTIS FARMA
      2004   -   EUCTR2004-000185-12-IT   Finland;Italy;Sweden;United Kingdom;
Equal   
   POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
      2006   -   EUCTR2006-003717-41-IT   Italy;
Equfina   
   Eisai Co., Ltd.
      2020   -   NCT04724109   Japan;
   Eisai Korea Inc.
      2021   -   NCT05225324   Korea, Republic of;
Eradication of Helcobacter Pylori   
   National University of Malaysia
      2012   -   NCT02112812   Malaysia;
Eradication therapy for H.pylori infection   
   National University of Malaysia
      2012   -   NCT02112812   Malaysia;
Eradication therapy for Helicobacter pylori   
   National University of Malaysia
      2012   -   NCT02112812   Malaysia;
Erythromycin   
   Virginia Commonwealth University
      2013   -   NCT02005029   United States;
Erythropoietin human recombinant (EPOrh)   
   International Center for Neurological Restoration, Cuba
      2008   Phase 1   NCT01010802   Cuba;
Escitalopram   
   LUNDBECK ITALIA
      2008   -   EUCTR2007-004009-93-IT   Italy;
   University College, London
      2019   Phase 3   NCT03652870   -
Escitalopram oxalate   
   University College London Comprehensive Clinical Trials Unit
      2019   Phase 3   EUCTR2018-002942-35-GB   United Kingdom;
Eszopiclone   
   University of Medicine and Dentistry of New Jersey
      2006   Phase 3   NCT00324896   United States;
Ethylmethylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester (**See other 2 names below)   
   University of Bristol
      2019   Phase 3   EUCTR2018-003219-23-GB   United Kingdom;
Etomidate   
   Department of Anesthesiology, the First Affiliated Hospital of Sun Yat-Sen University
      2020   Phase 4   ChiCTR2000039697   China;
Exelon   
   Oregon Health and Science University
      2011   Phase 4   NCT01340885   United States;
Exelon 4.6 mg/24 h transdermal patch   
   Novartis Farmacéutica S.A
      2008   Phase 3   EUCTR2007-000350-31-ES   France;Italy;Spain;
   Novartis Pharma AG
      2008   -   EUCTR2007-000350-31-FR   France;Italy;Spain;
Exelon 9.5 mg/24 h transdermal patch   
   Novartis Farmacéutica S.A
      2008   Phase 3   EUCTR2007-000350-31-ES   France;Italy;Spain;
   Novartis Pharma AG
      2008   -   EUCTR2007-000350-31-FR   France;Italy;Spain;
Exelon Patch (rivastigmine transdermal system)   
   University of Pennsylvania
      2011   Phase 4   NCT01519271   United States;
Exelon path transdermal   
   NOVARTIS FARMA
      2008   -   EUCTR2007-000350-31-IT   France;Italy;Spain;
Exelon ®   
   Research and Enterprise Department
      2012   Phase 2   EUCTR2011-003053-25-GB   United Kingdom;
Exenatide   
   Center for Neurology, Stockholm
      2020   Phase 2   NCT04305002   Sweden;
   University College London
      2014   Phase 2   EUCTR2013-003363-64-GB   United Kingdom;
   University College London Comprehensive Clinical Trial Unit
      2019   Phase 3   EUCTR2018-003028-35-GB   United Kingdom;
   University College, London
      2014   Phase 2   NCT01971242   United Kingdom;
      2010   Phase 2   NCT01174810   United Kingdom;
   University of Florida
      2018   Phase 1   NCT03456687   United States;
Exenatide 10 micrograms   
   University College London
      2010   Phase 2   EUCTR2009-018137-37-GB   United Kingdom;
Exenatide 5 micrograms   
   University College London
      2010   Phase 2   EUCTR2009-018137-37-GB   United Kingdom;
Exenatide extended release 2mg (Bydureon)   
   University College, London
      2020   Phase 3   NCT04232969   United Kingdom;
Exergame   
   University of Arizona
      2014   -   NCT02777060   United States;
F-18 FPCIT   
   Asan Medical Center
      2006   Phase 3   NCT00468078   Korea, Republic of;
FB-101   
   1ST Biotherapeutics, Inc.
      2019   Phase 1   NCT04165837   United States;
FLORBETABEN (18F)   
   Fundació Clínic per la Recerca Biomèdica
      2016   Phase 4   EUCTR2014-001014-25-ES   Spain;
   Institute for Neurodegenerative Disorders
      2016   Phase 2   EUCTR2015-004129-15-ES   Spain;
FPF1100NW   
   FP Pharmaceutical Corp.
      2012   Phase 2   JPRN-JapicCTI-122000   -
      -   Phase 3   JPRN-JapicCTI-121954   -
      -   Phase 2   JPRN-JapicCTI-101020   -
FPFS-1169   
   Fujimoto Pharmaceutical Corporation
      2006   Phase 2   EUCTR2006-000361-11-GB   United Kingdom;
Famotidine   
   University Health Network, Toronto
      2011   Phase 2   NCT01937078   Canada;
Febuxostat   
   Kamatani Naoyuki
      2019   Phase 1   JPRN-jRCTs031190115   Japan;
   StaGen Co. Ltd.
      2018   -   JPRN-UMIN000030930   Japan;
   Tsukuba International Clinical Pharmacology Clinic
      2016   -   JPRN-UMIN000024312   Japan;
Ferriprox   
   Centre Hospitalier Régional et Universitaire de Lille
      2016   Phase 3   EUCTR2015-003679-31-ES   Spain;
Ferrprox (Deferiprone)   
   Imperial College London
      2011   Phase 2   EUCTR2011-001148-31-GB   United Kingdom;
Fesoterodine   
   Sir Mortimer B. Davis - Jewish General Hospital
      2016   Phase 4   NCT02385500   Canada;
Fetal porcine cells, Neurocell-PD   
   Genzyme, a Sanofi Company
      1997   Phase 2   NCT00226460   United States;
Filgrastim   
   MinYoung Kim, M.D.
      2014   -   NCT02236065   Korea, Republic of;
Finamine tablets   
   Yiling Pharmaceutical Inc.
      2017   Phase 1   NCT04162275   China;
Finasteride   
   AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI
      2011   -   EUCTR2011-000612-26-IT   Italy;
Fipamezole   
   Juvantia Pharma Ltd
      2008   Phase 2   NCT00758849   France;Portugal;
      2007   Phase 2   NCT00559871   India;United States;
Fipamezole ODT   
   Valeant Pharmaceuticals International, Inc.
      2010   -   NCT01140841   United States;
Fipamezole ODT Cohort 2   
   Valeant Pharmaceuticals International, Inc.
      2010   -   NCT01149811   United States;
Fipamezole hydrochloride 30 mg oral disintegrating tablets   
   Juvantia Pharma Ltd
      2008   -   EUCTR2007-004890-24-PT   France;Portugal;
      2008   -   EUCTR2007-004890-24-FR   France;Portugal;
Fipamezole hydrochloride 60 mg oral disintegrating tablets   
   Juvantia Pharma Ltd
      2008   -   EUCTR2007-004890-24-PT   France;Portugal;
      2008   -   EUCTR2007-004890-24-FR   France;Portugal;
Fipamezole hydrochloride 90 mg oral disintegrating tablets   
   Juvantia Pharma Ltd
      2008   -   EUCTR2007-004890-24-PT   France;Portugal;
      2008   -   EUCTR2007-004890-24-FR   France;Portugal;
Flecainidum   
   Theranexus S.A.
      2018   Phase 2   EUCTR2017-004475-31-HU   Czech Republic;France;Germany;Hungary;United States;
      2018   Phase 2   EUCTR2017-004475-31-CZ   Czech Republic;France;Germany;Hungary;United States;
Florbetapir F 18   
   Avid Radiopharmaceuticals
      2009   Phase 2   NCT00857532   United States;
Fludrocortisone   
   Christian Baumann
      2012   Phase 2   NCT01993680   Switzerland;
   Royal Brisbane and Women's Hospital
      2005   Phase 1   NCT00103597   Australia;
Flumazenil   
   Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
      2013   -   JPRN-UMIN000011111   Japan;
   University of Michigan
      2018   Phase 1/Phase 2   NCT03462641   United States;
Fluoroscopic swallow evaluation   
   University of Florida
      2017   -   NCT03321019   United States;
Flutemetamol   
   Itoh Yoshiaki
      2019   -   JPRN-jRCTs051180214   Japan;
Flutemetamol F18   
   Skane University Hospital
      2017   -   NCT03174938   Sweden;
Folic Acid, Vitamin B6, Vitamin B12   
   North Shore Long Island Jewish Health System
      2006   -   NCT00853879   United States;
Foliglurax   
   H. Lundbeck A/S
      2019   Phase 1   NCT04175132   Sweden;
   PREXTON THERAPEUTICS B.V.
      2017   Phase 2   EUCTR2017-000135-14-IT   Austria;France;Germany;Italy;Spain;United Kingdom;
   Prexton Therapeutics B.V.
      2017   Phase 2   EUCTR2017-000135-14-GB   Austria;Germany;Spain;United Kingdom;
      2017   Phase 2   EUCTR2017-000135-14-ES   Austria;Germany;Italy;Spain;United Kingdom;
      2017   Phase 2   EUCTR2017-000135-14-DE   Austria;Germany;Italy;Spain;United Kingdom;
      2017   Phase 2   EUCTR2017-000135-14-AT   Austria;Germany;Spain;United Kingdom;
Foliglurax 10 mg (treatment A)   
   H. Lundbeck A/S
      2020   Phase 1   NCT04322227   France;
Foliglurax 30 mg (treatment B)   
   H. Lundbeck A/S
      2020   Phase 1   NCT04322227   France;
Foscarbidopa   
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2019   Phase 3   EUCTR2018-002144-85-IT   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
   AbbVie Deutschland
      2020   Phase 3   EUCTR2018-002144-85-DE   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002144-85-NL   Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002144-85-GB   Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002144-85-ES   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002144-85-DK   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002144-85-BE   Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
Foscarbidopa and Foslevodopa   
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2020   Phase 3   EUCTR2019-004235-23-IT   Australia;Canada;Italy;Japan;Netherlands;Russian Federation;United Kingdom;United States;
   Abbvie Deutschland GmbH & Co. KG
      2021   Phase 3   EUCTR2019-004235-23-SE   Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-004235-23-DE   Australia;Canada;Germany;Italy;Japan;Netherlands;Russian Federation;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004235-23-NL   Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004235-23-GB   Australia;Canada;Japan;Russian Federation;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004235-23-DK   Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
Foslevodopa   
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2019   Phase 3   EUCTR2018-002144-85-IT   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
   AbbVie Deutschland
      2020   Phase 3   EUCTR2018-002144-85-DE   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002144-85-NL   Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002144-85-GB   Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002144-85-ES   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002144-85-DK   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002144-85-BE   Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
Functional Magnetic Resonance Imaging   
   University of Florida
      2016   Phase 2   NCT02789020   United States;
Furosemide Injection   
   University of Alberta
      2021   Phase 3   NCT04706910   Canada;
G-CSF   
   Buddhist Tzu Chi General Hospital
      2010   Phase 2   NCT01227681   Taiwan;
GABAPENTINA KERN PHARMA   
   ASOCIACIÓN INSTITUTO BIODONOSTIA
      2012   Phase 2   EUCTR2011-005839-91-ES   Spain;
GE180 PET Scan   
   Aaron Ritter, MD
      2018   Phase 2   NCT03702816   United States;
GM1 ganglioside   
   Thomas Jefferson University
      1999   Phase 2   NCT00037830   United States;
GM608   
   Genervon Biopharmaceuticals, LLC
      2013   Phase 2   NCT01850381   United States;
GOCOVRI   
   Oregon Health and Science University
      2020   Phase 4   NCT04387773   United States;
GPI 1485   
   Eisai Inc.
      2002   Phase 2   NCT00209508   -
   University of Rochester
      2004   Phase 2   NCT00076492   United States;
GRF6021   
   Alkahest, Inc.
      2018   Phase 2   NCT03713957   Australia;France;United States;
GSK962040   
   GlaxoSmithKline Research and Development Limited
      2013   -   EUCTR2011-004438-32-SE   Australia;Germany;Sweden;United Kingdom;
      2013   -   EUCTR2011-004438-32-DE   Australia;Germany;Sweden;United Kingdom;
      2012   Phase 2   EUCTR2011-004438-32-GB   Germany;Sweden;United Kingdom;
GSK962040 (25 mg tablet)   
   GlaxoSmithKline
      2012   Phase 2   NCT01602549   Australia;Germany;Sweden;United Kingdom;
Galantamine   
   Memorial Hospital of Rhode Island
      2004   -   NCT00211588   United States;
Galantamine hydrobromide   
   Otto-von-Guericke University, Medical Faculty, Dpt. of Neurology
      2009   -   EUCTR2009-011093-15-DE   Germany;
Ganoderma   
   Xuanwu Hospital, Beijing
      2018   Phase 3   NCT03594656   China;
Genz-682452-AU   
   Genzyme Corporation
      2019   Phase 2   EUCTR2016-000657-12-GR   Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
      2018   Phase 2   EUCTR2016-000657-12-AT   Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000657-12-PT   Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000657-12-IT   Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000657-12-DE   Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
      2016   Phase 2   EUCTR2016-000657-12-SE   Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
      2016   Phase 2   EUCTR2016-000657-12-ES   Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
Ghrelin   
   Nagoya University Graduate School of Medicine
      2015   -   JPRN-UMIN000017036   Japan;
Glial Cell Line-Derived Neurotrophic Factor (GDNF)   
   North Bristol NHS Trust (NBT)
      2013   Phase 2   EUCTR2013-001881-40-GB   United Kingdom;
      2012   Phase 2   EUCTR2011-003866-34-GB   United Kingdom;
Glial cell line-derived neurotrophic factor   
   North Bristol NHS Trust
      2012   Phase 2   NCT03652363   -
Glucose   
   National Institute of Mental Health (NIMH)
      1998   -   NCT00004451   United States;
Glutathione   
   University of South Florida
      2003   Phase 2   NCT01177319   United States;
Glycopyrrolate   
   Ottawa Hospital Research Institute
      2016   Phase 2   NCT02382198   Canada;
Gold   
   101th Hospital of PLA
      2016   -   ChiCTR-DOC-16008645   -
   Department of Neurology, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital
      2014   -   ChiCTR-DDD-17010794   China;
   Guangdong General Hospital, Guangdong Academy of Medical Sciences
      2015   -   ChiCTR-DOD-15006097   China;
   Huashan Hospital Affiliated to Fudan University
      2020   Phase 0   ChiCTR2000037856   China;
   Huashan Hospital, Fudan University
      2020   Phase 0   ChiCTR2000038937   China;
   Renji Hospital (South Court), School of Medicine, Shanghai Jiao Tong University
      2020   Phase 0   ChiCTR2000036137   China;
   Renji hospital, School of Medicine, Shanghai Jiao Tong University
      2017   -   ChiCTR-DDD-16009569   China;
   Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
      2020   Phase 0   ChiCTR2000037239   China;
   Shanghai Jiao Tong University School of Medicine affiliated Shanghai General Hospital
      2020   Phase 0   ChiCTR2000032616   China;
   The First Affiliated Hospital of Chengdu Medical College
      2019   Phase 0   ChiCTR1900027306   China;
   The First Affiliated Hospital, Sun Yat-sen University
      2021   Phase 0   ChiCTR2100044662   China;
   Tongji hospital, Tongji University
      2019   -   ChiCTR1800015757   China;
   Xiangyang Hospital, Hubei University of Medicine
      2016   -   ChiCTR-DRD-16008778   China;
   Zhongshan Hospital, Fudan University
      2020   Phase 0   ChiCTR2000036006   China;
Gold Nanocrystals   
   Clene Nanomedicine
      2019   Phase 2   NCT03815916   United States;
Grapefruit   
   Osaka University Graduate School of Medicine Department of Neurosurgery
      2016   Phase 1   JPRN-UMIN000021236   Japan;
Green Tea Polyphenols (EGCG/ECG)   
   Xuanwu Hospital, Beijing
      2006   Phase 2   NCT00461942   China;
Group AD Anti-PD + Antidepressant   
   Teva Pharmaceutical Industries
      2009   -   NCT00955604   United States;
Group R Rasagiline   
   Teva Pharmaceutical Industries
      2009   -   NCT00955604   United States;
Group R+AD Rasagiline + Antidepressant   
   Teva Pharmaceutical Industries
      2009   -   NCT00955604   United States;
HA 1A ANTICORPO MONOCLONALE UMANO CLASSE IGM   
   BIOGEN IDEC RESEARCH LIMITED
      2018   Phase 2   EUCTR2016-004610-95-IT   Australia;Austria;Canada;France;Germany;Israel;Italy;Spain;Sweden;United Kingdom;United States;
HB-adMSCs   
   Hope Biosciences
      2019   -   NCT04064983   United States;
   Hope Biosciences Stem Cell Research Foundation
      2021   Phase 2   NCT04928287   United States;
      2021   -   NCT04772378   United States;
HEC122505MsOH   
   Sunshine Lake Pharma Co., Ltd.
      2021   Phase 1   NCT04625361   China;
HF0220   
   Hunter-Fleming Ltd
      2007   -   EUCTR2005-005791-32-SE   Sweden;United Kingdom;
      2006   Phase 2   EUCTR2005-005791-32-GB   Sweden;United Kingdom;
HP-3000 (ropinirole hydrochloride patch)   
   Hisamitsu Pharmaceutical Co., Inc.
      2011   Phase 2   JPRN-JapicCTI-111673   -
   Hisamitsu Pharmaceutical Co.,Inc.
      2015   Phase 3   JPRN-JapicCTI-152870   -
HP-3000 placebo   
   Hisamitsu Pharmaceutical Co.,Inc.
      2015   Phase 3   JPRN-JapicCTI-152870   -
      2012   Phase 2   JPRN-JapicCTI-121880   -
      2012   Phase 2   JPRN-JapicCTI-121879   -
HP-3000(ropinirole hydrochloride patch)   
   Hisamitsu Pharmaceutical Co.,Inc.
      2014   Phase 3   JPRN-JapicCTI-142748   -
      2012   Phase 2   JPRN-JapicCTI-121880   -
      2012   Phase 2   JPRN-JapicCTI-121879   -
Helicobacter pylori eradication therapy   
   University of Malaya
      2013   -   NCT02108704   Malaysia;
Heptaminol hydrochloride   
   PIERRE FABRE MEDICAMENT
      2008   Phase 3   EUCTR2007-002195-34-FR   France;
Herbal Medicinal Mixture (Roucongrong, Heshouwu etc.)   
   Fudan University
      2008   Phase 2/Phase 3   NCT00656253   China;
Hericium erinaceus mycelium   
   National Cheng-Kung University Hospital
      2020   -   NCT04428983   Taiwan;
High Protein. T-Diet plus Range   
   Vegenat, S.A.
      2010   -   NCT01192529   Spain;
High dose AFFITOPE® PD03A + Adjuvant   
   Affiris AG
      2014   Phase 1   NCT02267434   Austria;
High dose ANAVEX2-73   
   Anavex Life Sciences Corp.
      2018   Phase 2   NCT03774459   Australia;Spain;
High dose levodopa   
   Rush University Medical Center
      2018   -   NCT04956939   United States;
High-Frequency-Only Stimulation   
   The Cleveland Clinic
      2021   Phase 1   NCT05022147   United States;
Home based balance training   
   University of Arizona
      2014   -   NCT02777060   United States;
Human Amniotic Epithelial Stem Cells   
   Shanghai East Hospital
      2020   Early Phase 1   NCT04414813   -
Human Stem Cells   
   Celavie Bioscences, LLC
      2014   Phase 1   NCT02780895   Mexico;
Human neural stem cell   
   Second Affiliated Hospital of Soochow University
      2017   Phase 2/Phase 3   NCT03128450   China;
Hydrocortisone cream   
   University Medical Center Groningen
      2015   Phase 2   NCT02230930   Netherlands;
Hydrocortisone cream 10mg/g FNA Fagron   
   University Medical Center Groningen
      2015   Phase 2   EUCTR2014-000657-36-NL   Netherlands;
Hydrogen   
   Department of Neurology, Juntendo University School of Medicine
      2010   -   JPRN-UMIN000007497   Japan;
   Juntendo University Koshigaya Hospital
      2019   -   JPRN-UMIN000035602   Japan;
      2015   -   JPRN-UMIN000019090   Japan;
   Juntendo University School of Medicine, Neurology
      2013   -   JPRN-UMIN000010014   Japan;
   Nagoya University Graduate School of Medicine
      2015   -   JPRN-UMIN000019082   Japan;
   Nagoya graduate school of medicine university
      2015   -   JPRN-UMIN000019654   Japan;
   Stony Brook University
      2019   Phase 2/Phase 3   NCT03971617   United States;
Hydrolyzed guar gum   
   IRCCS San Raffaele
      2016   Phase 2   NCT04569656   Italy;
Hypoestoxide   
   University of Ibadan
      2022   Phase 1/Phase 2   NCT04858074   Nigeria;
Hypoxic Gas Mixture   
   Radboud University Medical Center
      2022   Phase 1/Phase 2   NCT05214287   Netherlands;
I-123-5-IA85380   
   National Institute of Neurological Disorders and Stroke (NINDS)
      2003   -   NCT00058721   United States;
I123   
   Tel-Aviv Sourasky Medical Center
      2013   Phase 2   NCT01931488   Israel;
IBEROGAST   
   Nantes University Hospital
      2016   Phase 2   NCT02719496   France;
INS-GSH   
   Gateway Institute for Brain Research
      2022   Phase 2   NCT05266417   United States;
IODIO IOFLUPANO-123I   
   UCB Biopharma SRL
      2021   Phase 2   EUCTR2020-003265-19-IT   Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
IOFLUPANE (123I)   
   MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
      2012   -   EUCTR2010-019894-13-IT   Italy;United States;
   Umeå University Hospital
      2015   Phase 2   EUCTR2015-003045-26-SE   Sweden;
IPT803   
   Tools4Patient
      2018   Phase 1/Phase 2   NCT03407378   Belgium;France;United States;
IPX054   
   Impax Laboratories, LLC
      2006   Phase 2   NCT00279825   United States;
      2005   Phase 2   NCT00253084   United States;
      2005   Phase 1/Phase 2   NCT00239564   United States;
IPX066   
   Impax Laboratories, LLC
      2011   Phase 3   NCT01411137   United States;
      2010   Phase 3   NCT01130493   France;Germany;Italy;United States;
      2010   Phase 3   NCT01096186   Canada;Estonia;Germany;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United States;
      2009   Phase 3   NCT00974974   Canada;France;Germany;Poland;Romania;Spain;Ukraine;United States;
      2008   Phase 2   NCT00869791   United States;
IPX066 145 mg LD   
   Impax Laboratories, LLC
      2009   Phase 3   NCT00880620   Canada;Estonia;Latvia;Lithuania;Romania;Ukraine;United States;
IPX066 195 mg LD   
   Impax Laboratories, LLC
      2009   Phase 3   NCT00880620   Canada;Estonia;Latvia;Lithuania;Romania;Ukraine;United States;
IPX066 245 mg LD   
   Impax Laboratories, LLC
      2009   Phase 3   NCT00880620   Canada;Estonia;Latvia;Lithuania;Romania;Ukraine;United States;
IPX066 95 mg LD   
   Impax Laboratories, LLC
      2009   Phase 3   NCT00880620   Canada;Estonia;Latvia;Lithuania;Romania;Ukraine;United States;
IPX066-145   
   IMPAX LABORATORIES, INC.
      2010   -   EUCTR2009-017238-39-IT   France;Germany;Italy;
   IMPAX Laboratories, Inc.
      2009   -   EUCTR2009-010193-38-LV   Estonia;Latvia;Lithuania;
      2009   -   EUCTR2009-010193-38-EE   Estonia;Latvia;Lithuania;
   IMPAX Pharmaceuticals a Division of IMPAX Laboratories, Inc.
      2009   -   EUCTR2009-010193-38-LT   Estonia;Latvia;Lithuania;
   Impax Laboratories, Inc.
      2010   -   EUCTR2009-017182-38-PL   Estonia;Germany;Latvia;Lithuania;Poland;Spain;
      2010   -   EUCTR2009-014688-37-PL   France;Germany;Poland;Spain;
      2009   Phase 3   EUCTR2009-014688-37-FR   France;Germany;Poland;Spain;
      2009   -   EUCTR2009-014688-37-ES   France;Germany;Poland;Spain;
      2009   -   EUCTR2009-014688-37-DE   France;Germany;Poland;Spain;
   Impax Laboratories, Inc. acting through its Impax Pharmaceutical Division (Impax)
      2010   -   EUCTR2009-017182-38-LV   Estonia;Germany;Latvia;Lithuania;Poland;Spain;
      2010   -   EUCTR2009-017182-38-LT   Estonia;Germany;Latvia;Lithuania;Poland;Spain;
      2010   -   EUCTR2009-017182-38-EE   Estonia;Germany;Latvia;Lithuania;Poland;Spain;
   Impax Laboratories, Inc. acting through its Impax Pharmaceuticals Division
      2010   Phase 3   EUCTR2009-017182-38-ES   Estonia;Germany;Latvia;Lithuania;Poland;Spain;
      2010   -   EUCTR2009-017182-38-DE   Estonia;Germany;Latvia;Lithuania;Poland;Spain;
   Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)
      2010   Phase 3   EUCTR2009-017238-39-FR   Belgium;France;Germany;Italy;
      2010   Phase 3   EUCTR2009-017238-39-DE   Belgium;France;Germany;Italy;
      2010   Phase 3   EUCTR2009-017238-39-BE   Belgium;France;Germany;Italy;
IPX066-195   
   IMPAX LABORATORIES, INC.
      2010   -   EUCTR2009-017238-39-IT   France;Germany;Italy;
   IMPAX Laboratories, Inc.
      2009   -   EUCTR2009-010193-38-LV   Estonia;Latvia;Lithuania;
      2009   -   EUCTR2009-010193-38-EE   Estonia;Latvia;Lithuania;
   IMPAX Pharmaceuticals a Division of IMPAX Laboratories, Inc.
      2009   -   EUCTR2009-010193-38-LT   Estonia;Latvia;Lithuania;
   Impax Laboratories, Inc.
      2010   -   EUCTR2009-017182-38-PL   Estonia;Germany;Latvia;Lithuania;Poland;Spain;
      2010   -   EUCTR2009-014688-37-PL   France;Germany;Poland;Spain;
      2009   Phase 3   EUCTR2009-014688-37-FR   France;Germany;Poland;Spain;
      2009   -   EUCTR2009-014688-37-ES   France;Germany;Poland;Spain;
      2009   -   EUCTR2009-014688-37-DE   France;Germany;Poland;Spain;
   Impax Laboratories, Inc. acting through its Impax Pharmaceutical Division (Impax)
      2010   -   EUCTR2009-017182-38-LV   Estonia;Germany;Latvia;Lithuania;Poland;Spain;
      2010   -   EUCTR2009-017182-38-LT   Estonia;Germany;Latvia;Lithuania;Poland;Spain;
      2010   -   EUCTR2009-017182-38-EE   Estonia;Germany;Latvia;Lithuania;Poland;Spain;
   Impax Laboratories, Inc. acting through its Impax Pharmaceuticals Division
      2010   Phase 3   EUCTR2009-017182-38-ES   Estonia;Germany;Latvia;Lithuania;Poland;Spain;
      2010   -   EUCTR2009-017182-38-DE   Estonia;Germany;Latvia;Lithuania;Poland;Spain;
   Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)
      2010   Phase 3   EUCTR2009-017238-39-FR   Belgium;France;Germany;Italy;
      2010   Phase 3   EUCTR2009-017238-39-DE   Belgium;France;Germany;Italy;
      2010   Phase 3   EUCTR2009-017238-39-BE   Belgium;France;Germany;Italy;
IPX066-245   
   IMPAX LABORATORIES, INC.
      2010   -   EUCTR2009-017238-39-IT   France;Germany;Italy;
   IMPAX Laboratories, Inc.
      2009   -   EUCTR2009-010193-38-LV   Estonia;Latvia;Lithuania;
      2009   -   EUCTR2009-010193-38-EE   Estonia;Latvia;Lithuania;
   IMPAX Pharmaceuticals a Division of IMPAX Laboratories, Inc.
      2009   -   EUCTR2009-010193-38-LT   Estonia;Latvia;Lithuania;
   Impax Laboratories, Inc.
      2010   -   EUCTR2009-017182-38-PL   Estonia;Germany;Latvia;Lithuania;Poland;Spain;
      2010   -   EUCTR2009-014688-37-PL   France;Germany;Poland;Spain;
      2009   -   EUCTR2009-014688-37-ES   France;Germany;Poland;Spain;
      2009   -   EUCTR2009-014688-37-DE   France;Germany;Poland;Spain;
   Impax Laboratories, Inc. acting through its Impax Pharmaceutical Division (Impax)
      2010   -   EUCTR2009-017182-38-LV   Estonia;Germany;Latvia;Lithuania;Poland;Spain;
      2010   -   EUCTR2009-017182-38-LT   Estonia;Germany;Latvia;Lithuania;Poland;Spain;
      2010   -   EUCTR2009-017182-38-EE   Estonia;Germany;Latvia;Lithuania;Poland;Spain;
   Impax Laboratories, Inc. acting through its Impax Pharmaceuticals Division
      2010   Phase 3   EUCTR2009-017182-38-ES   Estonia;Germany;Latvia;Lithuania;Poland;Spain;
      2010   -   EUCTR2009-017182-38-DE   Estonia;Germany;Latvia;Lithuania;Poland;Spain;
   Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)
      2010   Phase 3   EUCTR2009-017238-39-FR   Belgium;France;Germany;Italy;
      2010   Phase 3   EUCTR2009-017238-39-DE   Belgium;France;Germany;Italy;
      2010   Phase 3   EUCTR2009-017238-39-BE   Belgium;France;Germany;Italy;
IPX066-95   
   IMPAX LABORATORIES, INC.
      2010   -   EUCTR2009-017238-39-IT   France;Germany;Italy;
   IMPAX Laboratories, Inc.
      2009   -   EUCTR2009-010193-38-LV   Estonia;Latvia;Lithuania;
      2009   -   EUCTR2009-010193-38-EE   Estonia;Latvia;Lithuania;
   IMPAX Pharmaceuticals a Division of IMPAX Laboratories, Inc.
      2009   -   EUCTR2009-010193-38-LT   Estonia;Latvia;Lithuania;
   Impax Laboratories, Inc.
      2010   -   EUCTR2009-017182-38-PL   Estonia;Germany;Latvia;Lithuania;Poland;Spain;
      2010   -   EUCTR2009-014688-37-PL   France;Germany;Poland;Spain;
      2009   Phase 3   EUCTR2009-014688-37-FR   France;Germany;Poland;Spain;
      2009   -   EUCTR2009-014688-37-ES   France;Germany;Poland;Spain;
      2009   -   EUCTR2009-014688-37-DE   France;Germany;Poland;Spain;
   Impax Laboratories, Inc. acting through its Impax Pharmaceutical Division (Impax)
      2010   -   EUCTR2009-017182-38-LV   Estonia;Germany;Latvia;Lithuania;Poland;Spain;
      2010   -   EUCTR2009-017182-38-LT   Estonia;Germany;Latvia;Lithuania;Poland;Spain;
      2010   -   EUCTR2009-017182-38-EE   Estonia;Germany;Latvia;Lithuania;Poland;Spain;
   Impax Laboratories, Inc. acting through its Impax Pharmaceuticals Division
      2010   Phase 3   EUCTR2009-017182-38-ES   Estonia;Germany;Latvia;Lithuania;Poland;Spain;
      2010   -   EUCTR2009-017182-38-DE   Estonia;Germany;Latvia;Lithuania;Poland;Spain;
   Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)
      2010   Phase 3   EUCTR2009-017238-39-FR   Belgium;France;Germany;Italy;
      2010   Phase 3   EUCTR2009-017238-39-DE   Belgium;France;Germany;Italy;
      2010   Phase 3   EUCTR2009-017238-39-BE   Belgium;France;Germany;Italy;
IPX203   
   Impax Laboratories, LLC
      2020   Phase 3   EUCTR2018-002234-21-GB   Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-002233-37-PL   Canada;Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 3   NCT03877510   Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002234-21-ES   Czech Republic;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002234-21-DE   Czech Republic;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002234-21-CZ   Czech Republic;Czechia;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002233-37-IT   Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002233-37-GB   Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002233-37-DE   Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002233-37-CZ   Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2015   Phase 2   NCT02271503   United States;
IPX203 ER CD-LD   
   Impax Laboratories, LLC
      2018   Phase 3   NCT03670953   Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
IR CD-LD   
   Impax Laboratories, Inc.
      2010   -   EUCTR2009-014688-37-PL   France;Germany;Poland;Spain;
      2009   Phase 3   EUCTR2009-014688-37-FR   France;Germany;Poland;Spain;
      2009   -   EUCTR2009-014688-37-ES   France;Germany;Poland;Spain;
      2009   -   EUCTR2009-014688-37-DE   France;Germany;Poland;Spain;
   Impax Laboratories, LLC
      2018   Phase 3   NCT03670953   Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2016   Phase 2   NCT03007888   United States;
      2009   Phase 3   NCT00974974   Canada;France;Germany;Poland;Romania;Spain;Ukraine;United States;
      2008   Phase 2   NCT00869791   United States;
IR CD-LD (carbidopa-levodopa) tablets   
   Impax Laboratories, LLC
      2020   Phase 3   EUCTR2018-002233-37-PL   Canada;Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002233-37-IT   Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002233-37-GB   Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002233-37-DE   Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002233-37-CZ   Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
IR LD / CD   
   NEURODERM LTD.
      2020   Phase 3   EUCTR2018-004156-37-IT   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
   NeuroDerm Ltd.
      2020   Phase 3   EUCTR2018-004156-37-SK   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004156-37-SE   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004156-37-NL   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004156-37-BE   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004156-37-AT   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004156-37-CZ   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
IR LD/CD   
   NeuroDerm Ltd.
      2020   Phase 3   EUCTR2018-004156-37-PT   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
IRL752   
   Integrative Research Laboratories AB
      2017   Phase 2   EUCTR2017-001673-17-FI   Finland;Sweden;
IRL790   
   Integrative Research Laboratories AB
      2016   Phase 1/Phase 2   NCT03531060   -
   Integrative Research Laboratories AB (IRLAB)
      2019   Phase 2   EUCTR2017-003458-18-SE   Sweden;
      2017   Phase 2   EUCTR2017-003458-18-GB   Sweden;United Kingdom;
   Integrative Research Laboratories Sweden AB
      2021   Phase 2   EUCTR2020-002010-41-IT   France;Israel;Italy;Poland;Serbia;United States;
   Integrative Research Laboratories Sweden AB (IRLAB)
      2020   Phase 2   EUCTR2020-002010-41-FR   France;Israel;Italy;Poland;Serbia;United States;
IRX4204   
   Io Therapeutics
      2014   Phase 1   NCT02438215   United States;
ISC-hpNSC   
   Cyto Therapeutics Pty Limited
      2016   Phase 1   NCT02452723   Australia;
ITI-214   
   Intra-Cellular Therapies, Inc.
      2017   Phase 1/Phase 2   NCT03257046   United States;
IV Apomorphine   
   National Institute of Neurological Disorders and Stroke (NINDS)
      2002   Phase 2   NCT00040209   United States;
IV Levodopa   
   National Institute of Neurological Disorders and Stroke (NINDS)
      2005   Phase 2   NCT00108667   United States;
      2002   Phase 2   NCT00040209   United States;
      2001   Phase 2   NCT00013624   United States;
      2001   Phase 2   NCT00009048   United States;
      2000   Phase 2   NCT00006337   United States;
IZD174   
   Inflazome UK Ltd
      2020   Phase 1   NCT04338997   -
Idebenone   
   Second Affiliated Hospital of Soochow University
      2019   Phase 4   NCT03727295   -
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2020   Phase 2/Phase 3   NCT04152655   China;
IkT-148009   
   Inhibikase Therapeutics, Inc.
      2021   Phase 1   NCT04350177   United States;
Immediate Release carbidopa/levodopa 10/   
   Intec Pharma, Ltd.
      2016   Phase 3   EUCTR2015-003512-20-SK   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003512-20-HU   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003512-20-ES   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
Immediate Release carbidopa/levodopa 25/   
   INTEC PHARMA LTD
      2016   Phase 3   EUCTR2015-003512-20-IT   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
   Intec Pharma, Ltd.
      2016   Phase 3   EUCTR2015-003512-20-SK   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003512-20-PL   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003512-20-HU   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003512-20-GB   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003512-20-ES   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
Immediate release carbidopa/levodopa   
   Novartis
      2008   Phase 4   NCT00642356   United States;
   Novartis Pharmaceuticals
      2004   Phase 3   NCT00099268   Austria;Belgium;Canada;Finland;France;Germany;Greece;Italy;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
Impact   
   Oregon Research Institute
      2008   Phase 2   NCT00611481   United States;
Inbrija   
   University of Texas Southwestern Medical Center
      2022   -   NCT04957095   United States;
Incobotulinum Toxin A   
   Beth Israel Deaconess Medical Center
      2012   Phase 2   NCT01653132   United States;
      2012   Phase 2   NCT01565395   United States;
IncobotulinumtoxinA   
   Yale University
      2012   Phase 2   NCT02419313   United States;
IncobotulinumtoxinA (100 Units)   
   Merz Pharmaceuticals GmbH
      2014   Phase 3   NCT02091739   Germany;Poland;United States;
IncobotulinumtoxinA (75 Units)   
   Merz Pharmaceuticals GmbH
      2014   Phase 3   NCT02091739   Germany;Poland;United States;
Infudopa i.v.   
   Vastra Gotaland Region
      2018   Phase 1   NCT03419806   Sweden;
Infudopa s.c.   
   Vastra Gotaland Region
      2018   Phase 1   NCT03419806   Sweden;
Infusion Pump: CADD-Legacy® 1400 Pump   
   AbbVie (prior sponsor, Abbott)
      2011   Phase 2   NCT01479127   Japan;
Infusions of young plasma   
   Stanford University
      2016   Phase 1   NCT02968433   United States;
Inhaled VR040   
   South Glasgow University Hospitals NHS Trust
      2006   Phase 2   NCT01683292   United Kingdom;
Injection of Umbilical cord derived MSCs   
   University of Jordan
      2018   Phase 1/Phase 2   NCT03684122   Jordan;
Injection of apomorphine   
   University Hospital, Toulouse
      2011   Phase 3   NCT01504178   France;
Injection of normal saline   
   Yonsei University
      2013   Phase 1/Phase 2   NCT02018406   Korea, Republic of;
Inosine   
   Dept. of Clinical pharmacology and Neurology
      2016   Phase 1   JPRN-UMIN000009062   Japan;
   Ehime University Graduate School of Medicine
      2016   Phase 2   JPRN-UMIN000020527   Japan;
   Kamatani Naoyuki
      2019   Phase 1   JPRN-jRCTs031190115   Japan;
   Michael Alan Schwarzschild
      2016   Phase 3   NCT02642393   Puerto Rico;United States;
   Nagai Masahiro
      2016   Phase 2   JPRN-jRCTs061180060   Japan;
   StaGen Co. Ltd.
      2018   -   JPRN-UMIN000030930   Japan;
   The Parkinson Study Group
      2009   Phase 2   NCT00833690   United States;
   Tsukuba International Clinical Pharmacology Clinic
      2016   -   JPRN-UMIN000024312   Japan;
Inspiratory Muscle Training   
   Bezmialem Vakif University
      2018   -   NCT04228887   Turkey;
Insulin   
   dr.dargahi
      2020   Phase 2   NCT04687878   Iran, Islamic Republic of;
Intracerebral microinjections   
   NeuroGeneration
      2021   Phase 1/Phase 2   NCT03309514   -
Intranasal Insulin   
   Peter Novak
      2014   Phase 2   NCT02064166   United States;
Intranasal glutathione - (in)GSH   
   Bastyr University
      2012   Phase 1   NCT01398748   United States;
Intravenous Infusion   
   VA Office of Research and Development
      2019   -   NCT04064294   United States;
Intravenous Levodopa   
   National Institute of Neurological Disorders and Stroke (NINDS)
      2004   Phase 2   NCT00089622   United States;
      2004   Phase 2   NCT00086294   United States;
      2004   Phase 2   NCT00076674   United States;
Intravenous and Oral n-acetyl cysteine   
   Thomas Jefferson University
      2014   -   NCT02445651   United States;
Intravesical injection of Botulinum A toxin   
   University Of Perugia
      2008   Phase 4   NCT00822913   -
Ioflupane   
   Weill Medical College of Cornell University
      2018   Phase 1/Phase 2   NCT03675282   United States;
Ioflupane 123I (DATSCAN®)   
   University Hospital, Toulouse
      2009   Phase 2   NCT00940914   France;
Ioflupane I 123   
   Julie Gurwell
      2018   -   NCT03531086   United States;
Ioflupane [123 I]   
   Institute for Neurodegenerative Disorders
      2005   -   EUCTR2004-001485-41-GB   Spain;United Kingdom;
      2005   -   EUCTR2004-001485-41-AT   Austria;Spain;United Kingdom;
Ioflupane [123I]   
   Institute for Neurodegenerative Disorders
      2005   -   EUCTR2004-001485-41-ES   Spain;United Kingdom;
Ipratropium bromide (drug)   
   University Health Network, Toronto
      2004   Phase 2   NCT00296946   Canada;
Ips-nsc cells   
   Allife Medical Science and Technology Co., Ltd.
      2019   Early Phase 1   NCT03815071   -
Isicom   
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2010   -   EUCTR2009-017416-33-DE   Germany;
Isoflurane   
   Columbia University
      2003   -   NCT00615472   United States;
Isradipine   
   University of Rochester
      2014   Phase 3   NCT02168842   Canada;United States;
Isradipine CR   
   Northwestern University
      2009   Phase 2   NCT00909545   Canada;United States;
Istradefylline   
   Fukuoka University
      2016   -   JPRN-UMIN000024536   Japan;
   Hatano Taku
      2019   -   JPRN-jRCTs031180248   Japan;
   Ichinomiya Nishi Hospital
      2019   -   JPRN-UMIN000037422   Japan;
      2019   -   JPRN-UMIN000037421   Japan;
   Juntendo University Shizuoka Hospital
      2016   -   JPRN-UMIN000020288   Japan;
   KYOWA HAKKO UK LTD
      2005   -   EUCTR2004-002844-93-IT   Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2004-000817-20-IT   Italy;Latvia;Lithuania;Spain;
   Kyowa Hakko Kirin Company, Limited
      2009   Phase 3   NCT00957203   Japan;
      2009   Phase 3   NCT00955526   Japan;
      2007   Phase 2   NCT00455507   Japan;
   Kyowa Hakko Kirin Pharma, Inc.
      2013   Phase 3   NCT01968031   Canada;Czech Republic;Czechia;Germany;Israel;Italy;Poland;Serbia;United States;
   Kyowa Hakko U.K. Limited
      2005   -   EUCTR2004-002844-93-LV   Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2004-002844-93-LT   Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2004-002844-93-GB   Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2004-002844-93-ES   Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2004-002844-93-EE   Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2004-002844-93-AT   Austria;Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2004-000817-20-AT   Austria;Italy;Latvia;Lithuania;Spain;
      2004   Phase 3   EUCTR2004-000817-20-GB   Austria;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2004   -   EUCTR2004-000817-20-LV   Italy;Latvia;Lithuania;Spain;
      2004   -   EUCTR2004-000817-20-LT   Italy;Latvia;Lithuania;Spain;
      2004   -   EUCTR2004-000817-20-ES   Italy;Latvia;Lithuania;Spain;
   Kyowa Kirin Pharmaceutical Development, Inc.
      2005   Phase 3   NCT00199381   United States;
      2002   Phase 2/Phase 3   NCT00955045   United States;
   Osaka Red Cross Hospital
      2017   -   JPRN-UMIN000026492   Japan;
   Takahashi Makio
      2017   -   JPRN-jRCTs051180185   Japan;
   Tsuboi Yoshio
      2017   -   JPRN-jRCTs071180014   Japan;N A;
   University of Chicago
      2005   Phase 3   NCT00203957   United States;
Istradefylline ( KW-6002)   
   Kyowa Kirin Pharmaceutical Development, Inc.
      2004   Phase 3   NCT00199368   United States;
Istradefylline (KW-6002)   
   Kyowa Hakko Kirin Company, Limited
      2005   Phase 2   NCT00250393   Japan;
      2005   Phase 2   NCT00199355   Japan;
   Kyowa Hakko Kirin UK, Ltd.
      2004   Phase 3   NCT00199394   United Kingdom;
   Kyowa Kirin Pharmaceutical Development, Inc.
      2005   Phase 2   NCT00199433   United States;
      2004   Phase 3   NCT00199420   United States;
      2004   Phase 3   NCT00199407   United States;
      2002   Phase 2   NCT00456794   United States;
Istradefylline 20 mg or   
   Kyowa Hakko Kirin Pharma, Inc.
      2015   Phase 3   NCT02610231   Canada;Czech Republic;Czechia;Germany;Israel;Italy;Poland;Serbia;United States;
J-tube   
   AbbVie
      2013   Phase 3   NCT01960842   Japan;Korea, Republic of;Taiwan;
   AbbVie (prior sponsor, Abbott)
      2009   Phase 3   NCT00660387   New Zealand;United States;
      2009   Phase 3   NCT00360568   Germany;New Zealand;United States;
      2009   Phase 3   NCT00357994   Germany;United States;
      2008   Phase 3   NCT00335153   Australia;Canada;Czech Republic;Finland;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
JM-010   
   Bukwang Pharmaceutical
      2015   Phase 2   NCT02439203   South Africa;
   Contera Pharma
      2020   Phase 2   EUCTR2017-003415-19-IT   France;Germany;Italy;Spain;
      2018   Phase 2   EUCTR2017-003415-19-ES   France;Germany;Spain;
JM-010 group A   
   Contera Pharma
      2019   Phase 2   NCT03956979   France;Germany;Italy;Spain;
JM-010 group B   
   Contera Pharma
      2019   Phase 2   NCT03956979   France;Germany;Italy;Spain;
JNJ-31001074   
   BENEVOLENTAI BIO
      2017   Phase 2   EUCTR2017-000877-35-IT   Czech Republic;Czechia;Germany;Italy;Poland;Spain;United Kingdom;United States;
   BenevolentAI Bio
      2017   Phase 2   EUCTR2017-000877-35-GB   Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-000877-35-ES   Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-000877-35-DE   Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-000877-35-CZ   Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
JNJ31-31001074   
   BENEVOLENTAI BIO
      2017   Phase 2   EUCTR2017-000877-35-IT   Czech Republic;Czechia;Germany;Italy;Poland;Spain;United Kingdom;United States;
JP 1730   
   National Institute of Neurological Disorders and Stroke (NINDS)
      2002   Phase 2   NCT00040209   United States;
JP-1730/F01   
   Juvantia Pharma Ltd
      2008   -   EUCTR2007-004890-24-PT   France;Portugal;
      2008   -   EUCTR2007-004890-24-FR   France;Portugal;
JP-1730/F02   
   Juvantia Pharma Ltd
      2008   -   EUCTR2007-004890-24-PT   France;Portugal;
      2008   -   EUCTR2007-004890-24-FR   France;Portugal;
JP-1730/F03   
   Juvantia Pharma Ltd
      2008   -   EUCTR2007-004890-24-PT   France;Portugal;
      2008   -   EUCTR2007-004890-24-FR   France;Portugal;
JZP-110   
   Jazz Pharmaceuticals
      2017   Phase 2   NCT03037203   United States;
Jejunal extension tube   
   AbbVie
      2017   Phase 3   NCT02799381   Finland;Greece;Hungary;Italy;Slovakia;Spain;United States;
Jejunal extension tube (J-tube)   
   AbbVie (prior sponsor, Abbott)
      2006   Phase 4   NCT00141518   Norway;Sweden;
Juvit D3   
   Medical University of Gdansk
      2019   -   NCT04768023   Poland;
K0706   
   Sun Pharma Advanced Research Company (SPARC) Limited
      2019   Phase 2   EUCTR2018-003337-15-SK   Hungary;India;Poland;Slovakia;Spain;United States;
      2019   Phase 2   EUCTR2018-003337-15-HU   Hungary;India;Poland;Slovakia;Spain;United States;
      2019   Phase 2   EUCTR2018-003337-15-ES   Czech Republic;Hungary;India;Poland;Slovakia;Spain;United States;
   Sun Pharma Advanced Research Company Limited
      2019   Phase 2   NCT03655236   Hungary;India;Poland;Slovakia;Spain;United States;
      2017   Phase 1   NCT02970019   United States;
KDT-3594   
   Kissei Pharmaceutical Co., Ltd.
      2021   Phase 2   NCT04867551   Japan;
      2019   Phase 2   NCT03845387   Japan;
      2017   Phase 1   NCT03068481   Japan;
KM-819   
   Kainos Medicine Inc.
      2016   Phase 1   NCT03022799   Korea, Republic of;
KW-6002   
   KYOWA HAKKO UK LTD
      2005   -   EUCTR2004-002844-93-IT   Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2004-000817-20-IT   Italy;Latvia;Lithuania;Spain;
   Kyowa Hakko U.K. Limited
      2005   -   EUCTR2004-002844-93-LV   Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2004-002844-93-LT   Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2004-002844-93-GB   Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2004-002844-93-ES   Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2004-002844-93-EE   Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2004-002844-93-AT   Austria;Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2004-000817-20-AT   Austria;Italy;Latvia;Lithuania;Spain;
      2004   Phase 3   EUCTR2004-000817-20-GB   Austria;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2004   -   EUCTR2004-000817-20-LV   Italy;Latvia;Lithuania;Spain;
      2004   -   EUCTR2004-000817-20-LT   Italy;Latvia;Lithuania;Spain;
      2004   -   EUCTR2004-000817-20-ES   Italy;Latvia;Lithuania;Spain;
   National Institute of Neurological Disorders and Stroke (NINDS)
      2000   Phase 2   NCT00006337   United States;
KW-6002 (istradefylline)   
   KYOWA HAKKO KIRIN PHARMA, INC.
      2016   Phase 3   EUCTR2015-003887-34-IT   Canada;Czech Republic;Germany;Israel;Italy;Poland;Serbia;United States;
   Kyowa Hakko Kirin Pharma, Inc.
      2014   Phase 3   EUCTR2013-002254-70-IT   Canada;Czech Republic;Germany;Israel;Italy;Poland;Serbia;United States;
   Kyowa Kirin Pharmaceutical Development, Inc.
      2016   Phase 3   EUCTR2015-003887-34-PL   Canada;Czech Republic;Germany;Israel;Poland;Serbia;United States;
      2016   Phase 3   EUCTR2015-003887-34-DE   Canada;Czech Republic;Germany;Israel;Poland;Serbia;United States;
      2016   Phase 3   EUCTR2015-003887-34-CZ   Canada;Czech Republic;Germany;Israel;Poland;Serbia;United States;
      2014   Phase 3   EUCTR2013-002254-70-PL   Canada;Czech Republic;Germany;Israel;Poland;Serbia;United States;
      2014   Phase 3   EUCTR2013-002254-70-DE   Canada;Czech Republic;Germany;Israel;Poland;Serbia;United States;
      2014   Phase 3   EUCTR2013-002254-70-CZ   Canada;Czech Republic;Germany;Israel;Poland;Serbia;United States;
      2002   Phase 2   NCT00456586   United States;
KW-6356   
   Kyowa Kirin Co., Ltd.
      2020   Phase 1   NCT04342273   Japan;
      2019   Phase 1   NCT04070495   Japan;
      2019   Phase 1   NCT03970798   Japan;
      2018   Phase 2   NCT03703570   Japan;
      2016   Phase 2   NCT02939391   Japan;
KW-6356 High Dose   
   Kyowa Kirin Co., Ltd.
      2019   Phase 1   NCT03830528   Japan;
KW-6356 Low Dose   
   Kyowa Kirin Co., Ltd.
      2019   Phase 1   NCT03830528   Japan;
KW-6356 Middle Dose   
   Kyowa Kirin Co., Ltd.
      2019   Phase 1   NCT03830528   Japan;
KW-6356 X Dose   
   Kyowa Kirin Co., Ltd.
      2019   Phase 1   NCT03830528   Japan;
KW-6356 Y Dose   
   Kyowa Kirin Co., Ltd.
      2019   Phase 1   NCT03830528   Japan;
KW-6500   
   Kyowa Hakko Kirin Co., Ltd
      2010   Phase 3   NCT01063621   Japan;
      2010   Phase 3   NCT01058291   Japan;
      2009   Phase 3   NCT00955318   Japan;
Ketamine   
   PharmaTher Inc.
      2021   Phase 2   NCT04912115   United States;
Ketamine Infusion   
   Yale University
      2021   Phase 2   NCT04944017   United States;
Ketone Ester Elite endurance Nutrition Drink   
   University of Florida
      2019   -   NCT04477161   United States;
Ketone ester drink   
   University of Oxford
      2011   -   NCT01364545   United Kingdom;
Kinetra and Soletra (neurostimulator, Medtronic)   
   German Parkinson Study Group (GPS)
      2006   Phase 4   NCT00354133   France;Germany;
Kinoquinone (proposed)   
   BioElectron Technology Corporation (formerly Edison Pharmaceuticals Inc.)
      2016   Phase 2   EUCTR2015-001786-10-DE   Germany;United Kingdom;United States;
L-123 Ioflupane   
   Wisconsin Institute for Neurologic and Sleep Disorders S.C.
      2014   -   NCT02138682   United States;
L-3-(3,4-Dihydroxyphenyl)alanine   
   Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
      2007   -   EUCTR2006-000577-29-DE   Germany;United States;
L-DOPA   
   Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
      2007   -   EUCTR2006-000577-29-DE   Germany;United States;
   Ito Hidefumi
      2016   Phase 2   JPRN-jRCTs051180098   Japan;
   Osaka Redcross HospitalWakayama Prefectural Medical College
      2016   Phase 2   JPRN-UMIN000022533   Japan;
   Utano National Hospital, National Hospital Organization
      2016   Phase 3   JPRN-UMIN000022529   Japan;
L-DOPA/DDCI   
   Bial - Portela C S.A.
      2021   Phase 4   NCT04990284   -
L-DOPS   
   St. Joseph's Hospital and Medical Center, Phoenix
      2016   Phase 2   NCT02812147   United States;
L-Dopa/ MODOPAR   
   Chru de Lille
      2009   -   EUCTR2008-008210-38-FR   France;
L-tyrosine   
   New York Institute of Technology
      2014   Phase 0   NCT02259049   United States;
LCIG   
   NeuroDerm Ltd.
      2015   Phase 1   NCT02604914   United Kingdom;
LCIG (Duodopa)   
   Vastra Gotaland Region
      2018   Phase 1   NCT03419806   Sweden;
LD / BE   
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2011   -   EUCTR2010-022363-35-DE   Germany;
LD+DDCI   
   ASST Gaetano Pini-CTO
      2016   Phase 2   NCT02680977   Bolivia;
LD-DDCI   
   ASST Gaetano Pini-CTO
      2016   Phase 2   NCT02680977   Bolivia;
LD/CD   
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2010   -   EUCTR2009-017416-33-DE   Germany;
LEVODOPA (DC.IT) (FU)   
   NOVARTIS FARMA
      2004   -   EUCTR2004-000185-12-IT   Finland;Italy;Sweden;United Kingdom;
LEVODOPA (LD)   
   NEURODERM LTD.
      2016   Phase 2   EUCTR2015-005814-31-IT   Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States;
LEVODOPA / BENSERAZIDE 200 +   
LEVODOPA DC.IT FU   
   VERNALIS DEVELOPMENT LIMITED
      2006   -   EUCTR2006-004112-51-IT   Italy;
LEVODOPA INN   
   NOVARTIS FARMA
      2005   -   EUCTR2005-001032-72-IT   Czech Republic;Italy;Portugal;
LEVODOPA/BENZERASIDE   
   CHU de Poitiers
      2010   -   EUCTR2010-020769-25-FR   France;
LEVODOPA/CARBIDOPA   
   CHU de Poitiers
      2010   -   EUCTR2010-020769-25-FR   France;
LODALÈS®   
   CHU de Bordeaux
      2009   -   EUCTR2009-011736-35-FR   France;
LY03003   
   Luye Pharma Group Ltd.
      2020   Phase 1   NCT04630860   China;
      2018   Phase 1   NCT04629404   China;
      2018   Phase 1   NCT03733561   United States;
      2018   Phase 1   NCT03589066   United States;
      2013   Phase 1   NCT04627155   -
      2013   Phase 1   NCT02055274   United States;
LY03003 ( Rotigotine, extended-release microspheres)   
   Luye Pharma Group Ltd.
      2017   Phase 1   NCT04045678   China;
LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)   
   Luye Pharma Group Ltd.
      2020   Phase 1   NCT04384666   United States;
LY03003( the name of rotigotine)   
   Peking University Third Hospital
      2018   Phase 3   NCT04455555   China;
LY03003(Rotigotine,extended-release microspheres)   
   Luye Pharma Group Ltd.
      2020   Phase 3   NCT04571164   China;
LY03009 F1   
   Luye Pharma Group Ltd.
      2021   Phase 1   NCT04593511   Australia;
LY03009 F2   
   Luye Pharma Group Ltd.
      2021   Phase 1   NCT04593511   Australia;
LY03009 F3   
   Luye Pharma Group Ltd.
      2021   Phase 1   NCT04593511   Australia;
LY03009 F4   
   Luye Pharma Group Ltd.
      2021   Phase 1   NCT04593511   Australia;
LY300164   
   National Institute of Neurological Disorders and Stroke (NINDS)
      2000   Phase 2   NCT00004576   United States;
LY3154207   
   Eli Lilly and Company
      2017   Phase 2   NCT03305809   Canada;China;Puerto Rico;United States;
      2015   Phase 1   NCT02562768   United States;
Lactobacillus casei DG (Enterolactis duo®)   
   University of Salerno
      2019   -   NCT04293159   Italy;
Lactobacillus plantarum PS128   
   Professor Lu Neurological Clinic
      2018   -   NCT03566589   Taiwan;
Lactose   
   Ehime University Graduate School of Medicine
      2016   Phase 2   JPRN-UMIN000020527   Japan;
   Kansai Medical University
      2012   -   JPRN-UMIN000007896   Japan;
   Utano National Hospital, National Hospital Organization
      2016   Phase 3   JPRN-UMIN000022529   Japan;
Leptin   
   Nagoya University Graduate School of Medicine
      2015   -   JPRN-UMIN000017036   Japan;
Levetiracetam   
   1st Hospital of Social Security Services
      2006   Phase 2   NCT00291733   Greece;
   Technische Universität Dresden
      2006   Phase 4   NCT00307450   Germany;
   The University of Queensland
      2021   Phase 2   NCT04643327   Australia;
   UCB Pharma
      2003   Phase 2   NCT00160576   -
   University of South Florida
      2007   Phase 4   NCT00584025   United States;
Levodopa   
   AbbVie Inc
      2011   Phase 3   EUCTR2008-001329-33-GB   Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
      2010   Phase 3   EUCTR2008-001329-33-CZ   Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
      2009   -   EUCTR2008-001329-33-PT   Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
   Abbott Healthcare Products B.V.
      2009   -   EUCTR2006-005186-18-CZ   Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2008   Phase 3   EUCTR2006-005186-18-GB   Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2008   -   EUCTR2006-005186-18-PT   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2006-005186-18-DE   Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
   Abbott Laboratories
      2009   -   EUCTR2006-000578-53-DE   Germany;New Zealand;United States;
   Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
      2007   -   EUCTR2006-000577-29-DE   Germany;United States;
   Bial - Portela C S.A.
      2011   Phase 3   NCT01568073   Austria;Portugal;
      2011   Phase 3   NCT01227655   Portugal;
   CHU de Toulouse
      2010   Phase 3   EUCTR2010-018650-12-FR   France;
   Chinese Academy of Sciences
      2017   Phase 1/Phase 2   NCT03119636   China;
   CleveXel Pharma
      2016   Phase 2   NCT02641054   France;
   Department of Neurology, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital
      2014   -   ChiCTR-DDD-17010794   China;
   Department of Neuroscience, neurology
      2007   -   EUCTR2007-004985-41-SE   Sweden;
   Dept of Neuroscience, Uppsala University
      2008   -   EUCTR2008-003581-26-SE   Sweden;
   First Affiliated Hospital of Xinjiang Medical University
      2007   -   ChiCTR-TRC-07000027   China;
   Fujita Health University School of MedicineDepartment of Gastroenterology
      2020   Phase 4   JPRN-UMIN000040889   Japan;
   GlaxoSmithKline
      2011   -   NCT01545856   -
   Hamamatsu University School of Medicine
      2015   -   JPRN-UMIN000019524   Japan;
   Hatano Taku
      2019   -   JPRN-jRCTs031180248   Japan;
   Institute for Neurodegenerative Disorders
      2004   Phase 2   NCT00096720   United States;
   Institute of Clinical Pharmacology, Central South University
      2012   -   ChiCTR-OCS-12002720   -
   Institute of Psychology, Chinese Academy of Sciences
      2018   -   ChiCTR1800015331   China;
   Juntendo University School of Medicine
      2017   -   JPRN-UMIN000025645   Japan;
   Kansai Medical University
      2012   -   JPRN-UMIN000007896   Japan;
   Kevin J. Black, MD
      2017   Phase 1   NCT03205956   United States;
   Merck Sharp & Dohme Corp.
      2009   Phase 1   NCT00845000   United States;
   National Institute of Neurological Disorders and Stroke (NINDS)
      1998   Phase 3   NCT00004733   United States;
   Oregon Health and Science University
      2005   -   NCT00692328   United States;
   Orion Corporation Orion Pharma
      2007   -   EUCTR2007-002496-14-FI   Finland;
      2006   Phase 4   EUCTR2006-001755-36-GB   Germany;Sweden;United Kingdom;
      -   -   EUCTR2006-001755-36-DE   Germany;Sweden;United Kingdom;
   Orion Corporation Orion Pharma, FI-02200 Espoo, Finland
      2006   -   EUCTR2006-001755-36-SE   Germany;Sweden;United Kingdom;
   Orion Corporation, ORION PHARMA
      2005   -   EUCTR2004-005234-39-FI   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2004   -   EUCTR2004-000185-12-FI   Finland;Italy;Sweden;United Kingdom;
   Orion Corporation, ORION PHARMA, Finland
      2005   Phase 4   EUCTR2004-005234-39-GB   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
   Orion Corporation, ORION PHARMA, 02200 Espoo, Finland
      2008   -   EUCTR2004-005234-39-DE   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2004-000185-12-GB   Austria;Finland;Italy;Sweden;United Kingdom;
      2006   -   EUCTR2004-005234-39-LV   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2006   -   EUCTR2004-005234-39-LT   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2005   Phase 4   EUCTR2004-005234-39-IE   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2005   -   EUCTR2004-005234-39-SE   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2005   -   EUCTR2004-005234-39-DK   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2004   -   EUCTR2004-000185-12-SE   Finland;Italy;Sweden;United Kingdom;
      2004   -   EUCTR2004-000185-12-AT   Austria;Finland;Italy;Sweden;United Kingdom;
   Ouchi Yasuomi
      2015   -   JPRN-jRCTs041180070   Japan;
   Rush University Medical Center
      2011   Phase 2   NCT01351168   United States;
   Sage Therapeutics
      2016   Phase 2   NCT03000569   United States;
   Solvay Pharmaceuticals B.V.
      2009   -   EUCTR2006-005186-18-NL   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   Phase 3   EUCTR2006-005186-18-ES   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2007   -   EUCTR2006-005186-18-FI   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
   Solvay Pharmaceuticals BV.
      2008   -   EUCTR2006-005186-18-IT   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
   Solvay Pharmaceuticals GmbH
      2006   -   EUCTR2005-002654-21-NO   Norway;Sweden;
      2005   -   EUCTR2005-002654-21-SE   Sweden;
   Technische Universität Dresden
      2005   Phase 4   NCT00153972   Germany;
   The Affiliated Brain Hospital of Nanjing Medical University (Nanjing Brain Hospital)
      2020   Phase 4   ChiCTR2000039201   China;
   Tianjin Huanhu Hospital
      2019   Phase 0   ChiCTR1900025372   China;
   University Hospital, Toulouse
      2016   Phase 2/Phase 3   NCT02601586   France;
      2002   -   NCT01044992   France;
   Yagi Michio
      2021   Phase 1   JPRN-jRCT2051200104   Japan;
Levodopa (L-DOPA) + Standard care   
   Bial - Portela C S.A.
      2020   -   NCT03959540   United Kingdom;
Levodopa (L-dopa)   
   Biotie Therapies Inc.
      2011   Phase 2/Phase 3   NCT01283594   Argentina;Canada;Chile;Romania;Ukraine;United States;
Levodopa (delivered intravenously)   
   Oregon Health and Science University
      2010   -   NCT01003002   United States;
   VA Office of Research and Development
      2006   -   NCT00467597   United States;
Levodopa (drug), intraduodenal administration   
   University Hospital, Akershus
      2006   Phase 4   NCT00272688   Norway;
Levodopa / Benserazid   
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2011   -   EUCTR2010-022363-35-DE   Germany;
Levodopa 100 mg / benserazide   
   Bial - Portela C S.A.
      2005   Phase 1   NCT02778594   Portugal;
Levodopa 100 mg A CAP   
   Orion Corporation
      2017   Phase 2   EUCTR2015-004507-23-HU   Finland;Germany;Hungary;Latvia;
      2017   Phase 2   EUCTR2015-004507-23-FI   Finland;Germany;Hungary;Latvia;
      2016   Phase 2   EUCTR2015-004507-23-LV   Finland;Germany;Hungary;Latvia;
      2016   Phase 2   EUCTR2015-004507-23-DE   Finland;Germany;Hungary;Latvia;
Levodopa 125 mg A CAP   
   Orion Corporation
      2017   Phase 2   EUCTR2015-004507-23-HU   Finland;Germany;Hungary;Latvia;
      2017   Phase 2   EUCTR2015-004507-23-FI   Finland;Germany;Hungary;Latvia;
      2016   Phase 2   EUCTR2015-004507-23-LV   Finland;Germany;Hungary;Latvia;
      2016   Phase 2   EUCTR2015-004507-23-DE   Finland;Germany;Hungary;Latvia;
Levodopa 150 mg A CAP   
   Orion Corporation
      2017   Phase 2   EUCTR2015-004507-23-HU   Finland;Germany;Hungary;Latvia;
      2017   Phase 2   EUCTR2015-004507-23-FI   Finland;Germany;Hungary;Latvia;
      2016   Phase 2   EUCTR2015-004507-23-LV   Finland;Germany;Hungary;Latvia;
      2016   Phase 2   EUCTR2015-004507-23-DE   Finland;Germany;Hungary;Latvia;
Levodopa 25mg/   
   NeuroDerm Ltd.
      2019   Phase 3   NCT04006210   Austria;Belgium;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
Levodopa 75 mg A CAP   
   Orion Corporation
      2017   Phase 2   EUCTR2015-004507-23-HU   Finland;Germany;Hungary;Latvia;
      2017   Phase 2   EUCTR2015-004507-23-FI   Finland;Germany;Hungary;Latvia;
      2016   Phase 2   EUCTR2015-004507-23-LV   Finland;Germany;Hungary;Latvia;
      2016   Phase 2   EUCTR2015-004507-23-DE   Finland;Germany;Hungary;Latvia;
Levodopa Benserazide Madopar   
   IRCCS San Raffaele
      2014   Phase 4   NCT02741947   Italy;
Levodopa Benserazide Teva Italia   
   IRCCS San Raffaele
      2014   Phase 4   NCT02741947   Italy;
Levodopa CR (controlled release)   
   Research and Development University Hospital of North Staffordshire
      2014   -   EUCTR2014-000335-17-GB   United Kingdom;
Levodopa Cyclops   
   Pharmaceutical Technology and Biopharmacy, University of Groningen
      2018   Phase 2   EUCTR2017-004006-18-NL   Netherlands;
Levodopa MR   
   Orion Corporation, Orion Pharma
      2016   Phase 2   NCT02764125   Finland;Germany;Hungary;Latvia;
Levodopa acute challenge   
   Institut de Myologie, France
      2016   -   NCT02785978   France;
Levodopa and Domperidone   
   National Institute of Neurological Disorders and Stroke (NINDS)
      2000   Phase 2   NCT00006077   United States;
Levodopa and carbidopa   
   NeuroDerm Ltd.
      2013   Phase 2   NCT01883505   Israel;
Levodopa and carbidopa SC solution   
   NeuroDerm Ltd.
      2014   Phase 1/Phase 2   NCT02096601   Israel;United States;
Levodopa and carbidopa solution for SC administration   
   NeuroDerm Ltd.
      2012   Phase 1/Phase 2   NCT01725802   Israel;
Levodopa and decarboxylase inhibitor   
   AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELE
      2010   -   EUCTR2010-019396-29-IT   Italy;
   IMPAX LABORATORIES, INC.
      2010   -   EUCTR2009-017238-39-IT   France;Germany;Italy;
Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets   
   AbbVie (prior sponsor, Abbott)
      2009   Phase 3   NCT00357994   Germany;United States;
Levodopa carbidopa intestinal gel (LCIG)   
   AbbVie (prior sponsor, Abbott)
      2009   Phase 3   NCT00660387   New Zealand;United States;
      2009   Phase 3   NCT00357994   Germany;United States;
Levodopa dispersible   
   Seoul National University Hospital
      2015   Phase 4   NCT02769793   Korea, Republic of;
Levodopa infusion   
   Helsinki University
      2009   Phase 4   NCT00914134   Finland;
Levodopa powder for inhalation   
   Pharmaceutical Technology and Biopharmacy, University of Groningen
      2018   Phase 2   EUCTR2017-004006-18-NL   Netherlands;
Levodopa tablet   
   Western University, Canada
      2019   -   NCT04054960   Canada;
Levodopa, carbidopa, ODM-104   
   Orion Corporation, Orion Pharma
      2017   Phase 1   NCT03140956   Finland;
      2015   Phase 1   NCT02554734   Finland;
      2014   Phase 1   NCT02312232   Finland;
Levodopa, carbidopa, entacapone   
   Orion Corporation, Orion Pharma
      2015   Phase 1   NCT02554734   Finland;
Levodopa, decarboxylase inhibitor and COMT inhibitor   
   AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELE
      2010   -   EUCTR2010-019396-29-IT   Italy;
Levodopa-4'-Monophosphate   
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2020   Phase 3   EUCTR2019-004235-23-IT   Australia;Canada;Italy;Japan;Netherlands;Russian Federation;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002144-85-IT   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
   AbbVie Deutschland
      2020   Phase 3   EUCTR2018-002144-85-DE   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002144-85-NL   Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002144-85-GB   Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002144-85-ES   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002144-85-DK   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002144-85-BE   Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
   Abbvie Deutschland GmbH & Co. KG
      2021   Phase 3   EUCTR2019-004235-23-SE   Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-004235-23-DE   Australia;Canada;Germany;Italy;Japan;Netherlands;Russian Federation;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004235-23-NL   Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004235-23-GB   Australia;Canada;Japan;Russian Federation;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004235-23-DK   Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
Levodopa-Carbidopa   
   AbbVie
      2010   Phase 1   NCT01484990   Germany;Sweden;
Levodopa-Carbidopa Intestinal Gel   
   AbbVie (prior sponsor, Abbott)
      2013   Phase 3   NCT01736176   United States;
Levodopa-Carbidopa Intestinal Gel (LCIG)   
   AbbVie
      2017   Phase 3   NCT02799381   Finland;Greece;Hungary;Italy;Slovakia;Spain;United States;
Levodopa-Carbidopa Multilayer Extended Release Tablet   
   CombinatoRx, Inc
      2008   -   EUCTR2007-005033-11-DE   Germany;
Levodopa-Carbidopa XL tablet (M)   
   CombinatoRx, Inc
      2008   -   EUCTR2007-005033-11-DE   Germany;
Levodopa-carbidopa   
   EISAI LTD UK
      2007   -   EUCTR2006-005714-12-IT   Italy;
   Osmotica Pharmaceutical Corp.
      2007   Phase 2   NCT00558337   Argentina;
Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets   
   AbbVie (prior sponsor, Abbott)
      2009   Phase 3   NCT00660387   New Zealand;United States;
Levodopa-carbidopa Immediate Release (LC-IR) Tablets   
   AbbVie (prior sponsor, Abbott)
      2013   Phase 3   NCT01736176   United States;
Levodopa-carbidopa intestinal gel   
   AbbVie
      2013   Phase 3   NCT01960842   Japan;Korea, Republic of;Taiwan;
      2009   Phase 3   NCT00660673   Australia;Canada;Czech Republic;Czechia;Israel;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;United States;
   AbbVie (prior sponsor, Abbott)
      2009   Phase 3   NCT00360568   Germany;New Zealand;United States;
      2008   Phase 3   NCT00335153   Australia;Canada;Czech Republic;Finland;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
Levodopa-carbidopa intestinal gel (LCIG)   
   AbbVie (prior sponsor, Abbott)
      2006   Phase 4   NCT00141518   Norway;Sweden;
Levodopa-carbidopa-entacapone   
   Institut de Recerca del Hospital de la Santa Creu i Sant Pau
      2007   -   EUCTR2006-002408-32-ES   Spain;
Levodopa/Benzerazide   
   Bial - Portela C S.A.
      2010   Phase 2   NCT01568047   Romania;Ukraine;
      2009   Phase 2   NCT01568034   Portugal;Romania;Ukraine;
Levodopa/Carbidopa   
   Bial - Portela C S.A.
      2010   Phase 2   NCT01568047   Romania;Ukraine;
      2009   Phase 2   NCT01568034   Portugal;Romania;Ukraine;
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2010   -   EUCTR2009-017416-33-DE   Germany;
   Institut de Recerca del Hospital de la Santa Creu i Sant Pau
      2007   -   EUCTR2006-002408-32-ES   Spain;
Levodopa/Carbidopa (LD/CD)   
   AbbVie
      2020   Phase 3   NCT04380142   Australia;United States;
Levodopa/Carbidopa (Sinemet)   
   NeuroDerm Ltd.
      2015   Phase 1   NCT02486432   -
Levodopa/Carbidopa Solution   
   NeuroDerm Ltd.
      2020   Phase 3   EUCTR2018-004156-37-SK   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
Levodopa/Carbidopa(200mg/50mg)   
   Sandoz
      2012   Phase 4   NCT01683253   Korea, Republic of;
Levodopa/DDCI   
   Bial - Portela C S.A.
      2006   Phase 2   NCT03103399   -
Levodopa/benserazide   
   Bial - Portela C S.A.
      2009   Phase 1   NCT01533116   Canada;
Levodopa/benserazide 100/   
   Bial - Portela C S.A.
      2010   Phase 1   NCT02169414   France;
Levodopa/carbidopa   
   Bial - Portela C S.A.
      2011   Phase 1   NCT02170376   France;
      2009   Phase 1   NCT01533116   Canada;
      2009   Phase 1   NCT01519284   Portugal;
   Uppsala University
      2008   Phase 4   NCT00906828   Sweden;
      2008   Phase 4   NCT00888186   Sweden;
Levodopa/carbidopa 100/25   
   Bial - Portela C S.A.
      2010   Phase 1   NCT02169414   France;
Levodopa/carbidopa hydrate   
   ONO PHARMACEUTICAL CO.,LTD.
      2014   Phase 1   JPRN-JapicCTI-142702   -
Levodopa/carbidopa solution   
   NEURODERM LTD.
      2020   Phase 3   EUCTR2018-004156-37-IT   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
   NeuroDerm Ltd.
      2020   Phase 3   EUCTR2018-004156-37-SE   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004156-37-PT   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004156-37-NL   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004156-37-GB   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004156-37-ES   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004156-37-BE   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004156-37-AT   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004156-37-HU   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004156-37-CZ   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-002033-30-NL   Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002033-30-HU   Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002033-30-GB   Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2015-005814-31-PL   Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States;
      2017   Phase 2   EUCTR2015-005814-31-HU   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United States;
      2017   Phase 2   EUCTR2015-005814-31-ES   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United States;
      2017   Phase 2   EUCTR2015-005814-31-DE   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2015-005814-31-CZ   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States;
      2017   Phase 2   EUCTR2015-005814-31-BE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United States;
      2016   Phase 3   EUCTR2016-002033-30-FR   Belgium;Canada;Denmark;France;Hungary;Israel;Netherlands;Spain;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002033-30-ES   Belgium;Canada;Denmark;France;Israel;Netherlands;Spain;Sweden;United States;
      2016   Phase 3   EUCTR2016-002033-30-BE   Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-005814-31-AT   Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States;
      2016   Phase 2   EUCTR2015-005078-39-DE   Austria;Germany;Israel;Italy;United States;
      2016   Phase 2   EUCTR2015-005078-39-AT   Austria;Germany;Israel;Italy;United States;
Levodopa/carbidopa/entacapone   
   Novartis
      2006   Phase 4   NCT00391898   Spain;
   Novartis Pharma AG
      2006   -   EUCTR2005-001032-72-PT   Czech Republic;Italy;Portugal;
Levodopa/dopa decarboxylase inhibitor   
   Bial - Portela C S.A.
      2016   Phase 4   NCT02847442   Germany;
Liatermin   
   Amgen
      2003   Phase 1/Phase 2   NCT00111982   United States;
   North Bristol NHS Trust (NBT)
      2013   Phase 2   EUCTR2013-001881-40-GB   United Kingdom;
      2012   Phase 2   EUCTR2011-003866-34-GB   United Kingdom;
Liatermin (r-metHuGDNF)   
   Amgen
      2003   Phase 1   NCT00115427   United States;
Lidocaine   
   Dept. of Clinical pharmacology and Neurology, Ehime University
      2012   -   JPRN-UMIN000007617   Japan;
   Parkinson'
   s disease and Movement Disorder Center
Light box ( Litebook company)   
   McGill University Health Center
      2011   Phase 0   NCT01489982   Canada;
Light box (Litebook company)   
   McGill University Health Center
      2011   Phase 0   NCT01489982   Canada;
Linaclotide   
   The 988th Hospitail of Joint Logistic Support Force
      2021   Phase 4   ChiCTR2100043303   China;
Lingzhi (Ganoderma)   
   Xuanwu Hospital, Beijing
      2005   Phase 2   NCT00224263   China;
Lipopolysaccharide   
   University of Exeter
      2022   -   NCT05205291   United Kingdom;
Liquigen MCT oil   
   National Institute of Neurological Disorders and Stroke (NINDS)
      2021   Phase 1   NCT04584346   United States;
Liraglutide   
   Cedars-Sinai Medical Center
      2017   Phase 2   NCT02953665   United States;
Lisparin   
   Axxonis Pharma GmbH
      2006   -   EUCTR2005-001006-12-DE   Austria;Czech Republic;Germany;Italy;
      2006   -   EUCTR2005-001006-12-CZ   Austria;Czech Republic;Germany;Italy;
      2006   -   EUCTR2005-001006-12-AT   Austria;Czech Republic;Germany;Italy;
Lisuride Hydrogenmaleate   
   Axxonis Pharma GmbH
      2006   -   EUCTR2005-001006-12-DE   Austria;Czech Republic;Germany;Italy;
      2006   -   EUCTR2005-001006-12-CZ   Austria;Czech Republic;Germany;Italy;
      2006   -   EUCTR2005-001006-12-AT   Austria;Czech Republic;Germany;Italy;
Lisuride TTS   
   NEUROBIOTEC GMBH
      2007   -   EUCTR2006-003732-30-IT   Germany;Italy;Poland;
Lisuride TTS 10cm²   
   Axxonis Pharma AG
      2007   -   EUCTR2006-003732-30-DE   Germany;Italy;Poland;
   NeuroBiotec Pharma AG
      2008   -   EUCTR2006-003732-30-PL   Germany;Italy;Poland;
Lisuride TTS 20cm²   
   Axxonis Pharma AG
      2007   -   EUCTR2006-003732-30-DE   Germany;Italy;Poland;
   NeuroBiotec Pharma AG
      2008   -   EUCTR2006-003732-30-PL   Germany;Italy;Poland;
Lisuride Transdermal System   
   National Institute of Neurological Disorders and Stroke (NINDS)
      2004   Phase 2   NCT00089622   United States;
Lithium   
   University at Buffalo
      2019   Phase 1   NCT04273932   United States;
Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules   
   Beijing Friendship Hospital
      2021   Phase 4   NCT04871464   China;
Lixisenatide   
   University Hospital, Toulouse
      2018   Phase 2   NCT03439943   France;
Local Anesthesia (lidocaine hydrochloride)   
   Nantes University Hospital
      2014   -   NCT02236260   France;
Local Trade Name,   
   GlaxoSmithKline Research & Development Limited
      2013   -   EUCTR2011-002827-17-SK   Estonia;Korea, Republic of;Russian Federation;Slovakia;United States;
Lovastatin   
   National Taiwan University Hospital
      2017   Phase 2   NCT03242499   Taiwan;
Low dose AFFITOPE® PD03A + Adjuvant   
   Affiris AG
      2014   Phase 1   NCT02267434   Austria;
Low dose levodopa   
   Rush University Medical Center
      2018   -   NCT04956939   United States;
Low-Frequency-Only Stimulation   
   The Cleveland Clinic
      2021   Phase 1   NCT05022147   United States;
Lu 00-800   
   H. Lundbeck A/S
      2006   Phase 4   EUCTR2005-002038-36-GB   Austria;France;Germany;Greece;Italy;Spain;United Kingdom;
Lu AE04621   
   H. Lundbeck A/S
      2016   Phase 1   NCT02649608   United States;
Lu AF28996   
   H. Lundbeck A/S
      2020   Phase 1   NCT04291859   Netherlands;United States;
Lu AF82422   
   H. Lundbeck A/S
      2018   Phase 1   NCT03611569   United States;
Lubiprostone   
   Dokkyo Medical University
      2016   -   JPRN-UMIN000022023   Japan;
      2016   -   JPRN-UMIN000022022   Japan;
   University of Arkansas
      2009   -   NCT00669461   United States;
Lumbar Puncture   
   National Institute of Neurological Disorders and Stroke (NINDS)
      2017   Phase 1   NCT03104725   United States;
MANTADIX   
   CHU Toulouse
      2007   -   EUCTR2006-006684-22-FR   France;
MARS   
   Eisai Limited
      2007   Phase 3   EUCTR2007-000801-30-PL   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
      2007   Phase 3   EUCTR2007-000801-30-FR   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
      2007   Phase 3   EUCTR2007-000801-30-ES   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
      2007   Phase 3   EUCTR2006-002937-20-FR   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
      2007   -   EUCTR2007-000801-30-LV   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
      2007   -   EUCTR2007-000801-30-LT   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
      2007   -   EUCTR2007-000801-30-HU   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
      2007   -   EUCTR2007-000801-30-EE   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
      2007   -   EUCTR2007-000801-30-CZ   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
      2007   -   EUCTR2006-002937-20-HU   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
      2007   -   EUCTR2006-002937-20-ES   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
      2007   -   EUCTR2006-002339-26-PT   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-002339-26-HU   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-002339-26-ES   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-002339-26-DE   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2005-004314-33-GB   Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2005-004314-33-ES   Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2006-002937-20-LV   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
      2006   -   EUCTR2006-002937-20-LT   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
      2006   -   EUCTR2006-002937-20-EE   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
      2006   -   EUCTR2006-002937-20-CZ   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
      2006   -   EUCTR2006-002339-26-SE   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2006-002339-26-LT   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2006-002339-26-GB   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2006-002339-26-EE   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2006-002339-26-CZ   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2006-002339-26-BE   Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2006-002339-26-AT   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004314-33-SE   Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004314-33-PT   Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004314-33-LT   Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004314-33-HU   Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004314-33-EE   Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004314-33-DE   Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004314-33-CZ   Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004314-33-BE   Austria;Belgium;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2005-004314-33-AT   Austria;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2004   -   EUCTR2004-000361-35-CZ   Czech Republic;Italy;
ME2125 (safinamide mesilate)   
   Meiji Seika Pharma Co., Ltd.
      2015   Phase 3   JPRN-JapicCTI-153057   Japan;
      2015   Phase 2-3   JPRN-JapicCTI-153056   Japan;
MEDI1341   
   AstraZeneca
      2020   Phase 1   NCT04449484   United States;
      2017   Phase 1   NCT03272165   United Kingdom;United States;
MEG   
   Howard Gendelman, MD
      2013   Phase 1   NCT01882010   United States;
MEMANTINE HYDROCHLORIDE   
   H. Lundbeck A/S
      2007   Phase 3   EUCTR2005-002038-36-GR   Austria;France;Germany;Greece;Italy;Spain;United Kingdom;
      2006   Phase 3   EUCTR2005-002038-36-FR   Austria;France;Germany;Greece;Italy;Spain;United Kingdom;
      2006   -   EUCTR2005-002038-36-DE   Austria;France;Germany;Greece;Italy;Spain;United Kingdom;
      2006   -   EUCTR2005-002038-36-AT   Austria;France;Germany;Greece;Italy;Spain;United Kingdom;
METHYLPHENIDATE HYDROCHLORIDE   
   University Medical Center Groningen
      2010   -   EUCTR2009-012643-42-NL   Netherlands;
MIRAPEXIN*30CPR 0,   
   CASA DI CURA PRIVATA S.RAFFAELE - PISANA
      2009   -   EUCTR2009-015833-66-IT   Italy;
MK0657   
   Merck Sharp & Dohme Corp.
      2007   Phase 1   NCT00505843   United States;
MODOPAR   
   CHU de Toulouse
      2010   Phase 3   EUCTR2010-018650-12-FR   France;
MS Band 2   
   IRCCS San Camillo, Venezia, Italy
      2017   -   NCT03425877   Italy;
MSC   
   The University of Texas Health Science Center, Houston
      2020   Phase 2   NCT04506073   United States;
MSK-DA01 Cell Delivery Device   
   BlueRock Therapeutics
      2021   Phase 1   NCT04802733   Canada;United States;
Madopar   
   Universitätsklinik für Neurologie Innsbruck
      2010   -   EUCTR2010-019354-40-AT   Austria;
Madopar 125 mg T, tablets   
   BIAL-Portela & Ca, S.A.
      2021   Phase 4   EUCTR2020-002754-24-IT   Germany;Italy;Portugal;Spain;United Kingdom;
   Bial - Portela & Ca, S.A.
      2022   Phase 4   EUCTR2020-002754-24-DE   Germany;Italy;Portugal;Spain;United Kingdom;
      2021   Phase 4   EUCTR2020-002754-24-ES   Germany;Italy;Portugal;Spain;United Kingdom;
Madopar 125 mg, orodispersible tablet   
   Pharmaceutical Technology and Biopharmacy, University of Groningen
      2018   Phase 2   EUCTR2017-004006-18-NL   Netherlands;
Madopar 200+   
Madopar LT   
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2011   -   EUCTR2010-022363-35-DE   Germany;
Madopar Tab. 125 or Perkin Tab. 25-   
   SK Chemicals Co., Ltd.
      2021   Phase 4   NCT04821687   Korea, Republic of;
Madopar monotherapy   
   Peking University Third Hospital
      2018   Phase 4   NCT04968613   China;
Madopar® 125   
   Bial - Portela C S.A.
      2001   Phase 1   NCT02763852   Portugal;
Madopar® 125 mg T Tablets Levodopa 100 mg Benserazide 25 mg (as benserazide hydrochloride)   
   BIAL-Portela & Ca, S.A.
      2021   Phase 4   EUCTR2020-002754-24-IT   Germany;Italy;Portugal;Spain;United Kingdom;
Madopar® 250   
   Bial - Portela C S.A.
      2006   Phase 1   NCT03097211   Portugal;
      2006   Phase 1   NCT03094156   Portugal;
Madopar® HBS   
   Bial - Portela C S.A.
      2009   Phase 1   NCT02169466   Portugal;
Madopar® HBS 125   
   Bial - Portela C S.A.
      2004   Phase 1   NCT03091543   Portugal;
Magnesium oxide   
   Dokkyo Medical University
      2016   -   JPRN-UMIN000022023   Japan;
      2016   -   JPRN-UMIN000022022   Japan;
Maltodextrin   
   University of Florida
      2021   -   NCT04829760   United States;
Mannitol   
   Hadassah Medical Organization
      2018   Phase 2   NCT03823638   Israel;
Mantadix   
   CHU de Toulouse
      2012   Phase 2   EUCTR2011-005201-75-FR   France;
   University Hospital, Toulouse
      2007   Phase 4   NCT00632762   France;
Masitinib mesylate   
   AB Science
      2015   Phase 2   EUCTR2010-024424-26-SK   Bulgaria;Czech Republic;France;Germany;Hungary;Romania;Slovakia;South Africa;Spain;United States;
Massage with a spiky ball   
   University Medical Center Groningen
      2015   Phase 2   NCT02230930   Netherlands;
Mavoglurant   
   NOVARTIS FARMA
      2012   -   EUCTR2011-004378-27-IT   Austria;Canada;Germany;Hungary;Italy;Spain;United States;
   Novartis Pharma Services AG
      2012   -   EUCTR2011-004378-27-SK   Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
      2012   -   EUCTR2011-004378-27-HU   Austria;Canada;France;Germany;Hungary;Italy;Spain;United States;
      2012   -   EUCTR2011-004378-27-AT   Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
Medical Cannabis   
   Sheba Medical Center
      2021   -   NCT05106504   Israel;
Melatonin   
   Instituto Mexicano del Seguro Social
      2021   Phase 2/Phase 3   NCT04287543   Mexico;
   University College London
      2015   Phase 2   EUCTR2014-002697-37-GB   United Kingdom;
   University College, London
      2015   Phase 2   NCT02359448   United Kingdom;
Melatonin PR   
   Seoul National University Hospital
      2016   Phase 2   NCT02789592   Korea, Republic of;
Melatonin(Circadin®)   
   KIMJisun
      2016   Phase 4   NCT03258294   -
   Kuhnil Pharmaceutical Co., Ltd.
      2016   Phase 4   NCT02768077   -
Melevodopa and decarboxylase inhibitor   
   VERNALIS DEVELOPMENT LIMITED
      2006   -   EUCTR2006-004112-51-IT   Italy;
Melperon   
   OVATION PHARMACEUTICALS INC
      2007   -   EUCTR2007-002874-75-IT   Italy;
      2007   -   EUCTR2007-000307-15-IT   Italy;
Melperone HCl   
   Lundbeck LLC
      2005   Phase 2   NCT00125138   India;Italy;United States;
Memantin Orion   
   Regional Dementia Research Centre, Dept of Neurology
      2018   Phase 4   EUCTR2017-002707-10-DK   Denmark;
Memantine   
   Baylor College of Medicine
      2006   Phase 4   NCT00646204   United States;
   Department of Neurology, Juntendo University School of Medicine
      2013   -   JPRN-UMIN000010596   Japan;
   H. Lundbeck A/S
      2007   Phase 4   NCT00855686   Germany;
   Helse Stavanger HF
      2006   Phase 2   NCT00630500   Norway;Sweden;United Kingdom;
   Johns Hopkins University
      2006   -   NCT00294554   United States;
   Neurologisk afdeling F
      2005   Phase 2   EUCTR2004-004139-74-DK   Denmark;
   University Hospital, Lille
      2009   Phase 4   NCT01108029   France;
   Wayne State University
      2019   Phase 3   NCT03858270   United States;
   Zealand University Hospital
      2020   Phase 4   NCT04117178   Denmark;
Memantine (drug)   
   University of Aarhus
      2005   -   NCT00375778   Denmark;
Mesdopetam   
   Integrative Research Laboratories AB
      2020   Phase 2   NCT04435431   France;Israel;Italy;Poland;Serbia;United States;
   Integrative Research Laboratories Sweden AB
      2021   Phase 2   EUCTR2020-002010-41-IT   France;Israel;Italy;Poland;Serbia;United States;
   Integrative Research Laboratories Sweden AB (IRLAB)
      2020   Phase 2   EUCTR2020-002010-41-FR   France;Israel;Italy;Poland;Serbia;United States;
Mesdopetam (IRL790)   
   Integrative Research Laboratories AB
      2018   Phase 2   NCT03368170   Sweden;United Kingdom;
Mesencephalic Neuronal Precursor Cells   
   Bundang CHA Hospital
      2013   Phase 1/Phase 2   NCT01860794   Korea, Republic of;
Mesenchymal stem cells   
   Hebei Newtherapy BIo-Pharma technology Co., Ltd.
      2018   Phase 1   NCT03550183   China;
Mestinon   
   Department of Neurology, Roskilde Hospital
      2012   Phase 2   EUCTR2012-000122-21-DK   Denmark;
Metabolic Cofactor Supplementation   
   Istanbul Medipol University Hospital
      2019   Phase 2   NCT04044131   Turkey;
Metformin   
   Institute of Clinical Pharmacology, Central South University
      2012   Phase 1 study   ChiCTR-TTRCC-12002751   China;
   Peking Union Medical College Hospital
      2020   Phase 4   ChiCTR2000029465   China;
Methylphenidate   
   Department of Veterans Affairs
      2006   -   NCT00393562   United States;
   Hubert Fernandez
      2016   Early Phase 1   NCT02879136   United States;
   Laval University
      2010   Phase 4   NCT01244269   Canada;
   Oregon Health and Science University
      2004   Phase 2   NCT00359723   United States;
   University Hospital, Lille
      2009   Phase 4   NCT00914095   France;
Methylphenidate (MPD)   
   University of Cincinnati
      2007   Phase 4   NCT00526630   United States;
Methylprednisolone   
   Prevail Therapeutics
      2020   Phase 1/Phase 2   NCT04127578   Israel;United States;
Mid dose ANAVEX2-73   
   Anavex Life Sciences Corp.
      2018   Phase 2   NCT03774459   Australia;Spain;
Midazolam   
   Kyowa Kirin Co., Ltd.
      2019   Phase 1   NCT03970798   Japan;
   PharmaTher Inc.
      2021   Phase 2   NCT04912115   United States;
Midodrine   
   Philadelphia Veterans Affairs Medical Center
      2014   -   NCT02365012   United States;
   Vanderbilt University Medical Center
      2020   Early Phase 1   NCT04620382   United States;
      2016   Phase 1   NCT02897063   United States;
Minocycline   
   University of Rochester
      2003   Phase 2   NCT00063193   United States;
Minodronic acid   
   Department of Orthopaedic Surgery, Niigata University Medical and Dental Hospital
      2018   -   JPRN-UMIN000033285   Japan;
Mirabegron   
   Daniel Burdick, MD
      2014   Phase 4   NCT02092181   United States;
   HealthPartners Institute
      2015   Phase 4   NCT02536976   United States;
   Seoul National University Hospital
      2017   Phase 4   NCT03412513   Korea, Republic of;
Mirapex   
   Abbott Healthcare Products B.V.
      2009   -   EUCTR2008-000400-81-DE   Germany;Italy;Portugal;
   Boehringer Ingelheim
      2005   Phase 4   NCT00144300   United States;
   Rajesh Pahwa, MD
      2006   Phase 3   NCT00275275   United States;
   SOLVAY PHARMACEUTICALS B.V.
      2009   -   EUCTR2008-000400-81-IT   Germany;Italy;Portugal;
   Solvay Pharmaceuticals B.V.
      2008   Phase 2   EUCTR2008-004943-12-SK   Slovakia;
   Solvay Pharmaceuticals BV
      2009   -   EUCTR2008-000400-81-PT   Germany;Italy;Portugal;
Mirapex (pramipexole)   
   Institute for Neurodegenerative Disorders
      2004   Phase 2   NCT00096720   United States;
Mirapex ER   
   Seoul National University Hospital
      2011   Phase 4   NCT01515774   Korea, Republic of;
Mirapex LA   
   Boehringer Ingelheim
      2012   -   NCT01525641   Japan;
Mirapexin   
   NEUROBIOTEC GMBH
      2007   -   EUCTR2006-003732-30-IT   Germany;Italy;Poland;
Mirapexin / Sifrol   
   Boehringer Ingelheim España S.A.
      2006   Phase 4   EUCTR2005-003788-22-ES   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Mirapexin extended release various strengths   
   University Hospital of North Staffordshire
      2013   Phase 4   EUCTR2012-000801-64-GB   United Kingdom;
Mirapexin/Sifrol   
   Boehringer Ingelheim España S.A.
      2006   Phase 4   EUCTR2005-003788-22-ES   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
MitoQ   
   Antipodean Pharmaceuticals, Inc.
      2006   Phase 2   NCT00329056   Australia;New Zealand;
Modafinil   
   Department of Neurology and Clinical Pharmacology, Ehime University Graduate School of Medicine
      2015   -   JPRN-UMIN000019676   Japan;
   Department of Veterans Affairs
      2006   -   NCT00393562   United States;
   University of Arkansas
      2017   Early Phase 1   NCT03083132   United States;
   University of Chicago
      2016   Phase 2   NCT02857244   United States;
Modal   
   Oregon Health and Science University
      2021   -   NCT04468919   United States;
   Regis University
      2017   -   NCT04223245   United States;
   The Cleveland Clinic
      2020   Phase 2   NCT04634331   United States;
Modiodal   
   Theranexus S.A.
      2018   Phase 2   EUCTR2017-004475-31-HU   Czech Republic;France;Germany;Hungary;United States;
      2018   Phase 2   EUCTR2017-004475-31-CZ   Czech Republic;France;Germany;Hungary;United States;
Modopar 125   
   UHToulouse
      2016   Phase 2;Phase 3   EUCTR2015-001523-24-FR   France;
Modopar 62,5   
   UHToulouse
      2016   Phase 2;Phase 3   EUCTR2015-001523-24-FR   France;
Monoamine oxidase B inhibitors   
   NEWRON PHARMACEUTICALS
      2007   -   EUCTR2006-005861-21-IT   Italy;
      2004   -   EUCTR2004-000833-12-IT   Italy;Spain;
Montelukast Krka   
   Stockholm Health Care Services
      2021   Phase 2   EUCTR2020-000148-76-SE   Sweden;
Motion Analysis   
   Howard Gendelman, MD
      2013   Phase 1   NCT01882010   United States;
Moxifloxacin   
   Bial - Portela C S.A.
      2010   Phase 1   NCT01532115   France;
   Kyowa Kirin Co., Ltd.
      2020   Phase 1   NCT04342273   Japan;
   Sunovion
      2017   Phase 2   NCT03187301   Italy;United States;
Moxifloxacin infusion   
   UCB Pharma
      2006   Phase 1   NCT00292227   South Africa;
Muscimol   
   National Institute of Neurological Disorders and Stroke (NINDS)
      2009   Phase 1   NCT00921128   United States;
Mémantine   
   Chru de Lille
      2009   -   EUCTR2008-008210-38-FR   France;
N acetyl cysteine   
   Thomas Jefferson University
      2020   Phase 2   NCT04459052   United States;
N-0923   
   National Institute of Neurological Disorders and Stroke (NINDS)
      1999   Phase 2   NCT00001931   United States;
N-Acetylcysteine   
   National Institute of Neurological Disorders and Stroke (NINDS)
      2017   Phase 1   NCT03104725   United States;
N-acetylcysteine   
   University of Minnesota
      2011   Phase 1   NCT01427517   United States;
   Weill Medical College of Cornell University
      2012   Phase 1/Phase 2   NCT01470027   United States;
N-acetylcysteine capsule   
   University of Minnesota
      2014   Phase 2   NCT02212678   United States;
N.A.   
   INTEC PHARMA LTD
      2018   Phase 2   EUCTR2018-001209-95-IT   Italy;Spain;
N04BA   
   SynAgile Corporation
      2021   Phase 2   EUCTR2020-003372-41-IT   Italy;Luxembourg;Spain;
N04BC07   
   CHU Rennes
      2021   Phase 4   EUCTR2021-000826-89-FR   France;
N04BD02   
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.
      2011   -   EUCTR2009-015161-31-DE   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
      2011   -   EUCTR2009-015161-31-PT   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2011   Phase 3   EUCTR2009-015161-31-GB   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2011   -   EUCTR2009-015161-31-BG   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
   Schering-Plough Research Institute, a division of Schering Corporation
      2011   -   EUCTR2009-015161-31-PL   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2011   -   EUCTR2009-015161-31-CZ   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-015161-31-SE   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-015161-31-NL   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-015161-31-FI   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-015161-31-AT   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
NACOM 100   
   IMPAX LABORATORIES, INC.
      2010   -   EUCTR2009-017238-39-IT   France;Germany;Italy;
NACOM levodopa+cardidopa   
   MERCK SERONO SA
      2009   -   EUCTR2008-002769-30-IT   Italy;
NAL   
   Mundipharma Research GmbH & Co. KG
      2012   -   EUCTR2011-002901-31-DE   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   Phase 3   EUCTR2011-002901-31-GB   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   -   EUCTR2011-002901-31-HU   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   -   EUCTR2011-002901-31-CZ   Czech Republic;Germany;Hungary;Spain;United Kingdom;
NBTX-001   
   Nobilis Therapeutics Inc.
      2019   Phase 1   NCT04097080   Russian Federation;
ND0611   
   NeuroDerm Ltd.
      2010   Phase 1   NCT01103011   Israel;
ND0612   
   NEURODERM LTD.
      2020   Phase 3   EUCTR2018-004156-37-IT   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002780-17-IT   Austria;France;Italy;Netherlands;Spain;United States;
      2016   Phase 2   EUCTR2015-005814-31-IT   Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States;
      2016   Phase 2   EUCTR2015-005078-39-IT   Austria;Germany;Israel;Italy;United States;
   NeuroDerm Ltd.
      2020   Phase 3   EUCTR2018-004156-37-SK   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004156-37-SE   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004156-37-PT   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004156-37-NL   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004156-37-GB   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004156-37-ES   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004156-37-BE   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004156-37-AT   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004156-37-HU   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004156-37-CZ   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002780-17-FR   Austria;France;Italy;Netherlands;Spain;United States;
      2018   Phase 3   EUCTR2017-002780-17-ES   Austria;France;Italy;Netherlands;Spain;United States;
      2018   Phase 3   EUCTR2016-002033-30-NL   Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002033-30-HU   Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002033-30-GB   Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2015-005814-31-PL   Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States;
      2017   Phase 2   EUCTR2015-005814-31-HU   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United States;
      2017   Phase 2   EUCTR2015-005814-31-ES   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United States;
      2017   Phase 2   EUCTR2015-005814-31-DE   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2015-005814-31-CZ   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States;
      2017   Phase 2   EUCTR2015-005814-31-BE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United States;
      2016   Phase 3   NCT02782481   Israel;
      2016   Phase 3   EUCTR2016-002033-30-FR   Belgium;Canada;Denmark;France;Hungary;Israel;Netherlands;Spain;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002033-30-ES   Belgium;Canada;Denmark;France;Israel;Netherlands;Spain;Sweden;United States;
      2016   Phase 3   EUCTR2016-002033-30-BE   Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2016   Phase 2   NCT02726386   Austria;Czechia;France;Germany;Israel;Italy;Poland;Spain;United States;
      2016   Phase 2   EUCTR2015-005814-31-AT   Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States;
      2016   Phase 2   EUCTR2015-005078-39-DE   Austria;Germany;Israel;Italy;United States;
      2016   Phase 2   EUCTR2015-005078-39-AT   Austria;Germany;Israel;Italy;United States;
      2015   Phase 1   NCT02604914   United Kingdom;
      2012   Phase 1   NCT01486628   Israel;
ND0612 (Levodopa/Carbidopa solution)   
   NeuroDerm Ltd.
      2015   Phase 2   NCT02577523   Austria;Israel;Italy;United States;
ND1421   
   Schwarz Biosciences GmbH
      2006   Phase 2   EUCTR2005-004290-19-GB   Austria;Germany;Spain;United Kingdom;
      2006   -   EUCTR2005-004290-19-DE   Germany;Spain;United Kingdom;
      2005   -   EUCTR2005-004290-19-AT   Austria;Germany;Spain;United Kingdom;
ND1587   
   Schwarz Biosciences GmbH
      2008   -   EUCTR2006-006752-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-006907-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-006752-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006907-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006907-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006907-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006752-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006752-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006752-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      -   -   EUCTR2006-006907-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
   Schwarz Biosciences GmbH, UCB Group
      2007   Phase 3   EUCTR2006-006907-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-006752-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
ND1589   
   Schwarz Biosciences GmbH
      2008   -   EUCTR2006-006752-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-006907-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-006752-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006907-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006907-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006907-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006752-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006752-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006752-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      -   -   EUCTR2006-006907-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
   Schwarz Biosciences GmbH, UCB Group
      2007   Phase 3   EUCTR2006-006907-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-006752-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
ND1590   
   Schwarz Biosciences GmbH
      2008   -   EUCTR2006-006752-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-006907-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-006752-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006907-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006907-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006907-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006752-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006752-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006752-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      -   -   EUCTR2006-006907-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
   Schwarz Biosciences GmbH, UCB Group
      2007   Phase 3   EUCTR2006-006907-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-006752-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
ND1702   
   Schwarz Biosciences GmbH
      2008   -   EUCTR2006-006752-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-006907-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-006752-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006907-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006907-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006907-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006752-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006752-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006752-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      -   -   EUCTR2006-006907-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
   Schwarz Biosciences GmbH, UCB Group
      2007   Phase 3   EUCTR2006-006907-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-006752-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
NE3107   
   BioVie Inc.
      2021   Phase 1/Phase 2   NCT05083260   -
NERIXIA*IM EV 1F   
   FONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE
      2010   -   EUCTR2010-018904-94-IT   Italy;
NEUPRO 2 mg/24 h parche transdérmico   
   UCB Pharma SA
      2011   Phase 4   EUCTR2010-021394-37-ES   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;
NEUPRO 4 mg/24 h parche transdérmico   
   UCB Pharma SA
      2011   Phase 4   EUCTR2010-021394-37-ES   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;
NEUPRO 6 mg/24 h parche transdérmico   
   UCB Pharma SA
      2011   Phase 4   EUCTR2010-021394-37-ES   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;
NEUPRO 8 mg/24 h parche transdérmico   
   UCB Pharma SA
      2011   Phase 4   EUCTR2010-021394-37-ES   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;
NEUPRO*28CER 2MG/24H   
   FONDAZIONE SANTA LUCIA
      2012   -   EUCTR2012-001218-40-IT   Italy;
NEUPRO*28CER 4MG/24H   
   FONDAZIONE SANTA LUCIA
      2012   -   EUCTR2012-001218-40-IT   Italy;
NEUPRO*28CER 6MG/24H   
   FONDAZIONE SANTA LUCIA
      2012   -   EUCTR2012-001218-40-IT   Italy;
NEUPRO*28CER 8MG/24H   
   FONDAZIONE SANTA LUCIA
      2012   -   EUCTR2012-001218-40-IT   Italy;
NEUPRO*7CER 4MG/24H   
   FONDAZIONE SANTA LUCIA
      2012   -   EUCTR2012-001218-40-IT   Italy;
NEUPRO*7CER 6MG/24H   
   FONDAZIONE SANTA LUCIA
      2012   -   EUCTR2012-001218-40-IT   Italy;
NEUPRO*7CER 8MG/24H   
   FONDAZIONE SANTA LUCIA
      2012   -   EUCTR2012-001218-40-IT   Italy;
NJ-Tube: Silicon ED Tube   
   AbbVie (prior sponsor, Abbott)
      2011   Phase 2   NCT01479127   Japan;
NLX-112   
   Neurolixis SAS
      2021   Phase 2   EUCTR2020-006053-22-SE   Sweden;
NLY01   
   Neuraly, Inc.
      2020   Phase 2   NCT04154072   Canada;United States;
NO   
   Department of Anesthesiology, Affiliated Hospital of Guizhou Medical University
      2019   -   ChiCTR1900024459   China;
   The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
      2019   -   ChiCTR1900026156   China;
NPC transplantation   
   Chinese Academy of Sciences
      2017   Phase 1/Phase 2   NCT03119636   China;
NR2B NMDA Antagonist CP-101,606 (traxoprodil)   
   Pfizer
      2005   Phase 2   NCT00163085   United States;
NS 2330   
   Boehringer Ingelheim
      2003   Phase 2   NCT00148486   Canada;United States;
NS2330   
   National Institute of Neurological Disorders and Stroke (NINDS)
      2000   Phase 2   NCT00006077   United States;
NT 101   
   Merz Pharmaceuticals GmbH
      2014   Phase 3   EUCTR2012-005539-10-DE   Germany;Poland;United States;
NTCELL Implantation   
   Living Cell Technologies
      2016   Phase 2   NCT02683629   New Zealand;
NW-1015   
   MERCK SERONO SA
      2010   -   EUCTR2010-020109-34-IT   Italy;Spain;
      2009   Phase 3   EUCTR2008-005492-94-IT   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
   Merck Serono International S.A.
      2008   Phase 3   EUCTR2007-002963-28-ES   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain;
      2008   -   EUCTR2007-002964-90-ES   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
      2007   -   EUCTR2007-002964-90-NL   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
      2007   -   EUCTR2007-002964-90-FI   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
   Merck Serono S.A - Geneva
      2008   Phase 3   EUCTR2007-002964-90-GB   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Slovakia;Spain;United Kingdom;
   Merck Serono S.A-Geneva
      2009   -   EUCTR2007-002963-28-PT   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Spain;
   Merck Serono S.A. - Geneva
      2010   Phase 3   EUCTR2008-005492-94-BE   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2010   Phase 2   EUCTR2009-017174-20-FR   Austria;France;Germany;
      2010   -   EUCTR2010-020109-34-ES   Italy;Spain;
      2010   -   EUCTR2008-005492-94-NL   Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2007-002964-90-CZ   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-005492-94-SK   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-005492-94-GB   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-005492-94-FR   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-005492-94-ES   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   -   EUCTR2008-005492-94-HU   Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2007-002964-90-FR   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-002964-90-DE   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
      2007   Phase 3   EUCTR2007-002964-90-SK   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Slovakia;Spain;United Kingdom;
      2007   Phase 3   EUCTR2007-002963-28-SK   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain;
   Merck Serono S.A.-Geneva
      2008   -   EUCTR2007-002964-90-HU   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
   Merck Serono SA - Geneva
      2009   Phase 3   EUCTR2008-004146-88-SK   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain;
      2009   Phase 3   EUCTR2008-004146-88-ES   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain;
      2009   Phase 3   EUCTR2008-001966-10-SK   Austria;Estonia;Hungary;Slovakia;United Kingdom;
      2009   -   EUCTR2008-004146-88-PT   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Spain;
      2009   -   EUCTR2008-004146-88-PL   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Spain;
      2009   -   EUCTR2008-001966-10-HU   Austria;Estonia;Hungary;United Kingdom;
      2009   -   EUCTR2008-001966-10-GB   Austria;Estonia;Hungary;United Kingdom;
      2009   -   EUCTR2008-001966-10-EE   Austria;Estonia;Hungary;United Kingdom;
      2009   -   EUCTR2008-001966-10-AT   Austria;Estonia;Hungary;United Kingdom;
   NEWRON PHARMACEUTICALS
      2007   -   EUCTR2006-005861-21-IT   Italy;
      2006   -   EUCTR2006-005860-14-IT   Italy;
      2004   -   EUCTR2004-000835-27-IT   Italy;Spain;
      2004   -   EUCTR2004-000833-12-IT   Italy;Spain;
   Newron Pharmaceuticals
      2011   -   EUCTR2008-005492-94-PT   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
      2011   -   EUCTR2008-005492-94-FI   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
      2011   -   EUCTR2008-005492-94-CZ   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
      2011   -   EUCTR2008-005492-94-BG   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
      2010   -   EUCTR2008-004146-88-DE   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States;
      2009   Phase 3   EUCTR2008-004146-88-BG   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States;
      2009   -   EUCTR2008-005492-94-EE   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
      2009   -   EUCTR2008-005492-94-AT   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
      2009   -   EUCTR2008-004146-88-FI   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States;
      2009   -   EUCTR2008-004146-88-CZ   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States;
      -   -   EUCTR2008-005492-94-DE   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Taiwan;Thailand;United Kingdom;United States;
   Newron Pharmaceuticals S.P.A
      2005   Phase 3   EUCTR2004-000835-27-ES   Italy;Spain;
   Newron Pharmaceuticals S.p.A.
      2004   Phase 3   EUCTR2004-000833-12-ES   Italy;Spain;
   Newron Pharmaceuticals SpA
      2011   Phase 3   EUCTR2007-002964-90-BE   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Slovakia;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
      2010   -   EUCTR2007-002963-28-DE   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;South Africa;Spain;United States;
      2009   -   EUCTR2007-002964-90-AT   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
      2009   -   EUCTR2007-002963-28-PL   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Spain;
      2009   -   EUCTR2007-002963-28-CZ   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;South Africa;Spain;United States;
      2009   -   EUCTR2007-002963-28-BG   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;South Africa;Spain;United States;
      2008   -   EUCTR2007-002964-90-EE   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
      2007   -   EUCTR2007-002963-28-FI   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Poland;Portugal;South Africa;Spain;United States;
NW-1015E, EMD 1195686, MSC2191632B   
   Merck Serono S.A. - Geneva
      2011   -   EUCTR2009-017174-20-AT   Austria;Canada;France;Germany;South Africa;
      2010   -   EUCTR2009-017174-20-DE   Austria;Canada;France;Germany;South Africa;
NYX-458   
   Aptinyx
      2019   Phase 2   NCT04148391   United States;
Nabilone   
   Medical University Innsbruck
      2018   Phase 3   NCT03773796   Austria;
      2017   Phase 2   NCT03769896   Austria;
Nacom   
   Otto-von-Guericke University, Medical Faculty, Dpt. of Neurology
      2009   -   EUCTR2009-011093-15-DE   Germany;
Nacom 100   
   Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)
      2010   Phase 3   EUCTR2009-017238-39-BE   Belgium;France;Germany;Italy;
   Novartis Pharma Services AG
      2008   -   EUCTR2007-003134-42-DE   Germany;
Nadolol   
   CuraSen Therapeutics, Inc.
      -   Phase 2   EUCTR2020-006067-28-BE   Australia;Belgium;New Zealand;United Kingdom;
Nalmefene   
   University Hospital, Clermont-Ferrand
      2016   Phase 2   NCT02934919   France;
Naltrexone   
   University of Pennsylvania
      2009   Phase 4   NCT01052831   United States;
Nardil   
   TEVA Pharmaceuticals Industries Ltd
      2006   -   EUCTR2006-005140-89-NL   Netherlands;
Nebicapone   
   BIAL - Portela & Cª, SA
      2006   -   EUCTR2006-001793-24-PT   Austria;Portugal;
      2006   -   EUCTR2006-001793-24-AT   Austria;Portugal;
   Bial - Portela C S.A.
      2006   Phase 2   NCT03103399   -
      2006   Phase 1   NCT03097211   Portugal;
      2001   Phase 1   NCT02772627   Portugal;
Nebulizer   
   University of Florida
      2015   Phase 1   NCT02390089   United States;
Nelotanserin   
   Axovant Sciences Ltd.
      2016   Phase 2   NCT02871427   United States;
      2016   Phase 2   NCT02708186   United States;
Neu-120   
   Neurim Pharmaceuticals Ltd.
      2008   Phase 1/Phase 2   NCT00607451   Israel;
Neupro   
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2011   -   EUCTR2010-022363-35-DE   Germany;
   Luye Pharma Group Ltd.
      2020   Phase 1   NCT04384666   United States;
      2013   Phase 1   NCT02055274   United States;
   Peking University Third Hospital
      2021   -   NCT04957420   China;
   SCHWARZ PHARMA
      2008   -   EUCTR2006-006752-35-IT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
   UCB BIOSCIENCES GMBH
      2013   -   EUCTR2012-002840-26-IT   Austria;Bulgaria;Hungary;Italy;Russian Federation;Slovenia;Spain;Turkey;Ukraine;United States;
   UCB Biosciences GmbH
      2013   Phase 4   EUCTR2012-002608-42-GB   Argentina;France;Germany;Hungary;Korea, Republic of;Mexico;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-002840-26-SK   Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States;
      2013   -   EUCTR2012-002840-26-SI   Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States;
      2013   -   EUCTR2012-002840-26-RO   Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States;
      2013   -   EUCTR2012-002840-26-HU   Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States;
      2013   -   EUCTR2012-002840-26-ES   Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States;
      2013   -   EUCTR2012-002840-26-BG   Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States;
      2013   -   EUCTR2012-002840-26-AT   Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States;
      2013   -   EUCTR2012-002608-42-HU   Argentina;France;Germany;Hungary;Korea, Republic of;Mexico;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-002608-42-DE   Germany;Hungary;Poland;Slovakia;United Kingdom;United States;
      2012   -   EUCTR2012-002608-42-SK   Argentina;France;Germany;Hungary;Korea, Republic of;Mexico;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
Neupro (Reference)   
   Sandoz
      2019   Phase 1   NCT04183634   Germany;
Neupro 2 mg/24 h transdermal patch   
   SCHWARZ PHARMA Deutschland GmbH
      2007   -   EUCTR2006-005438-19-DE   Germany;
   Schwarz Pharma Deutschland GmbH, UCB Group
      -   -   EUCTR2009-014341-84-DE   Germany;
Neupro 2mg/24 h transdermal patch   
   Schwarz Biosciences GmbH
      2008   -   EUCTR2006-006752-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-006752-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006752-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006752-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006752-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
   Schwarz Biosciences GmbH, UCB Group
      2007   Phase 3   EUCTR2006-006752-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Neupro 2mg/24h transdermal patch   
   Schwarz Biosciences GmbH
      2007   Phase 3   EUCTR2006-006907-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006907-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006907-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006907-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      -   -   EUCTR2006-006907-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
   Schwarz Biosciences GmbH, UCB Group
      2007   Phase 3   EUCTR2006-006907-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
   UCB Pharma SA
      2011   Phase 4   EUCTR2010-021394-37-SK   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;
      2011   Phase 4   EUCTR2010-021394-37-BE   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;
      2011   -   EUCTR2010-021394-37-HU   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
      2011   -   EUCTR2010-021394-37-DE   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
      2011   -   EUCTR2010-021394-37-CZ   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
      2011   -   EUCTR2010-021394-37-BG   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
      2011   -   EUCTR2010-021394-37-AT   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
Neupro 4 mg/24 h transdermal patch   
   SCHWARZ PHARMA Deutschland GmbH
      2007   -   EUCTR2006-005438-19-DE   Germany;
   Schwarz Pharma Deutschland GmbH, UCB Group
      -   -   EUCTR2009-014341-84-DE   Germany;
Neupro 4Mg/24Hr Transdermal Patch   
   Luye Pharma Group Ltd.
      2018   Phase 1   NCT03733561   United States;
Neupro 4mg/24 h transdermal patch   
   Schwarz Biosciences GmbH
      2008   -   EUCTR2006-006752-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-006752-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006752-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006752-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006752-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
   Schwarz Biosciences GmbH, UCB Group
      2007   Phase 3   EUCTR2006-006752-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Neupro 4mg/24h transdermal patch   
   Schwarz Biosciences GmbH
      2007   Phase 3   EUCTR2006-006907-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006907-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006907-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006907-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      -   -   EUCTR2006-006907-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
   Schwarz Biosciences GmbH, UCB Group
      2007   Phase 3   EUCTR2006-006907-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
   UCB Celltech, UK - Registered Branch of UCB Pharma SA
      2011   -   EUCTR2011-000056-42-GB   United Kingdom;
   UCB Pharma SA
      2011   Phase 4   EUCTR2010-021394-37-SK   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;
      2011   Phase 4   EUCTR2010-021394-37-BE   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;
      2011   -   EUCTR2010-021394-37-HU   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
      2011   -   EUCTR2010-021394-37-DE   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
      2011   -   EUCTR2010-021394-37-CZ   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
      2011   -   EUCTR2010-021394-37-BG   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
      2011   -   EUCTR2010-021394-37-AT   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
Neupro 6 mg/24 h transdermal patch   
   SCHWARZ PHARMA Deutschland GmbH
      2007   -   EUCTR2006-005438-19-DE   Germany;
   Schwarz Pharma Deutschland GmbH, UCB Group
      -   -   EUCTR2009-014341-84-DE   Germany;
Neupro 6mg/24 h transdermal patch   
   Schwarz Biosciences GmbH
      2008   -   EUCTR2006-006752-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-006752-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006752-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006752-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006752-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
   Schwarz Biosciences GmbH, UCB Group
      2007   Phase 3   EUCTR2006-006752-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Neupro 6mg/24h transdermal patch   
   Schwarz Biosciences GmbH
      2007   Phase 3   EUCTR2006-006907-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006907-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006907-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006907-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      -   -   EUCTR2006-006907-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
   Schwarz Biosciences GmbH, UCB Group
      2007   Phase 3   EUCTR2006-006907-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
   UCB Celltech, UK - Registered Branch of UCB Pharma SA
      2011   -   EUCTR2011-000056-42-GB   United Kingdom;
   UCB Pharma SA
      2011   Phase 4   EUCTR2010-021394-37-SK   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;
      2011   Phase 4   EUCTR2010-021394-37-BE   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;
      2011   -   EUCTR2010-021394-37-HU   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
      2011   -   EUCTR2010-021394-37-DE   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
      2011   -   EUCTR2010-021394-37-CZ   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
      2011   -   EUCTR2010-021394-37-BG   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
      2011   -   EUCTR2010-021394-37-AT   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
Neupro 8 mg/24 h transdermal patch   
   SCHWARZ PHARMA Deutschland GmbH
      2007   -   EUCTR2006-005438-19-DE   Germany;
   Schwarz Biosciences GmbH
      2008   -   EUCTR2006-006752-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-006752-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006752-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006752-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006752-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
   Schwarz Biosciences GmbH, UCB Group
      2007   Phase 3   EUCTR2006-006752-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
   Schwarz Pharma Deutschland GmbH, UCB Group
      -   -   EUCTR2009-014341-84-DE   Germany;
Neupro 8mg/24h transdermal patch   
   Schwarz Biosciences GmbH
      2007   Phase 3   EUCTR2006-006907-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006907-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006907-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006907-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      -   -   EUCTR2006-006907-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
   Schwarz Biosciences GmbH, UCB Group
      2007   Phase 3   EUCTR2006-006907-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
   UCB Celltech, UK - Registered Branch of UCB Pharma SA
      2011   -   EUCTR2011-000056-42-GB   United Kingdom;
   UCB Pharma SA
      2011   Phase 4   EUCTR2010-021394-37-SK   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;
      2011   Phase 4   EUCTR2010-021394-37-BE   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;
      2011   -   EUCTR2010-021394-37-HU   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
      2011   -   EUCTR2010-021394-37-DE   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
      2011   -   EUCTR2010-021394-37-CZ   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
      2011   -   EUCTR2010-021394-37-BG   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
      2011   -   EUCTR2010-021394-37-AT   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
Neupro®   
   UCB Pharma
      2011   -   NCT01330290   Germany;
Neupro® 8 mg/24 h   
   Luye Pharma Switzerland AG
      2021   Phase 2   EUCTR2021-000867-65-DE   Germany;
Neuraceq   
   Fundació Clínic per la Recerca Biomèdica
      2016   Phase 4   EUCTR2014-001014-25-ES   Spain;
   Institute for Neurodegenerative Disorders
      2016   Phase 2   EUCTR2015-004129-15-ES   Spain;
NeuroEPO   
   International Center for Neurological Restoration, Cuba
      2015   Phase 1/Phase 2   NCT04110678   Cuba;
Neurohormonal mechanisms   
   Institut National de la Santé Et de la Recherche Médicale, France
      2017   -   NCT03272230   France;
Neurpro   
   Unità Malattie Neurodegenerative, Ospedale Cardinale Giovanni Panico, Tricase
      2013   -   EUCTR2013-000827-15-IT   Italy;
Niacin   
   VA Office of Research and Development
      2020   -   NCT03808961   United States;
      2016   -   NCT03462680   United States;
Niacinamide   
   VA Office of Research and Development
      2020   -   NCT03808961   United States;
Nicorette 10mg/ 16 h   
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2008   -   EUCTR2008-001336-13-FR   France;
Nicorette 15 mg/ 16 h   
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2008   -   EUCTR2008-001336-13-FR   France;
Nicorette 5 mg/ 16 h   
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2008   -   EUCTR2008-001336-13-FR   France;
Nicotine   
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2008   -   EUCTR2008-001336-13-FR   France;
   Department of Clinical Pharmacology and Neurology Ehime University graduated School of Medicine
      2015   -   JPRN-UMIN000016664   Japan;
   Neuraltus Pharmaceuticals, Inc.
      2009   Phase 1/Phase 2   NCT00957918   United States;
Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY)   
   El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
      2019   Phase 2   NCT03865121   Mexico;
Nicotine gum   
   New York Institute of Technology
      2015   -   NCT02452125   United States;
Nicotine patch   
   University of Vermont
      2010   Phase 4   NCT01216904   United States;
Nicotine transdermal patch   
   James BOYD MD
      2012   Phase 2   NCT01560754   Germany;United States;
Nicotinell 17,5 mg/24-Stunden-Pflaster   
   Philipps-University Marburg
      2011   Phase 2   EUCTR2010-020299-42-DE   Germany;United States;
Nicotinell 35 mg/24-Stunden-Pflaster   
   Philipps-University Marburg
      2011   Phase 2   EUCTR2010-020299-42-DE   Germany;United States;
Nilotinib   
   Georgetown University
      2014   Phase 1   NCT02281474   United States;
Nilotinib 150mg oral capsule [Tasigna]   
   Georgetown University
      2017   Phase 2   NCT02954978   United States;
Nilotinib 300mg oral capsule [Tasigna]   
   Georgetown University
      2017   Phase 2   NCT02954978   United States;
Nitrogen   
   Juntendo University School of Medicine, Neurology
      2013   -   JPRN-UMIN000010014   Japan;
None   
   The First Affiliated Hospital of University of Science and Technology of China (Southern District Phase 2)
      2021   Phase 0   ChiCTR2100048680   China;
Normal Saline   
   Vanderbilt University
      2008   Phase 2/Phase 3   NCT00608231   United States;
Normal saline   
   dr.dargahi
      2020   Phase 2   NCT04687878   Iran, Islamic Republic of;
Northera   
   The Cooper Health System
      2017   Phase 4   NCT03034564   United States;
Nortriptyline   
   Rutgers, The State University of New Jersey
      2003   Phase 2   NCT00062738   United States;
   University College, London
      2019   Phase 3   NCT03652870   -
Nortriptyline hydrochloride   
   University College London Comprehensive Clinical Trials Unit
      2019   Phase 3   EUCTR2018-002942-35-GB   United Kingdom;
OC oral solution treatment A   
   Orient Pharma Co., Ltd.
      2011   Phase 2   NCT01370811   United States;
OC oral solution treatment B   
   Orient Pharma Co., Ltd.
      2011   Phase 2   NCT01370811   United States;
OC oral solution treatment C   
   Orient Pharma Co., Ltd.
      2011   Phase 2   NCT01370811   United States;
OC oral solution treatment D   
   Orient Pharma Co., Ltd.
      2011   Phase 2   NCT01370811   United States;
OCT - TCE   
   Massachusetts General Hospital
      2019   -   NCT04566341   United States;
ODM-101   
   Orion Corporation
      2011   -   EUCTR2010-022200-46-LV   Finland;Germany;Latvia;Lithuania;
      2011   -   EUCTR2010-022200-46-LT   Finland;Germany;Latvia;Lithuania;
      2011   -   EUCTR2010-022200-46-FI   Finland;Germany;Latvia;Lithuania;
      -   -   EUCTR2010-022200-46-DE   Finland;Germany;Latvia;Lithuania;
ODM-101 105mg Carbidopa   
   Orion Corporation, Orion Pharma
      2011   Phase 2   NCT01766258   -
ODM-101 65mg Carbidopa   
   Orion Corporation, Orion Pharma
      2011   Phase 2   NCT01766258   -
ODM-104   
   Orion Corporation
      2017   Phase 2   EUCTR2015-004507-23-HU   Finland;Germany;Hungary;Latvia;
      2017   Phase 2   EUCTR2015-004507-23-FI   Finland;Germany;Hungary;Latvia;
      2016   Phase 2   EUCTR2015-004507-23-LV   Finland;Germany;Hungary;Latvia;
      2016   Phase 2   EUCTR2015-004507-23-DE   Finland;Germany;Hungary;Latvia;
OFF Dopaminergic Medication   
   The Cleveland Clinic
      2021   Phase 1   NCT05022147   United States;
ON Dopaminergic Medication   
   The Cleveland Clinic
      2021   Phase 1   NCT05022147   United States;
ONO-2160/CD   
   ONO PHARMACEUTICAL CO.,LTD.
      2014   Phase 1   JPRN-JapicCTI-142702   -
      2013   Phase 1   JPRN-JapicCTI-132189   -
ONO-2370   
   ONO PHARMACEUTICAL CO.,LTD.
      2016   Phase 2   JPRN-JapicCTI-153112   Japan;
ONO-2506PO   
   Ono Pharmaceutical Co. Ltd
      2004   Phase 2   NCT00212693   -
OPC   
   Bial - Portela C S.A.
      2011   Phase 1   NCT02169427   Netherlands;
OSU 6162 similar to (-)-OSU 6162   
   Björn Holmberg
      2010   Phase 1;Phase 2   EUCTR2009-016360-37-SE   Sweden;
OSU6162 similar to (-)-OSU 6162   
   A. Carlsson Research AB
      2014   Phase 2   EUCTR2013-002545-10-SE   Sweden;
OTHER NERVOUS SYSTEM DRUGS   
   EISAI LTD UK
      2007   -   EUCTR2006-005714-12-IT   Italy;
OXB-102   
   Sio Gene Therapies
      2018   Phase 1/Phase 2   NCT03720418   France;United Kingdom;
OXN 10 mg / 5 mg PR   
   Mundipharma Research GmbH & Co. KG
      2012   -   EUCTR2011-002901-31-DE   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   Phase 3   EUCTR2011-002901-31-GB   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   Phase 3   EUCTR2011-002901-31-ES   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   -   EUCTR2011-002901-31-HU   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   -   EUCTR2011-002901-31-CZ   Czech Republic;Germany;Hungary;Spain;United Kingdom;
OXN 20 mg / 10 mg PR   
   Mundipharma Research GmbH & Co. KG
      2012   -   EUCTR2011-002901-31-DE   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   Phase 3   EUCTR2011-002901-31-GB   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   Phase 3   EUCTR2011-002901-31-ES   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   -   EUCTR2011-002901-31-HU   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   -   EUCTR2011-002901-31-CZ   Czech Republic;Germany;Hungary;Spain;United Kingdom;
OXN 5 mg/2.5 mg PR   
   Mundipharma Research GmbH & Co. KG
      2012   -   EUCTR2011-002901-31-DE   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   Phase 3   EUCTR2011-002901-31-GB   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   Phase 3   EUCTR2011-002901-31-ES   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   -   EUCTR2011-002901-31-HU   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   -   EUCTR2011-002901-31-CZ   Czech Republic;Germany;Hungary;Spain;United Kingdom;
OXYCODO   
   Mundipharma Research GmbH & Co. KG
      2011   Phase 3   EUCTR2011-002901-31-ES   Czech Republic;Germany;Hungary;Spain;United Kingdom;
OXYCODONE HYDROCHLORIDE   
   UHToulouse
      2016   Phase 2;Phase 3   EUCTR2015-001523-24-FR   France;
OXYTOCIN SYNTHETIC   
   Abteilung für Neurologie der Medizinischen Universität Innsbruck
      2019   Phase 2   EUCTR2018-002877-23-AT   Austria;
Onabotulinumtoxin A Injection   
   University of North Carolina, Chapel Hill
      2018   Phase 2   NCT03301272   United States;
OnabotulinumtoxinA   
   Johns Hopkins University
      2018   Phase 1   NCT03069911   United States;
Ondansetron 8 mg film-coated tablets   
   University College London
      2020   Phase 2   EUCTR2019-003962-41-GB   United Kingdom;
Ondansetron hydrochloride dihydrate   
   University College London
      2020   Phase 2   EUCTR2019-003962-41-GB   United Kingdom;
Ongentys   
   BIAL - Portela & Ca, S.A.
      2016   Phase 4   EUCTR2016-002391-27-GB   Germany;United Kingdom;
      2016   Phase 4   EUCTR2016-002391-27-DE   Germany;United Kingdom;
   BIAL – Portela & Cª, S.A.
      2021   Phase 3   EUCTR2020-005011-52-FR   Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom;
      2021   Phase 3   EUCTR2020-005011-52-BE   Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom;
   BIAL-Portela & Ca, S.A.
      2021   Phase 3   EUCTR2020-005011-52-IT   Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom;
   Bial - Portela & Ca, S.A.
      2021   Phase 4   EUCTR2020-001175-32-PT   Germany;Italy;Portugal;Spain;United Kingdom;
      2020   Phase 4   EUCTR2020-001175-32-GB   Germany;Italy;Portugal;Spain;United Kingdom;
   Bial - Portela C S.A.
      2019   Phase 1   NCT03820037   United Kingdom;
      2018   Phase 1   NCT04265027   United Kingdom;
   SK Chemicals Co., Ltd.
      2021   Phase 4   NCT04821687   Korea, Republic of;
Ongentys 50 mg capsule rigide   
   BIAL-Portela & Ca, S.A.
      2021   Phase 4   EUCTR2020-002754-24-IT   Germany;Italy;Portugal;Spain;United Kingdom;
      2020   Phase 4   EUCTR2020-001175-32-IT   Germany;Italy;Portugal;Spain;United Kingdom;
Ongentys 50 mg hard capsules   
   BIAL-Portela & Ca, S.A.
      2021   Phase 4   EUCTR2020-002754-24-IT   Germany;Italy;Portugal;Spain;United Kingdom;
   Bial - Portela & Ca, S.A.
      2022   Phase 4   EUCTR2020-002754-24-DE   Germany;Italy;Portugal;Spain;United Kingdom;
      2021   Phase 4   EUCTR2020-002754-24-ES   Germany;Italy;Portugal;Spain;United Kingdom;
      2021   Phase 4   EUCTR2020-001176-15-PT   Germany;Portugal;
      2021   Phase 4   EUCTR2020-001176-15-DE   Germany;Portugal;
Opicapone   
   BIAL - Portela & Ca, S.A.
      2011   -   EUCTR2010-021860-13-DE   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
   BIAL-Portela & Ca, S.A.
      2021   Phase 4   EUCTR2020-002754-24-IT   Germany;Italy;Portugal;Spain;United Kingdom;
      2020   Phase 4   EUCTR2020-001175-32-IT   Germany;Italy;Portugal;Spain;United Kingdom;
   Bial - Portela & Ca, S.A.
      2020   Phase 4   EUCTR2020-001175-32-GB   Germany;Italy;Portugal;Spain;United Kingdom;
   Bial - Portela C S.A.
      2021   Phase 4   NCT04990284   -
      2021   Phase 4   NCT04986995   Portugal;
      2021   Phase 4   NCT04986982   United Kingdom;
      2021   Phase 3   NCT04978597   Bulgaria;
      2020   -   NCT03959540   United Kingdom;
   Neurocrine Biosciences
      2021   -   NCT04787965   United States;
      2018   Phase 1   NCT03496870   United States;
   ONO PHARMACEUTICAL CO.,LTD.
      2016   Phase 2   JPRN-JapicCTI-153112   Japan;
   Rabin Medical Center
      2013   Phase 3   NCT01851850   Israel;
Opicapone (OPC)   
   Bial - Portela C S.A.
      2017   Phase 1   NCT03116295   Germany;
      2014   Phase 1   NCT03116308   -
Opicapone 50 mg hard capsules   
   Bial - Portela & Ca, S.A.
      2021   Phase 4   EUCTR2020-001175-32-PT   Germany;Italy;Portugal;Spain;United Kingdom;
Optimal drug therapy   
   Vanderbilt University Medical Center
      2006   -   NCT00282152   United States;
Optimized antiparkinsonian treatment   
   AbbVie
      2017   Phase 3   NCT02799381   Finland;Greece;Hungary;Italy;Slovakia;Spain;United States;
Optimized oral treatment   
   University Hospital, Lille
      2020   Phase 1/Phase 2   NCT04332276   France;
Optional pharmacogenetic assessment   
   Tools4Patient
      2018   Phase 1/Phase 2   NCT03407378   Belgium;France;United States;
Oral Levodopa/Carbidopa   
   AbbVie (prior sponsor, Abbott)
      2011   Phase 2   NCT01479127   Japan;
Oral escitalopram   
   New York University School of Medicine
      2003   Phase 2/Phase 3   NCT00070941   United States;
Oral levodopa and carbidopa   
   NeuroDerm Ltd.
      2014   Phase 1/Phase 2   NCT02096601   Israel;United States;
Orally disintegrating selegiline (Zelapar)   
   Parkinson's Disease and Movement Disorder Center of Boca Raton
      2007   Phase 4   NCT00443872   United States;
Orfadin   
   Synosia Therapeutics AG
      2009   -   EUCTR2009-013670-41-FR   Czech Republic;France;
      2009   -   EUCTR2009-013670-41-CZ   Czech Republic;France;
Other Parkinson's Disease treatments   
   Merck Sharp & Dohme Corp.
      2007   Phase 2   NCT00537017   Argentina;Australia;Canada;Chile;Colombia;France;Guatemala;Hong Kong;Singapore;Spain;United States;
      2006   Phase 2   NCT00406029   Argentina;Australia;Canada;Chile;Colombia;France;Guatemala;Hong Kong;Italy;New Zealand;Peru;Singapore;South Africa;Spain;United States;
Over-encapsulated Entacapone Tablets   
   BIAL - Portela & Ca, S.A.
      2011   Phase 3   EUCTR2010-021860-13-RO   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
      2011   -   EUCTR2010-021860-13-SK   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
      2011   -   EUCTR2010-021860-13-ES   Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain;
      2011   -   EUCTR2010-021860-13-DE   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
      2011   -   EUCTR2010-021860-13-CZ   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
      2011   -   EUCTR2010-021860-13-BG   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
      2011   -   EUCTR2010-021860-13-AT   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
      2010   -   EUCTR2010-021860-13-PT   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
      2010   -   EUCTR2010-021860-13-LV   Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain;
      2010   -   EUCTR2010-021860-13-HU   Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain;
Over-encapsulated Modafinil   
   Theranexus S.A.
      2018   Phase 2   EUCTR2017-004475-31-HU   Czech Republic;France;Germany;Hungary;United States;
      2018   Phase 2   EUCTR2017-004475-31-CZ   Czech Republic;France;Germany;Hungary;United States;
Oxaloacetate (OAA)   
   University of Kansas Medical Center
      2012   Phase 2/Phase 3   NCT01741701   United States;
Oxybuprocaine   
   Utano National Hospital, National Hospital Organization
      2013   -   JPRN-UMIN000017695   Japan;
Oxybutynin and darifenacin   
   Department of Veterans Affairs
      2009   -   NCT00892450   United States;
Oxybutynin hydrochloride   
   Summit (Cambridge) Ltd.
      2007   -   EUCTR2007-004654-81-GB   United Kingdom;
Oxycodone/Naloxone Prolonged Release tablets   
   Mundipharma Research GmbH & Co KG
      2011   Phase 3   NCT01439100   Czech Republic;Germany;Hungary;Poland;Romania;Spain;United Kingdom;
Oxycodone/naloxone prolonged release tablets 10 mg /   
   Mundipharma Research GmbH & Co. KG
      2012   -   EUCTR2011-002901-31-DE   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   Phase 3   EUCTR2011-002901-31-GB   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   Phase 3   EUCTR2011-002901-31-ES   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   -   EUCTR2011-002901-31-HU   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   -   EUCTR2011-002901-31-CZ   Czech Republic;Germany;Hungary;Spain;United Kingdom;
Oxycodone/naloxone prolonged release tablets 20 mg /   
   Mundipharma Research GmbH & Co. KG
      2012   -   EUCTR2011-002901-31-DE   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   Phase 3   EUCTR2011-002901-31-GB   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   Phase 3   EUCTR2011-002901-31-ES   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   -   EUCTR2011-002901-31-HU   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   -   EUCTR2011-002901-31-CZ   Czech Republic;Germany;Hungary;Spain;United Kingdom;
Oxycodone/naloxone prolonged release tablets 5 mg /   
   Mundipharma Research GmbH & Co. KG
      2012   -   EUCTR2011-002901-31-DE   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   Phase 3   EUCTR2011-002901-31-GB   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   Phase 3   EUCTR2011-002901-31-ES   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   -   EUCTR2011-002901-31-HU   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   -   EUCTR2011-002901-31-CZ   Czech Republic;Germany;Hungary;Spain;United Kingdom;
Oxycontin LP   
   UHToulouse
      2016   Phase 2;Phase 3   EUCTR2015-001523-24-FR   France;
Oxygen   
   Tools4Patient
      2018   Phase 1/Phase 2   NCT03407378   Belgium;France;United States;
P2B001   
   Pharma Two B Ltd
      2018   Phase 3   EUCTR2017-001420-21-ES   Canada;France;Germany;Spain;United States;
      2018   Phase 3   EUCTR2017-001420-21-DE   Canada;France;Germany;Spain;United States;
   Pharma Two B Ltd.
      2018   Phase 3   NCT03329508   Canada;Germany;Spain;United States;
P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),   
   Pharma Two B Ltd.
      2013   Phase 2/Phase 3   NCT01968460   Israel;United States;
P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),   
   Pharma Two B Ltd.
      2013   Phase 2/Phase 3   NCT01968460   Israel;United States;
PARCOPA   
   UCB Pharma
      2004   Phase 3   NCT00139867   United States;
PAT   
   NYU Langone Health
      2017   -   NCT03178786   United States;
PBF-509   
   Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
      2014   Phase 1   NCT02111330   Spain;
      2012   Phase 1   NCT01691924   Spain;
PD patients H&Y=1.5-2 Medications OFF   
   Giovanni Mirabella
      2020   -   NCT03665493   Italy;
PD patients H&Y=1.5-2 Medications ON   
   Giovanni Mirabella
      2020   -   NCT03665493   Italy;
PD patients H&Y=3 Medications OFF   
   Giovanni Mirabella
      2020   -   NCT03665493   Italy;
PD patients H&Y=3 Medications ON   
   Giovanni Mirabella
      2020   -   NCT03665493   Italy;
PD vitamin supplementation   
   New York Institute of Technology
      2008   -   NCT01238926   United States;
PEG   
   The 988th Hospitail of Joint Logistic Support Force
      2021   Phase 4   ChiCTR2100043303   China;
PEG tube   
   AbbVie
      2013   Phase 3   NCT01960842   Japan;Korea, Republic of;Taiwan;
   AbbVie (prior sponsor, Abbott)
      2009   Phase 3   NCT00660387   New Zealand;United States;
      2009   Phase 3   NCT00360568   Germany;New Zealand;United States;
      2009   Phase 3   NCT00357994   Germany;United States;
      2008   Phase 3   NCT00335153   Australia;Canada;Czech Republic;Finland;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
PET   
   Zionexa
      2021   Phase 3   NCT04265209   -
PET/CT   
   Asan Medical Center
      2006   Phase 3   NCT00468078   Korea, Republic of;
PF-06412562   
   Milton S. Hershey Medical Center
      2018   Phase 1   NCT03665454   United States;
   Pfizer
      2014   Phase 1   NCT02006290   United States;
PF-06649751   
   Cerevel Therapeutics, LLC
      2021   Phase 3   EUCTR2019-002952-17-DE   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
      2021   Phase 3   EUCTR2019-002952-17-BG   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
      2021   Phase 3   EUCTR2019-002951-40-BG   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
      2021   Phase 3   EUCTR2019-002949-38-BG   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United States;
      2020   Phase 3   EUCTR2019-002952-17-HU   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
      2020   Phase 3   EUCTR2019-002952-17-CZ   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
      2020   Phase 3   EUCTR2019-002951-40-HU   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
      2020   Phase 3   EUCTR2019-002951-40-ES   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
      2020   Phase 3   EUCTR2019-002951-40-DE   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
      2020   Phase 3   EUCTR2019-002951-40-CZ   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
      2020   Phase 3   EUCTR2019-002950-22-HU   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
      2020   Phase 3   EUCTR2019-002949-38-PL   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
      2020   Phase 3   EUCTR2019-002949-38-HU   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
      2020   Phase 3   EUCTR2019-002949-38-ES   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
      2020   Phase 3   EUCTR2019-002949-38-DE   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
      2020   Phase 3   EUCTR2019-002949-38-CZ   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United States;
   Pfizer
      2016   Phase 2   NCT02847650   France;Germany;Israel;United States;
      2015   Phase 1   NCT02373072   Belgium;United States;
      2014   Phase 1   NCT02224664   Belgium;United States;
   Pfizer, Inc.
      2017   Phase 2   EUCTR2016-001575-71-ES   France;Germany;Israel;Spain;United States;
      2016   Phase 2   EUCTR2016-001575-71-DE   France;Germany;Israel;Spain;United States;
      2016   Phase 2   EUCTR2015-004912-39-ES   France;Germany;Japan;Spain;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-004912-39-DE   France;Germany;Japan;Spain;United Kingdom;United States;
PF-06649751 -   
   Pfizer Inc., 235 East 42nd Street, New York, New York
      2017   Phase 2   EUCTR2017-000128-81-ES   Canada;France;Germany;Spain;United States;
      2017   Phase 2   EUCTR2017-000128-81-DE   Canada;France;Germany;Spain;United States;
PF-06649751 high dose (15 mg QD)   
   Pfizer
      2016   Phase 2   NCT02687542   Canada;France;Germany;Japan;Spain;United States;
PF-06649751 low dose (1 mg QD)   
   Pfizer
      2016   Phase 2   NCT02687542   Canada;France;Germany;Japan;Spain;United States;
PF-06649751 middle dose 1 (3 mg QD)   
   Pfizer
      2016   Phase 2   NCT02687542   Canada;France;Germany;Japan;Spain;United States;
PF-06649751 middle dose 2 (7 mg QD)   
   Pfizer
      2016   Phase 2   NCT02687542   Canada;France;Germany;Japan;Spain;United States;
PF-06669571   
   Pfizer
      2015   Phase 1   NCT02565628   United States;
PG203   
   Celon Pharma S.A.
      2021   Phase 2   EUCTR2020-006004-16-PL   Poland;
PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj   
   Seoul National University Hospital
      2011   Phase 4   NCT01313819   Korea, Republic of;
PR Oxycodone   
   University Hospital, Toulouse
      2016   Phase 2/Phase 3   NCT02601586   France;
PR001   
   Prevail Therapeutics
      2020   Phase 1/Phase 2   NCT04127578   Israel;United States;
PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE   
   Pharma Two B Ltd
      2018   Phase 3   EUCTR2017-001420-21-ES   Canada;France;Germany;Spain;United States;
      2018   Phase 3   EUCTR2017-001420-21-DE   Canada;France;Germany;Spain;United States;
PRIM-DJ2727   
   The University of Texas Health Science Center, Houston
      2019   Phase 1   NCT03671785   United States;
      2017   Phase 1/Phase 2   NCT03026231   United States;
PROSCAR*30CPR RIV   
   AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI
      2011   -   EUCTR2011-000612-26-IT   Italy;
PRX002   
   Prothena Biosciences Limited
      2014   Phase 1   NCT02157714   United States;
      2014   Phase 1   NCT02095171   United States;
PRX002, ELT2, anti-alpha-synuclein monoclonal antibody   
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 2   EUCTR2020-004997-23-IT   Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd
      2021   Phase 2   EUCTR2020-004997-23-FR   Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-004997-23-AT   Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-000087-15-FR   Austria;France;Germany;Spain;United States;
      2017   Phase 2   EUCTR2017-000087-15-ES   Austria;France;Germany;Spain;United States;
      2017   Phase 2   EUCTR2017-000087-15-DE   Austria;France;Germany;Spain;United States;
      2017   Phase 2   EUCTR2017-000087-15-AT   Austria;France;Germany;Spain;United States;
   Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
      2021   Phase 2   EUCTR2020-004997-23-ES   Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
PS   
   Central Hospital, Nancy, France
      2021   -   NCT04933513   France;
PS128   
   Professor Lu Neurological Clinic
      2020   -   NCT04722211   Taiwan;
      2020   -   NCT04722198   Taiwan;
PT320   
   Peptron, Inc.
      2020   Phase 2   NCT04269642   Korea, Republic of;
PXT002331   
   PREXTON THERAPEUTICS B.V.
      2017   Phase 2   EUCTR2017-000135-14-IT   Austria;France;Germany;Italy;Spain;United Kingdom;
   Prexton Therapeutics
      2016   Phase 1   NCT02639221   United Kingdom;
   Prexton Therapeutics B.V.
      2017   Phase 2   EUCTR2017-000135-14-GB   Austria;Germany;Spain;United Kingdom;
      2017   Phase 2   EUCTR2017-000135-14-ES   Austria;Germany;Italy;Spain;United Kingdom;
      2017   Phase 2   EUCTR2017-000135-14-DE   Austria;Germany;Italy;Spain;United Kingdom;
      2017   Phase 2   EUCTR2017-000135-14-AT   Austria;Germany;Spain;United Kingdom;
PXT002331 -   
   Prexton Therapeutics
      2018   Phase 2   NCT03331848   -
PXT002331 - dose 1   
   Prexton Therapeutics
      2017   Phase 2   NCT03162874   Austria;France;Germany;Italy;Spain;United Kingdom;
PXT002331 - dose 2   
   Prexton Therapeutics
      2017   Phase 2   NCT03162874   Austria;France;Germany;Italy;Spain;United Kingdom;
PYM50028   
   Phytopharm
      2010   Phase 2   NCT01060878   Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
   Phytopharm plc
      2011   -   EUCTR2010-018534-44-HU   Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
      2011   -   EUCTR2010-018534-44-DE   Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
      2011   -   EUCTR2010-018534-44-CZ   Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
      2010   Phase 2   EUCTR2010-018534-44-GB   Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
PYRIDOSTIGMINE BROMIDE   
   Department of Neurology, Roskilde Hospital
      2012   Phase 2   EUCTR2012-000122-21-DK   Denmark;
Paracetamol   
   Bial - Portela C S.A.
      2014   Phase 1   NCT02305017   -
Parapres   
   INSTITUT DE RECERCA HSCSP
      2016   Phase 2   EUCTR2016-000679-25-ES   Spain;
Parcopa   
   Baylor College of Medicine
      2006   Phase 4   NCT00590122   United States;
   UCB Pharma
      2005   Phase 3   NCT00139880   United States;
Pardaprunox   
   Solvay Pharmaceuticals
      2006   Phase 3   NCT00335166   Australia;Czech Republic;Estonia;France;Germany;India;Italy;Lithuania;Malaysia;Netherlands;Poland;Portugal;South Africa;Spain;Taiwan;Thailand;United Kingdom;United States;
Pardoprunox   
   Abbott Products
      2009   Phase 2   NCT00903838   Germany;Italy;Portugal;
   Solvay Pharmaceuticals
      2007   Phase 3   NCT00407095   Albania;Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Latvia;Lithuania;Peru;Russian Federation;Ukraine;United States;
      2007   Phase 3   NCT00406588   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Latvia;Lithuania;Peru;Russian Federation;Ukraine;United States;
      2007   Phase 3   NCT00335374   Australia;Czech Republic;Estonia;France;Germany;India;Italy;Lithuania;Malaysia;Netherlands;Poland;Portugal;South Africa;Spain;Taiwan;Thailand;United Kingdom;United States;
      2007   Phase 3   NCT00332917   Argentina;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Finland;Former Serbia and Montenegro;India;Israel;Mexico;New Zealand;Peru;Romania;Russian Federation;Serbia;Slovakia;South Africa;Sweden;Ukraine;United States;
      2006   Phase 3   NCT00269516   Argentina;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Finland;Former Serbia and Montenegro;India;Israel;Mexico;New Zealand;Peru;Romania;Russian Federation;Serbia;Slovakia;South Africa;Sweden;Ukraine;United States;
Pardoprunox hydrochloride   
   Abbott Healthcare Products B.V.
      2009   -   EUCTR2008-000400-81-DE   Germany;Italy;Portugal;
   SOLVAY PHARMACEUTICALS B.V.
      2009   -   EUCTR2008-000400-81-IT   Germany;Italy;Portugal;
   Solvay Pharmaceuticals
      2009   Phase 3   EUCTR2007-001095-36-SK   Hungary;Slovakia;
      2008   Phase 3   EUCTR2007-001096-10-SK   Hungary;Slovakia;
      2008   -   EUCTR2007-001096-10-HU   Hungary;
      2008   -   EUCTR2007-001095-36-HU   Hungary;
   Solvay Pharmaceuticals B.V.
      2008   Phase 2   EUCTR2008-004943-12-SK   Slovakia;
   Solvay Pharmaceuticals BV
      2009   -   EUCTR2008-000400-81-PT   Germany;Italy;Portugal;
Paroxetine   
   Rutgers, The State University of New Jersey
      2003   Phase 2   NCT00062738   United States;
   University of Rochester
      2005   Phase 3   NCT00086190   Canada;Puerto Rico;United States;
Part 1, JM-010 component Group A   
   Bukwang Pharmaceutical
      2021   Phase 2   NCT04377945   United States;
Part 1, JM-010 component Group B   
   Bukwang Pharmaceutical
      2021   Phase 2   NCT04377945   United States;
Part 1, JM-010 component Group C   
   Bukwang Pharmaceutical
      2021   Phase 2   NCT04377945   United States;
Part 2, JM-010 combination Group A   
   Bukwang Pharmaceutical
      2021   Phase 2   NCT04377945   United States;
Part 2, JM-010 combination Group B   
   Bukwang Pharmaceutical
      2021   Phase 2   NCT04377945   United States;
Part 2, JM-010 component Group C   
   Bukwang Pharmaceutical
      2021   Phase 2   NCT04377945   United States;
Perampanel   
   Eisai Inc.
      2007   Phase 2   NCT00566462   United States;
      2004   Phase 2   NCT01634360   -
   Eisai Limited
      2007   Phase 3   NCT00505622   France;
Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J)   
   AbbVie (prior sponsor, Abbott)
      2013   Phase 3   NCT01736176   United States;
Percutaneous endoscopic gastrostomy tube   
   AbbVie
      2017   Phase 3   NCT02799381   Finland;Greece;Hungary;Italy;Slovakia;Spain;United States;
Percutaneous endoscopic gastrostomy tube (PEG tube)   
   AbbVie (prior sponsor, Abbott)
      2006   Phase 4   NCT00141518   Norway;Sweden;
Pergolide   
   Valeant Pharmaceuticals International, Inc.
      2008   -   NCT00624741   -
Phenlarmide Tablets   
   Yiling Pharmaceutical Inc.
      2019   Phase 1   NCT04164121   China;
Physical exam and UPDRS part III assessment   
   Howard Gendelman, MD
      2013   Phase 1   NCT01882010   United States;
Piclozotan   
   Asubio Pharmaceuticals, Inc.
      2007   Phase 2   NCT00623363   Guatemala;Romania;United States;
Pilocarpine   
   Nagoya University
      2017   -   JPRN-UMIN000026128   Japan;
   katsuno Masahisa
      2017   Phase 2   JPRN-jRCTs041180018   Japan;
Pimavanserin   
   ACADIA Pharmaceuticals Inc.
      2020   Phase 4   NCT04292223   United States;
      2019   Phase 2   NCT04164758   United States;
      2018   Phase 2   NCT03482882   United States;
   VA Office of Research and Development
      2022   Phase 4   NCT04373317   United States;
Pimavanserin (ACP-103)   
   ACADIA Pharmaceuticals Inc
      2009   Phase 3   EUCTR2007-003035-22-PT   Austria;Belgium;Canada;European Union;France;India;Italy;Portugal;Russian Federation;Sweden;Ukraine;United Kingdom;United States;
   ACADIA Pharmaceuticals Inc.
      2008   Phase 3   EUCTR2007-003035-22-GB   Austria;Belgium;Canada;European Union;France;India;Italy;Portugal;Russian Federation;Sweden;Ukraine;United Kingdom;United States;
   Acadia Pharmaceuticals Inc
      2008   Phase 2;Phase 3   EUCTR2007-003035-22-SE   Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom;
      2008   Phase 2;Phase 3   EUCTR2007-003035-22-BE   Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom;
Pimavanserin tartrate   
   ACADIA Pharmaceuticals Inc
      2009   Phase 3   EUCTR2007-003035-22-PT   Austria;Belgium;Canada;European Union;France;India;Italy;Portugal;Russian Federation;Sweden;Ukraine;United Kingdom;United States;
   ACADIA Pharmaceuticals Inc.
      2016   -   NCT02762591   -
      2010   Phase 3   NCT01174004   Canada;United States;
      2008   Phase 3   EUCTR2007-003035-22-GB   Austria;Belgium;Canada;European Union;France;India;Italy;Portugal;Russian Federation;Sweden;Ukraine;United Kingdom;United States;
   Acadia Pharmaceuticals Inc
      2009   Phase 2;Phase 3   EUCTR2007-003035-22-AT   Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom;
      2008   Phase 2;Phase 3   EUCTR2007-003035-22-SE   Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom;
      2008   Phase 2;Phase 3   EUCTR2007-003035-22-FR   Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom;
      2008   Phase 2;Phase 3   EUCTR2007-003035-22-BE   Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom;
      2008   -   EUCTR2007-003051-36-SE   Austria;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-003051-36-PT   Austria;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-003051-36-ES   Austria;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-003051-36-BE   Austria;Belgium;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-003051-36-AT   Austria;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002906-23-BG   Bulgaria;France;United Kingdom;
      2007   -   EUCTR2007-002906-23-GB   Bulgaria;France;United Kingdom;
      2007   -   EUCTR2007-002906-23-FR   Bulgaria;France;United Kingdom;
Pimavanserin tartrate (ACP-103)   
   ACADIA Pharmaceuticals Inc.
      2008   Phase 3   NCT00658567   Austria;Belgium;Italy;Poland;Portugal;Serbia;Spain;Sweden;United States;
      2007   Phase 3   NCT00550238   Austria;Belgium;Canada;France;India;Italy;Poland;Portugal;Russian Federation;Serbia;Sweden;Ukraine;United Kingdom;United States;
      2007   Phase 3   NCT00477672   Bulgaria;France;India;Russian Federation;Ukraine;United Kingdom;United States;
      2004   Phase 2   NCT01518309   United States;
Pioglitazone   
   University of Rochester
      2011   Phase 2   NCT01280123   United States;
Pirepemat   
   Integrative Research Laboratories AB
      2022   Phase 2   NCT05258071   -
Piribedil   
   Desitin Arzneimittel GmbH
      2010   Phase 3   NCT01007864   Germany;
      2009   -   EUCTR2009-012419-16-DE   Germany;
      2008   -   NCT00727727   Germany;
      2008   -   NCT00725478   -
   Henan University of Traditional Chinese Medicine
      2009   -   ChiCTR-TRC-12002150   China;
   Institut de Recherches Internationales Servier
      2006   Phase 2   EUCTR2005-000314-12-DE   Germany;Spain;
      2005   Phase 2   EUCTR2005-000314-12-ES   Germany;Spain;
   Institut de Recherches Internationales Servier (I.R.I.S.)
      2005   -   EUCTR2005-002010-38-DE   Germany;
Piribedil (Clarium)   
   Desitin Arzneimittel GmbH
      2009   -   NCT01519856   Germany;
Pitolisant   
   BIOPROJET
      2010   -   EUCTR2009-013886-24-SE   Czech Republic;Germany;Sweden;
      2010   -   EUCTR2009-013886-24-DE   Czech Republic;Germany;Sweden;
      2009   -   EUCTR2009-013886-24-CZ   Czech Republic;Germany;Sweden;
      2009   -   EUCTR2009-013885-14-FR   France;Spain;
      2009   -   EUCTR2009-013885-14-ES   France;Spain;
Pittsburgh Compound B   
   Sunnybrook Health Sciences Centre
      2016   -   NCT02524405   Canada;
Placebo   
   Meiji Seika Pharma Co., Ltd.
      2015   Phase 3   JPRN-JapicCTI-153057   Japan;
      2015   Phase 2-3   JPRN-JapicCTI-153056   Japan;
   ONO PHARMACEUTICAL CO.,LTD.
      2016   Phase 2   JPRN-JapicCTI-153112   Japan;
   Otsuka Pharmaceutical Co., Ltd.
      2009   Phase 3   JPRN-JapicCTI-090888   -
Plantago ovata husk   
   Rottapharm Spain
      2006   Phase 1   NCT00507715   Spain;
Posiphen   
   Annovis Bio Inc.
      2020   Phase 1/Phase 2   NCT04524351   United States;
Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin)   
   Hospices Civils de Lyon
      2019   -   NCT03970239   France;
Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin)   
   Hospices Civils de Lyon
      2019   -   NCT03970239   France;
Pramipexol   
   Axxonis Pharma GmbH
      2006   -   EUCTR2005-001006-12-DE   Austria;Czech Republic;Germany;Italy;
      2006   -   EUCTR2005-001006-12-CZ   Austria;Czech Republic;Germany;Italy;
      2006   -   EUCTR2005-001006-12-AT   Austria;Czech Republic;Germany;Italy;
   Shanghai General Hospital
      2020   Phase 0   ChiCTR2000037624   China;
Pramipexol Extended Release   
   Boehringer Ingelheim
      2007   Phase 3   NCT00479401   Argentina;Austria;Brazil;Czech Republic;Finland;Germany;Hungary;India;Japan;Malaysia;Russian Federation;Slovakia;Taiwan;Ukraine;United States;
      2007   Phase 3   NCT00466167   Austria;Czech Republic;Hungary;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United Kingdom;
Pramipexol Immediate Release   
   Boehringer Ingelheim
      2007   Phase 3   NCT00479401   Argentina;Austria;Brazil;Czech Republic;Finland;Germany;Hungary;India;Japan;Malaysia;Russian Federation;Slovakia;Taiwan;Ukraine;United States;
      2007   Phase 3   NCT00466167   Austria;Czech Republic;Hungary;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United Kingdom;
Pramipexole   
   Abbott Products
      2009   Phase 2   NCT00903838   Germany;Italy;Portugal;
   Boehringer Ingelheim
      2011   -   NCT01361009   China;
      2008   Phase 3   NCT00601523   Argentina;Austria;Czech Republic;Finland;France;Germany;Hungary;India;Japan;Malaysia;Netherlands;Russian Federation;Slovakia;Taiwan;Ukraine;United States;
      2008   -   NCT02236728   -
      2007   Phase 3   NCT00577460   Austria;Czech Republic;Hungary;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United Kingdom;
      2006   Phase 4   NCT00402233   United States;
      2006   Phase 4   NCT00321854   Austria;Finland;France;Germany;Italy;Japan;Spain;Sweden;United Kingdom;United States;
      2006   Phase 4   NCT00297778   Austria;Finland;France;Germany;Italy;Netherlands;Norway;Romania;Russian Federation;South Africa;Spain;Sweden;Ukraine;United Kingdom;
      2006   Phase 4   EUCTR2005-004949-34-FI   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   NCT00349310   Austria;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2004   -   NCT02248181   -
      2003   Phase 3   NCT00240409   China;
      2003   -   NCT02248207   -
      2002   -   NCT02248168   -
      1999   Phase 3   NCT02172573   -
      1998   Phase 4   NCT02233023   -
      1998   Phase 3   NCT02177357   -
      1998   -   NCT02248220   -
   Boehringer Ingelheim AB
      2006   Phase 4   EUCTR2005-004949-34-SE   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-003788-22-SE   Finland;Germany;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim Austria GmbH
      2006   -   EUCTR2005-004949-34-AT   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-003788-22-AT   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim España S.A.
      2006   Phase 4   EUCTR2005-003788-22-ES   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim España, S.A.
      2006   -   EUCTR2005-004949-34-ES   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim Limited
      2006   Phase 4   EUCTR2005-003788-22-GB   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim Ltd
      2006   Phase 4   EUCTR2005-004949-34-GB   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2006   -   EUCTR2005-004949-34-DE   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-003788-22-DE   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
   Department of Neurology, Brain Hospital Affiliated to Nanjing Medical University
      2019   Phase 0   ChiCTR1900021708   China;
   Department of Neurology, Juntendo University
      2011   -   JPRN-UMIN000006521   Japan;
   Geriatric Hospital of Hainan
      2019   -   ChiCTR1900022534   China;
   Huashan Hospital
      2011   -   NCT01470859   China;
   Institute of Clinical Pharmacology, Central South University
      2012   Phase 1 study   ChiCTR-TTRCC-12002751   China;
   Institute of Psychology, Chinese Academy of Sciences
      2018   -   ChiCTR1800015331   China;
   Kissei Pharmaceutical Co., Ltd.
      2019   Phase 2   NCT03845387   Japan;
   NEUROBIOTEC GMBH
      2007   -   EUCTR2006-003732-30-IT   Germany;Italy;Poland;
   Oregon Health and Science University
      2003   Phase 1   NCT00666653   United States;
   Qualissima
      2008   Phase 4   NCT01048229   -
   SOLVAY PHARMACEUTICALS B.V.
      2009   -   EUCTR2008-000400-81-IT   Germany;Italy;Portugal;
      2006   -   EUCTR2006-000678-57-IT   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
   Sandoz
      2012   Phase 4   NCT01673724   Korea, Republic of;
   Solvay Pharmaceuticals
      2006   Phase 3   NCT00335166   Australia;Czech Republic;Estonia;France;Germany;India;Italy;Lithuania;Malaysia;Netherlands;Poland;Portugal;South Africa;Spain;Taiwan;Thailand;United Kingdom;United States;
   The Affiliated Brain Hospital of Nanjing Medical University (Nanjing Brain Hospital)
      2020   Phase 4   ChiCTR2000039050   China;
   The Affiliated Brain Hospital of Nanjing Medical University( Nanjing Brain Hospital)
      2018   -   ChiCTR1800019942   China;
   Vanderbilt University Medical Center
      2019   Phase 1   NCT04249544   United States;
   West China Hospital of Sichuan University
      2020   Phase 1   ChiCTR2000035564   China;
Pramipexole 0.125 mg tablets   
   Boehringer Ingelheim
      1998   Phase 3   NCT00274131   -
Pramipexole 0.5 mg tablets   
   Boehringer Ingelheim
      1998   Phase 3   NCT00274131   -
Pramipexole ER   
   BOEHRINGER ING.
      2008   -   EUCTR2007-004235-37-IT   Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-000074-23-IT   Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
   BOEHRINGER INGELHEIM
      2008   Phase 3   EUCTR2007-004234-16-FR   Austria;Czech Republic;Finland;France;Hungary;Netherlands;Slovakia;
      2007   Phase 3   EUCTR2007-003353-90-FR   France;Germany;Netherlands;
   Boehringer Ingelheim
      2008   -   EUCTR2007-004235-37-GB   Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-003353-90-NL   France;Germany;Netherlands;
   Boehringer Ingelheim AB
      2008   -   EUCTR2007-004235-37-SE   Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-000074-23-SE   Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim España, S.A.
      2008   Phase 3   EUCTR2007-004235-37-ES   Austria;Czech Republic;Hungary;Italy;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2007-000074-23-ES   Austria;Czech Republic;Hungary;Italy;Slovakia;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim Finland Ky
      2008   -   EUCTR2007-004234-16-FI   Austria;Czech Republic;Finland;France;Hungary;Netherlands;
      2007   -   EUCTR2007-000073-39-FI   Austria;Czech Republic;Finland;Hungary;
   Boehringer Ingelheim Limited
      2007   -   EUCTR2007-000074-23-GB   Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim Pharma Ges mbH
      2008   Phase 3   EUCTR2007-004235-37-HU   Austria;Czech Republic;Hungary;Italy;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-004235-37-PL   Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-004235-37-CZ   Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-004234-16-HU   Austria;Czech Republic;Finland;France;Hungary;Netherlands;
      2007   Phase 3   EUCTR2007-000074-23-SK   Austria;Czech Republic;Hungary;Italy;Slovakia;Spain;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2007-000073-39-SK   Austria;Czech Republic;Finland;Germany;Hungary;Slovakia;
      2007   -   EUCTR2007-000074-23-HU   Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-000073-39-HU   Austria;Czech Republic;Finland;Hungary;
      2007   -   EUCTR2007-000073-39-AT   Austria;Czech Republic;Finland;Hungary;
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2007   -   EUCTR2007-003353-90-DE   France;Germany;Netherlands;
      2007   -   EUCTR2007-000074-23-AT   Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-000073-39-DE   Austria;Czech Republic;Finland;Germany;Hungary;
   Boehringer Ingelheim RCV GmbH & Co KG
      2009   -   EUCTR2007-004235-37-AT   Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2007-004234-16-AT   Austria;Czech Republic;Finland;France;Hungary;Netherlands;
      2008   Phase 3   EUCTR2007-004235-37-SK   Austria;Czech Republic;Hungary;Italy;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2008   Phase 3   EUCTR2007-004234-16-SK   Austria;Czech Republic;Finland;France;Hungary;Netherlands;Slovakia;
      2008   -   EUCTR2007-004234-16-CZ   Austria;Czech Republic;Finland;France;Hungary;Netherlands;
      2007   Phase 3   EUCTR2007-000074-23-CZ   Austria;Czech Republic;Hungary;Italy;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-000073-39-CZ   Austria;Czech Republic;Finland;Hungary;
   Boehringer Ingelheim bv
      2007   -   EUCTR2007-004234-16-NL   Austria;Czech Republic;Finland;France;Hungary;Netherlands;
   Pharma Two B Ltd.
      2018   Phase 3   NCT03329508   Canada;Germany;Spain;United States;
Pramipexole Extended Release   
   Boehringer Ingelheim
      2010   -   NCT01097421   Sweden;
      2007   Phase 3   NCT00558025   France;Germany;Netherlands;
      2007   Phase 2/Phase 3   NCT00560508   Japan;
Pramipexole IR   
   Boehringer Ingelheim
      2018   Phase 4   NCT03521635   China;
Pramipexole Immediate Release   
   Boehringer Ingelheim
      2007   Phase 3   NCT00558025   France;Germany;Netherlands;
      2007   Phase 2/Phase 3   NCT00560508   Japan;
Pramipexole SR   
   Boehringer Ingelheim
      2018   Phase 4   NCT03521635   China;
Pramipexole dihydrochloride extended-release tablets   
   Pharma Two B Ltd
      2018   Phase 3   EUCTR2017-001420-21-ES   Canada;France;Germany;Spain;United States;
      2018   Phase 3   EUCTR2017-001420-21-DE   Canada;France;Germany;Spain;United States;
Pramipexole dihydrochloride monohydrate   
   Abbott Healthcare Products B.V.
      2009   -   EUCTR2008-000400-81-DE   Germany;Italy;Portugal;
   Solvay Pharmaceuticals B.V.
      2008   Phase 2   EUCTR2008-004943-12-SK   Slovakia;
   Solvay Pharmaceuticals BV
      2009   -   EUCTR2008-000400-81-PT   Germany;Italy;Portugal;
Pramipexole dihydrochloride monohydrate extended release   
   University Hospital of North Staffordshire
      2013   Phase 4   EUCTR2012-000801-64-GB   United Kingdom;
Pramipexole extended release tablet   
   Boehringer Ingelheim
      2010   Phase 3   NCT01191944   China;
Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole)   
   First Affiliated Hospital of Zhejiang University
      2020   -   NCT04275492   China;
Pramipexole immediate release   
   Boehringer Ingelheim
      2008   -   NCT00651183   Austria;
Pramipexole immediate release tablet   
   Boehringer Ingelheim
      2010   Phase 3   NCT01191944   China;
Pramipexole or ropinirole   
   Desitin Arzneimittel GmbH
      2010   Phase 3   NCT01007864   Germany;
Prasinezumab   
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 2   EUCTR2020-004997-23-IT   Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd
      2021   Phase 2   EUCTR2020-004997-23-FR   Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-004997-23-AT   Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
   Hoffmann-La Roche
      2021   Phase 2   NCT04777331   Austria;Canada;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
   Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
      2021   Phase 2   EUCTR2020-004997-23-ES   Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride)   
   First Affiliated Hospital of Zhejiang University
      2020   -   NCT04275492   China;
Prednisone   
   Prevail Therapeutics
      2020   Phase 1/Phase 2   NCT04127578   Israel;United States;
Preladenant   
   Merck Sharp & Dohme Corp.
      2011   Phase 2   NCT01294800   Japan;
      2011   Phase 1   NCT01323855   Germany;
      2010   Phase 3   NCT01227265   Argentina;Chile;Colombia;Croatia;Latvia;Lithuania;Mexico;Russian Federation;Serbia;South Africa;Ukraine;United States;
      2010   Phase 3   NCT01215227   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2007   Phase 2   NCT00537017   Argentina;Australia;Canada;Chile;Colombia;France;Guatemala;Hong Kong;Singapore;Spain;United States;
      2006   Phase 2   NCT00406029   Argentina;Australia;Canada;Chile;Colombia;France;Guatemala;Hong Kong;Italy;New Zealand;Peru;Singapore;South Africa;Spain;United States;
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.
      2011   -   EUCTR2009-015161-31-DE   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
      2011   Phase 3   EUCTR2009-013552-72-GB   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2011   -   EUCTR2009-015162-57-PT   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2009-015161-31-PT   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2011   Phase 3   EUCTR2009-015162-57-GB   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-015162-57-BG   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-015161-31-GB   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2011   -   EUCTR2009-015161-31-BG   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2011   -   EUCTR2009-013552-72-BG   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      -   -   EUCTR2009-013552-72-DE   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
   Merck Sharp & Dohme corp.
      2011   Phase 3   EUCTR2009-015162-57-NL   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
   Schering Corporation, división Schering-Plough Research
      2010   Phase 3   EUCTR2009-013552-72-ES   Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
   Schering-Plough Research Institute, a division of Schering Corporation
      2011   Phase 3   EUCTR2009-015162-57-LV   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-015162-57-LT   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-015162-57-FI   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-015162-57-ES   Austria;Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
      2011   Phase 3   EUCTR2009-015162-57-CZ   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-013552-72-CZ   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-020112-11-LV   Argentina;Chile;Colombia;Croatia;Latvia;Lithuania;Mexico;Russian Federation;Serbia;South Africa;Ukraine;United States;
      2011   -   EUCTR2010-020112-11-LT   Argentina;Chile;Colombia;Croatia;Latvia;Lithuania;Mexico;Russian Federation;Serbia;South Africa;Ukraine;United States;
      2011   -   EUCTR2009-015162-57-SE   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2009-015162-57-PL   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2009-015162-57-AT   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2009-015161-31-PL   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2011   -   EUCTR2009-015161-31-CZ   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2011   -   EUCTR2009-013552-72-PL   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2010   Phase 3   EUCTR2009-015161-31-IT   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2009-015161-31-FR   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2009-013552-72-HU   Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2009-013552-72-FI   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-015161-31-SE   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-015161-31-NL   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-015161-31-FI   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-015161-31-AT   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-013552-72-SE   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-013552-72-IT   Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
   Schering-Plough Research Institute, division of Schering Corporation
      2011   -   EUCTR2009-015162-57-IT   Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
   Tokyo Metropolitan Institute of Gerontology
      2016   -   JPRN-UMIN000025638   Japan;
Preladenant 10 mg tablet   
   Merck Sharp & Dohme Corp.
      2010   Phase 3   NCT01155479   Argentina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2010   Phase 3   NCT01155466   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Japan;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Preladenant 2 mg tablet   
   Merck Sharp & Dohme Corp.
      2010   Phase 3   NCT01155479   Argentina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2010   Phase 3   NCT01155466   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Japan;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Preladenant 5 mg tablet   
   Merck Sharp & Dohme Corp.
      2010   Phase 3   NCT01155479   Argentina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2010   Phase 3   NCT01155466   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Japan;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Premarin ®   
   The Parkinson Study Group
      2003   Phase 2   NCT00234676   United States;
Pridia (Donepezil Hydrochloride)   
   The Newcastle upon Tyne Hospitals NHS Foundation Trust
      2012   Phase 3   EUCTR2009-015170-35-GB   United Kingdom;
Pridopidine   
   Prilenia
      2019   Phase 2   NCT03922711   United States;
Primary Cervical Dystonia (Trihexyphenidyl)   
   University of Florida
      2014   -   NCT02046447   United States;
Primavanserin tartrate   
   ACADIA PHARMACEUTICALS INC.
      2009   -   EUCTR2007-003035-22-IT   Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom;
Prior Donepezil   
   Eisai Inc.
      2003   Phase 3   NCT01327859   United Kingdom;
Prior Donzepezil   
   Eisai Inc.
      2003   Phase 3   NCT01327859   United Kingdom;
ProSavin   
   Axovant Sciences Ltd.
      2011   Phase 1/Phase 2   NCT01856439   France;United Kingdom;
   Oxford BioMedica
      2008   Phase 1/Phase 2   NCT00627588   France;United Kingdom;
   Oxford BioMedica (UK) Ltd
      2010   Phase 1;Phase 2   EUCTR2007-001109-26-GB   United Kingdom;
      2010   -   EUCTR2009-017253-35-GB   United Kingdom;
Probiotic   
   University of British Columbia
      2020   Phase 2   NCT03968133   Canada;
Probiotic Capsule   
   University of Malaya
      2017   -   NCT03377322   Malaysia;
Probiotics   
   Franca Marino
      2021   -   NCT05173701   Italy;
Probiotics with prebiotic   
   National University of Malaysia
      2018   Phase 3   NCT04451096   Malaysia;
Prolonged release tablet   
   Boehringer Ingelheim Finland Ky
      2007   -   EUCTR2007-000073-39-FI   Austria;Czech Republic;Finland;Hungary;
   Boehringer Ingelheim Pharma Ges mbH
      2007   Phase 3   EUCTR2007-000073-39-SK   Austria;Czech Republic;Finland;Germany;Hungary;Slovakia;
      2007   -   EUCTR2007-000073-39-HU   Austria;Czech Republic;Finland;Hungary;
      2007   -   EUCTR2007-000073-39-AT   Austria;Czech Republic;Finland;Hungary;
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2007   -   EUCTR2007-000073-39-DE   Austria;Czech Republic;Finland;Germany;Hungary;
   Boehringer Ingelheim RCV GmbH & Co KG
      2007   -   EUCTR2007-000073-39-CZ   Austria;Czech Republic;Finland;Hungary;
Prolopa®   
   Bial - Portela C S.A.
      2008   Phase 1   NCT02169895   Canada;
Propofol   
   Clinica Universidad de Navarra, Universidad de Navarra
      2014   Phase 4   NCT02256319   Spain;
   Columbia University
      2003   -   NCT00615472   United States;
   Department of Anesthesiology, the First Affiliated Hospital of Sun Yat-Sen University
      2020   Phase 4   ChiCTR2000039697   China;
   The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China
      2019   -   ChiCTR1900021760   China;
   University of Texas Southwestern Medical Center
      2020   -   NCT04502550   United States;
   West China Hospital, Sichuan University
      2016   -   ChiCTR-IOR-16010168   China;
   Xuanwu Hospital of CCMU
      2018   -   ChiCTR1800014542   China;
Propofol-Lipuro   
   Clínica Universidad de Navarra/Universidad de Navarra
      2014   -   EUCTR2014-000868-17-ES   Spain;
Propranolol HCl CF 40 mg tablet   
   Radboud University Nijmegen
      2017   Phase 3   EUCTR2016-004629-18-NL   Netherlands;
Psilocybin   
   Maastricht University
      2022   Phase 2   EUCTR2021-000041-40-NL   Netherlands;
Psilocybin therapy   
   Joshua Woolley, MD/PhD
      2021   Phase 2   NCT04932434   United States;
Psilocybine   
   Maastricht University
      2022   Phase 2   EUCTR2021-000041-40-NL   Netherlands;
Psyllium   
   University of Florida
      2021   -   NCT04829760   United States;
Pyridostigmine bromide   
   Christian Baumann
      2012   Phase 2   NCT01993680   Switzerland;
QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD   
   Pfizer
      2017   Phase 2   NCT03185481   United States;
QD to 15 mg QD PF-06649751   
   Pfizer
      2017   Phase 2   NCT03185481   United States;
QD to 7 mg QD PF-06649751 (de-escalated in parent study)   
   Pfizer
      2017   Phase 2   NCT03185481   United States;
QD to 7 mg QD PF-06649751 (if de-escalated in parent study)   
   Pfizer
      2017   Phase 2   NCT03185481   United States;
Quetiapine   
   ACADIA Pharmaceuticals Inc.
      2019   Phase 2   NCT04164758   United States;
   National Institute on Aging (NIA)
      2002   Phase 4   NCT00043849   United States;
   VA Office of Research and Development
      2022   Phase 4   NCT04373317   United States;
R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride   
   Fujimoto Pharmaceutical Corporation
      2006   Phase 2   EUCTR2006-000361-11-GB   United Kingdom;
R-metHuGDNF   
   North Bristol NHS Trust (NBT)
      2013   Phase 2   EUCTR2013-001881-40-GB   United Kingdom;
      2012   Phase 2   EUCTR2011-003866-34-GB   United Kingdom;
RAAV-GAD   
   Neurologix, Inc.
      2011   -   NCT01301573   United States;
RAS   
   Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
      2021   Phase 0   ChiCTR2100045506   China;
   University of Toronto
      2009   -   NCT03316365   -
RASAGILINA MESILATO   
   Teva Pharmaceutical Industries Ltd
      2009   Phase 4   EUCTR2009-011541-24-ES   France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
RASAGILINE MESILATE   
   Dresden University of Technology
      2011   -   EUCTR2010-023756-82-DE   Germany;
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
      2011   -   EUCTR2009-015162-57-PT   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2011   Phase 3   EUCTR2009-015162-57-GB   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-015162-57-BG   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
   Merck Sharp & Dohme corp.
      2011   Phase 3   EUCTR2009-015162-57-NL   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
   Pharma Two B Ltd
      2018   Phase 3   EUCTR2017-001420-21-ES   Canada;France;Germany;Spain;United States;
      2018   Phase 3   EUCTR2017-001420-21-DE   Canada;France;Germany;Spain;United States;
   Schering-Plough Research Institute, a division of Schering Corporation
      2011   Phase 3   EUCTR2009-015162-57-LV   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-015162-57-LT   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-015162-57-FI   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-015162-57-ES   Austria;Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
      2011   Phase 3   EUCTR2009-015162-57-CZ   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2009-015162-57-SE   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2009-015162-57-PL   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2009-015162-57-AT   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
REQUIP 21 CPR 0,   
   SCHWARZ PHARMA
      2004   -   EUCTR2004-002609-66-IT   Germany;Italy;
REQUIP*21CPR   
   CASA DI CURA PRIVATA S.RAFFAELE - PISANA
      2009   -   EUCTR2009-015833-66-IT   Italy;
REQUIP*21CPR 0,   
   GlaxoSmithKline R D
      2006   -   EUCTR2005-005423-34-IT   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
REQUIP*28CPR 8MG R.P.   
   CASA DI CURA PRIVATA S.RAFFAELE - PISANA
      2009   -   EUCTR2009-015833-66-IT   Italy;
REQUIP-LP   
   CHU de Toulouse
      2009   -   EUCTR2009-012529-12-FR   France;
REQUIP-MODUTAB ,   
   GlaxoSmithKline Research & Development Limited
      2013   -   EUCTR2011-002827-17-EE   Estonia;Korea, Republic of;Russian Federation;Slovakia;United States;
REQUIP-MODUTAB,   
   GlaxoSmithKline Research & Development Limited
      2013   -   EUCTR2011-002828-41-EE   Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Taiwan;United States;
RIV-TDS 13.3 mg/24 h   
   University of Bristol
      2019   Phase 3   EUCTR2018-003219-23-GB   United Kingdom;
RM-131   
   Motus Therapeutics, Inc.
      2013   Phase 2   NCT01955616   United States;
RO   
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2011   -   EUCTR2010-022363-35-DE   Germany;
RO7046015   
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 2   EUCTR2020-004997-23-IT   Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd
      2021   Phase 2   EUCTR2020-004997-23-FR   Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-004997-23-AT   Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-000087-15-FR   Austria;France;Germany;Spain;United States;
      2017   Phase 2   EUCTR2017-000087-15-ES   Austria;France;Germany;Spain;United States;
      2017   Phase 2   EUCTR2017-000087-15-AT   Austria;France;Germany;Spain;United States;
   Hoffmann-La Roche
      2017   Phase 2   NCT03100149   Austria;France;Germany;Spain;United States;
   Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
      2021   Phase 2   EUCTR2020-004997-23-ES   Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
RO7046015/PRASINEZUMAB   
   F. Hoffmann-La Roche Ltd
      2017   Phase 2   EUCTR2017-000087-15-DE   Austria;France;Germany;Spain;United States;
ROP+L-Dopa   
   GlaxoSmithKline
      2007   Phase 4   NCT00485069   Japan;
ROT-TDS 8 mg/24 h   
   Luye Pharma Switzerland AG
      2021   Phase 2   EUCTR2021-000867-65-DE   Germany;
RQ-00000010   
   Virginia Commonwealth University
      2016   Phase 1   NCT02838797   United States;
RVG 08740   
   Centre for Human Drug Research
      2020   Phase 2   EUCTR2020-000686-16-NL   Netherlands;
RVG 55618   
   Radboud University Nijmegen
      2017   Phase 3   EUCTR2016-004629-18-NL   Netherlands;
RVT-101   
   Axovant Sciences Ltd.
      2016   Phase 2   NCT02910102   United States;
RYAH-Medtech Inhaler   
   OMNI Medical Services, LLC
      2018   Phase 2   NCT03944447   United States;
Raclopride   
   Institute of Biomedical Research and Innovation
      2015   -   JPRN-UMIN000016485   Japan;
   Nagoya City Rehabilitation Agency
      2019   -   JPRN-UMIN000036952   Japan;
   National Institute of Neurological Disorders and Stroke (NINDS)
      2002   -   NCT00032812   United States;
   Tokyo Metropolitan Institute of Gerontology
      2014   -   JPRN-UMIN000014709   Japan;
Racol   
   St. Mariannna University School of Medicine
      2012   -   JPRN-UMIN000008057   Japan;
Radotinib HCl   
   Il-Yang Pharm. Co., Ltd.
      2021   Phase 2   NCT04691661   France;
Ramelteon   
   Massachusetts General Hospital
      2009   -   NCT00907595   United States;
   Southern California Institute for Research and Education
      2007   Phase 4   NCT00462254   United States;
Rasagilin   
   Technische Universität Dresden
      2009   -   EUCTR2008-005085-30-DE   Germany;
Rasagilina mesilato (12 weeks)   
   Universita di Verona
      2018   -   NCT03648671   Italy;
Rasagiline   
   Beijing Hospital
      2018   -   ChiCTR1800016949   China;
   Bial - Portela C S.A.
      2009   Phase 1   NCT01532141   France;
      2009   Phase 1   NCT01532128   France;
   Brown University
      2011   Phase 4   NCT01382342   United States;
   Chongqing Fortune Pharmaceutical Co., Ltd.
      2011   Phase 3   NCT01736891   China;
   Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
      2008   Phase 4   NCT00755027   Spain;
   Georgetown University
      2012   Phase 4   NCT01497652   United States;
   H. Lundbeck A/S
      2012   Phase 3   NCT01556165   China;
      2012   Phase 1   NCT01652313   China;
   Istanbul University
      2007   Phase 4   NCT00696215   Turkey;
   Lundbeck Italia S.p.A.
      2010   Phase 4   NCT01055379   Italy;
   Merck Sharp & Dohme Corp.
      2010   Phase 3   NCT01215227   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
   Pharma Two B Ltd.
      2018   Phase 3   NCT03329508   Canada;Germany;Spain;United States;
   Qualissima
      2008   Phase 4   NCT01048229   -
   Research and Development University Hospital of North Staffordshire
      2014   -   EUCTR2014-000335-17-GB   United Kingdom;
   Schering-Plough Research Institute, a division of Schering Corporation
      2010   Phase 3   EUCTR2009-015161-31-IT   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-013552-72-IT   Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
   Schering-Plough Research Institute, division of Schering Corporation
      2011   -   EUCTR2009-015162-57-IT   Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
   St. Josef Hospital Bochum
      2011   Phase 4   NCT01385735   Germany;
   TAKEDA PHARMACEUTICAL COMPANY LTD.
      2018   -   JPRN-JapicCTI-184181   Japan;
   TEVA
      2005   -   EUCTR2005-001416-42-IT   Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
   Takeda
      2018   -   NCT03727139   Japan;
   Technische Universität Dresden
      2011   Phase 4   NCT01442610   Germany;
   Teva Branded Pharmaceutical Products R&D, Inc.
      2012   Phase 4   NCT01723228   United States;
   Teva Neuroscience, Inc.
      2009   Phase 4   NCT01049984   United States;
   Teva Pharmaceutical Industries
      2013   Phase 1   NCT01879748   United States;
   Teva Pharmaceutical Industries Ltd
      2009   -   EUCTR2009-011541-24-IT   France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
   The Parkinson's Institute
      2009   Phase 4   NCT01007630   United States;
   Thomas Guttuso
      2014   -   NCT02278588   United States;
   UNIVERSITA` DEGLI STUDI DI PARMA
      2009   -   EUCTR2009-013004-31-IT   Italy;
   University of Florida
      2016   Phase 2   NCT02789020   United States;
      2009   Phase 4   NCT01168596   United States;
   University of Zurich
      2011   Phase 4   NCT01178047   Switzerland;
Rasagiline 1 mg capsule   
   Merck Sharp & Dohme Corp.
      2010   Phase 3   NCT01155479   Argentina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2010   Phase 3   NCT01155466   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Japan;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Rasagiline 1mg tablet   
   TEVA Pharmaceuticals Industries Ltd
      2006   -   EUCTR2006-005140-89-NL   Netherlands;
Rasagiline 2 mg tablet   
   TEVA Pharmaceuticals Industries Ltd
      2006   -   EUCTR2006-005140-89-NL   Netherlands;
Rasagiline Mesylate   
   Teva Neuroscience, Inc.
      1997   Phase 3   NCT00203060   United States;
   Teva Pharmaceutical Industries
      2005   Phase 3   NCT00256204   Argentina;Austria;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Portugal;Romania;Spain;United Kingdom;United States;
Rasagiline mesilate   
   TEVA Pharmaceuticals Industries Ltd
      2006   -   EUCTR2006-005140-89-NL   Netherlands;
   Teva Pharmaceuticals Industries LtD
      2005   Phase 3   EUCTR2005-001416-42-GB   Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-001416-42-ES   Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
      2005   -   EUCTR2005-001416-42-PT   Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
      2005   -   EUCTR2005-001416-42-HU   Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
      2005   -   EUCTR2005-001416-42-DE   Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
      2005   -   EUCTR2005-001416-42-AT   Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
Rasagiline mesylate   
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
      2011   -   EUCTR2009-015162-57-PT   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2011   Phase 3   EUCTR2009-015162-57-GB   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-015162-57-BG   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
   Merck Sharp & Dohme corp.
      2011   Phase 3   EUCTR2009-015162-57-NL   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
   Pharma Two B Ltd
      2018   Phase 3   EUCTR2017-001420-21-ES   Canada;France;Germany;Spain;United States;
      2018   Phase 3   EUCTR2017-001420-21-DE   Canada;France;Germany;Spain;United States;
   Schering-Plough Research Institute, a division of Schering Corporation
      2011   Phase 3   EUCTR2009-015162-57-LV   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-015162-57-LT   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-015162-57-FI   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-015162-57-ES   Austria;Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
      2011   Phase 3   EUCTR2009-015162-57-CZ   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2009-015162-57-SE   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2009-015162-57-PL   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2009-015162-57-AT   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
   Teva Pharmaceutical Industries
      2009   -   NCT01032486   Canada;
      2009   -   NCT00936676   Argentina;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Portugal;Romania;Spain;United Kingdom;United States;
      2004   Phase 3   NCT00203138   United States;
      2002   Phase 3   NCT00203164   United States;
      2001   Phase 3   NCT00203177   Canada;United States;
      2000   Phase 3   NCT00203125   United States;
   Teva Pharmaceutical Industries Ltd
      2009   Phase 4   EUCTR2009-011541-24-HU   France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   Phase 4   EUCTR2009-011541-24-GB   Argentina;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Portugal;Romania;Spain;United Kingdom;United States;
      2009   Phase 4   EUCTR2009-011541-24-FR   France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2009-011541-24-PT   France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2009-011541-24-NL   France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2009-011541-24-DE   France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
Rasagiline mesylate plus Mirapex   
   Teva Neuroscience, Inc.
      2006   Phase 4   NCT00399477   United States;
Rasagiline mesylate with Levodopa   
   Teva Neuroscience, Inc.
      2006   Phase 4   NCT00399477   United States;
Rasagiline mesylate with Requip   
   Teva Neuroscience, Inc.
      2006   Phase 4   NCT00399477   United States;
Rasagiline tablets   
   Teva Pharmaceuticals Industries LtD
      2005   Phase 3   EUCTR2005-001416-42-GB   Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-001416-42-ES   Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
      2005   -   EUCTR2005-001416-42-PT   Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
      2005   -   EUCTR2005-001416-42-HU   Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
      2005   -   EUCTR2005-001416-42-DE   Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
      2005   -   EUCTR2005-001416-42-AT   Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
ReQuip PR   
   GlaxoSmithKline
      2010   Phase 3   NCT01154166   China;
Recombinant human Cerebral Dopamine Neurotrophic Factor   
   Herantis Pharma Plc
      2018   Phase 1;Phase 2   EUCTR2018-000346-19-SE   Finland;Sweden;
      2018   Phase 1;Phase 2   EUCTR2018-000346-19-FI   Finland;Sweden;
      2017   Phase 1;Phase 2   EUCTR2015-004175-73-FI   Finland;
   Renishaw Neuro Solutions Ltd.
      2019   Phase 1;Phase 2   EUCTR2017-005170-19-FI   Finland;Sweden;
      2018   Phase 1;Phase 2   EUCTR2017-005170-19-SE   Finland;Sweden;
Recombinant-methionyl human glial cell line-derived neurotrophic factor   
   National Center for Research Resources (NCRR)
      2000   Phase 1   NCT00006488   United States;
Reduced Glutathione   
   Bastyr University
      2015   Phase 2   NCT02424708   United States;
   University of Washington
      2014   Phase 1   NCT02324426   United States;
Regular Novolin R   
   HealthPartners Institute
      2020   Phase 2   NCT04251585   United States;
Remifentanil   
   Columbia University
      2003   -   NCT00615472   United States;
   The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China
      2019   -   ChiCTR1900021760   China;
Remifentanyl   
   West China Hospital, Sichuan University
      2016   -   ChiCTR-IOR-16010168   China;
Reminyl   
   Otto-von-Guericke University, Medical Faculty, Dpt. of Neurology
      2009   -   EUCTR2009-011093-15-DE   Germany;
Reminyl Retard   
   UMCG
      2009   -   EUCTR2008-006278-13-NL   Netherlands;
Renishaw Drug Delivery System   
   Herantis Pharma Plc.
      2018   Phase 1/Phase 2   NCT03775538   Finland;Sweden;
      2017   Phase 1/Phase 2   NCT03295786   Finland;Sweden;
Repaglinide   
   Bial - Portela C S.A.
      2009   Phase 1   NCT01536366   Portugal;
Requip   
   Boehringer Ingelheim
      2005   Phase 4   NCT00144300   United States;
   Schwarz Biosciences GmbH
      2004   -   EUCTR2004-002609-66-DE   Germany;Italy;
Requip Modutab,   
   GlaxoSmithKline Research & Development Limited
      2013   -   EUCTR2011-002828-41-SK   Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Taiwan;United States;
Requip PR   
   GlaxoSmithKline
      2010   Phase 3   NCT01536574   China;
   Rajesh Pahwa, MD
      2006   Phase 3   NCT00275275   United States;
Requip XL prolonged-release   
   University Hospital of North Staffordshire
      2013   Phase 4   EUCTR2012-000801-64-GB   United Kingdom;
Requip prolonged release   
   University Hospital of North Staffordshire
      2013   Phase 4   EUCTR2012-000801-64-GB   United Kingdom;
Requip-Modutab   
   GlaxoSmithKline Research & Development Limited
      2007   -   EUCTR2006-006209-94-DE   Germany;
Resistant maltodextrin   
   Northwestern University
      2018   Phase 2   NCT03667404   United States;
Resistant starch   
   Saarland University
      2016   -   NCT02784145   Germany;
Resistive respiratory loads   
   University of Florida
      2017   -   NCT03321019   United States;
Restex Tabletten   
   BIAL-Portela & Ca, SA
      2009   -   EUCTR2009-012897-12-RO   Romania;
Rifampicin   
   Kyowa Kirin Co., Ltd.
      2019   Phase 1   NCT04070495   Japan;
Rifampin 300mg BID + istradefylline 40mg Day 8 only   
   Kyowa Hakko Kirin Pharma, Inc.
      2014   Phase 1   NCT02174250   United States;
Rifaximin   
   Mayo Clinic
      2012   Phase 3   NCT01662791   United States;
   Taipei Medical University Shuang Ho Hospital
      2019   Phase 1/Phase 2   NCT03958708   Taiwan;
   University of California, San Francisco
      2019   Phase 1/Phase 2   NCT03575195   United States;
   University of Cincinnati
      2015   Phase 2/Phase 3   NCT02470780   United States;
Ritalin   
   University Medical Center Groningen
      2010   -   EUCTR2009-012643-42-NL   Netherlands;
Rituximab   
   Prevail Therapeutics
      2020   Phase 1/Phase 2   NCT04127578   Israel;United States;
Rivastigmin Luye Transdermal Patches - 4.6mg/24h   
   University of Bristol
      2019   Phase 3   EUCTR2018-003219-23-GB   United Kingdom;
Rivastigmine   
   NOVARTIS FARMA
      2008   -   EUCTR2007-000350-31-IT   France;Italy;Spain;
   Novartis Farmacéutica S.A
      2008   Phase 3   EUCTR2007-000350-31-ES   France;Italy;Spain;
   Novartis Pharma AG
      2008   -   EUCTR2007-000350-31-FR   France;Italy;Spain;
   Research and Enterprise Department
      2012   Phase 2   EUCTR2011-003053-25-GB   United Kingdom;
   University Hospital, Lille
      2009   Phase 3   NCT00767091   France;
   VU University Medical Center
      2013   Phase 4   NCT01856738   Netherlands;
Rivastigmine CF   
   VU University Medical Center
      2013   Phase 4   EUCTR2013-001722-25-NL   Netherlands;
Rivastigmine Luye Transdermal Patch- 9.5mg/24h   
   University of Bristol
      2019   Phase 3   EUCTR2018-003219-23-GB   United Kingdom;
Rivastigmine Patch 9.5 cm2   
   University of California, San Francisco
      2010   Phase 4   NCT00988117   United States;
Rivastigmine Transdermal System   
   University of Bristol
      2020   Phase 3   NCT04226248   United Kingdom;
Rivastigmine capsule   
   Novartis
      2008   Phase 3   NCT00623103   Argentina;Australia;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;Turkey;United Kingdom;United States;
Rivastigmine transdermal patch   
   Novartis
      2008   Phase 3   NCT00623103   Argentina;Australia;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;Turkey;United Kingdom;United States;
   University of Maryland, Baltimore
      2019   Phase 4   NCT03840837   United States;
Rivastigmine transdermal system 13.3 mg/24 h   
   University of Bristol
      2019   Phase 3   EUCTR2018-003219-23-GB   United Kingdom;
Ropinirole   
   CHU de Toulouse
      2009   -   EUCTR2009-012529-12-FR   France;
   GlaxoSmithKline
      2010   Phase 1   NCT01435915   China;
      2007   Phase 2   NCT00460148   Germany;South Africa;
      2003   Phase 3   NCT00381472   Belgium;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
   GlaxoSmithKline Research & Development Limited
      2007   -   EUCTR2006-006209-94-DE   Germany;
   Kansai Medical University
      2010   -   JPRN-UMIN000003601   Japan;
   Otsuka Pharmaceutical Co., Ltd.
      2009   Phase 3   NCT01628926   Japan;
      2009   Phase 3   JPRN-JapicCTI-090888   -
   Pfizer
      2001   Phase 3   NCT00036218   Argentina;Mexico;Puerto Rico;United States;
   SCHWARZ PHARMA
      2004   -   EUCTR2004-002609-66-IT   Germany;Italy;
   Schwarz Biosciences GmbH
      2004   -   EUCTR2004-002609-66-DE   Germany;Italy;
   UNIVERSITA` DEGLI STUDI DI PARMA
      2009   -   EUCTR2009-013004-31-IT   Italy;
Ropinirole (as hydrochloride)   
   University Hospital of North Staffordshire
      2013   Phase 4   EUCTR2012-000801-64-GB   United Kingdom;
Ropinirole CR 2mg tablet   
   GlaxoSmithKline
      2013   Phase 3   NCT01929317   Japan;
Ropinirole CR 8mg tablet   
   GlaxoSmithKline
      2013   Phase 3   NCT01929317   Japan;
Ropinirole Hydrochloride   
   Agarwal, Pinky, M.D.
      2005   Phase 3   NCT00260793   United States;
   Roxane Laboratories
      2004   -   NCT00674310   -
      2004   -   NCT00673088   -
Ropinirole IR   
   GlaxoSmithKline
      2009   Phase 3   NCT00823836   Japan;
Ropinirole IR Tablets   
   GlaxoSmithKline
      2006   Phase 3   EUCTR2005-005423-34-ES   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
   GlaxoSmithKline Research & Development Ltd
      2006   Phase 3   EUCTR2005-005423-34-GB   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2005-005423-34-HU   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2005-005423-34-DE   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2005-005423-34-CZ   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
Ropinirole Implant   
   Titan Pharmaceuticals
      2017   Phase 1/Phase 2   NCT03250117   United States;
Ropinirole PR,   
   GlaxoSmithKline Research & Development Limited
      2013   -   EUCTR2011-002828-41-SK   Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Taiwan;United States;
      2013   -   EUCTR2011-002828-41-EE   Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Taiwan;United States;
      2013   -   EUCTR2011-002827-17-SK   Estonia;Korea, Republic of;Russian Federation;Slovakia;United States;
      2013   -   EUCTR2011-002827-17-EE   Estonia;Korea, Republic of;Russian Federation;Slovakia;United States;
Ropinirole PR/XR   
   GlaxoSmithKline
      2009   Phase 3   NCT00823836   Japan;
Ropinirole PR/XR Tablets   
   GlaxoSmithKline
      2006   Phase 3   EUCTR2005-005423-34-ES   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
   GlaxoSmithKline Research & Development Ltd
      2006   Phase 3   EUCTR2005-005423-34-GB   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2005-005423-34-HU   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2005-005423-34-DE   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2005-005423-34-CZ   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
Ropinirole PR/XR tablets   
   GlaxoSmithKline R D
      2006   -   EUCTR2005-005423-34-IT   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
Ropinirole Prolonged release   
   Seoul National University Hospital
      2009   Phase 4   NCT00986245   Korea, Republic of;
Ropinirole XL   
   GlaxoSmithKline
      2009   Phase 1   NCT01371682   Belgium;
Ropinirole XL (formerly CR)   
   GlaxoSmithKline
      2004   Phase 3   NCT00632736   Belgium;Czech Republic;France;Germany;Hungary;Italy;Philippines;Poland;Spain;United Kingdom;United States;
      2002   Phase 3   NCT00650104   Belgium;France;Netherlands;Norway;United States;
Ropinirole controlled-release (REQUIP CR) for RLS   
   GlaxoSmithKline
      2003   Phase 3   NCT00363727   United States;
Ropinirole hydrochloride   
   GlaxoSmithKline
      2006   Phase 3   EUCTR2005-005423-34-ES   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
   GlaxoSmithKline Research & Development Ltd
      2006   Phase 3   EUCTR2005-005423-34-GB   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2005-005423-34-HU   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2005-005423-34-DE   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2005-005423-34-CZ   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
Ropinirole hydrochloride extended-release tablet placebo   
   Hisamitsu Pharmaceutical Co.,Inc.
      2015   Phase 3   JPRN-JapicCTI-152870   -
Ropinirole hydrochloride prolonged release   
   University Hospital of North Staffordshire
      2013   Phase 4   EUCTR2012-000801-64-GB   United Kingdom;
Ropinirole immediate release   
   GlaxoSmithKline
      2006   Phase 3   NCT00331149   Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
Ropinirole monotherapy   
   GlaxoSmithKline
      2012   Phase 4   NCT01485172   Estonia;Korea, Republic of;Poland;Russian Federation;Slovakia;United States;
Ropinirole oral product   
   Titan Pharmaceuticals
      2017   Phase 1/Phase 2   NCT03250117   United States;
Ropinirole prolonged release   
   GlaxoSmithKline
      2006   Phase 3   NCT00331149   Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
Ropinirole prolonged release/extended release(PR/XR)   
   GlaxoSmithKline
      2007   Phase 2   NCT00434304   Japan;
Ropinirole/L-dopa   
   GlaxoSmithKline
      2012   Phase 4   NCT01494532   Argentina;Chile;Estonia;Korea, Republic of;Poland;Russian Federation;Slovakia;United States;
Rosuvastatin   
   Kyowa Kirin Co., Ltd.
      2019   Phase 1   NCT03970798   Japan;
Rotigotin   
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2011   -   EUCTR2010-022363-35-DE   Germany;
Rotigotina   
   FONDAZIONE SANTA LUCIA
      2012   -   EUCTR2012-001218-40-IT   Italy;
Rotigotine   
   Azienda Ospedaliera Cardinale G. Panico
      2013   Phase 2   NCT02103465   Italy;
   Department of Neurology, Changzheng Hospital, Second Military Medical University
      2016   -   ChiCTR-CPC-15007223   China;
   Ospedale Generale Di Zona Moriggia-Pelascini
      2013   -   NCT02100176   Italy;
   Research and Development University Hospital of North Staffordshire
      2014   -   EUCTR2014-000335-17-GB   United Kingdom;
   SCHWARZ BIOSCIENCES
      2005   Phase 3   EUCTR2004-002650-59-GB   United Kingdom;
   SCHWARZ PHARMA
      2007   -   EUCTR2006-006907-35-IT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2004   -   EUCTR2004-002609-66-IT   Germany;Italy;
      2004   -   EUCTR2004-000148-26-IT   Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
   SCHWARZ PHARMA Deutschland GmbH
      2007   -   EUCTR2006-005438-19-DE   Germany;
   Schwarz BioSciences Inc.
      2008   -   EUCTR2004-000148-26-HU   Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
      2008   -   EUCTR2004-000148-26-AT   Austria;Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
      2004   Phase 3   EUCTR2004-000148-26-ES   Austria;Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
      2004   -   EUCTR2004-000148-26-SE   Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
      2004   -   EUCTR2004-000148-26-FI   Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
      2004   -   EUCTR2004-000148-26-CZ   Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
   Schwarz Biosciences GmbH
      2008   -   EUCTR2006-006752-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-006907-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-006752-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006907-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006907-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006907-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006752-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006752-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2006-006752-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2004-002641-12-GB   Austria;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2004-002641-12-ES   Austria;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2004-002598-21-GB   Austria;United Kingdom;
      2005   -   EUCTR2004-002641-12-AT   Austria;Italy;Spain;United Kingdom;
      2004   -   EUCTR2004-002609-66-DE   Germany;Italy;
      2004   -   EUCTR2004-002598-21-AT   Austria;United Kingdom;
      -   -   EUCTR2006-006907-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
   Schwarz Biosciences GmbH, UCB Group
      2007   Phase 3   EUCTR2006-006907-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-006752-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
   Shandong Luye Pharmaceutical Co., Ltd./CMIC Co., Ltd.
      2019   Phase 1   JPRN-JapicCTI-194763   Japan;
   UCB BIOSCIENCES GmbH
      2013   Phase 4   NCT01782222   Austria;Hungary;Poland;Slovakia;Slovenia;Spain;United States;
      2012   Phase 4   NCT01744496   Germany;Hungary;Korea, Republic of;Poland;Slovakia;United States;
      2012   Phase 4   NCT01711866   Korea, Republic of;Malaysia;Singapore;Taiwan;United States;
      2012   Phase 3   NCT01723904   Australia;Korea, Republic of;Malaysia;Singapore;Taiwan;
   UCB Korea Co., Ltd.
      2012   Phase 4   NCT01523301   Korea, Republic of;
   UCB Pharma
      2012   Phase 3   NCT01646268   China;
      2012   Phase 3   NCT01646255   China;
      2012   Phase 3   NCT01536015   United States;
      2011   Phase 4   NCT01300819   Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Hungary;Italy;Romania;Slovakia;Spain;Switzerland;
      2007   Phase 4   NCT00594464   Germany;
      2007   Phase 3   NCT00593606   -
      2007   Phase 3   NCT00522379   Chile;India;Mexico;Peru;United States;
      2007   Phase 3   NCT00519532   Australia;Austria;Finland;Germany;Hungary;Italy;New Zealand;Poland;South Africa;Spain;United Kingdom;United States;
      2007   Phase 3   NCT00474058   Australia;Austria;Finland;Germany;Hungary;Italy;New Zealand;Poland;South Africa;Spain;United Kingdom;United States;
      2006   Phase 1   NCT01964573   Korea, Republic of;
      2006   Phase 1   NCT00292227   South Africa;
      2005   Phase 3   NCT00505687   Austria;Germany;Israel;Italy;South Africa;Spain;United Kingdom;United States;
      2004   Phase 3   NCT00501969   Australia;Austria;Croatia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;New Zealand;Norway;Poland;South Africa;Spain;Sweden;United Kingdom;
      2004   Phase 3   NCT00243945   Germany;
      2004   Phase 3   NCT00242008   United States;
      2002   Phase 3   NCT00599196   Australia;Austria;Belgium;Croatia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;South Africa;Spain;Sweden;Switzerland;United Kingdom;
      2002   Phase 3   NCT00594386   Canada;United States;
      2002   Phase 3   NCT00594165   Canada;United States;
   UCB Pharma SA
      2012   Phase 4   NCT01519882   United Kingdom;
      2011   -   EUCTR2010-021394-37-IT   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;
   Unità Malattie Neurodegenerative, Ospedale Cardinale Giovanni Panico, Tricase
      2013   -   EUCTR2013-000827-15-IT   Italy;
   University Hospital, Grenoble
      2012   Phase 3   NCT02786667   France;
   Wakayama Medical University
      2018   Phase 1   JPRN-UMIN000033409   Japan;
Rotigotine (Reference product PR 2.1.1)   
   UCB BIOSCIENCES GmbH
      2014   Phase 1   NCT02230904   Germany;
Rotigotine (Test product PR 2.3.1)   
   UCB BIOSCIENCES GmbH
      2014   Phase 1   NCT02230904   Germany;
Rotigotine Nasal Spray   
   Schwarz Biosciences GmbH
      2006   Phase 2   EUCTR2005-004290-19-GB   Austria;Germany;Spain;United Kingdom;
      2006   -   EUCTR2005-004290-19-DE   Germany;Spain;United Kingdom;
      2005   -   EUCTR2005-004290-19-AT   Austria;Germany;Spain;United Kingdom;
Rotigotine TTS (Test)   
   Sandoz
      2019   Phase 1   NCT04183634   Germany;
Rotigotine hydrochloride   
   Schwarz Biosciences GmbH
      2006   Phase 2   EUCTR2005-004290-19-GB   Austria;Germany;Spain;United Kingdom;
      2006   -   EUCTR2005-004290-19-DE   Germany;Spain;United Kingdom;
      2005   -   EUCTR2005-004290-19-AT   Austria;Germany;Spain;United Kingdom;
Rotigotine nasal spray   
   UCB Pharma
      2006   Phase 2   NCT00296192   Germany;
Rotigotine transdermal patch   
   Johns Hopkins University
      2016   Phase 4   NCT02365870   United States;
   UCB Pharma
      2011   Phase 1   NCT01338896   Austria;Germany;United Kingdom;
Rotigotine transdermal patch 2mg/24h(10cm2)   
   Schwarz Pharma Deutschland GmbH, UCB Group
      -   -   EUCTR2009-014341-84-DE   Germany;
Rotigotine transdermal patch 4mg/24h (20cm2)   
   Schwarz Pharma Deutschland GmbH, UCB Group
      -   -   EUCTR2009-014341-84-DE   Germany;
Rotigotine transdermal patch 6mg/24h (30cm2)   
   Schwarz Pharma Deutschland GmbH, UCB Group
      -   -   EUCTR2009-014341-84-DE   Germany;
Rotigotine transdermal patch 8mg/24h (40cm2)   
   Schwarz Pharma Deutschland GmbH, UCB Group
      -   -   EUCTR2009-014341-84-DE   Germany;
Rotigotine, extended-release microspheres   
   Luye Pharma Group Ltd.
      2013   Phase 1   NCT04044547   -
Rytary   
   Impax Laboratories, LLC
      2015   Phase 2   NCT02271503   United States;
S 90049   
   Institut de Recherches Internationales Servier (I.R.I.S.)
      2005   -   EUCTR2005-002010-38-DE   Germany;
S 90049 - F36   
   Institut de Recherches Internationales Servier
      2005   Phase 2   EUCTR2005-000314-12-ES   Germany;Spain;
S 90049 - F38   
   Institut de Recherches Internationales Servier
      2005   Phase 2   EUCTR2005-000314-12-ES   Germany;Spain;
S.c. apomorphine   
   SUNOVION PHARMACEUTICALS INC
      2018   Phase 3   EUCTR2016-003456-70-IT   Austria;France;Germany;Italy;Spain;United Kingdom;
   Sunovion Pharmaceuticals Inc.
      2018   Phase 3   EUCTR2016-003456-70-ES   Austria;Spain;United Kingdom;
      2018   Phase 3   EUCTR2016-003456-70-DE   Austria;France;Germany;Italy;Spain;United Kingdom;
      2018   Phase 3   EUCTR2016-003456-70-AT   Austria;France;Germany;Italy;Spain;United Kingdom;
      2017   Phase 3   EUCTR2016-003456-70-GB   Austria;France;Germany;Italy;Spain;United Kingdom;
S90049   
   Institut de Recherches Internationales Servier
      2006   Phase 2   EUCTR2005-000314-12-DE   Germany;Spain;
SA   
   HKBU School of Chinese Medicine
      2017   -   ChiCTR-IPR-17011987   China;
SAFINAMIDE METANSOLFONATO   
   OSPEDALE SANTA MARIA DELLA MISERICORDIA
      2021   Phase 3   EUCTR2018-004892-11-IT   Italy;
   ZAMBON SPA
      2019   Phase 4   EUCTR2017-002426-20-IT   Austria;France;Germany;Italy;Spain;
      2015   Phase 3   EUCTR2014-002600-24-IT   Austria;France;Germany;Italy;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
SAFINAMIDE METHANESULFONATE   
   ZAMBON SPA
      2019   Phase 4   EUCTR2017-002426-20-IT   Austria;France;Germany;Italy;Spain;
   Zambon SpA
      2019   Phase 4   EUCTR2017-002426-20-FR   Austria;France;Spain;
      2019   Phase 4   EUCTR2017-002426-20-AT   Austria;Spain;
      2018   Phase 4   EUCTR2017-002426-20-ES   Spain;
SAGE-217   
   Sage Therapeutics
      2016   Phase 2   NCT03000569   United States;
SAGE-718   
   Sage Therapeutics
      2020   Phase 2   NCT04476017   United States;
SAM   
   Shenzhen People's Hospital
      2017   -   ChiCTR1800019216   China;
   University of Valencia
      2020   -   NCT04353947   Spain;
SAM-e   
   New York University School of Medicine
      2003   Phase 2/Phase 3   NCT00070941   United States;
SAR402671, GZ402671 or GZ/SAR402671   
   Genzyme Corporation
      2019   Phase 2   EUCTR2016-000657-12-GR   Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
      2018   Phase 2   EUCTR2016-000657-12-AT   Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000657-12-PT   Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000657-12-IT   Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000657-12-DE   Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
      2016   Phase 2   EUCTR2016-000657-12-SE   Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
      2016   Phase 2   EUCTR2016-000657-12-ES   Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
SCH 420814   
   Merck Sharp & Dohme Corp.
      2009   Phase 1   NCT00845000   United States;
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.
      2011   -   EUCTR2009-015161-31-DE   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
      2011   Phase 3   EUCTR2009-013552-72-GB   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2011   -   EUCTR2009-015162-57-PT   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2009-015161-31-PT   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2011   Phase 3   EUCTR2009-015162-57-GB   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-015162-57-BG   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-015161-31-GB   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2011   -   EUCTR2009-015161-31-BG   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2011   -   EUCTR2009-013552-72-BG   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      -   -   EUCTR2009-013552-72-DE   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
   Merck Sharp & Dohme corp.
      2011   Phase 3   EUCTR2009-015162-57-NL   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
   Schering Corporation, división Schering-Plough Research
      2010   Phase 3   EUCTR2009-013552-72-ES   Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
   Schering Plough Research Institute
      2007   -   EUCTR2007-001717-42-FR   France;Spain;
      2006   -   EUCTR2005-005146-39-IT   Italy;
   Schering-Plough Research Institute, a division of Schering Corporation
      2011   Phase 3   EUCTR2009-015162-57-LV   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-015162-57-LT   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-015162-57-FI   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-015162-57-ES   Austria;Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
      2011   Phase 3   EUCTR2009-015162-57-CZ   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-013552-72-CZ   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-020112-11-LV   Argentina;Chile;Colombia;Croatia;Latvia;Lithuania;Mexico;Russian Federation;Serbia;South Africa;Ukraine;United States;
      2011   -   EUCTR2010-020112-11-LT   Argentina;Chile;Colombia;Croatia;Latvia;Lithuania;Mexico;Russian Federation;Serbia;South Africa;Ukraine;United States;
      2011   -   EUCTR2009-015162-57-SE   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2009-015162-57-PL   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2009-015162-57-AT   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2009-015161-31-PL   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2011   -   EUCTR2009-015161-31-CZ   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2011   -   EUCTR2009-013552-72-PL   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2010   Phase 3   EUCTR2009-015161-31-FR   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2009-013552-72-HU   Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2009-013552-72-FI   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-015161-31-SE   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-015161-31-NL   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-015161-31-FI   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-015161-31-AT   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2010   -   EUCTR2009-013552-72-SE   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
SCH 900800   
   Merck Sharp & Dohme Corp.
      2013   Phase 1   NCT01500707   -
SCH420814   
   Schering-Plough Research Institute, a division of Schering Corporation
      2010   Phase 3   EUCTR2009-015161-31-IT   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-013552-72-IT   Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
   Schering-Plough Research Institute, division of Schering Corporation
      2011   -   EUCTR2009-015162-57-IT   Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
SEP-363856   
   Sunovion
      2016   Phase 2   NCT02969369   United States;
SER-214   
   Serina Therapeutics
      2016   Phase 1   NCT02579473   United States;
SIFROL   
   Boehringer Ingelheim AB
      2007   -   EUCTR2007-000074-23-SE   Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim Limited
      2007   -   EUCTR2007-000074-23-GB   Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim Pharma Ges mbH
      2007   Phase 3   EUCTR2007-000074-23-SK   Austria;Czech Republic;Hungary;Italy;Slovakia;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-000074-23-HU   Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2007   -   EUCTR2007-000074-23-AT   Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim RCV GmbH & Co KG
      2007   Phase 3   EUCTR2007-000074-23-CZ   Austria;Czech Republic;Hungary;Italy;Spain;Sweden;United Kingdom;
SINEMET   
   EISAI LTD UK
      2007   -   EUCTR2006-005714-12-IT   Italy;
   Institute for Neurodegenerative Disorders
      2005   -   EUCTR2004-001485-41-ES   Spain;United Kingdom;
SINEMET - 100 MG + 25 MG COMPRESSE 50 COMPRESSE DIVISIBILI   
   INTEC PHARMA LTD
      2018   Phase 2   EUCTR2018-001209-95-IT   Italy;Spain;
SINEMET 10-100   
   Intec Pharma, Ltd.
      2016   Phase 3   EUCTR2015-003512-20-SK   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003512-20-HU   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003512-20-ES   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
SINEMET 100 mg + 25 mg compresse   
   BIAL-Portela & Ca, S.A.
      2021   Phase 4   EUCTR2020-002754-24-IT   Germany;Italy;Portugal;Spain;United Kingdom;
   SynAgile Corporation
      2014   Phase 2   EUCTR2014-002295-87-IT   Italy;
SINEMET 100 mg + 25 mg tablets   
   BIAL-Portela & Ca, S.A.
      2021   Phase 4   EUCTR2020-002754-24-IT   Germany;Italy;Portugal;Spain;United Kingdom;
   Bial - Portela & Ca, S.A.
      2022   Phase 4   EUCTR2020-002754-24-DE   Germany;Italy;Portugal;Spain;United Kingdom;
      2021   Phase 4   EUCTR2020-002754-24-ES   Germany;Italy;Portugal;Spain;United Kingdom;
SINEMET 125   
   Centre for Human Drug Research
      2020   Phase 2   EUCTR2020-000686-16-NL   Netherlands;
SINEMET 25-100   
   INTEC PHARMA LTD
      2016   Phase 3   EUCTR2015-003512-20-IT   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
   Intec Pharma, Ltd.
      2016   Phase 3   EUCTR2015-003512-20-SK   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003512-20-PL   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003512-20-HU   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003512-20-GB   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003512-20-ES   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
SINEMET 25/100   
   BIAL-Portela & Ca, SA
      2009   -   EUCTR2009-012897-12-RO   Romania;
   Bial - Portela & Cª, S.A.
      2008   -   EUCTR2008-003869-72-PT   Portugal;
SINEMET CR   
   Novartis Pharma AG
      2006   -   EUCTR2005-001032-72-CZ   Czech Republic;Italy;Portugal;
SINEMET Plus   
   NEURODERM LTD.
      2018   Phase 3   EUCTR2017-002780-17-IT   Austria;France;Italy;Netherlands;Spain;United States;
   NeuroDerm Ltd.
      2018   Phase 3   EUCTR2017-002780-17-FR   Austria;France;Italy;Netherlands;Spain;United States;
      2018   Phase 3   EUCTR2017-002780-17-ES   Austria;France;Italy;Netherlands;Spain;United States;
SINEMET*50CPR 100MG+   
   VERNALIS DEVELOPMENT LIMITED
      2006   -   EUCTR2006-004112-51-IT   Italy;
SINEMET® Plus 25 mg/100 mg Tablets   
   Civitas Therapeutics, Inc.
      2012   -   EUCTR2012-000181-37-GB   Israel;Serbia;United Kingdom;
SINEMET®-Plus Tablets   
   Impax Laboratories, Inc.
      2010   -   EUCTR2009-014688-37-PL   France;Germany;Poland;Spain;
      2009   Phase 3   EUCTR2009-014688-37-FR   France;Germany;Poland;Spain;
      2009   -   EUCTR2009-014688-37-DE   France;Germany;Poland;Spain;
SIRIO*30CPR EFF 25MG+   
   VERNALIS DEVELOPMENT LIMITED
      2006   -   EUCTR2006-004112-51-IT   Italy;
SK&F101468   
   GlaxoSmithKline Research & Development Limited
      2013   -   EUCTR2011-002828-41-SK   Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Taiwan;United States;
      2013   -   EUCTR2011-002828-41-EE   Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Taiwan;United States;
      2013   -   EUCTR2011-002827-17-SK   Estonia;Korea, Republic of;Russian Federation;Slovakia;United States;
      2013   -   EUCTR2011-002827-17-EE   Estonia;Korea, Republic of;Russian Federation;Slovakia;United States;
      2007   -   EUCTR2006-006209-94-DE   Germany;
SKF-101468A   
   GlaxoSmithKline R D
      2006   -   EUCTR2005-005423-34-IT   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
SLV308   
   SOLVAY PHARMACEUTICALS B.V.
      2009   -   EUCTR2008-000400-81-IT   Germany;Italy;Portugal;
   Solvay Pharmaceuticals
      2009   Phase 3   EUCTR2007-001095-36-SK   Hungary;Slovakia;
      2008   Phase 3   EUCTR2007-001096-10-SK   Hungary;Slovakia;
      2008   -   EUCTR2007-001096-10-HU   Hungary;
      2008   -   EUCTR2007-001095-36-HU   Hungary;
      2005   Phase 3   NCT00134251   Bulgaria;Former Serbia and Montenegro;Malta;Serbia;
SLV308 (mono) hydro   
   Solvay pharmaceuticals
      2006   Phase 3   EUCTR2006-000678-57-GB   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
SLV308 (mono) hydrochlo   
   Solvay Pharmaceuticals
      2006   Phase 3   EUCTR2006-000858-45-SK   Finland;Slovakia;Sweden;
SLV308 (mono) hydrochlori   
   Solvay Pharmaceuticals
      2006   -   EUCTR2006-000859-18-CZ   Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
   Solvay pharmaceuticals
      2007   -   EUCTR2006-000859-18-PT   Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
      2007   -   EUCTR2006-000859-18-NL   Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
      2007   -   EUCTR2006-000678-57-CZ   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
      2006   -   EUCTR2006-000859-18-LT   Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
      2006   -   EUCTR2006-000859-18-EE   Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
      2006   -   EUCTR2006-000678-57-NL   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
      2006   -   EUCTR2006-000678-57-LT   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
      2006   -   EUCTR2006-000678-57-EE   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
      2006   -   EUCTR2006-000678-57-DE   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
   Solvay pharmaceuticals B.V.
      2006   -   EUCTR2006-000678-57-PT   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
SLV308 (mono) hydrochloride   
   Solvay Pharmaceuticals
      2007   -   EUCTR2006-000858-45-SE   Finland;Sweden;
      2006   Phase 3   EUCTR2006-000858-45-SK   Finland;Slovakia;Sweden;
      2006   -   EUCTR2006-000859-18-CZ   Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
      2006   -   EUCTR2006-000858-45-FI   Finland;Sweden;
      2006   -   EUCTR2005-006033-32-SK   Finland;Slovakia;Sweden;
      2006   -   EUCTR2005-006033-32-SE   Finland;Slovakia;Sweden;
      2006   -   EUCTR2005-006033-32-FI   Finland;Slovakia;Sweden;
      2005   -   EUCTR2005-002432-10-MT   Malta;
   Solvay pharmaceuticals
      2007   Phase 3   EUCTR2006-000678-57-FR   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
      2007   -   EUCTR2006-000859-18-PT   Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
      2007   -   EUCTR2006-000859-18-NL   Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
      2007   -   EUCTR2006-000859-18-DE   Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
      2007   -   EUCTR2006-000678-57-CZ   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
      2006   Phase 3   EUCTR2006-000678-57-GB   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
      2006   -   EUCTR2006-000859-18-LT   Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
      2006   -   EUCTR2006-000859-18-EE   Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
      2006   -   EUCTR2006-000678-57-NL   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
      2006   -   EUCTR2006-000678-57-LT   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
      2006   -   EUCTR2006-000678-57-EE   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
      2006   -   EUCTR2006-000678-57-DE   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
   Solvay pharmaceuticals B.V.
      2006   -   EUCTR2006-000678-57-PT   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
SLV308 (mono)hydrochloride   
   SOLVAY PHARMACEUTICALS B.V.
      2006   -   EUCTR2006-000678-57-IT   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
SLV308 hydrochloride   
   Abbott Healthcare Products B.V.
      2009   -   EUCTR2008-000400-81-DE   Germany;Italy;Portugal;
   Solvay Pharmaceuticals B.V.
      2008   Phase 2   EUCTR2008-004943-12-SK   Slovakia;
   Solvay Pharmaceuticals BV
      2009   -   EUCTR2008-000400-81-PT   Germany;Italy;Portugal;
SLV308(mono)hydrochloride   
   Solvay Pharmaceuticals
      2007   -   EUCTR2006-005183-91-LV   Latvia;Lithuania;
      2007   -   EUCTR2006-005183-91-LT   Latvia;Lithuania;
      2007   -   EUCTR2006-005182-20-LV   Latvia;Lithuania;
      2007   -   EUCTR2006-005182-20-LT   Latvia;Lithuania;
SND 919 CL2 Y   
   BOEHRINGER INGELHEIM
      2008   Phase 3   EUCTR2007-004234-16-FR   Austria;Czech Republic;Finland;France;Hungary;Netherlands;Slovakia;
      2007   Phase 3   EUCTR2007-003353-90-FR   France;Germany;Netherlands;
   Boehringer Ingelheim
      2008   -   EUCTR2007-004235-37-GB   Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-003353-90-NL   France;Germany;Netherlands;
      2006   Phase 4   EUCTR2005-004949-34-FI   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim AB
      2008   -   EUCTR2007-004235-37-SE   Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
      2006   Phase 4   EUCTR2005-004949-34-SE   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-003788-22-SE   Finland;Germany;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim Austria GmbH
      2006   -   EUCTR2005-004949-34-AT   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-003788-22-AT   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim España S.A.
      2006   Phase 4   EUCTR2005-003788-22-ES   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim España, S.A.
      2008   Phase 3   EUCTR2007-004235-37-ES   Austria;Czech Republic;Hungary;Italy;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004949-34-ES   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim Finland Ky
      2008   -   EUCTR2007-004234-16-FI   Austria;Czech Republic;Finland;France;Hungary;Netherlands;
      2007   -   EUCTR2007-000073-39-FI   Austria;Czech Republic;Finland;Hungary;
   Boehringer Ingelheim Limited
      2006   Phase 4   EUCTR2005-003788-22-GB   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim Ltd
      2006   Phase 4   EUCTR2005-004949-34-GB   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim Pharma Ges mbH
      2008   Phase 3   EUCTR2007-004235-37-HU   Austria;Czech Republic;Hungary;Italy;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-004235-37-PL   Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-004235-37-CZ   Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-004234-16-HU   Austria;Czech Republic;Finland;France;Hungary;Netherlands;
      2007   Phase 3   EUCTR2007-000073-39-SK   Austria;Czech Republic;Finland;Germany;Hungary;Slovakia;
      2007   -   EUCTR2007-000073-39-HU   Austria;Czech Republic;Finland;Hungary;
      2007   -   EUCTR2007-000073-39-AT   Austria;Czech Republic;Finland;Hungary;
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2007   -   EUCTR2007-003353-90-DE   France;Germany;Netherlands;
      2007   -   EUCTR2007-000073-39-DE   Austria;Czech Republic;Finland;Germany;Hungary;
      2006   -   EUCTR2005-004949-34-DE   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-003788-22-DE   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim RCV GmbH & Co KG
      2009   -   EUCTR2007-004235-37-AT   Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2007-004234-16-AT   Austria;Czech Republic;Finland;France;Hungary;Netherlands;
      2008   Phase 3   EUCTR2007-004235-37-SK   Austria;Czech Republic;Hungary;Italy;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2008   Phase 3   EUCTR2007-004234-16-SK   Austria;Czech Republic;Finland;France;Hungary;Netherlands;Slovakia;
      2008   -   EUCTR2007-004234-16-CZ   Austria;Czech Republic;Finland;France;Hungary;Netherlands;
      2007   -   EUCTR2007-000073-39-CZ   Austria;Czech Republic;Finland;Hungary;
   Boehringer Ingelheim bv
      2007   -   EUCTR2007-004234-16-NL   Austria;Czech Republic;Finland;France;Hungary;Netherlands;
SND 919 CL2Y   
   BOEHRINGER ING.
      2008   -   EUCTR2007-004235-37-IT   Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-000074-23-IT   Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim AB
      2007   -   EUCTR2007-000074-23-SE   Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim España, S.A.
      2007   Phase 3   EUCTR2007-000074-23-ES   Austria;Czech Republic;Hungary;Italy;Slovakia;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim Limited
      2007   -   EUCTR2007-000074-23-GB   Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim Pharma Ges mbH
      2007   Phase 3   EUCTR2007-000074-23-SK   Austria;Czech Republic;Hungary;Italy;Slovakia;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-000074-23-HU   Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2007   -   EUCTR2007-000074-23-AT   Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim RCV GmbH & Co KG
      2007   Phase 3   EUCTR2007-000074-23-CZ   Austria;Czech Republic;Hungary;Italy;Spain;Sweden;United Kingdom;
SNN0031   
   NeuroNova AB
      2009   -   EUCTR2007-007853-30-SE   Sweden;
   Newron Sweden AB
      2013   Phase 1   NCT01829867   Sweden;
      2009   Phase 1/Phase 2   NCT00866502   Sweden;
SOLIGEN   
   Institute for Neurodegenerative Disorders
      2005   -   EUCTR2004-001485-41-ES   Spain;United Kingdom;
SPECT   
   Zionexa
      2021   Phase 3   NCT04265209   -
SPECT imaging   
   Tel-Aviv Sourasky Medical Center
      2013   Phase 2   NCT01931488   Israel;
SPM 926   
   SCHWARZ PHARMA
      2004   -   EUCTR2004-002609-66-IT   Germany;Italy;
SPM 962   
   Otsuka Pharmaceutical Co., Ltd.
      2009   Phase 3   NCT01631825   Japan;
      2009   Phase 3   NCT01628926   Japan;
      2009   Phase 3   JPRN-JapicCTI-090888   -
      2008   Phase 2/Phase 3   NCT01628965   Japan;
      2007   Phase 2/Phase 3   NCT00537485   Japan;
      2006   Phase 2   NCT01631812   Japan;
      2006   Phase 2   NCT01628848   Japan;
      2005   Phase 2   NCT01634243   Japan;
   SCHWARZ BIOSCIENCES
      2005   Phase 3   EUCTR2004-002650-59-GB   United Kingdom;
   SCHWARZ PHARMA
      2004   -   EUCTR2004-002609-66-IT   Germany;Italy;
   Schwarz BioSciences Inc.
      2008   -   EUCTR2004-000148-26-HU   Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
      2008   -   EUCTR2004-000148-26-AT   Austria;Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
      2004   Phase 3   EUCTR2004-000148-26-ES   Austria;Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
      2004   -   EUCTR2004-000148-26-SE   Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
      2004   -   EUCTR2004-000148-26-FI   Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
      2004   -   EUCTR2004-000148-26-CZ   Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
   Schwarz Biosciences GmbH
      2005   Phase 3   EUCTR2004-002641-12-GB   Austria;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2004-002641-12-ES   Austria;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2004-002598-21-GB   Austria;United Kingdom;
      2005   -   EUCTR2004-002641-12-AT   Austria;Italy;Spain;United Kingdom;
      2004   -   EUCTR2004-002598-21-AT   Austria;United Kingdom;
   UCB Pharma
      2004   Phase 3   NCT00244387   Germany;
      2004   Phase 3   NCT00243971   Germany;
SPM962   
   Schwarz Biosciences GmbH
      2004   -   EUCTR2004-002609-66-DE   Germany;Italy;
   Unità Malattie Neurodegenerative, Ospedale Cardinale Giovanni Panico, Tricase
      2013   -   EUCTR2013-000827-15-IT   Italy;
SQJZ herbal mixtures   
   Dongzhimen Hospital, Beijing
      2015   Phase 2   NCT02616120   China;
SR57667B   
   Sanofi
      2004   Phase 2   NCT00220272   Canada;Finland;France;Netherlands;Spain;Switzerland;United Kingdom;
      2003   Phase 2   NCT00228150   Austria;Canada;Denmark;France;Germany;Morocco;Netherlands;Portugal;South Africa;Spain;Sweden;Tunisia;United Kingdom;
STALEVO*100CPR 100/25/   
   AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELE
      2010   -   EUCTR2010-019396-29-IT   Italy;
STALEVO*100CPR 50/12,5/   
   AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELE
      2010   -   EUCTR2010-019396-29-IT   Italy;
SYN115   
   BIOTIE THERAPIES INC.
      2015   Phase 3   EUCTR2014-005630-60-IT   Austria;Canada;Czech Republic;Germany;Italy;Spain;United States;
   Biotie Therapies Inc.
      2015   Phase 3   EUCTR2014-005630-60-ES   Austria;Canada;Czech Republic;European Union;Germany;Spain;United States;
   Biotie Therapies Inc. (a wholly owned subsidiary of Acorda Therapeutics Inc.)
      2015   Phase 3   EUCTR2014-005630-60-CZ   Austria;Canada;Czech Republic;European Union;Germany;Spain;United States;
   Biotie Therapies Inc.(a wholly owned subsidiary of Acorda Therapeutics Inc.)
      2016   Phase 3   EUCTR2014-005630-60-AT   Austria;Canada;Czech Republic;European Union;Germany;Spain;United States;
      2015   Phase 3   EUCTR2014-005630-60-DE   Austria;Canada;Czech Republic;European Union;Germany;Spain;United States;
SYN115 Tablets,   
   Biotie Therapies Inc.
      2012   -   EUCTR2011-005054-59-RO   Argentina;Canada;Chile;Romania;Ukraine;United States;
SYN120   
   Biotie Therapies Inc.
      2014   Phase 2   NCT02258152   United States;
Safety observation   
   Amgen
      2005   -   NCT00148369   Canada;United Kingdom;United States;
Safinamida   
   Merck Serono S.A. - Geneva
      2010   -   EUCTR2010-020109-34-ES   Italy;Spain;
Safinamide   
   Alain Kaelin
      2019   Phase 4   NCT03968744   Switzerland;
   IRCCS San Raffaele
      2018   Phase 4   NCT03843944   Italy;
   MERCK SERONO INTERNATIONAL SA
      2008   Phase 3   EUCTR2007-002963-28-IT   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain;
   MERCK SERONO SA
      2009   Phase 3   EUCTR2008-004146-88-IT   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain;
      2009   -   EUCTR2008-002769-30-IT   Italy;
   Merck Serono International S.A.
      2008   Phase 3   EUCTR2007-002963-28-ES   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain;
      2008   -   EUCTR2007-002964-90-ES   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
      2007   -   EUCTR2007-002964-90-NL   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
      2007   -   EUCTR2007-002964-90-FI   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
   Merck Serono S.A - Geneva
      2008   Phase 3   EUCTR2007-002964-90-GB   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Slovakia;Spain;United Kingdom;
   Merck Serono S.A-Geneva
      2009   -   EUCTR2007-002963-28-PT   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Spain;
   Merck Serono S.A. - Geneva
      2011   -   EUCTR2009-017174-20-AT   Austria;Canada;France;Germany;South Africa;
      2010   Phase 3   EUCTR2008-005492-94-BE   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2010   Phase 2   EUCTR2009-017174-20-FR   Austria;France;Germany;
      2010   -   EUCTR2009-017174-20-DE   Austria;Canada;France;Germany;South Africa;
      2010   -   EUCTR2008-005492-94-NL   Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2007-002964-90-CZ   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-005492-94-SK   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-005492-94-GB   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-005492-94-FR   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-005492-94-ES   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   -   EUCTR2008-005492-94-HU   Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2007-002964-90-FR   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-002964-90-DE   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
      2007   Phase 3   EUCTR2007-002964-90-SK   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Slovakia;Spain;United Kingdom;
      2007   Phase 3   EUCTR2007-002963-28-SK   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain;
   Merck Serono S.A.-Geneva
      2008   -   EUCTR2007-002964-90-HU   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
   Merck Serono SA - Geneva
      2009   Phase 3   EUCTR2008-004146-88-SK   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain;
      2009   Phase 3   EUCTR2008-004146-88-ES   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain;
      2009   Phase 3   EUCTR2008-001966-10-SK   Austria;Estonia;Hungary;Slovakia;United Kingdom;
      2009   -   EUCTR2008-004146-88-PT   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Spain;
      2009   -   EUCTR2008-004146-88-PL   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Spain;
      2009   -   EUCTR2008-001966-10-HU   Austria;Estonia;Hungary;United Kingdom;
      2009   -   EUCTR2008-001966-10-GB   Austria;Estonia;Hungary;United Kingdom;
      2009   -   EUCTR2008-001966-10-EE   Austria;Estonia;Hungary;United Kingdom;
      2009   -   EUCTR2008-001966-10-AT   Austria;Estonia;Hungary;United Kingdom;
   NEWRON PHARMACEUTICALS
      2007   -   EUCTR2006-005861-21-IT   Italy;
      2006   -   EUCTR2006-005860-14-IT   Italy;
      2004   -   EUCTR2004-000835-27-IT   Italy;Spain;
      2004   -   EUCTR2004-000833-12-IT   Italy;Spain;
   Newron
      2011   Phase 2   NCT01264861   United States;
      2010   Phase 2   NCT01211587   Spain;United States;
      2010   Phase 2   NCT01113320   Austria;Canada;France;Germany;South Africa;
      2009   Phase 3   NCT00865579   Romania;
      2007   Phase 3   NCT01286935   -
      2007   Phase 3   NCT01187966   -
      2005   Phase 3   NCT00642889   -
      2004   Phase 3   NCT00643045   -
   Newron Pharmaceuticals
      2011   -   EUCTR2008-005492-94-PT   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
      2011   -   EUCTR2008-005492-94-FI   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
      2011   -   EUCTR2008-005492-94-CZ   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
      2011   -   EUCTR2008-005492-94-BG   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
      2010   -   EUCTR2008-004146-88-DE   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States;
      2009   Phase 3   EUCTR2008-004146-88-BG   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States;
      2009   -   EUCTR2008-005492-94-EE   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
      2009   -   EUCTR2008-005492-94-AT   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
      2009   -   EUCTR2008-004146-88-FI   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States;
      2009   -   EUCTR2008-004146-88-CZ   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States;
      -   -   EUCTR2008-005492-94-DE   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Taiwan;Thailand;United Kingdom;United States;
   Newron Pharmaceuticals S.P.A
      2005   Phase 3   EUCTR2004-000835-27-ES   Italy;Spain;
   Newron Pharmaceuticals S.p.A.
      2004   Phase 3   EUCTR2004-000833-12-ES   Italy;Spain;
   Newron Pharmaceuticals SpA
      2011   Phase 3   EUCTR2007-002964-90-BE   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Slovakia;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
      2010   -   EUCTR2007-002963-28-DE   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;South Africa;Spain;United States;
      2009   -   EUCTR2007-002964-90-AT   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
      2009   -   EUCTR2007-002963-28-PL   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Spain;
      2009   -   EUCTR2007-002963-28-CZ   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;South Africa;Spain;United States;
      2009   -   EUCTR2007-002963-28-BG   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;South Africa;Spain;United States;
      2008   -   EUCTR2007-002964-90-EE   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
      2007   -   EUCTR2007-002963-28-FI   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Poland;Portugal;South Africa;Spain;United States;
   Zambon SpA
      2019   Phase 3   NCT03881371   China;
Safinamide (as add-on therapy)   
   Newron
      2007   Phase 3   NCT00605683   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Israel;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States;
Safinamide + Levodopa   
   Newron
      2009   Phase 1/Phase 2   NCT01026428   Italy;
Safinamide Methanesulfonate   
   Zambon SpA
      2019   Phase 4   NCT03841604   Austria;France;Germany;Italy;Spain;
      2019   Phase 3   NCT03987750   -
Safinamide metansolfonato (12 weeks)   
   Universita di Verona
      2018   -   NCT03648671   Italy;
Safinamide methansulfonate   
   Zambon SpA
      2019   Phase 4   EUCTR2017-002426-20-FR   Austria;France;Spain;
      2019   Phase 4   EUCTR2017-002426-20-AT   Austria;Spain;
      2018   Phase 4   EUCTR2017-002426-20-ES   Spain;
Safinamide, MAO-B inhibitor   
   Newron
      2009   Phase 3   NCT01028586   Switzerland;
Safinimide 50-100 mg/day   
   Newron
      2009   Phase 3   NCT00627640   Australia;Austria;Belgium;Canada;Estonia;France;Germany;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Slovakia;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
Sage leaf   
   Newcastle Upon tyne Hospitals NHS Foundation Trust
      2007   -   EUCTR2007-002899-34-GB   United Kingdom;
Saline   
   NeuroDerm Ltd.
      2011   Phase 1/Phase 2   NCT01229332   Israel;
   Yale University
      2012   Phase 2   NCT02419313   United States;
Saline Intranasal Delivery   
   Bastyr University
      2012   Phase 1   NCT01398748   United States;
Saracatinib   
   King's College London
      2019   Early Phase 1   NCT03661125   United Kingdom;
Sarcosine Capsule   
   China Medical University Hospital
      2010   -   NCT01785628   Taiwan;
Sargramostim   
   Howard Gendelman, MD
      2013   Phase 1   NCT01882010   United States;
   University of Nebraska
      2019   Phase 1   NCT03790670   United States;
Sarizotan   
   EMD Serono
      2004   Phase 3   NCT00105508   United States;
Sarizotan HC1   
   EMD Serono
      2004   Phase 3   NCT00105521   United States;
Sarizotan HCl   
   EMD Serono
      2002   Phase 2   NCT00314288   Belgium;Bulgaria;Canada;France;Germany;Hungary;Portugal;Romania;South Africa;United Kingdom;United States;
Sarizotan Hydrochloride   
   MERCK KGaA
      2004   Phase 3   EUCTR2004-001594-25-ES   Austria;Finland;Spain;
Sarizotan hydrochloride   
   MERCK S.P.A.
      2004   -   EUCTR2004-001593-10-IT   Italy;United Kingdom;
   Merck KGaA
      2005   Phase 3   EUCTR2005-000444-84-GB   Austria;Finland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-000444-84-ES   Austria;Finland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2005-000444-84-FI   Finland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2005-000444-84-AT   Austria;Finland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-001594-25-AT   Austria;Finland;Spain;
      2004   -   EUCTR2004-001594-25-FI   Finland;Spain;
Sedation with IV propofol   
   Hadassah Medical Organization
      2006   -   NCT00355927   Israel;
Selegiline   
   Department of Neurology, Juntendo Koshigaya Hospital
      2012   -   JPRN-UMIN000008477   Japan;
   FP Pharmaceutical Corp.
      2012   Phase 2   JPRN-JapicCTI-122000   -
      -   Phase 3   JPRN-JapicCTI-121954   -
      -   Phase 2   JPRN-JapicCTI-101020   -
   Institute of Psychology, Chinese Academy of Sciences
      2018   -   ChiCTR1800015331   China;
   Ito Hidefumi
      2016   Phase 2   JPRN-jRCTs051180098   Japan;
   Longhua Hospital Shanghai University of Traditional Chinese Medicine
      2018   -   ChiCTR1800018017   China;
      2018   -   ChiCTR1800017949   China;
   Osaka Redcross HospitalWakayama Prefectural Medical College
      2016   Phase 2   JPRN-UMIN000022533   Japan;
   Research and Development University Hospital of North Staffordshire
      2014   -   EUCTR2014-000335-17-GB   United Kingdom;
   Second Affiliated Hospital of Soochow University
      2020   Phase 4   NCT04870372   China;
   The Second Affiliated Hospital of Soochow University
      2020   Phase 4   ChiCTR2100045946   China;
   Union Medical College Affiliated Hospital of Tongji Medical College, Huazhong University of science and technology
      2020   Phase 0   ChiCTR2000037828   China;
   University of South Florida
      2014   Phase 4   NCT02225548   United States;
Selegiline HCl 5 PCH   
   TEVA Pharmaceuticals Industries Ltd
      2006   -   EUCTR2006-005140-89-NL   Netherlands;
Semaglutide   
   Oslo University Hospital
      2019   Phase 2   NCT03659682   -
Semi continuous intra-oral administration of LD/CD   
   IRCCS San Raffaele
      2015   Phase 2   NCT02763137   Italy;
Senfrol monotherapy   
   Peking University Third Hospital
      2018   Phase 4   NCT04968613   China;
Seroquel   
   King’s College London & King’s College Hospital
      2005   Phase 4   EUCTR2004-002608-13-GB   United Kingdom;
Sertraline   
   National Cheng-Kung University Hospital
      2015   Phase 1/Phase 2   NCT02917122   -
   Zhejiang University
      2011   -   NCT01437189   China;
Sevoflurane   
   The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China
      2019   -   ChiCTR1900026956   China;
Sham Surgery   
   Ceregene
      2006   Phase 2   NCT00400634   United States;
   Sangamo Therapeutics
      2009   Phase 1/Phase 2   NCT00985517   United States;
Sham compression   
   Vanderbilt University Medical Center
      2020   Early Phase 1   NCT04620382   United States;
Sham tDCS   
   National Cheng-Kung University Hospital
      2015   Phase 1/Phase 2   NCT02917122   -
Sham tPCS   
   Western University, Canada
      2019   -   NCT04054960   Canada;
Sifol   
   Boehringer Ingelheim AB
      2006   -   EUCTR2005-003788-22-SE   Finland;Germany;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim Austria GmbH
      2006   -   EUCTR2005-003788-22-AT   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim España S.A.
      2006   Phase 4   EUCTR2005-003788-22-ES   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim Limited
      2006   Phase 4   EUCTR2005-003788-22-GB   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Sifrol   
   BOEHRINGER ING.
      2007   -   EUCTR2007-000074-23-IT   Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim
      2007   -   EUCTR2007-003353-90-NL   France;Germany;Netherlands;
      2006   Phase 4   EUCTR2005-004949-34-FI   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim AB
      2006   Phase 4   EUCTR2005-004949-34-SE   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-003788-22-SE   Finland;Germany;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim Austria GmbH
      2006   -   EUCTR2005-004949-34-AT   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-003788-22-AT   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim Limited
      2006   Phase 4   EUCTR2005-003788-22-GB   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim Ltd
      2006   Phase 4   EUCTR2005-004949-34-GB   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2007   -   EUCTR2007-003353-90-DE   France;Germany;Netherlands;
      2006   -   EUCTR2005-003788-22-DE   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Sifrol 0,088   
   Axxonis Pharma AG
      2007   -   EUCTR2006-003732-30-DE   Germany;Italy;Poland;
   NeuroBiotec Pharma AG
      2008   -   EUCTR2006-003732-30-PL   Germany;Italy;Poland;
Sifrol 0,18   
   Axxonis Pharma AG
      2007   -   EUCTR2006-003732-30-DE   Germany;Italy;Poland;
   NeuroBiotec Pharma AG
      2008   -   EUCTR2006-003732-30-PL   Germany;Italy;Poland;
Sifrol 0,35   
   Axxonis Pharma AG
      2007   -   EUCTR2006-003732-30-DE   Germany;Italy;Poland;
   NeuroBiotec Pharma AG
      2008   -   EUCTR2006-003732-30-PL   Germany;Italy;Poland;
Sifrol 0,7   
   Axxonis Pharma AG
      2007   -   EUCTR2006-003732-30-DE   Germany;Italy;Poland;
   NeuroBiotec Pharma AG
      2008   -   EUCTR2006-003732-30-PL   Germany;Italy;Poland;
Sifrol, 0,35 mg Tablette   
   Axxonis Pharma GmbH
      2006   -   EUCTR2005-001006-12-AT   Austria;Czech Republic;Germany;Italy;
Sifrol, 0,70 mg Tablette   
   Axxonis Pharma GmbH
      2006   -   EUCTR2005-001006-12-AT   Austria;Czech Republic;Germany;Italy;
Sifrol, Mirapexin   
   Boehringer Ingelheim España, S.A.
      2006   -   EUCTR2005-004949-34-ES   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Sifrol®   
   Boehringer Ingelheim
      2002   -   NCT02231255   -
      2000   -   NCT02231294   -
Sildenafil   
   Bispebjerg Hospital
      2003   Phase 4   NCT01941732   Denmark;
   Loma Linda University
      2002   Phase 2   NCT02162979   United States;
Silodosin   
   Juntendo University School of Medicine
      2012   -   JPRN-UMIN000008138   Japan;
Simvastatin   
   Plymouth Hospitals NHS Trust
      2015   Phase 3   EUCTR2015-000148-40-GB   United Kingdom;
   University Hospital Plymouth NHS Trust
      2016   Phase 2   NCT02787590   United Kingdom;
Simvastatine   
   CHU de Bordeaux
      2009   -   EUCTR2009-011736-35-FR   France;
Sinemet   
   Acorda Therapeutics
      2019   Phase 1   NCT03887884   United States;
   DR. REDDY’S LABORATORIES LIMITED
      2017   Phase 2   EUCTR2017-000262-30-IT   Italy;
   Institut de Recerca del Hospital de la Santa Creu i Sant Pau
      2007   -   EUCTR2006-002408-32-ES   Spain;
   Institute for Neurodegenerative Disorders
      2005   -   EUCTR2004-001485-41-GB   Spain;United Kingdom;
      2005   -   EUCTR2004-001485-41-AT   Austria;Spain;United Kingdom;
   NOVARTIS FARMA
      2005   -   EUCTR2005-001032-72-IT   Czech Republic;Italy;Portugal;
      2004   -   EUCTR2004-000185-12-IT   Finland;Italy;Sweden;United Kingdom;
   Orion Corporation, ORION PHARMA
      2005   -   EUCTR2004-005234-39-FI   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2004   -   EUCTR2004-000185-12-FI   Finland;Italy;Sweden;United Kingdom;
   Orion Corporation, ORION PHARMA, Finland
      2005   Phase 4   EUCTR2004-005234-39-GB   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
   Orion Corporation, ORION PHARMA, 02200 Espoo, Finland
      2008   -   EUCTR2004-005234-39-DE   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2004-000185-12-GB   Austria;Finland;Italy;Sweden;United Kingdom;
      2006   -   EUCTR2004-005234-39-LV   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2006   -   EUCTR2004-005234-39-LT   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2005   Phase 4   EUCTR2004-005234-39-IE   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2005   -   EUCTR2004-005234-39-SE   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2005   -   EUCTR2004-005234-39-DK   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2004   -   EUCTR2004-000185-12-SE   Finland;Italy;Sweden;United Kingdom;
      2004   -   EUCTR2004-000185-12-AT   Austria;Finland;Italy;Sweden;United Kingdom;
   UMCG
      2009   -   EUCTR2008-006278-13-NL   Netherlands;
Sinemet (carbidopa/levodopa)   
   Acorda Therapeutics
      2012   Phase 2   NCT01617135   Israel;Serbia;United Kingdom;
Sinemet (comparator)   
   XenoPort, Inc.
      2010   Phase 2   NCT01171313   United States;
Sinemet (levodopa/carbidopa)   
   Orion Corporation, Orion Pharma
      2009   Phase 1   NCT01070628   Finland;
Sinemet 200mg/   
   Orion Corporation, Orion Pharma
      2008   Phase 2   NCT00562198   Finland;
Sinemet 25-100 Oral Tablet   
   XenoPort, Inc.
      2009   Phase 1/Phase 2   NCT00914602   United States;
Sinemet 25/100   
   Bial - Portela C S.A.
      2001   Phase 1   NCT02763839   Portugal;
Sinemet CR   
   CombinatoRx, Inc
      2008   -   EUCTR2007-005033-11-DE   Germany;
   Huashan Hospital
      2011   -   NCT01470859   China;
   McGill University Health Centre/Research Institute of the McGill University Health Centre
      2017   Phase 4   NCT03111485   Canada;
Sinemet CR 25Mg-100Mg Extended-Release Tablet   
   Intec Pharma Ltd.
      2018   Phase 2   NCT03576638   -
Sinemet IR   
   Depomed
      2012   Phase 2   NCT01515410   United States;
Sinemet Plus   
   Institut de Recerca del Hospital de la Santa Creu i Sant Pau
      2015   Phase 4   EUCTR2015-002631-17-ES   Spain;
Sinemet plus (levodopa/carbidopa)   
   NOVARTIS FARMACEUTICA, S.A
      2006   -   EUCTR2006-000680-28-ES   Spain;
Sinemet-Plus Tablets   
   Impax Laboratories, Inc.
      2009   -   EUCTR2009-014688-37-ES   France;Germany;Poland;Spain;
Sinemet®   
   Acorda Therapeutics
      2016   Phase 1   NCT02812394   United States;
   Bial - Portela C S.A.
      2005   Phase 2   NCT02834507   -
      2005   Phase 1   NCT02774564   Portugal;
   Civitas Therapeutics, Inc.
      2012   -   EUCTR2012-000181-37-GB   Israel;Serbia;United Kingdom;
   Intec Pharma Ltd.
      2016   Phase 3   NCT02605434   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
   Orion Corporation Orion Pharma
      2007   -   EUCTR2007-002496-14-FI   Finland;
Sinemet® 100/   
   Bial - Portela C S.A.
      2009   Phase 1   NCT01533077   Canada;
Sinemet® 100/25   
   Bial - Portela C S.A.
      2008   Phase 1   NCT02169479   Canada;
      2004   Phase 1   NCT03091868   Portugal;
Sinemet® CR   
   CombinatoRx, Inc
      2008   -   EUCTR2007-005033-11-DE   Germany;
Sinemet® CR 100/25   
   Bial - Portela C S.A.
      2008   Phase 1   NCT02169453   Canada;
Sinemet® controlled release (Carbidopa/levodopa)   
   Bristol-Myers Squibb
      2007   -   NCT00460954   Canada;
Sinemet®25-100   
   Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
      2007   -   EUCTR2006-000577-29-DE   Germany;United States;
Sirolimus   
   Prevail Therapeutics
      2020   Phase 1/Phase 2   NCT04127578   Israel;United States;
Sitagliptin   
   Peking Union Medical College Hospital
      2020   Phase 4   ChiCTR2000029465   China;
Sodium chloride   
   Shanghai Tongji Hospital, Tongji University
      2017   -   ChiCTR-INR-17012013   China;
Sodium oxybate   
   Baylor College of Medicine
      2004   -   NCT00641186   -
Sodium phosphate enema, oral rifaximin and polyethylene glycol   
   Torre Médica Santé
      2018   Phase 1   NCT04730245   Mexico;
Solifenacin   
   VA Office of Research and Development
      2018   Phase 3   NCT03149809   United States;
Solifenacin Succinate (VESIcare)   
   University of South Florida
      2007   Phase 4   NCT00584090   United States;
Solifenacin succinate (VESIcare)   
   University of South Florida
      2010   Phase 4   NCT01018264   United States;
Solu-Cortef, powder for solution for injection, 100mg, and 'Act-O-Vial'   
   University Medical Center Groningen
      2015   Phase 2   EUCTR2014-000657-36-NL   Netherlands;
Solution de chlorhydrate de dopamine anaérobie   
   InBrain Pharma SAS
      2020   Phase 1;Phase 2   EUCTR2020-000155-12-FR   France;
Soluzione di levodopa/carbidopa   
   NEURODERM LTD.
      2016   Phase 2   EUCTR2015-005814-31-IT   Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States;
      2016   Phase 2   EUCTR2015-005078-39-IT   Austria;Germany;Israel;Italy;United States;
Sorbitol   
   Istanbul Medipol University Hospital
      2019   Phase 2   NCT04044131   Turkey;
Soy protein   
   Chulalongkorn University
      2011   Phase 4   NCT01662414   Thailand;
Spheramine (BAY86-5280)   
   Bayer
      2003   Phase 2   NCT00206687   Austria;France;Germany;Spain;United States;
      2000   Phase 2   NCT00761436   United States;
Spiropent   
   CuraSen Therapeutics, Inc.
      2020   Phase 2   EUCTR2020-003796-17-GB   United Kingdom;
      -   Phase 2   EUCTR2020-006067-28-BE   Australia;Belgium;New Zealand;United Kingdom;
SpotOn balance glasses   
   SpotOn Therapeutics Ltd.
      2018   -   NCT03942172   Israel;
Stalevo   
   Molecular NeuroImaging
      2004   Phase 2   NCT00200447   -
   NOVARTIS FARMA
      2005   -   EUCTR2005-001032-72-IT   Czech Republic;Italy;Portugal;
      2004   -   EUCTR2004-000185-12-IT   Finland;Italy;Sweden;United Kingdom;
   Novartis Pharma AG
      2006   -   EUCTR2005-001032-72-PT   Czech Republic;Italy;Portugal;
   Orion Corporation Orion Pharma
      2006   Phase 4   EUCTR2006-001755-36-GB   Germany;Sweden;United Kingdom;
      -   -   EUCTR2006-001755-36-DE   Germany;Sweden;United Kingdom;
   Orion Corporation Orion Pharma, FI-02200 Espoo, Finland
      2006   -   EUCTR2006-001755-36-SE   Germany;Sweden;United Kingdom;
   Orion Corporation, ORION PHARMA
      2005   -   EUCTR2004-005234-39-FI   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2004   -   EUCTR2004-000185-12-FI   Finland;Italy;Sweden;United Kingdom;
   Orion Corporation, ORION PHARMA, Finland
      2005   Phase 4   EUCTR2004-005234-39-GB   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
   Orion Corporation, ORION PHARMA, 02200 Espoo, Finland
      2008   -   EUCTR2004-005234-39-DE   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2004-000185-12-GB   Austria;Finland;Italy;Sweden;United Kingdom;
      2006   -   EUCTR2004-005234-39-LV   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2006   -   EUCTR2004-005234-39-LT   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2005   Phase 4   EUCTR2004-005234-39-IE   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2005   -   EUCTR2004-005234-39-SE   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2005   -   EUCTR2004-005234-39-DK   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
      2004   -   EUCTR2004-000185-12-SE   Finland;Italy;Sweden;United Kingdom;
      2004   -   EUCTR2004-000185-12-AT   Austria;Finland;Italy;Sweden;United Kingdom;
   Orion Corporation, Orion Pharma
      2016   Phase 2   NCT02764125   Finland;Germany;Hungary;Latvia;
      2011   Phase 2   NCT01766258   -
      2006   Phase 4   NCT00462007   Germany;Sweden;United Kingdom;
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2022   Phase 4   NCT04952194   -
Stalevo (levodopa/ carbidopa/ entacapone)   
   Orion Corporation, Orion Pharma
      2009   Phase 1   NCT01070628   Finland;
Stalevo (levodopa/carbidopa/entacapona)   
   NOVARTIS FARMACEUTICA, S.A
      2006   -   EUCTR2006-000680-28-ES   Spain;
Stalevo (levodopa/carbidopa/entacapone)   
   Orion Corporation, Orion Pharma
      2005   Phase 4   NCT00125567   Denmark;Finland;Germany;Ireland;Sweden;United Kingdom;
Stalevo 100   
   NOVARTIS FARMACEUTICA, S.A
      2006   -   EUCTR2006-000680-28-ES   Spain;
Stalevo 100 mg/ 25 mg/ 200 mg Filmtabletten   
   Novartis Pharma Services AG
      2008   -   EUCTR2007-003134-42-DE   Germany;
Stalevo 100 mg/25 mg /   
   Novartis Pharma AG
      2006   -   EUCTR2005-001032-72-CZ   Czech Republic;Italy;Portugal;
Stalevo 100/25/   
   Orion Corporation
      2011   -   EUCTR2010-022915-21-SE   Finland;Sweden;
      2011   -   EUCTR2010-022915-21-FI   Finland;Sweden;
Stalevo 150   
   Institut de Recerca del Hospital de la Santa Creu i Sant Pau
      2007   -   EUCTR2006-002408-32-ES   Spain;
   NOVARTIS FARMACEUTICA, S.A
      2006   -   EUCTR2006-000680-28-ES   Spain;
Stalevo 150/37.5/   
   Orion Corporation
      2011   -   EUCTR2010-022915-21-SE   Finland;Sweden;
      2011   -   EUCTR2010-022915-21-FI   Finland;Sweden;
Stalevo®   
   Asan Medical Center
      2015   -   NCT02452606   Korea, Republic of;
   Orion Corporation Orion Pharma
      2007   -   EUCTR2007-002496-14-FI   Finland;
Standard LD/CD   
   IRCCS San Raffaele
      2015   Phase 2   NCT02763137   Italy;
Static, dynamic and functional balance exercises with dual task   
   Istanbul University-Cerrahpasa
      2019   -   NCT03939559   -
Stilnoct   
   Aston University
      2018   Phase 2   EUCTR2017-004297-34-GB   United Kingdom;
Stimulator OFF   
   Maastricht University Medical Center
      2015   -   NCT02632279   Netherlands;
Stimulator ON   
   Maastricht University Medical Center
      2015   -   NCT02632279   Netherlands;
Strattera   
   Oregon Health and Science University
      2011   Phase 4   NCT01340885   United States;
Study Drug   
   Pfizer
      2010   -   NCT01270711   -
Subcutaneous apomorphine   
   Sunovion
      2018   Phase 3   NCT03391882   Austria;France;Germany;Italy;Spain;United Kingdom;
Subcutaneous hydrocortisone   
   University Medical Center Groningen
      2015   Phase 2   NCT02230930   Netherlands;
Subjects will undergo the 123-I IBVM imaging visit   
   Institute for Neurodegenerative Disorders
      2007   Phase 0   NCT00556764   United States;
Sugar Pill   
   New York Institute of Technology
      2014   Phase 0   NCT02259049   United States;
   Oregon Health and Science University
      2009   -   NCT00794313   United States;
Sugar pill   
   Henry Ford Health System
      2015   Phase 2   NCT02066571   United States;
   Rush University Medical Center
      2011   Phase 2   NCT01351168   United States;
      2010   Phase 2   NCT01341080   United States;
Sulforaphane   
   Central South University
      2021   Phase 2   NCT05084365   -
Sumanirole   
   Pfizer
      2003   Phase 3   NCT00058838   Argentina;Australia;Austria;Belgium;Colombia;France;Germany;Greece;Italy;Mexico;Peru;Puerto Rico;Spain;United States;
      2001   Phase 3   NCT00036218   Argentina;Mexico;Puerto Rico;United States;
      2000   Phase 3   NCT00036205   Argentina;Colombia;Puerto Rico;United States;
Supressi. T-Diet plus Range   
   Vegenat, S.A.
      2010   -   NCT01192529   Spain;
Suvorexant   
   Burdick, Daniel, M.D.
      2016   Phase 4   NCT02729714   United States;
Synthetic Oxytocin   
   Abteilung für Neurologie der Medizinischen Universität Innsbruck
      2019   Phase 2   EUCTR2018-002877-23-AT   Austria;
Syntocinon 40 IU/ml nasal spray   
   Abteilung für Neurologie der Medizinischen Universität Innsbruck
      2019   Phase 2   EUCTR2018-002877-23-AT   Austria;
TACROLIMUS TABLETS   
   Kyoto University Hospital
      2018   Phase 3   JPRN-JMA-IIA00385   Japan;
TAK-071   
   Takeda
      2020   Phase 2   NCT04334317   United States;
TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt)   
   Novartis
      2002   Phase 1/Phase 2   NCT00407212   Brazil;Canada;France;Germany;Italy;Netherlands;Portugal;United Kingdom;United States;
TD-9855   
   THERAVANCE BIOPHARMA ANTIBIOTICS, INC.
      2019   Phase 3   EUCTR2018-003289-15-IT   Austria;Bulgaria;Canada;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
   Theravance Biopharma
      2016   Phase 2   NCT02705755   United States;
   Theravance Biopharma Ireland Limited
      2020   Phase 3   EUCTR2018-003941-41-PT   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-003941-41-AT   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-003289-15-PT   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-003289-15-DE   Austria;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003941-41-PL   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003941-41-IT   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003941-41-HU   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003941-41-GB   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003941-41-ES   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003941-41-EE   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003941-41-BG   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003289-15-PL   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003289-15-HU   Austria;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003289-15-GB   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003289-15-ES   Austria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003289-15-EE   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003289-15-DK   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003289-15-BG   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003289-15-AT   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
TECHNETIUM (99MTC) EXAMETAZIME   
   IDIBAPS
      2016   Phase 2   EUCTR2015-004238-85-ES   Spain;
THN02   
   Theranexus S.A.
      2018   Phase 2   EUCTR2017-004475-31-HU   Czech Republic;France;Germany;Hungary;United States;
      2018   Phase 2   EUCTR2017-004475-31-CZ   Czech Republic;France;Germany;Hungary;United States;
THN102 Dosage A   
   Theranexus
      2018   Phase 2   NCT03624920   Czechia;France;Germany;Hungary;United States;
THN102 Dosage B   
   Theranexus
      2018   Phase 2   NCT03624920   Czechia;France;Germany;Hungary;United States;
THN102 Dosage C   
   Theranexus
      2018   Phase 2   NCT03624920   Czechia;France;Germany;Hungary;United States;
TO   
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2010   -   EUCTR2009-017416-33-DE   Germany;
TOZ   
   Biotie Therapies
      2017   Phase 3   EUCTR2016-003961-25-HU   Australia;Canada;Czech Republic;European Union;Germany;Hungary;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003961-25-GB   Australia;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003961-25-ES   Australia;Canada;Czech Republic;European Union;Germany;Hungary;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003961-25-DE   Australia;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003961-25-CZ   Australia;Canada;Czech Republic;European Union;Germany;Hungary;Spain;United Kingdom;United States;
TRIGEL   
   LobSor Pharmaceuticals AB
      2015   Phase 1   NCT02448914   Sweden;
TULOBUTEROL HYDROCHLORIDE   
   CuraSen Therapeutics, Inc.
      2020   Phase 2   EUCTR2020-003796-17-GB   United Kingdom;
TVP-1012   
   TEVA
      2005   -   EUCTR2005-001416-42-IT   Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
   TEVA Pharmaceuticals Industries Ltd
      2006   -   EUCTR2006-005140-89-NL   Netherlands;
   Takeda
      2015   Phase 3   NCT02337764   Japan;
      2015   Phase 3   NCT02337751   Japan;
      2015   Phase 3   NCT02337725   Japan;
      2015   Phase 2/Phase 3   NCT02337738   Japan;
   Teva Pharmaceuticals Industries LtD
      2005   Phase 3   EUCTR2005-001416-42-GB   Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-001416-42-ES   Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
      2005   -   EUCTR2005-001416-42-PT   Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
      2005   -   EUCTR2005-001416-42-HU   Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
      2005   -   EUCTR2005-001416-42-DE   Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
      2005   -   EUCTR2005-001416-42-AT   Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
TVP-1012 (1 mg/day) with levodopa   
   TAKEDA PHARMACEUTICAL COMPANY LTD.
      2015   Phase 3   JPRN-JapicCTI-152762   -
Tadalafil   
   University of South Florida
      2014   Phase 4   NCT02225548   United States;
Talampanel   
   National Institute of Neurological Disorders and Stroke (NINDS)
      2005   Phase 2   NCT00108667   United States;
   Teva Pharmaceutical Industries
      2006   Phase 1/Phase 2   NCT00036296   Canada;United States;
Talineuren   
   InnoMedica Schweiz AG
      2021   Phase 1   NCT04976127   Switzerland;
Targinact 10 mg/5 mg prolonged-release tablets   
   Mundipharma Research GmbH & Co. KG
      2012   -   EUCTR2011-002901-31-DE   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   Phase 3   EUCTR2011-002901-31-GB   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   Phase 3   EUCTR2011-002901-31-ES   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   -   EUCTR2011-002901-31-HU   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   -   EUCTR2011-002901-31-CZ   Czech Republic;Germany;Hungary;Spain;United Kingdom;
Targinact 20 mg/10 mg prolonged-release tablets   
   Mundipharma Research GmbH & Co. KG
      2012   -   EUCTR2011-002901-31-DE   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   Phase 3   EUCTR2011-002901-31-GB   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   Phase 3   EUCTR2011-002901-31-ES   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   -   EUCTR2011-002901-31-HU   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   -   EUCTR2011-002901-31-CZ   Czech Republic;Germany;Hungary;Spain;United Kingdom;
Targinact 5 mg/2.5 mg prolonged-release tablets   
   Mundipharma Research GmbH & Co. KG
      2012   -   EUCTR2011-002901-31-DE   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   Phase 3   EUCTR2011-002901-31-GB   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   Phase 3   EUCTR2011-002901-31-ES   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   -   EUCTR2011-002901-31-HU   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   -   EUCTR2011-002901-31-CZ   Czech Republic;Germany;Hungary;Spain;United Kingdom;
Tasmar   
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2010   -   EUCTR2009-017416-33-DE   Germany;
   Dept of Neuroscience, Uppsala University
      2008   -   EUCTR2008-003581-26-SE   Sweden;
Tavapadon   
   Cerevel Therapeutics, LLC
      2021   Phase 3   NCT04760769   Australia;Czechia;France;Germany;Italy;Poland;Spain;United States;
      2020   Phase 3   NCT04542499   Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
      2020   Phase 3   NCT04223193   Australia;France;Germany;Hungary;Italy;Poland;Serbia;Spain;Ukraine;United States;
      2019   Phase 3   NCT04201093   Australia;Bulgaria;Canada;Czechia;France;Germany;Israel;Italy;Poland;Spain;Ukraine;United States;
Terazosin   
   Cedars-Sinai Medical Center
      2020   Phase 2   NCT04386317   United States;
   Jordan Schultz
      2019   Phase 1/Phase 2   NCT03905811   United States;
Terazosin therapy   
   Cedars-Sinai Medical Center
      2021   Phase 2   NCT05109364   -
Tigan®   
   Ipsen
      2007   Phase 4   NCT00489255   United States;
Tissue samplings   
   Michael J. Fox Foundation for Parkinson's Research
      2015   -   NCT02572713   Canada;United States;
Tocovid Suprabio (HOV-12020)   
   National Neuroscience Institute
      2021   Phase 2   NCT04491383   Singapore;
Tolcapon   
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2010   -   EUCTR2009-017416-33-DE   Germany;
Tolcapone   
   Dept of Neuroscience, Uppsala University
      2008   -   EUCTR2008-003581-26-SE   Sweden;
   Uppsala University
      2008   Phase 4   NCT00906828   Sweden;